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ABSTRACT
Background: Clinically defined cancer-related anaemia is common in cancer patients but 
the impact of mild/moderate anaemia Is undetermined, when combined with cancer 
symptoms and/or the side effects of therapy. Blood transfusion is the standard 
treatment; however there are significant risks and costs. It Is important that the decision 
to give blood Is carefully considered but it is not clear how these decisions are made. 
Purpose: To explore the cultural practices which shape the culture of transfusion; and to 
Identify the key elements, which influence clinical decision making in blood transfusion In 
haemato-oncology and lung cancer patients.
Method: The assessment and decision making processes for blood transfusion were 
explored using six patient and nine clinician interviews; and observation based on 
ethnographic methodology. Data were analyzed using thematic analysis.
Findings: The findings fell into four main areas. First, the findings suggested that 
anaemia and transfusion are commonplace in the clinical setting; and because many 
patients live with anaemia and It may not be viewed as an Illness {The ubiquity of 
anaemia and transfusion). Second, there is a great deal of uncertainty surrounding the 
diagnosis and management of this clinical problem; but this uncertainty was 
acknowledged by both patients and clinicians {Acknowiedgement of uncertainty). Third, 
clinicians and to some extent patients, are socialized Into the practice of the sub­
discipline {Socialization of practice); and fourth that the haemoglobin level was used as a 
distinct fragment of Information on which to assess for the presence of anaemia and 
base the decision to treat with blood transfusion {Disaggregation of the body).
Conclusion: By understanding the complexity of factors for variation In practice In the 
clinical context, new models for learning transfusion skills can be developed.
Furthermore, different collaborative groups could be organized to develop optimal
9
transfusion practices, for example to include nurse-prescribing of blood components. 
(299 words)
Key words:
Blood transfusion/transfusion practice
Clinical decision making
Haemoglobin
Ethnography
Oncology
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Glossary of terms
Actlgraphy: A non invasive method of monitoring sleep and activity patterns. The 
patient continuously wears a device like a wrist watch on their non-dominant arm which 
monitors activity which can be later analyzed using software
Acute Myeloid Leukaemia (AML): An acute onset cancer of the white blood cells, 
where the cancer arises In the bone marrow. The most common acute leukaemia In 
adults
ADE: Combination chemotherapy for the treatment of AML; a combination of cytarabine, 
daunorubicin and etoposide
Allogeneic blood: Blood donated from another individual, which Is typically stored and 
then provided through a transfusion
Alloimmunization: The process of making an antibody against a foreign antigen 
Anaemia: A condition in which the blood Is deficient in red blood cells. In haemoglobin 
or total volume
Anglogenesis: Blood vessel formation. Angiogenesis that forms In cancer is the 
growth of blood vessels from surrounding tissue to a solid tumour. This is caused by the 
release of chemicals from the tumour, which activates normal angiogenic pathways 
Biood components: Red blood cells; white blood cells, plasma and platelets are 
components that can be removed from a donor and transferred to a recipient or returned 
to a donor
Clinicians: Healthcare professionals Including physicians and nurses 
COPDM: Combination chemotherapy for aggressive lymphoma includes the
combination: cyclophosphamide; vincristine; prednisolone; doxorubicin; high dose 
methotrexate
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Cytokines: Extracellular hormones or messengers, secreted mainly by macrophages 
and T cells, that interact with the immune, nervous and endocrine system 
DHAP: Treatment for relapsed non-Hodgkin’s lymphoma Including combination
chemotherapy; dexamethasone; cytarabine and cisplatin
Diffuse Large B cell Non-Hodgkin’s Lymphoma: The most common sub-type of non- 
Hodgkin’s lymphoma (NHL); comprising about 30% of all NHL’s 
Endogenous: Originating or arising within the body
Erythroid hypoplasia: Decreased production of red blood cells by the bone marrow 
Erythropoiesis: The process of making red blood cells
Erythropoietin: A chemical normally produced by the kidney; stimulates the bone 
marrow to make red blood cells
Ethnography: Aspect of cultural anthropology concerned with the descriptive 
documentation of a living culture
FACT-An: Functional Assessment of Cancer Therapy-Anaemia quality of life
questionnaire
Ferritin: An iron carrying protein which is a more accurate monitor of long term iron 
body status than the blood iron level
Functionality: The ability of a patient to undertake activities of daily living 
Haemato-oncoiogy: The study and treatment of cancers affecting the blood and bone 
marrow and lymphatic systems; leukaemia, myeloma and lymphoma 
Haemoglobin: The oxygen carrying protein of the biood
Haematologist: A doctor in the branch of medical science that studies blood and blood 
forming tissues
Function: A description of performance status of a patient 
Immunomoduiation: Modification or alteration or disruption of the immune system
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interleukin: A chemical messenger secreted by cells of the immune system that act by 
affecting other parts of the Immune system
Leucocyte depletion: Blood components which have had most of the leucocytes 
(white biood cells) removed
Lymphoblastic Lymphoma: A very aggressive form of non Hodgkin’s lymphoma, 
which requires aggressive therapy
Myeiodysplastic syndrome (MDS): Disease in which the bone marrow does not
function normally; can transform Into acute leukaemia
Myelosuppression: A fall in blood counts caused by radiotherapy or chemotherapy 
Normochromic: Normal in colour; when the blood has normal haemoglobin levels 
Normocytic: Red blood cell of normal size and shape
Nucleic acid testing: Technology for amplifying genetic material in order to test for the 
presence of blood contaminants 
Oncology: The study of cancer
Precautionary principle: When information about the potential risks Is incomplete,
basing decisions about the best ways to manage or reduce risk
Prions: Protein segments that may cause Infection that leads to some forms of
dementia
Quality of life: An evaluation of health status, relative to the patient’s age, expectations 
and physical and mental capabilities
RCHOP: A combination of five drugs to treat non-Hodgkln’s iymphoma. It consists of 
RItuxImab; cyclophosphamide; doxorubicin; vincristine and prednisolone 
Social construction: relates to any phenomena which Is Invented or constructed by the 
participants in a particular culture or society, existing because people agree to behave as 
if It exists or follow the rules.
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stage: Refers to the “stage of the cancer” e.g. advanced or early stage
Supportive care: Care given to Improve the quality of life of patients who have a serious
or life threatening disease
Tradition: Custom or belief; a long established action or pattern of behavior In a 
community or group of people, often one that has been handed down from generation to 
generation; a body of long established customs and beliefs viewed as a set of 
precedents
Transfusion trigger: The critical point at which a decision is made to give a blood 
transfusion
Variant Creutzfeidt Jacob disease: A transmissible, rapidly progressing, fatal
neurodegenerative disorder called a spongiform degeneration that seems to be related 
to “mad cow disease”
Venous Thromboembolic Events (VTE’s): A clinical event caused by a thrombosis 
(attached or fixed clot) and/or embolus (mobile clots)
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CHAPTER 1 
Introduction
in this chapter, some background information Is provided on the subjects of, cancer 
related anaemia and biood transfusion. The researcher’s clinical background and the 
development of the research problem, in the clinical context are explained. The outline 
of the study is described, and how It evolved from observations In practice; followed by 
an Introduction to the literature review and evolution of the methodology. It concludes by 
providing a summary of the findings.
1.1 An Introduction to cancer-related anaemia
Clinically defined cancer-related anaemia (haemoglobin of less than 12g/dl) Is a common 
clinical problem for patients and occurs as a consequence of either the disease process 
or as a side effect of the anti-cancer therapy. The direct effects on the patient vary, 
ranging from negligible effect to debilitating symptoms and It may be difficult for the 
patient and the healthcare professional to establish the symptoms of anaemia as distinct 
from symptoms of disease or therapy. Cancer frequently causes fatigue, and also 
breathlessness, which are both symptoms of anaemia. These symptoms can worsen or 
improve with therapy depending on disease and stage. The degree of anaemia can also 
fluctuate and It can be difficult to determine the Impact of anaemia In the patient 
assessment when the other variables of disease and treatment effects are taken into 
account.
Many quality of life studies have been undertaken In attempts to demonstrate that 
anaemia has deleterious effects on cancer patients particularly in relation to fatigue, and 
that by increasing the haemoglobin, the patients’ function and quality of life improves.
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However, many of these have been in the erythropoietin studies which results in an 
intrinsic rise in haemoglobin. It may be that allogeneic blood does not have the same 
Impact or that the effects are unpredictable. More recent evidence now reveals that 
Increasing the patients’ haemoglobin, through the use of erythropoietin agents can have 
a negative effect on outcomes, (Leyland-Jones 2003; Henke et al 2003; Overgaard 
2006; Leyland-Jones et a! 2005); therefore, the decision to treat the anaemia requires 
careful consideration. The perception may be that anaemia is common in cancer 
patients and that it is important to treat. This may have been largely due to the attention 
given to erythropoietin therapy evidence as well as the historical approach of treating 
anaemia with blood transfusion, or it may be other Influences such as the culture or 
practices within the clinical setting or Individual behaviors. Alternatively, although 
cancer related anaemia is described as a common clinical problem It may be that it is 
only moderate to severe anaemia which Impacts on the patient, therefore it Is only in 
these circumstances that the risk of transfusion Is justifiable. Less severe anaemia may 
be Inconsequential, and therefore unnecessary to treat; it may be the side effects of 
disease and treatment take priority over the symptoms of anaemia, which may influence 
the decision to treat. It may be that when less severe anaemia is placed In the context of 
the life threatening nature of cancer that it becomes less of a clinical priority In some 
clinical settings. Together all of these factors imply that managing cancer related 
anaemia is complex and it is unclear how the decisions are made to treat anaemia with 
blood transfusion, therefore, substantiating the need for this research.
1.2 An introduction to blood transfusion
It Is routine practice to correct anaemia In the UK by using red blood cell transfusions. 
Around 2.5 million units of blood are transfused every year In the UK; a figure which
17
increases every year (RCN 2006; Soldan et al 1999) and approximately 20% of this 
donated blood In the UK Is used in cancer patients (Wallis 2006). Blood transfusion is 
therefore ubiquitous in the acute healthcare settings yet there Is relatively limited 
evidence of its efficacy In Improving outcomes when compared with the practice of other 
treatments, for example, drug therapy. It is accepted that by Increasing the 
haemoglobin, it can Increase function, but studies have not been undertaken In Individual 
tumour groups, which will be evidenced In the literature review; It may be that different 
tumours have different responses In terms of benefit and/or outcome.
There are also potential complications of transfusion. Including transmission of Infectious 
diseases, transfusion reactions, alloimmunization, lung injury, over-transfuslon and 
Immune modulation with possible adverse effects on tumour growth (Goodnough et al 
2005; Toy et al 2005). The safety of blood transfusion has Improved significantly over the 
past 20 years, primarily due to Improvements In donor-blood screening and stringent 
quallty-control measures. In spite of these improvements risks remain with blood 
transfusion (Williamson et al 1999). The history of transfusion-associated Infection with 
human Immuno-deficiency virus (HIV) and variant Creutzfeidt Jakob Disease (vCJD), 
and the fear of future unknown pathogens, for example other harmful prions or micro­
organisms not yet identified or developed by mutation, are partly responsible for 
Increasingly conservative allogeneic red blood cell transfusion practices (Goodnough et 
al 1999). Increasing costs and complexity such as leucocyte depletion and nucleic acid 
testing in producing the end product also contribute to this conservative approach. 
Historically patients were routinely transfused to maintain a haemoglobin level of around 
10g/dl but over the years there has been a gradual reluctance to transfuse for the 
reasons mentioned earlier. It has been suggested that this growing tendency for the
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lowering of the transfusion threshold has gone too far and patients may be under­
transfused (Valeri et al 1998) with mild to moderate anaemia being left untreated (Celia 
and Bron1999; Glaspy et al 1997; Henry 1992; Koeller 1998). This has been strongly 
emphasized In the erythropoietin literature, which will be described in section 2.3.
It may be that transfusions are so commonplace and historical that traditional practices 
exist; transfusion behaviours may be habitual rather than focusing on individual patient 
needs. Blood transfusion Is a well established mode of treatment and the education and 
learning in clinical practice has not been previously explored, for example, how 
transfusion behaviours are learned. Mandatory transfusion training exists in acute 
settings but much of the focus relating to transfusion practice revolves around safety 
aspects, such as correct identification and checking procedures, rather than at the point 
of decision to treat, to explore if the blood transfusion is actually necessary. Within 
cancer care It may be low priority consideration when compared to other aspects of care. 
It is largely a traditional approach whereby two units of blood are ordered in response to 
the haemoglobin value.
It Is unclear at present If the benefits outweigh the risks of transfusion in the treatment of 
mild or moderate anaemia and how much consideration Is given to this uncertainty when 
making clinical decisions. In summary, the process of assessment of anaemia and the 
subsequent decision to treat anaemia using blood transfusion requires further 
exploration. The interactions between patients and clinician and/or nurse require further 
examination to explore the reality of transfusion practice; that is an exploration Into the 
culture of transfusion practice within the cancer care setting.
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1.3 The researcher’s background
The researcher’s clinical background Is haemato-oncology and her interest in cancer 
related anaemia began when In the clinical role as nurse manager of a haemato- 
oncology day unit and out-patient department. Approximately 40-50 patients attended 
the department every day with a variety of haemato-oncology malignancies. Many 
patients were transfusion-dependent, and multiple transfusion episodes, In different 
patients, occurred every day. The decisions to transfuse were based on a combination 
of the haemoglobin and conversation with the patient, which usually included questions 
about fatigue and breathlessness on exertion. The day unit nurses made the 
assessments whilst taking the blood samples and sometimes made the decision to send 
a cross match sample and cannulate the patient because they anticipated the patient 
would require a blood transfusion. The norm was for the nurse to make the decision to 
transfuse; cross match and order the blood and later have it legitimized and legalized by 
the medical staff who would prescribe the blood components. An additional driving 
force, for speed of assessment, was the need for timely ordering otherwise the patient 
would be unable to complete their transfusion during the visit to the day unit. In other 
words, behaviours developed in a pragmatic way to ensure the practicalities of 
completing the transfusion episode, within the day unit hours of operation and also to 
circumvent restrictive professional practices.
During the four year period as manager, three Interesting reflections shaped the 
researcher’s thinking and, ultimately the development of this research project. Firstly, 
observing junior haematologlsts’ behaviour and the change In their blood prescribing 
behaviors following the completion of their transfusion medicine course at National Blood 
Transfusion Service. Pre-course the haematologlsts would happily be guided by the day
20
unit nurses. Post course, they would be more challenging and less likely to want to 
transfuse patients. This implied a relationship to skills and knowledge but may also be 
related to attitudes; In summary the intervention (transfusion course) resulted in more 
questioning behaviours. Secondly, sometime during the four year period there was a 
period of financial difficulty; up to that time it had been common practice to use a 
transfusion trigger of 10g/dl and the hospital guidelines were amended to use a new 
trigger of 8g/dl In an effort to reduce the blood transfusion component spend. There was 
reluctance by the clinical teams to do this initially, however the researcher observed this 
change In clinical practice appeared to have minimal Impact on the patients. Thirdly, the 
researcher observed that an individual patient could present with a low haemoglobin 
level and symptoms and multiple clinicians (nurse or medical) could make different 
transfusion decisions. There appeared to be little consistency and the reason for this 
was unclear; the decisions were negotiated between the clinicians, or occasionally one 
clinician would over-rule another, but frequently the nurses made the ultimate decision 
because of the practicalities of completing a transfusion episode within the hours of 
operation of the day unit.
In summary, these reflections contributed to the development of a Master’s degree 
research project (Bishop 2004). This was a quasl-experlmental design to determine the 
Impact of transfusion on the functional status of blood transfusion-dependent haemato- 
oncology patients; it was a crossover-design study whereby six patients were transfused 
for four weeks using a trigger of 8g/dl (low trigger) then crossed over to a transfusion 
trigger of 10g/dl (high trigger), with a two week washout period. Actlgraphy and quality of 
life questionnaires were used to measure any differences on functionality of patients 
when maintained at low or high haemoglobin. Actigraphy is a non-invaslve technique
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whereby the patient wears a device like a wristwatch on their non-dominant arm and it 
continuously monitors sleep, wake and activity patterns, by using sophisticated software 
to capture movement. The study had some methodological flaws; for example, 
maintenance at either trigger was only for a four week period and this study period may 
have been too short to determine any impact or changes of the haemoglobin level on 
functional status. Furthermore, the data analysis was limited by the numbers of patients 
who completed the study and because of the problems of reliably integrating the 
actigraphy and questionnaire data. The patients who appeared to benefit the most from 
blood transfusion were those who had not previously received chemotherapy. The 
emphasis of the study was on the patient functional status, however, it could not explain 
the variation in transfusion decision making and therefore ultimately the variation In 
clinical practice.
A change In clinical position to Nurse Consultant In a different institution resulted In 
further questions. At the new Institution, guidelines were well established and present In 
every clinical area, however, there was an impression that blood component guidelines 
were not adhered to. Different practices occurred, In that the clinics were dislocated 
from the day units and the medical and nursing assessments were separate. For 
example, a patient may attend clinic for medical review where the decision to transfuse is 
agreed; however, at the point of care delivery, or during the booking procedure the 
decision may change, following discussion or review by the nurse. A clinical audit was 
undertaken which revealed a variation In practice In terms of transfusion triggers In 
haemato-oncology and oncology (see Service Development Project; Part 2). The 
oncology unit appeared to use a higher trigger, which may have been because of the
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effects of radiotherapy guidelines which specify a higher trigger, but limitations of the 
audit meant this information was not available.
It emerged that transfusion practice varied but the reasons for this were unclear; It could 
be related to the:
Indeterminacy of anaemia and treatment
The knowledge skills and experience of clinicians or nurses
Available clinical evidence
Situational factors such as the environment or financial constraints 
The presence or absence of guideiines 
Individual patlent/cllniclan factors or other factors
Further research was required to explore these factors and place cancer related 
anaemia and transfusion practice in the context of the clinical setting. If the complexity 
of factors for variation in practice In the context of the clinical setting could be 
understood, new models of care, or different collaborative groups could be organized to 
develop optimal transfusion practices. In addition, by exploring the culture of transfusion 
of practice, further research questions may emerge, for example, what skills and 
knowledge are required to practice optimal transfusion practice?
Initially, the early ideas for the research project could be summarized into two distinct 
areas; firstly, the effect of anaemia on the patient and the response to an Increase In the 
haemoglobin following a transfusion; how did the patients feel when they were anaemic 
and did they experience improvement post transfusion, and did this Influence the
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decision to treat cancer related anaemia? Secondly, what Individual, social, situational 
and cultural factors Influenced the decision to transfuse and was the patient Involved In 
the assessment and decision to transfuse? The challenge was to develop a research 
project that would answer these questions and the evolution of the research Is described 
In Section 1.5 and In more detail In Chapter 3.
1.4 Developing the literature review
The literature review needed to be extensive and broadened beyond the simplistic 
starting point of cancer related anaemia and blood transfusion to Include some of the 
Influencing factors, for example, the culture and clinical decision making. The literature 
review expanded as the research project developed. It was difficult to establish what 
aspects of transfusion practice were Important to explore therefore a novel approach, 
using a relationship diagram, was developed and the researcher found this assisted with 
the organisation of the literature review and ensured all relevant aspects were covered 
(Figure 1.4). This was an Iterative process and the literature review needed to be re­
defined as the project evolved, as new Information emerged. Relationship diagrams are 
a useful and effective way of organising and Identifying links between concepts, topics 
and variables (Finn 2005). They are also helpful In maintaining an overview of the 
different components of a complex topic and help to convey Information that would be 
difficult to achieve In a written piece of work, allowing the complexity to be appreciated, 
but still allowing the Individual components and their connections to be viewed. A 
relationship diagram was devised to facilitate the literature review and guide the 
researcher to develop general themes to explore the literature. In summary, the 
relationship diagram was used not only to reflect the Initial understanding of the subject 
but also helped to actively promote understanding and give rise to new Insights, for
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example, the deeply entrenched traditional practice of blood transfusion. This was 
particularly useful when re-vlslting the literature review following the data collection and 
during the data analysis period.
Figure 1.4: Relationship diagram
(CRA: Cancer related anaemia; DTT: Decision to Treat)
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1.5 Summary of the research project
Developing the research project, like the literature review, was an Iterative process. The 
purpose of this study was to explore the culture of transfusion practice and provide more 
In depth knowledge and understanding of the Impact and assessment of cancer related 
anaemia and Its treatment with blood transfusion. The objectives were:
• To explore the cultural practices which shape the culture of transfusion
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• To identify the key elements, which influence clinical decision making in blood 
transfusion
The study was limited to haemato-oncology and lung cancer patients as cancer-related 
anaemia Is common In these patient groups (52% and 38% respectively, Ludwig et al 
2004); and the clinical teams who cared for these patients were the subjects for 
Interview. The Incidence of anaemia In the different types of cancer patients Is 
described In more detail In section 2.2. The Initial study design had Included a quasi 
experimental component whereby a combination of actlgraphy and quality of life 
questionnaires would be used to establish the Impact of the anaemia on the patient. The 
patients were to be followed throughout their treatment trajectory and the effects of 
transfusion monitored longitudinally using FACT-An (Functional Assessment of Cancer 
Therapy-Anaemla subscale, Celia 1997) and actlgraphy for 90 days. The original 
research therefore had two distinct parts; the first part was designed to focus on the 
patient and the impact of anaemia and transfusion and the second part to focus on 
transfusion decision making and behaviours. The effect of the anaemia on the ability of 
the patient to physically function was to be measured by using a combination of 
questionnaires and actlgraphy; actlgraphy Is a non-lnvaslve means of measuring activity, 
sleep and rest patterns (see glossary). The clinical decision making was to be explored 
by using a combination of observation and Interviews, using an ethnographic 
methodology. However, the design was subsequently altered to Include patient 
Interviews, and the actlgraphy and questionnaires abandoned, not only to answer the 
research questions, but also because of methodological flaws In the original design and 
difficulty In recruiting patients to the 90 day study period. The actlgraphy and 
questionnaire may not have captured the patient experience of anaemia and transfusion 
and also It became apparent following some of the clinician Interviews that patients were
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involved in the decision making. It emerged that by interviewing patients, more detail of 
the experience and their Involvement would be possible. Therefore the final research 
design was a combination of observation and patient and clinician Interviews using an 
ethnographic methodology. This evolutionary process of the final research methodology 
and design will be described In more detail in Chapter 3.
The change In research design, that is the abandoned quasl-experlmental components 
of the study (actlgraphy and questionnaires) and substitution with patient interviews, was 
discussed and agreed with the research supervisors. The project required a substantial 
amendment to be submitted to the ethics committee and the patients were subsequently 
interviewed. This added information about the culture of anaemia and the management 
with blood transfusion from the patient perspective that otherwise would not have been 
available. The assessment process and patlent-cllnlclan Interaction was explored using 
interviews and observation based on ethnographic methodology; but the change In study 
design Included patient Interviews to establish their views on the Impact of the anaemia 
and give Insight Into their Involvement In the decision to transfuse. This provided data to 
explore the clinical decision making process to determine the influencing factors on the 
decision to treat the anaemia with blood transfusion.
Data on the clinics and environment were collected to provide Information on the 
frequency of anaemia in this clinical setting and how the clinics functioned because this 
may Influence behaviours. Eight clinical staff and six patients were Interviewed and the 
Interviews transcribed over a nine month period. Observations were undertaken In the 
clinics and day units and field notes transcribed. The researcher’s Influence and her 
Interpretation was considered and reflected In the researcher’s diary and Is described In
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the ethical Issues section 4.5 and conclusion chapter (Chapter 7). Preliminary data 
analysis began at the point of data collection and a modified thematic analysis using 
Spradley (1980). Early themes emerged, for example, uncertainty, and these provided 
the foundations of further data collection and analysis.
The findings fell Into four main areas. First, the findings suggested that anaemia and 
transfusion are commonplace In the clinical setting; and because many patients live with 
anaemia and It may not be viewed as an Illness {The ubiquity of anaemia and 
transfusion). Second, the findings suggest that there Is a great deal of uncertainty 
surrounding the diagnosis and management of this clinical problem; but this uncertainty 
was acknowledged by both patients and clinicians {Acknowiedgement of uncertainty). 
Third, the findings suggest that clinicians and to some extent patients are socialized Into 
the practice of the sub-disclpllne {Sociaiization of practice)’, and fourth that the 
haemoglobin level was used as a distinct fragment of Information on which to assess for 
the presence of anaemia and base the decision to treat with blood transfusion 
{Disaggregation of the body).
The Implications of the findings are discussed In Chapters 6 and 7 with particular 
reference as to how the transfusion culture Influences decision making and how cancer 
related anaemia Is managed In the clinical setting; with recommendations for clinical 
practice and further research.
1.6 Summary
In summary the researcher's background, history, clinical experience and skills and 
knowledge and attitudes shaped the evolution of this research project. From the early
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belief that anaemia and blood transfusion practice was an Important clinical Issue came 
the understanding that cancer related anaemia may not be viewed as an Illness, by 
clinicians or patients that warranted discussion and debate in the clinical setting. The 
reasons for this were multiple, Interconnected and complex. The researcher used the 
multiple data sets (demographic data; clinic data; Interview data; observation of practice 
data) to create a version of the reality, but It should be remembered this Is the 
researcher’s version of reality and others’ interpretations may differ. However, the 
different data sets added rigor to the results of this study, by demonstrating the recurrent 
themes within the different data sets.
This chapter has provided some initial background to the study and a brief overview. 
The first step was to explore the literature using the categories described In section 1.4. 
It has been explained briefly how the use of an ethnographic approach would provide a 
way to explore the research question, but a greater understanding of ethnographic 
methodology was required and advice sought on how to undertake ethnographic 
observation and Interviews. This Is outlined in more detail In Chapter 3. Data collection 
was undertaken over a 9 month period and data analysis took a further four months. 
The data analysis and findings are described in detail In Chapter 5. The discussion and 
Implications for practice and future research evolved; and these are described in 
Chapters 6 and 7 respectively. In summary, it was a case of protracted but fluid 
evolution with continued refinement and re-deflnitlon to produce the final ethnography 
and thesis.
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CHAPTER 2 
Literature Review
This chapter summarises a review of the relevant literature. First, the literature was 
reviewed to establish the Incidence and pathophysiology of cancer related anaemia; this 
helped to clinically define the anaemia and explore the biological basis for the 
Indeterminacy of anaemia. Second, the literature was reviewed to explore the current 
evidence for the Impact of the anaemia and to establish the Importance of managing 
anaemia appropriately. The review Included the extensive erythropoietin literature as 
much of the recent research Into cancer related anaemia management has attempted to 
determine the benefits of Increasing the haemoglobin by using erythropoietin therapy. 
Third, the literature was explored to determine the symptoms and assessment of 
anaemia and what assessment strategies are used by clinicians; the rationale for 
Including this Is that one of the challenges of managing this type of anaemia lies In 
distinguishing the symptoms of anaemia from symptoms of the cancer, particularly the 
more subjective symptom of fatigue. Fourth, the transfusion literature was reviewed to 
describe the current evidence for transfusion thresholds and the risks and benefits of 
blood transfusion; this would provide a basis of understanding of any factors which may 
influence transfusion decision making or attitudes to blood transfusion. Finally, It Is 
unknown what factors Influence how blood transfusion behaviours are learned and 
practiced therefore the clinical decision making literature was explored In addition to the 
literature focussing on social Interactions and the development of cultural knowledge In 
clinical settings.
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In summary, the literature review was undertaken to understand current knowledge 
about cancer related anaemia and treatment with blood transfusion. The decision to 
treat cancer related anaemia Is complicated because of Individual patient adaptations to 
anaemia; the range of symptoms cancer patients experience, and because haemoglobin 
levels fluctuate according to disease status and therapy; and It Is unclear If clinicians 
observe trends in haemoglobin or If they assess the haemoglobin level In Isolation. It Is 
also unclear how the patient Is Involved and If the patient Is In concordance with the 
clinician when making the clinical decision to transfuse and this justified an exploration 
Into the literature of patient factors, which may Influence the decision making. In 
summary, like any literature review, the overall aim was to determine the gaps In the 
literature and guide the researcher In developing the design of the study. This chapter 
concludes with a summary of the literature and the purpose of this research.
2.1 Search Methods
The following search strategy was utilised for this review, using text and keyword and 
MESH terms In each database:
Anemla/anaemla 
Blood transfusion 
Blood transfusion guidelines 
Cancer related anaemla/anemla 
Cancer related fatigue
Fatlgue/lethargy/tlredness/asthenla/breathlessness 
Erythropoletln/erythropoletln/Erythrold Stimulating Agents/ESA's 
Lung cancer/breathlessness
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Haemato-oncology/haematology 
Clinical judgement/clinical decision making 
Culture/medical culture
The following databases were used to obtain relevant studies for this review.
• The Cochrane Controlled Trials Register (Central/CCTR)
• MEDLINE (1966 to July 2008)
• EMBASE (1980 to July 2008)
• CINAHL (1982 to July 2008)
• British Nursing Index (January 1984 to July 2008)
• AMED (1985 to July 2008)
• SIGLE (1980 to July 2008)
• Dissertation Abstracts International (1861 to July 2008)
Reference lists of ail articles obtained were checked for additional studies. In addition 
textbooks were acquired on ethnography, clinical judgement and decision making.
2.2 Incidence and pathophysiology of anaemia In cancer
Clinically defined cancer-related anaemia Is reported as a common problem In cancer 
patients, and even more so In patients with haematologlcal and lung malignancies, with 
an Incidence of 52% and 38% respectively (Ludwig et al 2004). The consequences of 
anaemia, namely fatigue, and cardiovascular and respiratory symptoms, can adversely 
affect patients' quality of life and may even alter their response to treatment (Ludwig and 
Fritz 1998; Ludwig and Strasser 2001). Moreover anaemia Is often associated with the
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presence of several adverse prognostic parameters and is Itself a predictor of poor 
prognosis (Caro ef a/2001).
2.2.1. Clinical definition and Incidence
The pathogenesis of cancer-related anaemia is variable, but may Involve bleeding, 
erythrold hypoplasia, reduced red cell survival, nutritional deficiencies, decreased 
erythropoietin levels, haemolysis and poor Iron re-utliisatlon by bone marrow 
(Bokemeyer 2005; Estrin et al 1999). Furthermore, cancer-related anaemia is 
exacerbated by myelosuppresslve chemotherapy and may be aggravated by 
radiotherapy (Barrett-Lee ef a/2000).
Anaemia can be defined as a deficiency In the concentration of haemoglobin (Hb) 
containing red blood cells, and Is a widely prevalent complication amongst cancer 
patients, but the Incidence and severity varies according to the type of malignancy 
(Groopman and Itrl et al 1999). A large European study, the “EGAS” survey (n=15,367) 
was conducted to prospectlvely evaluate the prevalence, Incidence and treatment of 
anaemia in European cancer patients (Ludwig et al 2004). Thirty-nine per cent of 
patients were diagnosed with an Hb of less than 12g/dl at enrolment, 10% had an Hb of 
less than lOg/dl and 1% had an Hb of less than 8g/dl (see Table 2.2.1 for classification 
of anaemia; Groopman and Itrl 1999). The EGAS survey was undertaken to Inform 
clinicians of the frequency of cancer related anaemia and may have been used as a 
drive for using erythropoietin. The conflict here is although the EGAS survey reports the 
frequency of anaemia as high the actual number of patients that would need transfusion 
according to current guidelines Is greatly reduced (10% with Hb less than lOg/dl and 1% 
with an Hb of less than 8g/dl). Therefore there may be a large number of patients who
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are technically anaemic at diagnosis, however, only a very small proportion would be 
eligible for treatment according to transfusion recommendations.
The EGAS study also demonstrated rates of anaemia were shown, not surprisingly, to 
rise during treatment, especially with chemotherapy. They also varied by tumour type, 
for example, patients who had haematologlcal and lung cancers had substantially higher 
rates of anaemia than other types of cancer. Patients with breast, head and neck and 
uro-genltal cancers had rates below the average at enrolment (30%, 25% and 29% 
respectively). It Is most common In haematologlcal malignancies where 52-64% of 
patients had haemoglobin values between 8 and 10g/dl and 19-23% had haemoglobin 
values less than 8g/dl (Nowrouslan ef a /1996).
Table 2.2.1: The National Gancer Institute Anaemia classification (Groopman and Itrl 
1999)
Grade Glassification Haemoalobln level
Grade 0 Within Normal Limits (WNL) 12-16g/dl (women) 
14-18g/dl (men)
Grade 1 Mild 10g/dl-WNL
Grade 2 Moderate 8.0-10.Og/dl
Grade 3 Serious/severe 6.5-7.9g/dl
Grade 4 Life threatening <6.5g/dl
This classification of anaemia Is universally accepted and will be used during this thesis 
to describe levels of anaemia.
2.2.2 Pathophysiology of cancer related anaemia
The pathophysiology of cancer related anaemia Is multi-factorial (Mercadante ef al 2000; 
Splvak ef al 2005). There are numerous causes that could have produced the anaemia
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in cancer but In a considerable number of cases there Is no bone marrow Infiltration, 
blood loss, haemolysis, renal, hepatic or endocrine disorders or nutritional deficiencies 
that could explain the anaemia (Nouwrouslan 2005). This cancer-related anaemia, has 
many haematologlcal and biochemical similarities with anaemias that occur in chronic 
inflammatory diseases, such as rheumatoid arthritis and chronic infectious diseases, 
such as tuberculosis, systemic fungal Infections and acquired Immunodeficiency 
syndrome (Nouwrouslan 2005).
Tumour-associated factors such as tumour bleeding, haemolysis, deficiency In folic acid 
and vitamin B12, can be acute or chronic. In the advanced stages of haematologlcal 
malignancies, bone marrow Involvement often leads to progressive anaemia and In 
clinical practice this causes ethical dilemmas when to stop transfusing. In addition. 
Interaction between tumour-cell populations and the Immune system can lead to the 
release of cytokines, especially Interferon-alpha, lnterleukln-1 and tumour necrosis 
factor. This disrupts endogenous erythropoietin synthesis In the kidney and suppresses 
differentiation of erythrold precursor cells In the bone marrow. As a result, patients with 
tumour anaemia may have relatively low levels of erythropoietin for the grade of anaemia 
observed (Splvak et al 2005). In most cases the anaemia Is hyporegeneratlve (slow to 
recover), normocytic and normochromic characterised by a normal or reduced serum 
Iron and transferring saturation despite a normal or elevated ferritin (form of iron; see 
glossary) level (Nouwrouslan 2005).
Recent Investigations show that the anaemia may be the result of an activation of the 
Immune and Inflammatory system and certain cytokines such as Interferon (IFNs), 
Tumour Necrosis Factor (TNF) or Interleukins (IL) could potentially be involved in Its
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development (Diagram 2.2.2). The concentrations of these cytokines are found to be 
increased in cancer patients and in other patients with chronic disease and their levels 
correlate with the degree of anaemia (Nouwrouslan 2005). In cancer related anaemia 
the red blood cell survival Is shortened to 60-90 days (normal Is 120 days) (Zucker 
1985), but the more Important factor contributing to the development of anaemia appears 
to be a relative failure of erythropolesis to compensate for this shortened survival. The 
pathogenic mechanisms postulated to be Involved In this process are Impaired Iron 
utilisation (Lee 1983, Zucker 1985), suppression and shortened survival of erythrold 
progenitor cells and Inadequate erythropoietin production.
Diagram 2.2.2: Pathophysiology of anaemia (Supplied by courtesy of Amgen with 
permission)
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Administration of erythropoietin has been shown to correct the anaemia In a proportion of 
patients and it has also been demonstrated that not only does this therapy increase 
serum levels of erythropoietin but It may also overcome the suppression of erythrold 
progenitors and Improve Iron mobilisation. Erythropoietin therapy and related literature 
will be described In more detail In the following section (section 2.3). Alternatively the 
anaemia could be corrected by administering blood transfusion and this would 
essentially increase the numbers of circulating red blood cells transiently and therefore it 
could be expected the benefits would be short-lived as the underlying causes of the 
anaemia would not be affected. It may even be that the transfusion could have a 
negative feedback mechanism and suppress the production of erythropolsis further 
thereby inhibiting the production of endogenous red blood cells.
2.2.3 Treatment effects
As stated cancer therapy can increase the Incidence and Intensity of the anaemia. The 
pathophysiological effects are multiple, but at the most simplistic level It Is a direct effect 
of the therapy on the bone marrow, resulting In temporary myelosuppresslon. Some 
agents have other effects, for example, It Is believed platinum-based chemotherapy 
regimens may diminish endogenous erythropoietin production by damaging renal tubular 
cells (Wood 1995) and myelotoxic chemotherapy can compromise erythrold precursor 
cells. As a consequence, dose-lntenslfied treatment regimens or shortened treatment 
intervals as well as multimodal therapies can Increase the degree of anaemia further 
(Groopman and Itrl 1999). For example, severe (grade 3) anaemia In elderly patients 
with haematologlcal malignancies may occur In up to 74% In patients with Non-HodgkIn 
Lymphoma after standard CHOP treatment (Groopman and Itrl 1999). In addition, some 
of the newer chemotherapeutic agents such as taxanes or vinorelblne are strongly
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myelosuppresslve and frequently cause severe anaemia (Groopman and Itrl 1999). The 
highly variable response to cancer therapy, which Is dose and therapy dependent, and 
further complicated by Individual patient factors could be a criticism of cancer related 
anaemia studies In that frequently It Is researched as a collective when In fact It Is more 
complex and unpredictable due to Individual therapy and patient responses.
2.2.4 Effects of anaemia on the tumour
An Important aspect of anaemia In patients with malignant disease is the effect of the 
anaemia on the tumour Itself. For several cancers, Including cervical carcinoma, head 
and neck, prostate, bladder and lung cancer as well as lymphoma; anaemia Is known to 
be an Independent factor associated with a worse prognosis (Caro et al 2001). Other 
studies have shown Hodgkin's disease, chronic lymphocytic leukaemia, cervical 
carcinoma and cancer of the head and neck, anaemia has been reported as an 
independent prognostic factor (Hasenclever 1998; Nowrouslan 2002). This Is partly due 
to confounding factors because advanced cancers usually present with lower 
haemoglobin levels at diagnosis compared with early-stage cancers and also have 
poorer survival outcomes. Besides this, one causal explanation might be the Improved 
oxygenation of tumour tissue at higher haemoglobin levels. Since tumour cells become 
resistant by tumour hypoxia. Improved oxygenation may prevent hypoxia maintaining 
tumour cells sensitive to radiation and most chemotherapy drugs. Early studies 
suggested that anaemia, with the consequence of Increased tumour hypoxia, might 
result In a poorer response to chemo or radiotherapy as described previously (Hockel et 
al 1993; Nordsmark et al 1996; Vaupei and Hockel 2000; Vaupel et al 2002). More 
recently, hypoxia may be more prevalent In anaemic patients than In patients with normal 
Hb levels (Vaupel and Mayer 2005) and tumour hypoxia may Impair the effectiveness of
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radiotherapy and oxygen-dependent chemotherapies (Hockel et al 1993; Schrijvers 
1999; Vaupel and Mayer 2005).
Anaemia is associated with a poor outcome In patients treated with radiotherapy, 
because anaemia results In poor tumour oxygenation and tumour hypoxia reduces 
Ionisation sensitivity (Vaupel et al 2001). Radlo-blological studies have shown that 
tumour hypoxia leads to less radiation induced cytotoxIc-free radicals resulting In less 
radlatlon-lnduced DNA damage and tumour cell kill. Tumour oxygenation Is also 
Impaired by haemoglobin levels of more than 14 g/dl In women and more than 15 g/dl In 
men which result In increased viscosity and a drop In effective perfusion (Vaupel et al
2002). It was therefore suggested to keep the haemoglobin levels during radiotherapy 
within a potentially optimal range of 12-14 g/di for women and 13-15 g/dl for men In order 
to achieve maximum tumour oxygenation (Vaupel et al 2002). These observations 
generated the hypothesis that strategies to diminish cancer-related anaemia might not 
only alleviate anaemia-related symptoms but also Improve tumour response and overall 
survival. It is unknown what the Impact of this evidence and hypothesis has in that it 
may result In a tendency to over-transfuse as the healthcare professional may feel that 
transfusion will benefit outcome. Furthermore, In the practice of clinical oncology 
(clinicians who prescribe radiotherapy and chemotherapy) It would be common practice 
to maintain higher haemoglobin levels in patients who are receiving radiotherapy. 
Medical and nursing teams may be accustomed to this practice and not be discerning of 
this when making clinical decisions, resulting In a tendency to over transfuse.
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2.3 Erythropoietin literature
The erythropoietin literature Is extensive and Is therefore Important to review to give 
Insight to the benefits and risks of maintaining a higher haemoglobin level. More recent 
literature suggests a reduction in confidence In erythropoietin therapy which may have 
an Impact on the decision to transfuse. The erythropoietin literature will be described In 
relation to the Impact of erythropoietin’s effect on the tumour and the results of the 
erythropoietin trials and the possible Impact of the literature on clinical practice, for 
example NICE guidelines.
2.3.1 Definition of erythropoietin and Impact on tumour growth
Human erythropoietin Is a 166 amino acid glycoprotein hormone and It Is the principle 
regulator of red cell production, stimulating the proliferation and differentiation of 
erythrold precursors In the bone marrow. Recombinant erythropoietin and epoletin beta 
are commercially available erythropoietins with almost Identical sequences to the native 
protein and Darbopoletin Alfa Is a synthetic form of erythropoietin with a similar action 
but Is longer acting (Minton ef a/2008).
Erythropoietin receptors have been detected In numerous cancers (Arcasoy et al 2003; 
Arcasoy et al 2005; Dagnon ef al 2005; McBroom ef al 2005; Leo ef al 2006) and It Is 
also possible that endogenously produced or exogenously administered erythropoietin 
promotes the proliferation and survival of erythropoietin receptor expressing cancer cells 
(Feldman ef al 2006; Yasuda ef al 2003; Mohyeldin ef al 2005; Henke et al 2006). 
There is an ongoing debate about the validity of those studies, because the antibodies 
used most often lacked erythropoietin receptor specificity (Elliot ef al 2006; Osterborg ef 
al 2007). Thus, the Interpretation of the observations made In many of those studies is
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questionable. Besides this, other researchers have postulated a antl-apoptotic effect of 
erythropoietins on other tissues Including neural (Brines et al 2000; Brines et al 2004) 
and cancer cells (Urn et al 2007). In addition, It has been proposed that there Is link 
between endogenous erythropoietin and anglogenesis in vivo (Hardee et al 2007] Ribatti 
et a/2007a; RIbattI et a/2007b). It has been suggested that endogenous erythropoietin 
Is needed to promote tumor anglogenesis and to maintain the viability of endothelial cells 
(Bohllus ef a/2008) This seems a logical proposal, In that erythropoietin could enhance 
tumour growth, however, the clinical Implications of these findings have not been clarified 
to date.
Correction of anaemia by the use of erythropoietin may have a positive Impact on 
treatment outcomes (Blohmer et al 2002; Grogan et al 1999; Glaser ef al 2001; 
LIttlewood ef al 2001), however, these studies have Improved Intrinsic haemoglobin 
levels by erythropoietin, not by transfusion and there has been conflicting results 
(Bohllus ef a/2006). Furthermore, It could be that If the haemoglobin Is maintained there 
may be less treatment dose reductions. More recent Investigation suggests that 
outcomes are worse following correction of anaemia (Leyland-Jones ef al 2003; Henke 
ef al 2003; Overgaard ef al 2006; Leyland-Jones ef al 2005) and It could be hypothesised 
that anaemia may be a natural response to tumour control. It is unclear the mechanisms 
Involved as these studies were using erythropoietin and It may be the endocrine function 
that Is Important as opposed to the Increase In haemoglobin that led to the worse 
outcomes.
Overall, the evidence from both in vitro and In vivo studies as well as clinical trials Is 
Insufficient to draw firm conclusions whether erythropoietins promote tumor proliferation
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or not (Bohllus et al 2008). In summary, a direct relationship between the presence of 
erythropoietin receptors on tumor cells and tumor proliferation In response to exogenous 
erythropoietins has not been established to date. The Impact of the erythropoietin data 
on blood transfusion practice has not been evaluated and although data Is not conclusive 
the Information that erythropoietins may have a negative effect on outcome may shift the 
balance from erythropoietin therapy In favour of blood transfusion once more.
2.3.2 Erythropoietin therapy trials
Randomized placebo-controlled studies have shown that treatment with erythropoietin 
raises haemoglobin levels, reduces transfusion needs and improves quality of life In 
anaemic patients with cancer (Boogaerts et al 2003; Osterborg et al 2002), however, 
erythropoietin responses In patients with cancer related anaemia appears to differ 
considerably depending on the type of underlying malignancy (Jacobs et al 1989; Ludwig 
and Fritz 1998; Miller et al 1990; Nowrouslan 2005). Studies have shown that as 
haemoglobin Increased with erythropoeltin therapy, functional capacity parameters 
Improved significantly and It Is Important to note that where there was no Increase In 
haemoglobin there was no Improvement In energy level, activity level and overall quality 
of life (Demetri et al 1998; Glaspy et al 1997; LIttlewood et al 2001). For the average 
Increase In haemoglobin (2g/dl), there was a statistically and clinically significant 
Improvement In each quality of life parameter (LIttlewood ef a/2001). An equivalent rise 
In haemoglobin can be achieved by a two-unit blood transfusion but It may be that 
Increasing intrinsic haemoglobin via erythropoietin therapy may have more functional 
benefits, than by Increasing haemoglobin via allogeneic blood, particularly as the effects 
of transfusion are probably transient and difficult to sustain longer term (Osterborg et al 
1998). This would make erythropoietin therapy the preferable treatment for anaemia.
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Furthermore, a more recent Cochrane review showed that there was only a small but 
significant improvement in cancer related fatigue In chemotherapy patients receiving 
erythropoietin or darbopoletin (Minton et al 2008).
Early erythropoietin therapy trials showed a trend towards Improved survival In patients 
treated with erythropoietin (Antonadou ef a/2001; LIttlewood ef a/2001; Vansteenklste ef 
al 2002). However more recent published trials have raised the concern regarding the 
impact of erythropoietin agents on survival In oncology and hematology patients and 
these have reported Increased mortality in patients treated with erythropoietins (Henke ef 
al 2003; Leyland-Jones ef al 2003; Overgaard ef al 2006; Wright ef al 2007). Three 
clinical studies reported Increased tumor progression or death due to tumor progression 
In patients receiving erythropoietin (Henke ef al 2003; Leyland-Jones ef al 2003; 
Leyland-Jones ef al 2005; Overgaard ef al 2006). The Henke ef al (2003) and Leyland- 
Jones ef al (2003) studies had survival as a primary endpoint, although the robustness of 
these data has been questioned because of the methodological limitations of these 
studies (Aapro ef al 2004); this meta-analysis of nine randomized controlled trials 
examining the effects of erythropoietin on tumour progression and survival in cancer 
patients. They concluded that treatment with erythropoietin has no impact on survival In 
anaemic patients but may be associated with a reduced risk of tumour progression 
(Aapro ef al 2004), however, this has since been shown to not be the case in more 
recent studies as described above. The conflicting evidence was summarized In a 
recent Cochrane review assessing the effects of erythropoietin (erythropoietin or 
darbopoletin) to either prevent or treat anaemia In cancer patients (Bohllus et al 2006). 
This was a systematic review of 57 trials with 9353 patients. Not surprisingly, the use of 
erythropoietin significantly reduced the relative risk of red blood cell transfusions (RR
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0.64: 95% Cl 0.60-0.68, 42 trials, n=6510). On average participants In the erythropoietin 
group received one unit of blood less than the control group. There was suggestive 
evidence that erythropoietin may improve the quality of life but the relative risk for 
Thrombo-Embollc Events (VTE’s) was Increased In patients receiving erythropoietin 
compared to the control group (RR1.67, 95% Cl 1.35 to 2.06; 35 trials, n= 6796). 
Studies have Implicated the tumor-mediated activation of the haemostatic system In both 
the formation of tumour stroma and In tumor metastasis hence the tendency for VTE’s In 
some patients, (Francis et al 7998; Levine et al 2003), however It appears that 
erythropoietin therapy can Increase this risk further.
The Bohllus et al (2006) Cochrane Review also concluded that uncertainties remain on 
how erythropoietin affects tumour response or overall survival as described earlier. In 
summary, the evidence In favour for and against erythropoietin has alternated as data 
has emerged over the years. Although erythropoietin therapy Is not currently 
recommended for use In the NHS by NICE (with the exception of ovarian cancer) the 
evidence for and against for erythropoeltin and has received significant Interest by 
clinicians as overall It has appeared to Improve quality of life. This Is now balanced 
against significant risks but even the Improvements In quality of life have to be reviewed 
with caution as allogenic blood transfusion Is unlikely to have the same beneficial effects 
as Intrinsic blood.
2.3.3 Impact of the erythropoietin literature
As mentioned, the research of management of cancer related anaemia has been 
dominated by the erythropoietin studies In recent years. Personal experience 
demonstrated clinicians’ frustrations when erythropoietin was not approved by NICE and
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many use erythropoietin for their private patients In preference over blood transfusion, 
probably because the pharmaceutical support of the multiple erythropoietin studies. It is 
not clear what the Impact of this has been and how much this has Influenced practice. In 
contrast there has been a dearth of research In the use of transfusion for the 
management of cancer related anaemia, perhaps because of the Initial hopes that 
erythropoietin would solve this clinical problem. Blood transfusion Is a costly treatment 
and yet Is not subject to the same scrutiny as erythropoietin and the reasons for this are 
not clear.
Over the years the nature of clinical research funding has undergone a dramatic change, 
shifting away from public funding and resulting In the pharmaceutical Industry being the 
largest sponsor of medical based research (Freemantle et al 2005). Although this has 
beneficial effects and has provided the needed support for research, resulting in medical 
advances this has also caused concern over conflicts of Interest (Bodenhelmer 2000). 
Furthermore, several studies and systematic reviews have shown an association 
between industry sponsorship and pro-lndustry conclusions (Bekelman et al 2003; 
Kjaegard and Als-Nlelson 2002). The conflicting results In the randomized controlled 
trials (RCTs) of erythropoietin use may be an example of the powerful Influences and 
conflicts of Interests Involved In pharmaceutical sponsored studies and from a personal 
perspective have been Influential in the researcher’s scrutiny of RCT’s. In summary, 
there are probably many reasons for the conflicting results In the erythropoietin studies, 
for example, there may be biased Interpretation of results or selective reporting; for 
example many are reporting Improved survival however, these studies were not 
designed to evaluate survival and therefore may not have been powered sufficiently to 
make such conclusions.
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2.3.4 Summary of erythropoietin literature
In conclusion, a few points should be considered before accepting the hypothesis that 
the role of erythropoietin in cancer is already defined. Biological pre-cllnlcal studies have 
Identified at least two opposite actions of erythropoietin on cancer cells, one favoring the 
growth and the other enhancing the cell’s sensitivity to treatment. The proof that patients 
benefit from correction of mild or moderate anaemia Is not definitive. It may be that 
translational research projects may be the most appropriate type of study before any 
further clinical trials are developed (Apolone 2004). Furthermore, the two patient groups 
In which adverse events were demonstrated were head and neck cancers (Henke et al
2003) and breast cancer (Leyland-Jones et al 2003) and It may be more basic science 
Investigations have to be undertaken In different tumour types to assess the effects of 
erythropoietin on different tissues. This demonstrates the problem whereby In a 
proportion of the studies cancer patients tend to be grouped In studies of cancer-related 
anaemia as a homogenous group. It may be Improving the haemoglobin by either 
erythropoietin or transfusion may be of more benefit In some tumour types and not 
others and In fact may be detrimental In some tumour types If tumour hypoxia Is the 
means by which tumour growth Is reduced or the presence/lack of erythropoietin 
receptors Is significant. A further consequence of the large volume of erythropoietin 
studies may be that although not transferable to transfusion practice, they may Influence 
clinician perceptions about Increasing the haemoglobin. Furthermore, even If 
erythropoietin may result In an Improvement In fatigue and other quality of life 
parameters It may not offset the risk to outcome. Patients’ perceptions of the 
management of their anaemia have not been explored In a qualitative study previously, 
either In transfusion or erythropoietin studies.
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2.4 The impact of anaemia on symptoms and Quality of Life (QoL)
The clinical manifestation and severity of anaemia can vary considerably among 
Individual patients. Moderate to severe anaemia can cause signs and symptoms such 
as headache, palpitations, tachycardia and shortness of breath. Fatigue, depression and 
Impaired cognitive function account for most of the symptoms that diminish quality of life 
as a result of anaemia (Maxwell 1984; Pecorelll 2000; WInnlngham et a /1994). Chronic 
anaemia can result In severe organ damage affecting the cardiovascular system, 
Immune system, lungs, kidneys and the central nervous system (Ludwig and Strasser
2001). This section will describe the literature relating to the symptoms of anaemia and 
Its relationship with fatigue, followed by a summary of the impact of anaemia on the 
patient.
2.4.1 The symptoms of anaemia
In addition to physical symptoms, the subjective Impact of cancer-related anaemia on 
quality of life, mental health and social activities may be substantial but there may be an 
assumption that all of these are the direct Impact of the anaemia. However, one could 
argue that a cancer diagnosis and consequences of treatment would have the same 
Impact without the presence of anaemia. There Is evidence this Is not the case as 
clinical studies have reported correlations between haemoglobin levels and quality of life 
(Celia 1997; Holzner et al 2002; Lind et al 2002). One of the common anaemia-related 
problems is fatigue, which Impairs the patient’s ability to perform normal dally activities 
(Ludwig and Strasser 2001; Vogelzang et a /1997), but again, It could be argued fatigue, 
occurs independently of anaemia and persists long after the anaemia has resolved, 
although It can worsen with anaemia.
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Anaemia in cancer Is associated with debilitating symptoms and poorer health-related 
quality of life (Smith and Tchekmedylan 2001; Tchekmedylan 2002). Severe symptoms 
may also result In dose reductions or delays of chemotherapy; a combination of these 
factors may lead to higher tumour burden and a decreased overall survival (Glaser et al 
2001; Grau and Overgaard 2000; Knocke et al 1999). More recent evidence of these 
factors Is described In the previous section. As mentioned previously, these 
observations generated the hypothesis that strategies to diminish cancer-related 
anaemia may alleviate fatigue and Improve quality of life. When faced with a patient 
with fatigue and other debilitating symptoms It is not clear If clinicians and nurses 
respond to these somewhat subjective symptoms or If their decision making Is based on 
a response to the haemoglobin level. This will be explored further In the section on 
clinical decision making (Section 2.7).
2.4.2 Anaemia and fatigue
Anaemia and Its relationship to fatigue warrants further exploration because It has been 
demonstrated anaemia Is associated with greater fatigue (Ahlberg et al 2003; Glaus 
1998; Stone et al 2000a). Cancer-related fatigue Is described as an abstract, 
multidimensional subjective experience, affecting 70 to 100% of the cancer patient 
population (Mock 2001). It has a profound effect on the whole person, physically, 
emotionally and mentally (Ahlberg et al 2003), and can persist for months or even years 
following completion of treatment. If fatigue Is chronic It Implies that transfusion may not 
be the Ideal therapy as It only has transitory effect. Fatigue can have a phenomenal 
Impact on a patient's life. Interfering with dally activities (Curt et al 2000) and also may 
potentially have devastating social and economic consequences (Fietchner and Bottomly
2002). Fatigue can hinder a patient's chance of remission or even cure, owing to the
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effect it can have on the desire to continue with treatment (Morrow et al 2001). Indeed, 
fatigue is frequently reported to be the most bothersome symptom to the patient with 
cancer and is certainly a major quality of life issue (Bruera et a! 1989; Celia 1997; 1998; 
Littlewood efa/2001; Mo rant 1996; Portenoy and Itri 1999; Sobrero efa/2001; Yellen et 
a /1997).
The reported prevalence of fatigue among cancer patients varies between 60-100% 
(Groopman and Itri 2000; Irvine et a /1994). The Stone et al study (2000) compared four 
groups of patients recently diagnosed with breast, prostate or inoperable non-small cell 
lung cancer or receiving inpatient palliative care, the two latter groups had a higher 
degree of fatigue than did the former two groups, suggesting factors other than anaemia 
are important. A significant correlation between disease burden and fatigue was also 
noted. Furthermore in a study of elderly patients with a new diagnosis of cancer (early 
vs. late stage), late stage was associated with greater fatigue and pain (Given et a!
2001). Thus overall the results of these studies support the notion that tumour stage Is 
associated with degree of fatigue but not necessarily with anaemia because of the large 
differences In incidence. In summary, fatigue may be a reflection of tumour bulk and 
disease progression and can be difficult to separate from symptoms of anaemia.
In addition, many patients who are not anaemic also report high levels of fatigue (Wang 
et a! 2001) and there are many studies that report fatigue increases during radiotherapy 
(Hickok et a! 1999; Janda et a! 2000) and chemotherapy (Groopman and Itri 1999; 
Littlewood et al 2001; Richardson et al 1998) and long after therapy Is complete (Wang 
et al 2001). The worsening fatigue scores as chemotherapy progressed were in the 
presence of stable haemoglobin scores in a phase HI erythropoietin study (Littlewood et
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al 2001 ) suggesting that the chemotherapeutic effects were a stronger influence in the 
development of fatigue.
Cancer related fatigue is multifactorial with physical and psychological components 
(Ream and Richardson 1996) and the aetiology is not well understood (Celia et a /1997; 
Yellen et al 1997). Due to the complex nature of fatigue there is an ongoing debate on 
how to measure fatigue (Celia et al 1997; Groopman and Itri 2000). Most importantly, 
fatigue appears to be a symptom underestimated by oncologists. In a survey designed 
to characterize the epidemiology of cancer related fatigue from the patients’, oncologists’ 
and caregivers’ perspective, 61% of the patients reported fatigue affected their daily life 
more than pain (Vogelzang et al 1997). Conversely, 37% of the oncologists reported 
that fatigue was a more prominent problem than pain, it may be further study is 
warranted because for some tumour types, for example, lymphoma and leukaemia, pain 
is generally not an Issue. The assessment of fatigue would be an integral component of 
assessment of anaemia but other contributing factors such as disease stage and/or 
therapy should be considered and it is not clear if this is taken Into account when making 
the decision to treat the anaemia.
Several studies have examined the impact of fatigue on daytime functioning, daytime 
sleepiness and altered circadian rhythms in the haematology population. Fatigue has 
been associated with sleep disturbances in patients with the following haematological 
malignancies; leukaemia, lymphoma and multiple myeloma (Lee et al 2004). Wang and 
colleagues (2002) studied a convenience sample of 246 patients with leukaemia or 
lymphoma. Single item scales were used to rate symptom severity from 0-10 and the 
most common complaint was “waking up during the night” (77%) followed by “not feeling
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rested” (60%) and “waking up too early” (59%). Fatigue was related to sleep 
disturbances, pain, opioid use and gastrointestinal symptoms. Analysis of anaemia was 
not included in this study. Most interesting was the finding that fatigue was related to 
changes in sleep patterns rather than duration of the night's sleep; a finding that 
supports prior studies of persons with other types of cancer before, during and after 
radiation therapy (Smets et a/ 1998a; Smets et al 1998b). Bishop (2004) demonstrated 
increasing sleep disturbance and declining activity on an actigraph of a patient who was 
dying; this was progressive and independent of anaemia. Berger et al (2007) 
demonstrated sleep maintenance problems that contributed to fatigue prior to 
chemotherapy and moderate to severe fatigue after chemotherapy in 130 breast cancer 
patients using actigraphy. Andrykowski et al (1997) followed a heterogeneous 
population of 138 adults for 18 months post-transplant and found that fatigue and sleep 
problems did not greatly diminish over time. This is suggestive that disease status, 
treatment effects and sleep disturbance may be a more powerful influence on fatigue 
than anaemia; although blood laboratory values are not described in this latter study, it 
would be expected that blood counts would have normalized 18 months post therapy.
At the clinical level, however it appears the relationship between fatigue and anaemia is 
universally accepted and the majority of patients with a malignancy experience anaemia 
at some stage throughout the course of treatment or as a consequence of the disease 
itself (Sadler et al 2002). Although this relationship Is accepted it is often not until 
haemoglobin levels are considerably low before fatigue becomes an issue because the 
body adapts to the lower concentration of haemoglobin and it may not be until the 
anaemia becomes severe that it impacts on fatigue. In fact, some studies failed to find 
any correlation between anaemia and fatigue (Bruera et al 1989) or poor association
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only (Morant 1996). But because anaemia is one of the few contributing factors, which 
can be controlled by healthcare professionals it can become the main focus of concern 
and therefore it could be hypothesized that this would contribute to a tendency to over­
transfuse. The Bruera study was of patients with advanced breast cancer and it may be 
other factors were more significant in this population; as described earlier. Although 
anaemia is involved in the pathogenesis of cancer-related fatigue perhaps Its importance 
should not be overestimated. For example, a study of the correlates of fatigue amongst 
227 assorted cancer patients an 98 controls revealed that although there was as 
significant association between fatigue severity and haematocrit the magnitude of the 
correlation was quite weak (R= -0.22, p<0.05, Stone et al 2000a). Equally weak 
correlations have been found between haematocrit and quality of life (Crawford et al
2002) and in another study of a mixed cancer population it was reported that anaemia 
could explain only 8% of the variation of fatigue scores (Lind et al 2002). In view of 
these studies perhaps anaemia may be a modest contributor to fatigue and a different 
approach to assessment is required to establish the impact of anaemia.
2.4.3 Summary of impact of anaemia
In summary, the presence of cancer-related anaemia probably decreases patients’ 
quality of life, and may impact on fatigue (Demetri 2001; Glaspy 2001; Ludwig and 
Strasser 2001) and is associated with shorter survival times in some cancer patients 
(Caro et al 2001). It is difficult to separate the anaemia related fatigue and quality of 
life factors from cancer-related fatigue and the impact the cancer has on the quality of 
life, and this may explain in part why some of the studies have failed to show a 
correlation between anaemia (or haematocrit) and fatigue. This has implications for the 
assessment of anaemia which will be discussed in the following section. It would be
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useful to replicate some of the erythropoietin studies to determine if using blood 
transfusion to increase the haemoglobin level to 12g/dl makes an impact in quality of life 
and function, however, the ethics Involved would be difficult to resolve, for example to 
justify exposing patients to additional transfusion,
2.5 Assessment of cancer-related anaemia
It is reported that in order to establish the impact of anaemia, clinical evaluation should 
include history taking, physical examination and laboratory testing (Loney and 
Chernecky 2000; Smith and Tchekmedyian 2002); however, the significance of anaemia 
and fatigue to the patient are often overlooked in routine assessments and optimal 
methods for assessing and treating this remain unclear (Gillespie 2002). One of the 
contributing factors in this variation of assessment of anaemia could be that it is 
dependent on the patient's symptoms, however there is wide variation in the 
presentation of anaemia, and the clinical symptoms do not always correlate with 
haemoglobin concentration. It is not clear what the actual practice of assessment is 
within the clinical setting and although laboratory evidence is recommended it may be 
that this is not available at the time of consultation in some settings. It is also not clear 
who makes the final decisions or what the patients' involvement is in the decision making 
process. In summary, the manifestation and severity of anaemia vary considerably 
among individual patients and the patient -  healthcare professional interactions and 
processes are not known which culminate in the final decision to treat with blood 
transfusion. There appears to be a lack of literature available exploring this process in 
depth, therefore the literature will be described in relation to assessment, the patients’ 
assessments and the context of the assessment.
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2.5.1 Assessing the impact of anaemia
it was demonstrated in section 2.2.1 the haemoglobin level is used to define anaemia 
and the degree of anaemia (mild, moderate, severe and life threatening). Many patients 
with chronic anaemia are apparently asymptomatic with a haemoglobin concentration of 
8g/dl but when patients’ symptoms have been formally evaluated using functional 
assessment, those with haemoglobin concentrations of 12g/dl reported less fatigue and 
a better quality of life (Celia 1997). However, chemotherapy and radiotherapy may 
confound the situation and the impact of anaemia in cancer patients may not be as 
clearly defined as this; for example, some chemotherapy regimens are known to Induce 
more fatigue as described in section 2.2.3. Some would argue that if symptoms are 
searched for properly, they are present when the haemoglobin levels are less than 
12g/dl (Smith and Tchekmedyian 2002), others would argue it is not until the levels are 
much lower and treatment is not indicated until the level falls below 8g/dl (Hill ef a/2002). 
However it may not be this simple; it may be that symptoms of disease and side effects 
of therapy mimic the symptoms of anaemia and the Hill et al (2002) was a study of non­
cancer patients. The level of haemoglobin at which the patient becomes symptomatic 
varies between individuals and reports in the literature are not consistent, therefore it 
may be that haemoglobin level is not a good indicator of the impact of the anaemia and 
therefore should not be the main influence in deciding to treat the anaemia, until low 
levels are reached or predicted, i.e. severe anaemia.
Identification of risk groups may also be important. The patients who are most at risk are 
those who present with anaemia at the point of diagnosis as well as those who are 
scheduled to receive platinum containing regimens (Bokemeyer 2005). Co-morbid 
conditions such as nutritional deficiencies and Infection require identification and risk
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factors and treatment history have also been identified (Gillespie 2003). For example 
cachexia has been identified as a cause of fatigue (Ahlberg et al 2003; Inui 1999; 
Kuzrock 2001) and may be induced by loss of nutrients as a result of anorexia, nausea 
and vomiting or hypermetabolism. The age of the patient, that is, older patients, and 
those who have a degree of cardiovascular or respiratory compromise may be more at 
risk of being unable to tolerate anaemia and the prevalence of both cancer and anaemia 
increases with age (Balducci 2007)
Although it has been demonstrated that cancer anaemia can lead to tissue hypoxia and 
can impact on virtually all organs of the body (Bokemeyer 2005; Ludwig and Strasser 
2001) it is likely the awareness of the impact of anaemia (like fatigue) remains 
inconsistent among healthcare-providers and patients or it may be that in actual practice, 
these consequences of anaemia are not measurable or evident. The main reported 
clinical manifestations include fatigue, exertional dyspnoea, palpitations, dizziness, 
vertigo, depression, impaired cognitive function, nausea, anorexia, sleeping disorders 
and loss of libido (Foubert and Wujcik 2005; Ludwig and Fritz 1998). It could be argued 
that many of these symptoms could be directly attributed to the cancer and/or therapy, 
and do not occur until the anemia is severe. Of these signs and symptoms, fatigue is the 
most commonly reported symptom of cancer-related anaemia (Glaspy ef al 1997) and 
symptom of cancer and cancer treatment with prevalence estimates ranging from 60- 
96% (Vogelzang et a /1997). In clinical practice it is likely that It Is the mild (10g/dl-WNL) 
to moderate (8.0-10.Og/dl) anaemia which are therefore the most difficult to assess and 
the treatment decisions more variable. It could be argued that a more discerning 
assessment should be applied for this group of patients; or the patients themselves are 
involved in the decision making as they may be more likely to gauge the impact of the
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anaemia. To a lesser degree it may be that patients with severe anaemia (6.5-7.9g/dl) 
may tolerate low levels of haemoglobin depending on other factors such as age, speed 
of onset and the presence of cardiovascular disease, but this is not always predictable. 
Patients with more life-threatening anaemia (<6.5g/dl) would likely require blood 
transfusion as a life saving intervention in order to stabilize the cardiovascular and 
respiratory symptoms and unless for terminal care this decision Is usually more easily 
defined. In summary, the assessment of the anaemia is inextricably linked to balancing 
the risks and benefits of blood transfusion and the clinical decision to treat the anaemia; 
this will be incorporated Into the following sections.
2.5.2 The patients’ assessment
Patients’ subjective perceptions of how recent symptoms or changes have affected their 
lifestyle are important, especially as anaemia may present with gradual or vague 
complaints (Loney and Chernecky 2000). Changes in a patient’s ability to carry out daily 
activities, to perform family and work roles and social activities can profoundly affect their 
quality of life, and these could potentially be assessed in the clinical setting. Many 
quality of life assessment tools are available but many can be burdensome for patients to 
complete (Foubert and Wujcik 2005). Of the many measures available only one is 
designed specifically for cancer anaemic patients, the Functional Assessment of Cancer 
Therapy-Anaemia (Appendix 1) or FACT-An (Celia 1997). The FACT-An subscale 
comprises the FACT-F subscale incorporating the FACT-General questionnaire (27 
questions on four QOL dimensions: physical, functional, emotional and social well being) 
with 13 additional fatigue-specific items and seven non-fatigue items (Celia 1997). The 
FACT-F subscale used alone or as part of the FACT-An questionnaire is a brief, 
validated and reliable assessment. These subscales successfully demonstrated an
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association between fatigue and anaemia in a large survey of cancer patients in a 
community setting (Celia 1998). For this reason, FACT-An has been widely used in the 
anaemia literature examining quality of life. However, Oliva et al (2002) questioned the 
reliability and internal validity of FACT-An. They studied quality of life in 17 adult patients 
with anaemia secondary to myelodysplastic syndrome (MDS). Only the physical, 
functional and fatigue components of the questionnaire showed acceptable levels of 
internal consistency (Cornbach’s standardized reliability coefficient alpha of 0.74, 0.9 and 
0.83 respectively). Most importantly, the seven-item non-fatigue component of the 
anaemia subscale was not reliable in this group (alpha-0.57). It could be related to the 
fact this group of patients may not have undergone any chemotherapy for their MDS; 
however this was not clear in the paper. Olivo et al (2002) suggest the reported 
relationship between haemoglobin and quality of life may have stemmed from a change 
in transfusion use. This is also justified because the supportive care of transfusion itself 
acts on the self-perception of well being in a multi-dimensional context (e.g. 
understanding of the severity of anaemia, frequent day care admissions, an association 
with a worsening prognosis or fear of transfusion adverse events) and in such patients it 
may actually introduce confounding answers to each of the quality of life measurements. 
In other words it is possible that patients who reported increased quality of life simply 
because they received fewer, if any, transfusions.
Gabrilove et al (2001), in response to this criticism of the FACT-An, did a muitivariate 
analysis comparing haemoglobin, QOL and visits to the hospital that resulted in either no 
transfusion or transfusion. Patients overall QOL scores during each visit were regressed 
with age, sex and haemoglobin as covariates. If transfusion was the mechanism through 
which haemoglobin affected QOL it should have been observed that a significant and
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large coefficient on the haemoglobin variable among patients who received transfusion 
and a small and insignificant coefficient among patients who did not receive transfusion. 
However, this was not the case; the coefficients on the haemoglobin variables were 
similar in size and not statistically significantly different from each other. Similar results 
were observed for the activity and energy quality of life parameters. This suggests that 
either the FACT-An may not be a reliable and valid tool or more importantly suggests the 
minimal impact of transfusion on the quality of life parameters.
2.5.3 The context of the assessment
It is recommended in the literature that a full comprehensive assessment is important, 
however, the clinical context may be an important factor, as discussed more 
comprehensively later in section 2.7. In the clinical setting where time may be limited, 
Portenoy and Itri (1999) recommend asking three simple questions to assess the impact 
of fatigue severity over time, which includes asking the patient to rate their fatigue on a 
scale of one to ten and if it interferes with their ability to function. Changes over time are 
important because it has been demonstrated that symptoms can fluctuate during the 
course of chemotherapy (Richardson et al 1998). Payne (2002) indicated that fatigue 
fluctuated during the course for chemotherapy and continued after treatment ended. 
There have been similar findings in radiotherapy studies (Magnan and Mood 2003). The 
negative consequences of over-simplifying the clinical problem by asking questions only 
about fatigue may result in over-transfusion, because as described earlier the presence 
of anaemia is not the only factor resulting in fatigue. Other clinical contributing factors 
are relevant, for example, the stage of disease and where the patient is on their 
treatment pathway.
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In summary, it has been suggested in the literature that a thorough assessment of 
anaemia should include laboratory parameters, physical symptoms and quality of life 
parameters (Foubert and Wujcik 2005) in addition to consideration where the patient is in 
their disease and treatment trajectory, but the reality may not reflect this. A number of 
assessment tools are available for the assessment of cancer-related anaemia but a 
number of these multi-dimensional tools are time consuming and burdensome for the 
patient to complete. In addition, there has been conflicting evidence of their reliability 
and validity. It may be that patient-clinician interaction should form the basis of the 
decision to treat, as long as the clinician has the appropriate skills and knowledge on 
which to base the decision. Time and resources are generally limited in busy oncology 
clinics and the patient-healthcare professional interaction may be the only activity, which 
will reliably continue. It could be suggested that current clinical practice may require a 
quick and easy to use, evidence based screening tool that can be properly evaluated 
and incorporated into the patient-healthcare professional consultation, however, It is 
unlikely such a tool could be developed, because of the variable and subjective nature of 
the impact of cancer related anaemia, therefore the focus should perhaps shift to the 
quality of patient-clinician interaction and relationship, the skills and knowledge of the 
workforce and changes in systems and behaviors. This has not been previously 
explored in anaemia research.
2.6 Risks and benefits of blood transfusion
Blood transfusion is the standard approach to the correction of anaemia, but caries 
significant risks including transfusion reactions, serious infections, iron overload and 
reduced immuno-competence (Littlewood efa/  2001). Donor selection is becoming 
more stringent therefore should a real shortage of donors develop, patients receiving
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blood for less certain indications, such as mild or moderate cancer related anaemia may 
be the first to be rationed. However, more importantly, any unnecessary risks to patients 
should be avoided, particularly if there is little proven benefit. Alternatively, if some 
patients benefit from blood transfusion then it is equally important that these patients 
should not be rationed. The level at which the benefits of blood transfusion outweigh the 
risks is a matter of continued debate and uncertainty which warranted exploration of the 
current literature review.
If a patient has no obvious symptoms of anaemia he/she is usually transfused when their 
haemoglobin is less than 8.0g/dl. This is a “pragmatic” guideline suggested by the 
British Society of Haematology (BCSH 2001); however, as stated previously, the BSCH 
state that randomised controlled trials for evidence-based guidelines for the transfusion 
of blood have yet to be undertaken (BCSH 2001). In addition, there is considerable 
variation in transfusion practice between different countries and even within different 
departments, (Foubert and Wujcik 2005) in spite of the presence of clinical guidelines 
(Barrett-Lee et al 2000). The NHS transfusion guidelines recommend that if the 
haemoglobin is between 7-10g/dl the decision to transfuse should be based on the 
clinical condition of the patient (NHS Executive 2006) and this may account for some of 
the variation In practice. Blood transfusion guidelines and mandatory transfusion 
education are available in all hospital settings, but optimal transfusion practices may not 
exist and the reasons for this are complex. Healthcare professionals may weigh the 
levels of evidence and symptoms differently, for example, and patients may be 
transfused on the basis of laboratory values rather than full assessment of the impact of 
cancer-related anaemia balanced against the risks of transfusion. This decision to treat 
may be related to their levels of skills and knowledge regarding the assessment of
60
cancer-related anaemia and transfusion practice; or it may be influenced by the 
availability of resources or patient pressure. Ritualistic practices may exist for example, 
a national audit revealed 88% of transfusions were two-unit transfusions (Barrett-Lee et 
al 2000), which suggests the treatment is not tailored to the individual.
This section will explore the literature in relation to the risks and costs of blood 
transfusion, studies that have examined the effects of different transfusion thresholds 
and the benefits of transfusion.
2.6.1 The risks and cost of blood transfusion
As stated previously, new pathogens, such as vCJD, may result in the shrinking of the 
donor pool and If the supply reduces further, it may result in more scarce resources (i.e. 
blood components) having to be used more carefully (Thomas 2005). Costs are 
escalating as collection, testing, processing and administration and safety systems 
become more complex in preparing the final blood transfusion component (Varney and 
Guest 2003); the NHS cost for an adult transfusion is estimated at £185 but estimated to 
be £635 for red blood cells, when hospital stay, management of complications and cost 
to society were included (Varney and Guest 2003). Using this cost as a guide within 
cancer care this equates to approximately £320 million per annum spend on blood 
transfusion within the UK. Drug costs are subject to scrutiny in healthcare settings yet it 
is unclear if cost is a consideration when deciding to treat anaemia with blood 
transfusion.
Potential complications associated with blood transfusion are transmission of infectious 
diseases, transfusion reactions and allo-immunisation, over transfusion and immune
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modulation with possible adverse effects on tumour growth (Landers 1996). Other 
complications such as allergic reactions and death due to major incompatibilities are also 
of concern. The risks of transfusion-related transmissions are 1:180,000 per units of 
blood transfused for hepatitis B virus, 1:1,600,000 for hepatitis C virus and 1:1,900,000 
for HiV in the US (Goodnough 2003). The development of intensified anti-cancer 
therapies has increased the risk of blood transfusion (Bohlius et al 2006) and the use of 
growth factors such as GGSF (Granulocyte Colony Stimulating Factor) means that dose 
reductions due to neutropenia can be avoided because red cells and platelets can be 
supported with transfusion. Moreover, with improved survival and the use of more 
intensive chemotherapy regimes, the requirement for blood transfusions has increased 
while the donor supply has diminished (Williamson ef a /1999).
Historically, there has been a fascination with blood (Thomas 2005), and a number of 
beliefs about the nature and function of blood have been described In Helman (1990); for 
example it provides lay theories about a variety of illnesses including “thin blood” causing 
anaemia (p26). Helman describes how the clinician should be aware of the “possible 
hidden symbolism in any lay conceptualizations about blood’ (p26); in today's western 
world it is associated with transmission of infection and it is not clear what the impact of 
this is. Conversely blood transfusion may historically be perceived as life saving as it is 
a well established therapy, for example it was in 1946 that the National Blood 
Transfusion Service was founded and blood was routinely used as a life saving therapy. 
These represent opposing views; firstly that blood may cause harm in the form of a 
transfusion transmitted infection and secondly it may be life saving. It Is not clear how 
individual clinicians and patients perceive the risks balanced against the benefit.
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Unlike many other countries, the donation of blood in the UK is entirely voluntary and for 
this reason it may be viewed as an inexpensive resource. Furthermore, because of the 
historical use of blood it may also be seen as a natural product, a good product that 
saves lives, and it may be that many healthcare professionals are unaware of the 
amount of processing that the final product has been subjected to, and the real cost of 
blood transfusion.
It is only In more recent years that blood transfusion has been recognised as carrying 
significant risk. For example, the advent of Serious Hazards of Transfusion (SHOT) 
reporting and mandatory training highlight the risks; however, neither of these systems 
emphasise the need to avoid the transfusion in the first instance. In addition, the 
transference of life threatening viruses, such as HIV and more recently vCJD, via 
transfusion has also increased the awareness that transfusion is not without risk and 
perhaps patients, clinicians and nurses are more reluctant to want to transfuse because 
of this. Since the high profile infection risks, the price of blood transfusion has risen and 
new regulations have been Introduced. Actions against negligence and consumer 
protection iegislation have led to implementation of further safety initiatives such as 
mandatory training. Furthermore the number of people willing to donate is declining and 
is compounded by increasingly strict donor eligibility criteria (Ferriman 1998; Simon 
2003; Sullivan et al 2007). This could all result in a tendency to under-transfuse to 
minimise risk and exposure to unknown pathogens. Patients and the public may 
perceive transfusion as a risky medical procedure (Lowe and Ferguson 2003) and not 
surprisingly, there is a negative association between perceived risk and acceptability 
(Ferguson et al 2005). Conversely Ferguson et al (2005) demonstrated in a 
questionnaire survey of the general public that blood substitutes are also perceived as
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risky and in fact have more risks than donor blood which implies that patients still 
perceive blood to be a relatively safe product. It is not known how cancer patients 
perceive blood transfusion and if they perceive it Is essential or if they believe there are 
alternatives to transfusion. Lee (2006) describes how surveys of lay people over the last 
decade indicate that public concern about transfusion safety has remained prevalent, 
dominated by the fear of contracting HIV, It may be that patients do not offer a true 
reflection of symptoms in an effort to avoid transfusion or believe blood transfusion is 
desirable in an effort to reduce symptoms, especially fatigue.
2.6.2 Transfusion thresholds
Transfusion thresholds (or triggers) have reduced over the years with the drive to 
conserve blood and reduce costs. This has been successful in some clinical areas for 
example the use of per-operative blood transfusion. There has been little evidence to 
support the growing trend for the conservative approach in the management of anaemia 
however there have been some studies in the acute setting. A pilot study of 84 patients 
with hip fractures used physical activity as a measure of the adequacy of post-operative 
haemoglobin concentration (Carson et al 1998). No difference was found between 
patients who received transfusions to maintain the haemoglobin above lOg/dl and 
patients who received transfusions when they were symptomatic or when their 
haemoglobin concentration feii below 8g/dl. However, it is difficult to transfer these 
findings to a cancer population for several reasons because the pathophysiology of 
cancer-related anaemia is more complex and the treatment may require more than 
simple replacement. The erythropoiesis in this surgical cohort would be normal 
therefore the body’s natural replacement of red cells would be normal. Furthermore, the 
study was on carried out whilst these patients were inpatients where activity is limited,
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whilst the oncology outpatient population are attempting to have a “normal” life and 
undertake some activities of living.
The Carson study was one of the ten randomized controlled trials summarized in a 
Cochrane review of studies examining transfusion thresholds and the effects on clinical 
outcomes (Hill et a! 2002). All of the studies examined surgical, trauma or intensive care 
patients and no study had been carried out during the outpatient period. Johnson et al 
(1992) found no difference in exercise endurance in liberally transfused Coronary Artery 
Bypass Graft (CABG) patients and in those who had been conservatively managed. 
Bracey et al (1999) applied a self-assessment tool to determine if similar patients who 
followed a restrictive transfusion protocol, felt fatigued and therefore were less willing to 
undergo rehabilitation; they found no difference in vigor in these patients compared with 
those who followed a liberal transfusion protocol. The review concluded that the limited 
published evidence supports the use of restrictive transfusion triggers in patients who are 
free of cardiac disease; however, they recommended that future trials should be carried 
out to discover the effects of conservative transfusion triggers on functional status. They 
concluded that the trials were of poor quality but also recommended research should be 
carried out in different patient populations.
2.6.3 Benefits of transfusion
The management of anaemia in cancer is frequently aimed at improving fatigue levels 
and this could technically be described as a main benefit of the transfusion. Despite the 
prevalence and impact of cancer related fatigue there is limited data available with 
regards to the precise aetiology, pattern over time and exacerbating and relieving factors 
for fatigue (Fletchner and Bottomly 2002). This complicates the development of effective
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management interventions, including blood transfusion (Dimeo 2002). The aetiology of 
the fatigue pathway remains to be fully established and a number of causes have been 
suggested, such as, the effect of tumour and cancer treatment, co-morbid medical 
conditions including anaemia, hypothyroidism, cytokines, sleep problems, psychological 
factors such as anxiety and depression and loss of functional status (Lucia et al 2003; 
Mustian et al 2007; Wagner and Celia 2004). The cause of fatigue may also differ 
between individuals as well as according to the phase of the disease and the type of 
treatment received (Ryan et al 2007) and in summary is highly individualized and 
multifactorial as described in section 2.4.2. In an attempt to improve management of 
cancer related fatigue the National Comprehensive Cancer Network (NCCN 2005) has 
developed guidelines. Initially any treatable factors that may cause fatigue should be 
identified and treated. The panel identified seven factors; pain, emotional distress, sleep 
disturbance, anaemia, nutrition, activity level and co-morbidities. If the patient does not 
have any treatable contributing factors or cancer related fatigue persists, then additional 
treatment is recommended depending on the patient's clinical status. This incorporates 
education and counseling, general strategies for the management of fatigue, 
pharmacological and non-pharmacological interventions. In line with these guidelines 
the role of non-pharmacological interventions in the management of fatigue is supported 
by Mustian et al (2007) and colleagues who have identified psychosocial therapies, 
physical exercise, and a range of other interventions as potentially beneficial. These 
factors make it difficult for the clinical teams to manage fatigue and the presence of 
anaemia may offer to the clinician a potential solution of management; in that the 
clinician may offer a transfusion when faced with a fatigued patient. This would have a 
perceived benefit of relieving fatigue and of some importance may be the fact that it is a 
relatively quick and simple solution as opposed to other fatigue management strategies
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described. Equally, as there are not many solutions to fatigue and the symptom is 
exacerbated by chemotherapy and radiotherapy; it may be tempting to offer transfusion 
as a strategy. Again, this may result in over-transfusion practices and is related to the 
process of clinical decision making. It is not clear from the current research available if 
clinicians transfuse patients in an attempt to lessen fatigue and other symptoms.
2.6.4 Consequences of withholding transfusion
Over the years the threshoid has gradually declined form 10g/dl to 8 g/dl with little 
evidence and no risk reports, as described earlier in the researcher’s own clinical 
practice. The reality may be that the restrictive guideline is only adhered to in selected 
clinical settings or situations. This rigid numerical trigger ignores Individual patient 
factors and the underlying pathophysiological consequences determining each patient’s 
individual tissue oxygen demands as described in section 2.2. Some of the literature 
relating to non-malignant anaemia reports that a thorough knowledge of oxygen 
transport and the physiology of anaemia are still considered to be the most important 
factor In guiding decisions on transfusion (Hébert et al 2004; Madjdpour and Spahn
2005) but this is difficult to assess in this clinical setting. Adaptive responses to a 
decrease in haemoglobin concentration include blood flow alterations to central organs 
and a shift in the oxy-haemoglobin dissociation curve thereby allowing more oxygen to 
be released to the tissues (Morisaki and Sibbald 2004). The body is therefore capable of 
adapting and some patients can function to near normal levels with haemoglobin levels 
of 7g/dl. “Whole body oxygen delivery (DO^) is the product of blood flow or cardiac 
output and arteriai oxygen confenf” (Madjdpour and Spahn 2005; p33). The rationale for 
giving blood should be to increase arterial oxygen content as well as volume thereby 
increasing DO  ^which essentially restores adequate tissue oxygenation.
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Hébert et al (2004) Identified 18 studies examining blood transfusion on oxygenation 
variables. All studies showed a significant increase in haemoglobin but four of them 
showed no Increase in DO  ^and of the fourteen that did show an increase in DO ,^ only 
five showed a parallel increase in physically dissolved oxygen. The lack of increase in 
oxygen consumption could be explained by lack of oxygen debt (lack of oxygen in the 
tissues) prior to transfusion (Madjdpour and Spahn 2005). Earlier studies showed that in 
the presence of oxygen debt and tissue hypoxia there was a concomitant increase in 
oxygen uptake following blood transfusion (Fitzgerald et a /1997). Madjdpour and Spahn
(2005) surmise that there are factors that are likely to predict if a patient will respond to 
blood transfusion, but it would appear that in clinical practice It would be impossible to 
know which patients had adapted to the anaemia and which of those had oxygen debt.
Casutt et al (1999) examined 170 blood transfusions in 67 anaemic cardiac patients and 
took measurements five hours before and after transfusion. They found pre-transfusion 
haemoglobin; preoperative ejection fraction and age were unrelated to individual 
responses in cardiac index, DO  ^and increase in physically dissolved oxygen. Spahn 
(1999) argues that impaired functionality of stored blood could be a cause of the lack of 
increase in dissolved oxygen. Earlier studies suggested that “old blood" (blood stored for 
more than 25 days) may be less effective transporters of oxygen (Offner 2004), and 
some studies have shown that “old blood” has a negative effect on incidence of infection 
(Marik and Sibbald 1993; Vamvakis 2002) however, more recent reviews have 
concluded that current evidence on the effect of storage duration of red cells is 
insufficient and that additional trials are necessary to define the role of age of cells on 
outcome (Ho ef a/2003; Napolitano and Corwin 2004).
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A more recent study tested the hypothesis that serious complications and mortality after 
cardiac surgery are increased when transfused red cells are stored for more than 2 
weeks (Koch et al 2008). Data was examined from patients given blood transfusions 
during heart surgery. A total of 2,872 patients received 8,802 units of blood that had 
been stored for 14 days or less (“newer blood”) and 3,130 patients received 10,782 units 
of blood that had been stored for more than 14 days (“older blood”). The median duration 
of storage was 11 days for newer blood and 20 days for older blood. They found that 
patients who were given older units had higher rates of in-hospital mortality (2.8% vs. 
1.7%, P=0.003), incubation beyond 72 hours (7% vs. 5.6%, P=0.001), kidney failure 
(2.7% vs. 1.6%, P=0.003), and sepsis or septicemia (4.0% vs. 2.8%, P=0.01). The 
composite of complications was more common in patients given older blood (25.9% vs. 
22.4%, P=0.001) and “older" blood was associated with an increase in the risk-adjusted 
rate of the composite outcomes (P=0.03). At one year, mortality was significantly less in 
the patients given newer blood (7.4% vs. 11.0% P<0.001). These studies have yet to be 
replicated in the oncology setting but imply there may be further risks of transfusion, 
particularly if “old blood” is transfused.
In summary, what these studies may imply is that there is a unique response to 
transfusion, which may have a physiological basis and is dependent on a degree of 
oxygen debt or may be related to factors in the donated blood itself. There would be no 
way of predicting this in the clinical setting therefore other factors would have to be relied 
on to make an assessment of the impact of anaemia and the decision that blood would 
be safe to administer in balancing the benefits over the risk. It may also be that unique 
factors in the blood product Itself may determine the degree of benefit (i.e. the response)
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to blood and that again this would not be possible to predict or more Importantly in the 
later studies that there may be deleterious effects of the “older” blood transfusion and 
these are not currently considered in practice. The age of the blood product is not 
considered when issued for a cancer patient; many of whom may be severely immuno­
compromised whilst having a transfusion.
2.6.5 Summary
There may be an assumption that transfusion will improve quality of life, similar to what 
has been shown by erythropoietin administration. Allogeneic blood transfusion may not 
give the benefits of intrinsic haemoglobin and carries additional risk, but currently 
erythropoietin is only recommended in selected situations (e.g. ovarian cancer with Hb 8- 
10g/dl receiving platinum based therapy) by NICE; therefore transfusion remains the 
option for NHS patients for the treatment of cancer-related anaemia (NICE 2008). The 
prevalence of mild to moderate anaemia and the potential clinical and functional impact 
on patients make it important to have a systematic approach to the diagnosis and 
treatment of anaemia. However there is widespread variation of transfusion practice and 
limited understanding of the decision to treat cancer-related anaemia.
In summary, many of the assumed benefits of allogeneic blood transfusion therapy are 
questioned and the potential hazards of transfusion may have been underestimated. 
Recent evidence suggests that in many clinical settings there are significant under- 
recognised hazards of transfusion and it may be detrimental to the patient to support 
higher haemoglobin levels. Blood transfusion should perhaps not be the default 
therapeutic decision when evidence for efficacy is lacking and there is clinical uncertainty 
as in the case of moderate or mild anaemia. It should be a carefully considered decision
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with the risks and benefits considered in each unique clinical episode. Isbister (2007, 
p10) donated allogeneic blood should only be used as therapy when:
• There is evidence of potential benefit
• There are no alternatives
• A quality product is available
• The risks are appropriately considered and balanced against the benefits
It is clear that in NHS settings there is no alternative to blood transfusion (except for 
NICE criteria 2008) but it is unlikely that there is assurance of complete safety, absolute 
benefit and consideration of risks and benefits in blood transfusion practice. In this 
context the clinical decision to give blood appears to be complicated, but the practice 
may not reflect this complexity. For example, it is not known in the clinical setting if 
healthcare professionals consider the risks of transfusion when making the clinical 
decision to transfuse. It also begins to raise questions about what skills and knowledge 
are required to make these decisions; how are these learned in practice, and who is best 
placed to make the decisions?
2.7 Clinical Decision Making
It is difficult to know which healthcare professional group is best placed to assess the 
impact of anaemia. Nurses' roles have been extended to include prescribing and the 
next step would be for nurses to prescribe blood (Piri and Green 2008); in addition as 
blood transfusion is not a drug it is not subjected to the same prescribing controls as 
medicines (Blood Safety and Quality Regulations 1995). It could be argued oncology 
and/or haematology nurses can play a key role In the assessment of cancer related
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anaemia through their frequency of contact with patients during clinic, day care visits, 
telephone conversations and the ensuing relationship. The day unit nurses may have a 
wealth of experience through repeated exposure to patients receiving transfusions in the 
day care units. Alternatively, the healthcare professional with the greatest skills and 
knowledge of cancer related anaemia may be the most appropriate to assess anaemia 
and it could be assumed this is physicians; however it may also be important the 
healthcare professional has expert decision making skills. It has been previously 
described in the literature review that it may be difficult to assess cancer related anaemia 
and that some uncertainty may exist; therefore expert clinical decision making skills may 
be necessary to reduce the uncertainty. This section explores the literature to see how 
clinical decisions are made; what influences thought processes (cognition) and therefore 
decision making and finally a summary of relevant cognitive theories. The last section is 
important because this study is an attempt to understand this process in the clinical 
setting.
2.7.1 Making a diagnosis; expertise and decision making
Experienced clinicians use a variety of methods of arriving at a diagnosis, depending on 
their familiarity with the clinical problem (Table 2.7.2). Difficult and unfamiliar problems 
require the slower full systematic history and examination methods, while the familiar 
well-encountered problems are quickly diagnosed with pattern recognition. Novices 
soon discover that more information is derived from the history than the examination (Del 
Mar ef a/2006). This implies familiarity with the patient may improve outcome in addition 
to improving "pattern recognition” assessment and decision making. It Is sometimes 
described as a subconscious or intuitive process (Norman ef a /1992) and can be difficult 
for clinicians to articulate how the diagnosis is achieved. According to Del Mar ef al
72
(2006) investigations should be used to confirm or exclude a diagnosis, however, it is not 
clear in the assessment and treatment of cancer related anaemia if this is the case.
Table 2.7.1 Different cognitive models to arrive at a diagnosis (Del Mar et a! 2006, p14)
Type of cognitive process Characteristics Examples
Full systematic history and 
examination
Slow: exhaustlve-mlnimizes 
the forgetting of important 
possibilities
New patient with suspected 
cancer
Hypothetico-deductive
reasoning
Faster: concentrates the 
gathering of information into 
provisional diagnoses 
generated very early, 
raising new possibilities 
readily
Surgeons’ diagnosis of 
acute abdominal pain
Pattern recognition Fastest: relies on 
experience. Less helpful 
for problems not 
encountered before, or 
remembered
Spot diagnosis of mumps
Hypothetico-deductive reasoning (analytical thinking) is used when faced with a more 
challenging diagnosis. Anaemia may be more difficult to diagnose when complicated by 
symptoms of disease and/or treatment. Each piece of information gathered either 
increases or decreases the hypothesized diagnosis as the clinician considers several
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possible diagnoses. Clinicians attempt to match the presentation within their internal 
“schema” (Coderre et a /2003) Information gathering is an important part of achieving an 
accurate diagnosis but there is a risk that too much emphasis is placed on pieces of 
evidence, for example, laboratory values or if the patient has too many problems at once 
(Del Mar et al 2006). Evidence also shows that there can be an error in the clinicians’ 
knowledge base which can cause them to focus on a sign or symptom that is not able to 
accurately validate a diagnosis (Gruppen et a! 1999).
Typically, arriving at a diagnosis involves taking a history, physical examination and then 
using investigations to confirm or exclude a diagnosis. Generally, evidence has shown 
the more experienced clinicians use the history as a means to diagnose with the 
examination and systems review to confirm the diagnosis, i.e. it is the conversations that 
reveal the most information (Del Mar ef a/2006; Hampton et a! 1975; Hoffbrand 1989). 
This process however is poorly understood and has not been explored in the clinical 
assessment and decision making in the cancer related anaemia and if there are other 
influences in the clinical setting.
2.7.2 Context of the decision
Studies evaluating relationships between physician background characteristics (e.g. 
years of practice and medical training) and quality of care have found few consistent 
associations in decision making (Wigton et a! 1999). One possibility is the task is too 
complex or there is too much uncertainty, therefore different decisions are made. 
Clinical judgments and decisions are not isolated cognitive events and they can only be 
meaningfully conceptualized in relation to the task; and that task will occur within a 
unique clinical context (Dowie and Elstein 1999). Clinical cognitive theory acknowledges
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this to some extent but clinicians (nurses and doctors) operate in particular clinical 
settings and wider social contexts and these influence to varying degrees, depending on 
the unique culture or the nature of the task. Dowie and Elstein (1999) develop the 
argument further to explore the effects of the economic context and the scarcity of 
resources; the ethical and legal context which is the influence of the ethical codes of 
consideration of the “social" or “common good\p34) and the professional context which 
is about the risk of errors and accusations of negligence. In other words, the clinicians’ 
decisions may be influenced by resource availability, or for example. In the palliative care 
setting a clinician may continue to transfuse a patient because of the ethical dilemma of 
withdrawing supportive blood transfusion. Decision-making therefore can be affected by 
the severity of the potential outcomes In comparison to the anticipated regret for different 
pathways not taken (Col et a! 1997) e.g. a healthcare professional might be more likely 
to transfuse a patients because he/she considers the risks of anaemia to be greater and 
more worrying than the risks of transfusion. The ethical issues are also powerful 
influences in blood transfusion for example, it is difficult to withdraw blood transfusion in 
the palliative care setting if the patient has had blood transfusion support throughout 
active therapy period (Stone et a! 2000b); and as mentioned previously the availability of 
resources may influence the decision to transfuse.
Site of practice (area of clinical practice; the institution; place of work) variables have 
been better predictors of quality than have characteristics of individual physicians. A 
study by Salem-Schatz et a! (1993) explored the relationship between physicians’ 
knowledge and attitudes regarding the use of blood products, and the quality of their 
transfusion practice, based on in depth physician interviews and medical record reviews. 
The sample included 296 transfusion episodes ordered by 17 physicians in 2 teaching
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hospitals. The quality of transfusion practice was defined as the proportion of a 
physician’s transfusion episodes scored as justified, as determined by explicit chart audit 
plus implicit physician review. Large baseline differences were observed between the 
two hospitals; 48% of transfusions in Hospital A were justified compared with 81% in 
Hospital B. At the physician level, knowledge of transfusion indications and receptivity to 
input from colleagues were significantly associated with higher quality transfusion 
practice (p = 0.01 and p = 0.02 respectively). These findings suggest that in addition to 
organizational context, physician characteristics may be associated with the quality of 
care related to a specific clinical practice and the degree to which others are involved in 
the final decision to transfuse. This was a quantitative study using questionnaires and 
retrospective casenote analysis but did not explore the detail of the processes and 
discussions that occurred culminating in the diagnosis of cancer related anaemia and the 
decision to transfuse.
When there is uncertainty about the management of a problem, or when it appears there 
Is variation of practice, generally evidence based guidelines are employed to facilitate 
management and improve the skills and knowledge of the healthcare professionals, with 
other drivers being to reduce costs and improve safety. Most of the safety initiatives 
about transfusion are driven by national policy and mandatory “Serious Hazards of 
Transfusion (SHOT) reporting Williamson ef a /(1999). The practice of transfusion fulfills 
all of these criteria. The best form of these guidelines incorporates all the current 
evidence and explicitly states the potential harms and benefits of treatments. Some 
evidence is available on the management of cancer related anaemia but It is a naïve 
assumption that when research evidence is made available it is accessed by 
practitioners, appraised and then applied in practice via clinical practice guidelines (NHS
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Executive 1996). In addition, despite the growth of clinical practice guidelines, their 
actual value is infrequently assessed through formal evaluation procedures (Carter
1996).
Control of transfusion practice is attempted by the production and implementation of 
transfusion protocols and/or guidelines and mandatory transfusion education; these are 
practiced in all hospital settings, but optimal transfusion practices may not exist and the 
reasons for this may be more complex than anticipated (Brunskill et al 2008). Brunskill 
et a /(2008) summarise by stating:
“ A better understanding of and more investment in implementation research 
should be a priority for transfusion given the background of the high costs of 
blood, the scarcity of blood as a resource and the risks associated with 
transfusion, initial work on improving our knowledge on the different influences 
on transfusion prescribing behaviour is important and would feed directly into any 
studies designed to explore different interventions for practice change” (pi 5).
In summary, guidelines cannot incorporate all the factors that may be important to a 
patient or clinician in making a decision, such as the clinical context of that decision, the 
social interactions between the patients and the clinicians or how transfusion practice is 
learned within the organization; and this may be why guidelines do not always result in 
the desired outcome which is control of the practice. The first steps may be to explore 
further the influences on the decision and from there develop any change required to 
develop future practice.
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In summary there are a multitude of influences on clinical decision making in the clinical 
setting; increased workload, lack of time, poor communication and traditional working 
practices may all contribute to less than optimal decision making practices (Firth-Cozens
1997) and it may be the context of the decision that is paramount. More subtle 
influences are the effects of resource availability; ethical considerations and professional 
codes of conduct. The following section describes some theories of cognition from the 
literature that attempt to incorporate the context of the decision.
2.7.3 Cognitive theory
Section 2.7,1 introduced some of the types of thinking that are used, describing intuition 
and analysis in relation to experience of the clinician; section 2.7.2 showed there are 
both external and internal influences on how decisions are made. This section describes 
how some researchers have developed theories of cognition to explain how the real 
world influences decision making. Hammond et a! (1980) defined intuitive thought as 
rapid, unconscious data processing achieved by combining available information and 
averaging it; he describes intuitive thought as having low consistency and only 
moderately accurate. Analysis is at the other end of what he describes as the cognitive 
continuum and has the opposite features in being slow, conscious and consistent. He 
describes intuitive and analytical thinking as poles of a continuum because most thinking 
is a combination of both. However, the task is also on a continuum; in cognitive 
continuum theory, tasks are considered to occupy a position ranging from analysis 
inducing to intuition inducing, indicated by task features that influence the model of 
cognition that the thinker will adopt. These include:
• The complexity of the task (e.g. number of pertinent cues will increase use of 
intuitive thinking)
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• The ambiguity of the content of the task (e.g. unfamiliarity induces intuition; high 
accuracy requirement induces analysis)
• The form of task presentation (e.g. if sub-tasks are required analysis is induced; 
time constraints will induce intuition) (Hammond ef a /1980; 1986)
Hamm (1999) also describes how the ability of a task feature to induce a mode of 
cognition also depends on what the thinker knows; therefore the knowledge of the 
decision maker influences the final decision. Dreyfus and Dreyfus (1986) took this 
further and developed a theory of expert cognition and described five stages that one 
must go through to be an expert (novice; advanced beginner; competent; proficient and 
expert). The novice must think analytically to perform; the advanced beginner has 
learned to perceive intuitively but must stiii apply rules; the competent person exercises 
both perception and action components of the skill intuitively but the proficient person 
perceives the whole situation intuitively but makes decisions analytically and finally the 
expert makes these decisions intuitively as well. The Dreyfus theory emphasises the 
relationship of thinking with experience and the Hammond Cognitive Continuum Theory 
emphasis that the task dictates the type of thinking used. Hamm (1999) describes how 
performance is likely to be the most accurate when the clinician’s mode is appropriate to 
his/her level of experience, for each level of task. ‘Together the two theories provide an 
explanation for variations in cognition on different tasks at different stages in careef 
(Hamm 1999; pi 01); these may prove useful when analyzing how clinicians make their 
decisions regarding blood transfusion as the nature and context of the task may be as 
important as the experience of the clinician (nurse/doctor).
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2.8 Social interaction ism and the development of culture
The previous section described the influences on clinical decision making but described 
how the decisions are not made in isolation, therefore the interactions and relationships 
between clinicians and patients warrant further investigation. It is the behaviours in a 
setting that shape the clinical culture. Culture refers to “ the shared patterns of group 
behaviour acquired through intergenerational learning; knowledge and behaviour shared 
by a grouf^* (Winkelman 2009, p430) and in the context of this study it refers to the 
transfusion behaviours in the different clinical settings. All societies, Including clinical 
settings, have characteristics that endure over time despite the Individuals changing 
within that society; and It was of interest to the researcher if transfusion practices 
endured because of characteristics of the clinical setting to determine if this was an 
Influence on clinical practice. The sections that follow will describe the literature in 
relation to the development of clinical cultures and how the interactions between 
individuals within the culture are significant in shaping behaviours. The importance of 
the social interactionism justifies the argument for using an interpretive ethnographic 
methodology, whereby meaning is Interpreted from the social interactions between the 
individuals; the methodology of the study will be described in more detail in Chapter 3
2.8.1 Social interactionism
Earlier in the literature review it was described how clinical decisions can be made (2.7); 
it was also described how the task and the experience of the clinician can influence the 
decisions but learning and thinking does not occur in isolation. Atkinson (1995) 
describes how decision making can be a collective organisational activity and is 
frequently undertaken in complex organisational settings (not just clinics or hospitals). 
Decisions may be subject to debate and question, therefore the individual characteristics
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as described in the earlier section on clinical decision making is by no means the whole 
story. Atkinson describes this as “Clinical decision making is not the outcome of 
Individual minds, operating In a social vacuum" (p54). This implies clinical practice and 
the quality of decision making as discussed in section 2.7 may be related to more social, 
interactional and situational factors.
Giddens (2008) describes the process whereby societies have “structural continuity over 
time” (p163), which perpetuates values, norms and social practices. He describes how 
socialization is the process whereby an individual gradually becomes knowledgeable and 
skilled in the ways of the culture in which they exist, if this is translated to the clinical 
setting. It may be that some of the traditional transfusion behaviours are a result of 
socialization in practice; the clinician may become knowledgeable and skilled In 
transfusion because of what is learned through Interactions with others, and not merely 
by undertaking education and training. Equally the patient may become socialized into 
the behaviours of being a patient within the unique clinical setting.
The interactions therefore between individuals are important and it was described in 
section 2.7 how decision making is not made in isolation; interactions between 
individuals take place through symbols and the interpretation of meanings and is 
described as “symbolic interactionism” (Giddens 2008; p107). Giddens further states:
“Symbolic Interactionism stresses the exchange of symbols between individuals 
in social interaction. Unlike other theories, symbolic interactionism emphasizes 
the small-scale interactions of individuals, not society as a whole” (p26).
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The basic principles of symbolic interactionism can therefore be summarised as follows:
• Human beings possess the capacity for thought which is shaped by the social 
interaction
• People learn meanings and symbols through social interaction
• People are able to modify or alter the meanings and symbols they use in 
interactions by interpreting the situations they are in (Baert 2004)
Symbolic interactionism, especially the work of George Herbert Mead (1863-1931) traces 
Its roots back to pragmatism in philosophy with other influences from Georg Simmei 
(1858-1918) and GHF Hegel (1770-1831) (Baert 2004). Mead developed three 
Important themes: firstly a focus on the Interaction between actors and the social world; 
secondly view that the actors and the social world are dynamic and thirdly the centrality 
of actors to interpret the social world. Mead recognised the importance of observable 
behaviours but also stressed the Importance of covert behaviours. Alternatively, Erving 
Goffman (1922-1982) described this as “dramaturgy”, which is a view of social life as a 
series of dramatic performances, but like Mead implies that the self is not always 
revealed. Goffman also described how the self is shaped by the dramatic interactions 
between social actors and their audiences. The basic unit of analysis in Goffman’s work 
is “the tearri' and how the members of the team use impression management to maintain 
a particular image of themselves when interacting with others. According to Goffman 
these “frontë' tend to become institutionalised and are therefore selected rather than 
created; he was interested in “encounterd' that is face to face interactions where people 
are constantly in the presence of others. In summary, both Mead and Goffman portray a 
dynamic self, actively intervening in the world and like Mead, Goffman emphasised the
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extent to which people are reflexive beings, by being able to monitor their actions and 
therefore having the ability to manipulate their surroundings.
In this context, it is the “ciinician-clinician” and “patient -  clinician" interactions which form 
part of the area of study, for example, how is anaemia explained and what does it mean 
or how is the haemoglobin used to define anaemia. To the members of all societies, the 
human body is more than just a physical being; it is also the focus of a set of beliefs 
about its social and psychological significance, its structure and function. Therefore 
anaemia may have different meanings for individuals and transfusion practice may be 
influenced by individual and group beliefs. Although social behaviour is guided to some 
extent by the forces such as roles, norms or shared expectation, individuals perceive 
reality differently according to their backgrounds, interests and motivations. Giddens 
describes how Individuals shape reality through the decisions and actions they take, in 
other words, “reality is not fixed or static, it is created through human interactions [  ]  it is 
a social construction of realit/ (p130). Studying social interaction in everyday life by 
using ethnographic methodology sheds light on larger social systems and institutions, 
justifying its use in this study, as this is a study and analysis of everyday behaviour in 
situations of face to face interaction; it is described as a form of study of micro-socioiogy 
(a study of face to face interactions). Therefore the interactionist theorist views 
individuals as active and creative participants who construct their social world, not as 
passive conforming objects of socialization.
2.8.2 Cultural knowledge
Cultural knowledge plays a key role In most work based practices and activities (Eraut 
and Hirsh 2007). Much of the discrete cultural knowledge is acquired informally through
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participation in working practices and much of this is unconscious and clinicians may be 
unaware of the influence on their behaviour; “it Is implicit learning normally associated 
with the concept of socializatiort' (Eraut and Hirsh 2007; p5). Eraut (1997; 1998) 
describes this socialized knowledge as “personal knowledge and capabilitÿ' and is 
defined as “what Individual persons bring to situations that enable them to think, interact 
and perforni' (p i28). It incorporates knowledge; skills and practices; personal 
understanding of people and situations; accumulated memories and episodic events 
(Eraut 2000; 2004) and other aspects of expertise; practical wisdom and self knowledge, 
attitudes, values and emotions. The evidence of personal knowledge mainly comes from 
observations and this implies a holistic rather than fragmented approach to knowledge 
and links to symbolic interactionism in that the individual is active in the learning. It also 
Implies the influence of the culture on learning and behaviours; It is currently not clear if 
these cultural factors influence cancer related anaemia practice and if these influence 
transfusion behaviours. By using an ethnographic methodology to study the social 
interactions and processes and individual characteristics such as knowledge, skills and 
attitudes a social construction of transfusion practice could be developed; a creation of 
the social Interaction of Individuals and the group. It could be argued that transfusion 
practice is common sense knowledge and Luckman and Berger (1966) in their study of 
the social construction of reality, describe this type of knowledge as those things that 
individuals take for granted. They emphasize that “obvious” facts of social reality may 
differ among different people, even when in the same culture. It was described earlier 
how transfusion is a well established therapy which has existed in many clinical settings 
for many years and transfusion practice may represent an “obvious” social construct. To 
study transfusion practice In more detail may illuminate the ways In which transfusion
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behaviours are learned and create a construction of transfusion practices in the clinical 
context.
2.8.3 Patient factors
It was described In section 2.8.2 how patients may be active in the social interactions 
that culminate in them receiving a blood transfusion, however, it is not clear from the 
literature if patients are concerned about anaemia or how involved they are in the 
assessment and decision to treat. It is known that patients now rate fatigue as their most 
common and debilitating side effect (Bruera et al 1989; Morant 1996; Portenoy and Itri 
1999; Sobrero ef a/2001 Celia 1997; 1998; Littlewood et al 2001; Yellen et al 1997) but 
the fatigue experienced may not actually be a reflection of the anaemia as previously 
discussed in section 2.4. Patient websites for example. Cancer Bacup Fatigue 
Management, recommend blood transfusion as a treatment for fatigue and also list 
anaemia second to cancer treatment as the cause and the NHS website for 
breathlessness lists anaemia as a common cause of fatigue (Cancer Bacup 2008). 
Patients, who seek information about fatigue management, particularly if it is 
recommended in the patient literature, may also seek transfusion in an effort to combat 
fatigue, but this is unknown. It may be assumed that patients are actively involved in the 
assessment and decision making of their anaemia management and that they are 
included in the social constructs of transfusion practice, but this is not known.
Conversely it has been described how patients can be distant from the point of care and 
decision making; the patient may also be read and Interpreted “in absentia” tor example 
in the Multi-Disciplinary Team (MDT) meetings (Atkinson 1995; 62). Atkinson describes 
the latter as being where the body Is transformed Into a series of signs and
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representations by means of a “complex array of technologies of inspectloii' (Atkinson 
1995; 63), e.g. the Computerised Tomography (CT) scan; the laboratory results; the 
histopathoiogy and so forth and this is not uncommon. These items of information are 
combined by individual clinicians or groups of clinicians to create an assessment and/or 
decision. It is not known if this occurs in the management of cancer related anaemia, for 
example, if anaemia is managed from a distance; or If the patient is involved or if the 
management of anaemia is by individuals or groups of clinicians.
in general, patient participation in medical decisions appears to be increasing; possibly 
as a result of dissatisfaction or due to basic questioning of physician expertise. One 
review concluded that because of uncertainties associated with most medical decisions, 
clinicians who assume complete autonomy for decisions put themselves in a difficult 
ethical position (Brody 1980). As medical decisions become more complex and are 
associated with greater costs to the patient, clinicians have been increasingly motivated 
to incorporate patient preferences in critical decisions (Zook and Moore 1980). The 
question of how value judgments should be Incorporated into decisions is difficult; 
although it is the patient who lives with the decision, many patients believe that the 
clinician who regularly treats the conditions is best able to understand the outcomes and 
ascertain what risks are worth taking (Eraker and Poiitser 1999). A patient survey of 51 
patients receiving transfusion revealed that patients would like more information about 
transfusion, mainly because of concerns about viral transmission and nearly 40% 
thought written consent should be obtained prior to transfusion (Murphy et al 1997). A 
study of nurses and patient preference for involvement in their care, revealed nurses 
over-estimated patients' preferences to be actively involved in their care (Florin et al
2006). It is suggested that patients should be assessed for their preference, for
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example, a passive roie, a collaborative role or active role (Florin et al 2006). in 
summary, it is not clear what Impact or involvement the patient has on the decision to 
treat anaemia, if any; or if the patient is influenced by the culture of the clinical setting. It 
may be that increasingly patients will be more involved in their care as balancing risks 
and benefits may be more important where patients increasingly seek claims for clinical 
errors, as this would result in more ownership of the decision by the patient, and less 
with the clinician.
2.8.4 Summary
This section has described the literature of social Interactionism and cultural learning and 
gives some insight into the development of the research design and the rationale for 
using an ethnographic methodology. To study the social interactions that occur in blood 
transfusion practice, some participant observation would be justified as some 
understanding of the everyday lives of the participants would be necessary to 
understand the context of the actions and behaviours of individuals; and the process by 
which the clinicians and patients construct the situation through their interaction. Further 
Insight is gained by interviewing the participants. By combining the data sets a 
construction of transfusion practice could be created by Interpreting meaning from what 
behaviours and interactions are observed or described. This justifies the use of 
ethnography, but given the close contact required, the researcher would have to 
consider her own values and strive to be objective in the conduct of the research. As 
described earlier this is achieved by using the different data sets to validate the 
interpretations developed by the researcher and by using reflexivity to seif-critlque and 
self appraise and continually re-visit the data. This will be described in more detail in the
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development of the methodology chapter (Chapter 3), and the analysis will be described 
in more detail in Chapter 5.
2.9 Literature review summary
At a basic physiological level it could be argued that reliable monitors of tissue 
oxygenation and haemostasis are required to study the benefits (or lack thereof) of blood 
transfusion. This is unlikely in the near future, therefore, pragmatic guidelines defining 
transfusion triggers have been developed in an effort to control practice, and prevent 
over-use of blood products. The quest for a universal transfusion trigger i.e. one that 
would be applicable to patients of all ages under all circumstances should probably be 
abandoned (Hardy 2004); and therefore most guidelines define a range, e.g. 7-10g/dl for 
chronic management, in simplistic terms, transfusions should be tailored to the patients 
needs at the moment the need arises, but it is not clear if this happens in clinical practice 
or how the decision is made. Future research and development should perhaps focus 
on the determination of optimal transfusion strategies in various patient populations and 
on reliable monitors to guide transfusion therapy (Hardy 2004); but it could be arguable 
that should disease specific guidelines and monitoring be developed, practice may still 
vary because of other more powerful influences, which may initially not be obvious.
In summary, the assessment and decision to treat cancer related anaemia is a complex 
one and the details of the process are relatively unclear, it may be that the laboratory 
value is the greatest influence or it may be patient or resource issues also impact on the 
assessment and decision to treat. If the behaviours and practice can be examined in 
greater detail, and how they are learned, then It may give some insight as to how to
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improve the assessment and management of cancer related anaemia and guide what 
changes may be required to change transfusion prescribing behaviours,
2.9.1 Implications for practice
As described earlier the anaemia experienced by the oncology patients is usually more 
chronic in nature and has a physiological cause and therefore differs from patients who 
suffer blood loss. It Is seldom life threatening unless a patient has experienced an acute 
bleed. Therefore, in principle red cell transfusions for patients with chronic anaemia 
should be given at intervals to maintain the haemoglobin just above the lowest 
concentration that is not associated with symptoms of anaemia, but as previously 
discussed it may be difficult to determine what this concentration is for individual 
patients. Many patients do not receive any treatment for mild anaemia and It is not until 
the patient becomes moderately or severely anaemic that treatment is initiated, it is not 
clear what are the determining factors for the decision to treat, for example, is it 
particular symptoms or is it primarily the haemoglobin level or is there other cultural or 
social influences? Most clinical practice guidelines recommend restrictive red cell 
transfusion practice with the goal of minimizing exposure to allogeneic blood (from an 
unrelated donor) as well as reducing healthcare costs. They tend to set a transfusion 
trigger of 8g/di In the absence of cardiovascular disease. However, in cancer related 
anaemia most patients would be transfused with haemoglobin of less than 8g/di and very 
few people If more than 12g/dl. (NICE 2004).
The volume of transfusion any given patient receives varies according to diagnosis, 
complexity and tumour type (Bokemeyer 2005; Estrin et a /1999; Ludwig et a /2004). As 
mentioned previously eighty-eight per cent of transfusion episodes in the cancer
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population are two- unit transfusions (Barrett-Lee et al 2000). This suggests there may 
be ritualistic practice in transfusion with a tendency to treat laboratory values rather than 
make a clinical decision to treat and aim for a specific transfusion target (Foubert and 
Wujcik 2005) or to treat symptoms of anaemia. Again, the rationale for this decision is 
not clear; it could be argued that unless it is clear of the reasons for these decisions, it 
would be difficult to improve practice.
Cost and resources may influence the decision to treat anaemia. As mentioned the cost 
of the actual blood product is increasing but in addition to this there are the added costs 
of the administration of the blood transfusion (for example, nursing and laboratory time, 
beds, management of adverse events). The actual number of blood donations 
Increased by 2% in 2000-2001 but the cost of transfusion increased by 256% to £898 
million (Varney and Guest 2003) with the direct cost of the blood product accounting for 
only 19% of the total cost of transfusion (Crimieux et al 2000). This could be an 
influence on the haematologists whose transfusion prescribing behaviours changed 
following the transfusion course at the blood transfusion centres, which was an 
observation in practice described earlier.
It may be that a clinician faced with an anaemic patient In clinic may want to order a 
blood transfusion; however, limited resources may result in a delay or no transfusion at 
all. Furthermore, a lack of day care beds may result in unnecessary patient admissions 
for blood transfusion and the Barrett-Lee audit demonstrated 25% of transfused cancer 
patients were admitted as inpatients for their blood transfusion (Barrettt-Lee et al 2000). 
This is difficult to interpret as It may be patients were admitted for other co-morbidities. 
The NICE (2008) guidance on the use of erythropoietin was based on the assumption
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that 25% of patients require overnight stay for biood transfusion, which again could be 
argued that this was not a decision that considered patients may have been admitted 
because of a co-morbidity. From personal experience it is very rare to admit an 
ambulatory patient solely for transfusion. These patients would normally be deferred 
until there is an available time in the day unit rather than being booked as an in-patient, 
however, this will vary according to clinical setting. At present It is unclear as to how 
much resource availability influences the decision to treat patients with blood transfusion.
Anecdotal data has revealed that transfusion practice varies widely between different 
institutions and clinical settings, even within the same institution and the reasons for this 
are unclear. In summary, the amelioration of cancer-related anaemia with biood 
transfusion should be considered a priority in the presence of confirmed symptoms and 
when there is evidence that the patient responds to biood transfusion. The aim should 
be to provide best supportive care In this population, with the emphasis on neither, over- 
or, under-transfusing of blood and a more discerning approach may be required. If there 
Is inappropriate resource or environment to support this practice, then service 
development or adjustment may be required. Furthermore, if a deeper understanding of 
how decisions are made in the clinical setting it will inform as to what interventions or 
change in behaviours that needs to be developed to improve practice.
2.9.2 Implications for research
The presence of cancer related anaemia reportedly decreases quality of life and 
increases fatigue levels but It may be difficult to differentiate between symptoms of 
anaemia from disease and treatment influences, and there could be a risk that patients
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are unnecessarily exposed to treatment of anemia. Some patients appear to benefit 
more from blood transfusion than others and it is not uncommon for patients to express 
that they feel no benefits following a blood transfusion. It may be that attempts to 
provide best supportive care of anaemia are unpredictable but blood conservation 
strategies should be maximized, or blood transfusion should be at a minimum clinically 
justifiable. This would justify a study attempting to explore if discerning transfusion 
decision making was practiced in a variety of clinical settings and if not, what are the 
influences on the reasons for non discriminatory prescribing of blood.
A further criticism of many of the anaemia and erythropoietin studies is that tumour types 
are frequently grouped together and the impact of anaemia and effects of erythropoietin 
and haemoglobin level may be different for different tumour groups. It may be useful to 
explore any differences in practice in different tumour groups, and the reasons for this; 
as this may explain some of the differences in practice. This would justify the rationale 
for examining haemato-oncology and lung cancer as symptomology may have different 
impact on patients and there may be behavioural differences between the sub­
specialisms.
In the clinical setting the traditional approach to treating cancer related anaemia is “the
two-unit transfusion”; this is probably a response to haemoglobin levels but this is not
clear. The haemoglobin level may not be a good indicator of the impact of the anaemia
and therefore should not be the main Influence in deciding to treat the anaemia, unless
low levels are reached or predicted. The literature describes the importance of a full
assessment of anemia but this may or may not be important and the actual practices of
assessment and treatment of cancer related anaemia have not been explored. Exploring
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the actual practices within healthcare settings necessitates a qualitative approach which 
wouid capture the reality of practice. It Is argued here that a qualitative research 
methodology, such as ethnography, with some participant observation in clinics and day 
units where the assessments or decisions are made is an appropriate approach to 
studying this clinical issue. Participant observation could give some insights Into the 
culture of the management of anaemia, which is thought to be based on traditional 
practices. By using a combination of observation and interviews an interpretation of the 
social constructs involved in the management of anaemia could be developed; the 
management of anaemia may not be merely a response to a biomedical fact (e.g. a 
decision based on a response to the haemoglobin level), but may be influenced by a 
range of social, situational or institutional processes or factors.
An attempt to establish why there Is variation in transfusion decisions would require more 
detailed qualitative approaches of enquiry, for example, with interview techniques with 
healthcare professionals to explore what decision making criteria Is used in deciding 
whether to transfuse a patient or not. The literature review revealed there may be some 
uncertainty in the treatment of cancer related anaemia, and further uncertainty with 
variable responses to transfusion, therefore the decision to treat is complex. The 
Medical Research Council (MRC 2000; 2008) have produced a framework for evaluating 
complex Interventions and suggest if a particular intervention Is already widely practiced, 
it may be useful to establish the theoretical basis that suggests the intervention has the 
desired outcomes or “it may be formal theory of individual or organisational behaviour, 
organisational constraints or types of behaviours that promote or inhibit change” (MRC 
2000, p4). The MRC concludes that qualitative research is important in understanding 
why something happens and that it may be valuable In ascertaining whether
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inappropriate beliefs and assumptions may be leading to the wrong interventions (MRC 
2000, p9). The updated MRC guidance (MRC 2008) also describes how research into 
the context of the intervention can be valuable in determining how an intervention works 
or how it can be optimised and “can identify contextual factors associated with variation 
in outcomed' (p12); and describes how the context of an intervention can be crucial to 
treatment success or failure. By combining fieldwork observation and interviewing key 
healthcare professionals it would be anticipated a picture of the reality of transfusion 
practice would emerge. More accurate and detailed assessment of cancer related 
anaemia may result in more, not less, use of blood if the current literature is to be 
believed; but it may be the overall aim should be to use blood appropriately, thereby only 
exposing the risk of transfusion to those who will have direct benefit from the blood 
transfusion.
In summary, the arguments described (the complex decision; the social interactions; the 
context of the interactions and decision) provide rationale for further research in the 
assessment and treatment of cancer related anaemia. The need to develop more 
efficient services, or services which are at the least clinically justifiable, is not only a 
response to government policy initiatives for greater economic and professional 
accountability but It has ethical implications; the aim of any improvements in transfusion 
practice would be to optimise the patient's quality and quantity of life without exposing 
him/her to unnecessary risks and ensuring that any transfusions are at a minimum 
clinically justifiable. This research project was, therefore designed to both inform and 
influence the management of cancer-related anaemia and transfusion practice, by 
contributing to the body of knowledge about decision making in the clinical setting and 
the cultural influences at play.
94
2.9.3 The purpose of the research
This chapter described the literature review which laid the foundations for the 
development of the research by identifying gaps in knowledge and explored the influence 
of cultural and social factors to ultimately inform the research methodology. The purpose 
of this study was therefore:
• To explore the cultural practices which shape the culture of transfusion
• To identify the key elements, which Influence clinical decision making in blood
transfusion in haemato-oncology and lung cancer patients.
Mixed data collection methods were used within an ethnographic methodology for the 
reasons described In section 2.9.2. The evolution of the research and ethnographic 
methodology will be described in more detail in Chapter 3.
95
CHAPTER 3 
Methodology
This chapter begins by reflecting on the purpose of the study and incorporating the 
important elements of the literature review. It is followed by a brief description of the 
original research design and the deficiencies of that design; followed by a description of 
the evolution of the final research design based on interpretive ethnographic 
methodology. Ethnography is described in more detail, with reference to the literature 
and Includes sections on the influence of the researcher, the methodological framework 
and ethnographic observation and interviews, it concludes with a summary of the 
chapter.
The literature review assisted the researcher to develop the purpose of the research and 
similarly the purpose of the research informed the evolution of the methodological 
foundations of the project; and proved to be a creative and iterative process. The 
original research design was briefly described in Chapter 1 (section 1.5); this included a 
quasi experimental component (actigraphy and FAGT-An questionnaire) and an 
ethnographic methods component (clinician interviews and observation). From the 
outset it was recognized combining these data sets wouid be difficult and the risk would 
be that the research would result in large volumes of data that could not reliably be 
integrated. This was highlighted by the ethics committee. Furthermore, as described in 
Chapter 1, the actigraphy and questionnaire may not have captured the patient 
experience of anaemia and transfusion. Following commencement of the study, and 
completion of some of the observation fieldwork, and clinician interviews. It became
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apparent that patients' involvement In the decision making may be important; it emerged 
that by interviewing patients more detail of the experience and their involvement would 
be possible. In other words patients formed part of the social functioning of the group 
involved in the management of cancer related anaemia and transfusion practice. 
Furthermore some of the staff interviewed suggested that patients should also be 
interviewed and some doubt emerged at the outset of the study that the original design 
using actigraphy and questionnaires would fail to meet the objectives of the research 
project. It is argued here that ethnography was valuable because it offered a way of 
holistically exploring the relationships and behaviours within the clinical setting and this is 
described in more detail in the following section. Therefore the final research design was 
a combination of observation and patient and clinician interviews using an ethnographic 
methodology and patient Interviews were Included with the aim of exploring the culture of 
transfusion practice.
3.1 Reflections on the purpose of the research
The researcher reflected on the purpose of the research, which was to explore the 
cultural practices which shape the culture of transfusion; and to identify the key 
elements, which influence clinical decision making in blood transfusion in haemato- 
oncology and lung cancer patients. The risk was that the questionnaire and actigraphy 
data would provide simplistic and reductionist data that wouid not provide the whole 
story, for example, the patient interpretations of what anaemia and transfusion meant for 
them. This change of researcher thinking is more succinctly described in the “Integration 
of knowledge, research and practice” paper and later in this thesis In Chapter 7, but 
resulted in a transition from a positivist approach to an interpretive approach, it was not 
a simple case of measuring the problem, for example, how many patients were fatigued
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or how much activity and rest they had; it was more about listening to what patients had 
to say, observing behaviors and exploring the ideas and concerns which the subjects 
themselves described and interpreting meaning from these descriptions. Add her about 
symbolic interactionism. In summary, researchers who use qualitative methods aim to 
use “a holistic perspective which preserves the complexities of human behaviour” (Black 
1994; 425) and therefore seek to find closeness to the reality rather than just skimming 
the surface.
With the purpose of exploring the transfusion culture in mind, different elements needed 
to be examined. Diagram 3.1 demonstrates the possible elements which may influence 
the culture of transfusion practice; this was developed from the literature review and 
personal experiences. In general terms, individual characteristics such as experience, 
skills and knowledge were considered (both of patients and clinicians); the interactions 
between the individuals and their behaviours; the practices that existed within the 
organization, for example, the opportunities to learn; the meaning of cancer related 
anaemia and biood transfusion for the individuals; the difficulty or simplicity of the task 
(I.e. the clinical decision) and various artifacts that may influence the behaviours for 
example resource, the clinic sizes and laboratory results.
All of these factors could potentially shape the culture and therefore needed to be 
considered at the design stage and throughout the research journey, it shaped the 
design evolution in the sense that the methodology should be able to explore all of the 
elements above and provided rationale for the change from the original research design, 
to include patient interviews in addition to staff interviews in an attempt to explore the
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elements that contribute to the culture of transfusion practice. This transition is described 
in more detail in the following section.
Diagram 3.1 Possible elements for exploration of the transfusion culture
Experience
Arteficts-
(Hfc/resources)
Transfusion
Culture
3.2 Quasi-experimental design to understand the impact of transfusion on the patient 
The original research design as described earlier, was a quasi-experimental approach to 
assess the impact of cancer related anaemia and the impact of transfusion on a cohort of 
anaemic cancer patients. It was limited to haemato-oncology and lung cancer patients. 
The rationale at this stage for choosing these two groups was because the incidence of 
cancer related anaemia is high in these two groups (Estrin et al 1999; Ludwig et al 
2004). The original aim was to establish if there was a relationship between 
haemoglobin levels and blood transfusion with their levels of activity and fatigue. A
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repeated- measures design obviated the need for a meaningful control group as subjects 
serve as their own control group. The original study design included following ten 
patients (five haemato-oncology and five lung patients) with actigraphy for 90 days and 
FACT-An applied at two weekly intervals for the 90 day period. The transfusion culture 
and the elements that Influenced clinical decision making was to be explored by using 
ethnographic clinician interviews and observation in the haemato-oncology and lung 
cancer clinical settings.
The FACT-An scale questionnaire was chosen in the original research design to 
measure the functional status of participants (Appendix 1) (Celia 1997). The FACT-An 
has been used widely in studies measuring the impact of anaemia, for example in CABG 
patients (Bracey et al 1999) and erythropoietin studies (Demetri et al 1998; Glaspy et al 
1997). It was also in the original design to use actigraphy. Actigraphy is a technique, 
which uses a simple, non-invasive instrument worn like a wristwatch (actiwatch) that is 
capable of measuring performance levels in and around the home, as patients go about 
their normal day-to-day activities. It’s usefulness in evaluating functional performance is 
based on the premise that day-to-day activities require varying degrees of physical 
movement. It was believed that this small study would determine if this technique were 
useful in examining cancer-related fatigue and the effects of anaemia on activity and 
functional status. The justification of using FACT-An, and actigraphy was that a pattern 
of fatigue and activity would be established in relation to transfusion. The aim of this 
quasi-experimental component of the study was to present the data in a descriptive, 
diagrammatic and pictorial manner and initially it was felt that this would allow a large 
amount of empirical data to be handled in an unbiased and objective manner, particularly
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as the actigraphy data would be objective. It was hoped that this would provide data that 
could bring some certainty to the uncertain world of managing cancer related anaemia.
Descriptive statistics constitute the clearest and most straightforward means of 
expressing mathematical relationships between variables (Hallett 1997) but the 
limitations are that a simplified reductionist picture emerges. However, the literature 
review had revealed the indeterminacy of anaemia and transfusion practice and if the 
original design had been adhered to, the detail of all the patients’ contributing factors to 
the transfusion culture described in the previous section could not be explored; all that 
may be revealed is what is already known in that the physiological basis of anaemia and 
response to transfusion is unpredictable. It was described earlier in section 2.9.2 the 
MRC (2000; 2008) research guidelines for complex interventions also recommends 
including exploration of behaviours, parameters of behaviours and methods of organising 
and delivering those behaviours (e.g. type of practitioner, setting and location). This 
adds weight to the decision to change the research design to explore the context of the 
anaemia and decision to transfuse. Furthermore, the positivist perspective would be to 
assume experiment and science can solve this uncertainty, however the interpretive 
approach would be to accept this uncertainty and try to understand the meaning of 
anaemia and the human response (either patient or clinician) to the anaemia and 
transfusion behaviours in the clinical setting.
At the outset the aim was the mixed methodology of combining quasi experiment using 
actigraphy and FACT-An would offer an element of qualification and even interpretation 
to the qualitative work (staff interviews) by providing a set of methods by which complex 
meanings and relationships within a set of data can be clarified and understood, for
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example, linking activity levels with the date of blood transfusion and haemoglobin levels. 
But it was not clear what data sets e.g. actlgraph data would illuminate the interview or 
observation data or vice versa; this was a major methodological flaw in the early design 
in that there would be a risk data could not be combined in a reliable way or that data 
could be redundant or over-simplified because the process of data analysis did not have 
reliable foundations. For example, there was no precedent for ethnographic data (from 
interviews and observation) being combined with questionnaire data and actigraphy 
data. It was one of the informal comments from the local ethics committee that a large 
amount of data would be produced and how reliably could the data be analysed and 
linked. Furthermore, by not including patient interviews from the outset, not all of the 
components that may influence the transfusion culture and behaviours would be 
included, for example, the patient experience and interactions with clinicians.
In summary, the aim of quasi-experimental phase of the study was to establish the 
impact of anaemia and transfusion on the patient using four data coliection methods 
(actigraphy, questionnaires and ethnographic interviews and observation) over a period 
of time on a cohort of haemato-oncology and lung cancer patients. The rationale for 
using both questionnaire and actigraphy was to capture subjective and objective data 
respectively. However, as data emerged from some of the staff interviews and 
observations in the clinic it was felt that patient interviews would yield important 
information. Some of the research questions could not be answered by actigraphy and 
FACT-An data; for example the questions concerning patient attitudes about receiving a 
blood transfusion and their involvement in the process. The FACT-An would not reveal 
any information on how patients feel following a transfusion and any subjective 
improvement in function as FACT-An was to be applied at 2 week intervals and not timed
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to coordinate with blood transfusions. This would have been logistically impossible. 
Following some of the staff interviews it was clear the patient was involved in the 
assessment and decision making process therefore it was a logical progression to 
include patient investigation within the same methodological framework as staff. In 
addition, several of the staff who were interviewed presumed that patients would also be 
interviewed, particularly to establish the patient involvement in the assessment of the 
anaemia and any decisions made regarding treatment.
One haemato-oncology patient was initially recruited in the original design phase; 
however, she was admitted to hospital with a severe neutropenic episode therefore she 
was taken off the study. Following discussion with the research supervisors and further 
consideration of the design a substantial amendment was submitted for approval. The 
amendment was to abandon the original quasi experimental design (FACT-An and 
actigraphy) in order to undertake some patient interviews using an ethnographic 
methodology similar to the staff interviews. This would have the following advantage of 
not being dependent on patients surviving the 90 day study period and without hospital 
admission but more importantly allow for exploration into the elements that possibly 
shape transfusion culture as described in section 3.1 as well as give insight into how 
patients actually feel when they are anaemic (their experience); what interactions they 
have with clinicians, the benefits they feel following a transfusion as weii as their 
attitudes to blood. The substantial amendment was approved and the patient interviews 
were undertaken.
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3.3 The Blood Transfusion Audit
Prior to the development of this research proposal an audit was undertaken to establish 
the transfusion trigger and compliance with blood transfusion guidelines. This revealed a 
difference in transfusion triggers between haematology and oncology, the haematology 
trigger was 7.8g/dl and the oncology trigger was 9.2g/dl (Appendix 2: Table 3.3a). This 
provided further rationale to exploring transfusion practice in haemato-oncology and lung 
cancer in order to explore why there was variation in transfusion triggers in the two 
disciplines. It also revealed that the majority of transfusions were two unit transfusions 
(Appendix 2: Table 3.3b). The results of this audit stimulated the development of this 
research project, as further understanding of anaemia and transfusion practice was 
required. Details of the audit are in the “Service Development Project” (Part 2). The 
audit demonstrated the volume of blood usage within oncology and haemato-oncology 
over a three month period. Initially, the service development project outcomes were that 
more education and training may be required in an effort to improve compliance to 
guidelines. The audit also stimulated more questions about why the transfusion practice 
may differ between oncology and haemato-oncology and the possibility of other 
influential patient or staff behaviours.
There were constraints to this audit as the oncology diagnosis data was not accurate so 
it could not be established which tumour types or radiotherapy/ chemotherapy treatment 
sub-groups received more/iess blood transfusion. There were also missing data in 
haemato-oncology, which made comparison between transfusion practice in terms of 
single/multiple transfusions and timing of transfusions impossible. Time constraints 
meant only 202 oncology blood transfusion patient episodes were examined.
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3.4 The evolution of the study’s methodology
In summary, by combining the researcher’s personal experience, the literature review 
findings and the service development project (blood transfusion audit), the final research 
project and methodology emerged. The ethnographic interviews and observations were 
undertaken but in no fixed order, as the project developed, and adaptations were made. 
The order was related to subject and researcher availability. It was an iterative process, 
for example, as knowledge and insight was gained into the assessment of cancer-related 
anaemia and transfusion practice, the content of the interviews changed and different 
personnel were approached in the clinics for more information.
As described in the Chapter 1, personal experience and observation contributed to the 
early evolution of the research, but the researcher experience influenced the project 
throughout all phases and cannot be separated. Assumptions were made in the service 
development project that by merely improving the skills and knowledge of the clinical 
teams that transfusion practice would improve, however the literature review (Section 
2.8) showed that tacit knowledge, social interactions and the culture could influence 
behaviours (Eraut and Hirsh 2007). Earlier in this chapter it was described how the 
reality of transfusion practice was to be explored therefore the underpinning 
methodology was questioned and the purpose of the research revisited. In summary, it 
was this final process; and a combination of the experience and interpretation of the 
literature and audit; and preliminary reflection of the purpose of the study and early 
analytic reflection (clinician interview and observation data) with the supervisors that 
culminated in the final design and underpinning methodology (Diagram 3.4). This 
amendment resulted in a difficult change of attitude and philosophical and ontological
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perspective of the principal researcher, but was necessary to achieve the aim and 
objectives of the study.
Diagram 3.4: The evolution of the study’s methodology
Researcher
experience
Service
development
project
... Development of final 
ie»ea#dimeU*oWoloBY
Literature
review
Preliminary 
analyt c 
reflection
The original design had a partly positivist methodological basis and was partly 
quantitative and partly qualitative and the new design was underpinned only by 
qualitative methodology. There can be conflict between qualitative and quantitative 
methodologies as they are based on competing philosophical positions of positivism and 
naturalism and this was personally experienced by the researcher, and is described in 
more detail in chapter 7 (7.5:The reflexive ethnographic journal) and the paper “Overview 
of integration of knowledge, research and practice” (Part 1). It also contributed to the
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potential difficulty of reliably integrating numerical and graphical data (from the actlgraph 
and questionnaire) with interview and observation data.
Naturalistic research strategies pay attention to what humans feel, perceive and do in 
natural settings that are not experimentally contrived or controlled (Atkinson et al 2001 ). 
A number of qualitative research paradigms derive from naturalism and can Involve long 
investigative processed in order for the researcher to make sense of a social 
phenomenon by contrasting, comparing, replicating and classifying the object of study 
(Cresswell 2002). Naturalism emerged as a challenge to positivism In the 1990’s; up to 
this point the latter dominated in the health and human sciences (Hammersley 1992). 
Naturalism proposes that as far as possible the social world should be studied in its 
“natural statd' and not disturbed by the researcher (Hammersley and Atkinson 1997; p7). 
Naturalism draws on wide range of philosophical and sociological ideas, but especially 
on symbolic Interactionism (described in section 2.8.1), phenomenology and 
hermeneutics (collectively called “interpretivism), (Hammersley and Atkinson 1997; p7). 
Alternatively, positivism argues there is a real world which is independent of people’s 
perceptions.
However, despite the differences between positivism and naturalism they are both 
committed to realism (Atkinson et al 2001). Both are underpinned by the belief that there 
is an objective reality and that the task of social research is to represent social 
phenomena in a literal way, documenting their features and explaining their occurrences 
(Hammersley 1992). They fail to take into account that social researchers are part of the 
world that the study. Thus the process of understanding inevitably reflects the prejudices 
of the researcher. Naturalist and social researchers and logical positivism researchers
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assume that the distance from the data ensures validity; that is, it reduces researcher 
effect (Spencer 2001). The world is revealed to people, not constructed by them and 
therefore causal relationships can be created and for positivists the most important 
feature of scientific theory can be confirmed or rejected with certainty. Interpretivism 
refers to epistemologies or theories about how knowledge of the world is obtained; 
interpretivism loosely relies on interpreting or understanding the meanings that people 
attach to their actions and ethnography is often described as interpretivist or at least anti­
positivist (O’Reilly 2009). In summary, neither positivism nor naturalism provides an 
adequate framework as both neglect the fact the researcher is part of the social world of 
study. It is argued here that ethnography is particularly valuable not only because of the 
attention to context and synthesis of findings from different methods (interviews and 
observation) but also because it offers a holistic way of exploring the relationships that 
underpin clinical practice (Savage 2006a).
In the mid 1980s anti-realism and post-modernism were developed to challenge the 
assumption of an objective reality (Hammersley 1992). In its place, subtle realism 
(Hammersley 1990), analytical realism (Altheide & Johnson 1998) and critical realism 
were suggested. Even though these approaches have their differences, they all share a 
common theme, that knowledge is based on assumptions and human constructions and 
the concept of reflexivity was introduced. Post modernists accept the real world is 
complex, ambiguous and at times messy and contemporary social researchers argue 
that human behavior can only be understood within the context it occurs. The social 
world cannot be understood in terms of simple causal relationships, because human 
actions are based on or influences by social and cultural meanings through motives, 
beliefs, rules, discourse and values. Behavior is linked to the meaning that a situation
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has for a person (Bloor 2001), which by nature would make it complicated and perhaps 
difficult to understand all the nuances involved, but ethnography provides a 
methodological foundation to explore this.
Qualitative research can be subject to criticism as lacking scientific rigor, however, 
qualitative research aims to make sense of or interpret phenomena in terms of the 
meaning people bring to phenomena. However, if the culture of transfusion practice was 
to be reliably explored it is argued here that after a thorough consideration of the 
available theoretical approaches within the qualitative paradigm, ethnography was 
chosen as the most appropriate strategy of inquiry to address the aim of the study. One 
could argue in this case that the reality of anaemia and transfusion practice within the 
cancer care setting was the aim of the study; therefore the ethnographic approach may 
be more likely to represent the reality. Denzin (1997) describes how by using an 
ethnographic methodology:
The ethnographer discovers the multiple truths that operate in the social word; 
these stories move people to action and they rest on a distinction between fact 
and truth [  ]. Truth and facts are socially constructed, and people build stories 
around the meanings of facts. Ethnographers collect and tell these multiple 
versions of the truth (pxv)
The clinical practice occurs in the clinical setting and all that it encompasses, including 
feelings and subjectivity, hence the final methodological design of ethnographic 
interviews and observation of all parties, including the patients, seemed logical. The 
researcher’s instinctive approach to this research was to try to make a quasi 
experimental (positivist) methodology “fit” with the purpose of the study. It was therefore 
a convoluted journey to arrive at the final research design but it felt more comfortable,
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and helped to “complete the picture” in a way that the quasi experimental methodology 
may not have fulfilled. It could be argued that this journey may have been necessary for 
the researcher to change epistemological stance; or that natural tendencies meant that 
the researcher’s ability to undertake an ethnographic study would be limited. This will be 
discussed in more detail later when summarizing the reflective journal in section 7.6. It 
has been demonstrated in this section that the dominant critical element for the author 
was a return to the original research question and purpose of study, to reach a 
conclusion as to what methodology and design could fulfill all elements of the study.
3.5 Ethnographic methodology
From the literature review and the clinical audit results it is clear there are many facts 
known about the incidence of cancer-related anaemia and the volume and practice of 
blood transfusion. However, as mentioned there is limited understanding of how a 
patient presents with anaemia in the clinical setting and the interactions that follow with 
the healthcare professionals that culminates in the decision to treat the anaemia with a 
blood transfusion. To gain more insight into the process, an examination of the “culture 
of transfusion practice” would be required. Ethnography is "the work of describing a 
culturd' and typically uses observation techniques to both study and learn from people 
(Spradley 1980; p3). The ethnographic researcher may use many approaches to 
explore a social group or cultural tradition but the ultimate aim is to conduct the research 
in the "natural context” and takes into account the flaws, restrictions and opportunities 
that encompass the lives of the participants in a given social situation (Serrant-Green 
2007; p4). There is an attempt to interpret the culture by eliciting meaning from 
observation and interviews of the participants. Given that there was so much variation in 
the clinical practice of the management of cancer related anaemia it was the obvious
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methodological basis for this research and one could argue that patient interviews should 
have been included in the original research design. This ethnographic approach would 
allow for exploration into the factors that underlie variation in practice and explore the 
impact of the individual patient and staff factors. Furthermore, by taking an interpretive 
stance within ethnography offers a holistic way of exploring the relationships between the 
different behaviours and interactions that underpin the clinical practice of transfusion; it is 
the small scale interactions between individuals that required exploration and the 
exchange of symbols in social interaction, that is the "symbolic interactionism" described 
in section 2.8.1 that is being explored in this study. For example, drawing on the work of 
Mead it is the covert as well as the over behaviours which are of interest to the 
researcher and the Interactions that occur between individuals. G off man referred to "the 
team" as a group of people who cooperate to maintain a particular definition of a 
situation; he describes this as "situational propriety’ (Goffman 1963) which refers to the 
way in which the meaning of actions or concepts is dependent on the context in which 
they emerge. This notion ties in with the earlier point in section 2.7 in that as human 
beings we gradually learn practical and tacit knowledge which enables us to understand 
the meaning of actions within a particular context. Goffman provided insights into the 
complex interrelationship between self-presentation and others, and social theorists such 
as Giddens developed this further to describe how this notion is central to the production 
of social order and predictability in daily social interaction. It may be that blood 
transfusion practice for example can be explained by this symbolic order because it is 
dependent on the coordination of everyday social interaction. It is the social interactions 
in "the teamd' which are examined in this study using an ethnographic methodology.
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3.5.1 The researcher’s influence
The researcher is integral to the success of ethnographic research and is intimately 
bound in the research pathway as described earlier, from the project’s inception the 
researcher’s experience, attitudes and epistemological stance shaped this project. One 
way of making the researcher’s Influence transparent is by keeping a reflexive diary; in 
this way the diary can be analysed at project completion to describe this journey of 
learning, thinking and reflection. Brewer (2000) describes the researcher involvement in 
ethnography:
"Ethnography is the study of people in naturally occurring settings or field by 
methods of data collection which capture their social meanings and ordinary 
activities, involving the researcher participating directly in the setting if not also 
the activities, in order to collect data in a systematic mannef’ (p6).
Delamont (2004) describes further:
"Participant observation, ethnography and fieldwork are all used 
interchangeably.,.they can all mean spending long periods watching people, 
coupled with talking to them about what they are doing, thinking and saying, 
designed to see how they understand their world’ (p218)
The researcher spent periods of time interviewing and observing and although they may 
not be technically described as “long periods”, the research design was developed to try 
to “understand their world” of transfusion. There is “no escape” for the researcher and 
she had to first acknowledge her own attitudes, behaviours and persuasions and how
112
they impact on the way in which the research is undertaken; a level of reflexivity was 
required to attempt to establish the reality of practice. The reflexive diary was essential 
for data analysis and insight into changing attitudes as the research progressed. In 
summary, ethnography as a study approach requires the researcher to become partially 
immersed in the field by making careful records of observations and asking participants 
for an explanation. The methodology of this phase of the study is strongly “em/c" an 
approach that involves eliciting meaning and perceptions from the informant’s viewpoint 
(Morse 1994), rather than the researcher’s viewpoint, which is known as “etid\ although 
the researcher should be aware of their own personal attitudes and experiences as this 
may influence the interpretation of what is being observed. This is an important 
consideration in study design when determining the level of participation by the 
researcher.
The style of writing of the ethnography is worth a mention. Critics of ethnography note 
the tendency of ethnographers to write in the first person as if their account was the one 
true voice of authority (Hammersley and Atkinson 1995; O’ Reilly 2009). Whilst it is 
important to place oneself in the research and in context, there is no prescriptive method 
for writing the ethnography but the “legacy of the reflexive turn is the demand to think 
consciously about writing styles and the nature of the argument (O’Reilly 2009, 190); for 
example, it has to be decided if it is written in past or present tense; first person or an 
authoritative voice. In summary, the researcher used the advice of O’Reilly (2009):
“..whatever is decided about the writing, our responsibility is to those we study. 
Studies can be rich, evocative, colourful, and a pleasure to read, but should 
retain an authoritative status as a piece of scholarly research if this is what we
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have told our participants. Similarly, we cannot forget there is a real world out 
there that we studied, social actors who allowed us into their lives to do so and 
maybe gatekeepers who permitted access to the group.” (190)
In conclusion, the researcher decided to write in the authoritative voice and attempt to 
locate herself in the different cultures of haemato-oncology and lung cancer (Clifford and 
Marcus 1986) through descriptions of her clinical observations and interview 
transcriptions within the clinical arena of cancer related anaemia. It could be argued a 
true ethnography does not necessarily fit the order of a doctorate thesis and the 
prescriptive chapters that are required, but this is a scholarly document that has a 
predetermined construction; it was therefore important to write an account that was 
neither overtly subjective nor lacking in methodological detail (Bennett 2002).
3.5.2 The methodological framework of ethnography
Ethnography is concerned with people's behaviours in everyday contexts rather than 
under unnatural or experimental circumstances. Data is usually collected by observation 
and interviews and tends to be flexible and unstructured to avoid pre-fixed assumptions 
that impose on what people say or do. Bloor (2001) encompasses all the previous points 
asserting that ethnography is the product of engagement with a group of people, the 
observer’s understanding and a reflexive concern with the relationship between the 
researcher and participants. Rather than ignoring the influence of the researcher as 
described in the previous section, ethnographers show the nature of the relationship and 
how they use reflexivity to tease out the participants’ experience and their own. For 
example, the researcher’s background was in haemato-oncology with less experience in
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oncology and therefore It was important not to make assumptions about the practices 
within oncology but use the data as the evidence.
One way of addressing the differences and commonalities in perspectives is through the 
approach of analytic realism (Altheide and Johnson 1998). This is based on the view 
that the social world is an Interpreted world, not a literal one, but one which is always 
constructed by the ethnographers who study them. While the ethnographer’s 
commitment is to obtain people’s perspectives on social reality, analytic realism 
recognises that most fields have multiple participants and multiple perspectives. This 
means the ethnographer must attempt to report this multiplicity and demonstrate where 
her voice is in relation to the others. Because of the researcher’s background it is 
therefore appropriate to frame this study within analytic realism; in this way feelings, 
perceptions, behaviours and actions of the staff and patient participants will be included 
and reflect the multiple voices and perspectives that influence the assessment and 
decision to treat cancer related anaemia. In summary, ethnography seeks to explain 
both specific aspects of a culture (what all members are aware of and take for granted, 
e.g. blood is donated and readily available and no questions are asked about it’s use) 
and tacit elements, which are outside one’s awareness, (e.g. attitude to blood 
transfusion, intuitive decision making).
3.5.3 Ethnographic observation and interview
Observation can be a useful tool for exploring and uncovering the knowledge base and 
clinical practice in a chosen setting (Kennedy 1999). Observation helps us to make 
sense of the world around us and guides our decisions and actions, it has been 
suggested that there is a need to distinguish between the technical/rational type of
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knowledge (knowing that) based on empirics and the “know how” based on professional 
artistry (McIntosh 1996, p320). The healthcare professional may have the knowledge 
and skills to rationalize the decision to transfuse but may use tacit knowledge to aid the 
decision or it may be due to personal characteristics, for example, confidence to withhold 
transfusion until stronger evidence is available. In addition, groups of health 
professionals may make different decisions to those of individuals. Although a group 
may agree for example to not transfuse unless the haemoglobin is less than 8g/dl as per 
hospital guideline, a healthcare professional faced with an individual patient may tend to 
err on the side of caution or rely on personal experience or it may be more strongly 
influenced by how well they know the individual patient. Therefore exploration of the 
knowledge underpinning the decision-making surrounding the decision to treat cancer 
related anaemia requires a research approach that could account for the complexity of 
the activity, give consideration to the personal characteristics of those involved and the 
context of the care setting where these decisions are made.
Participant observation combined with in depth interviewing has the potential to 
illuminate previously covert patterns of behavior and decision-making and would yield 
richer data (Hammersley and Atkinson 1995). In this research, the "participant as the 
observer “ was the model adopted whereby the specialist nurse (the researcher) 
observed in the clinic and took field-notes; she was an occasional participant in these 
clinics, and had experience in assessing and managing anaemia. It has been suggested 
there is a spectrum of participation, where the researcher is either a complete observer, 
or at the other extreme a complete participant whereby the data is collected covertly 
(Figure 3.5.4). The extreme forms may be unethical because they violate either the right 
to autonomy or hide the fact that the researched are being are observed (Hammersley
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and Atkinson 1995) although the ESRC guidelines (2007) approve extreme forms for 
some social research. The reality is that the researcher was somewhere between these 
two extremes and combined overt and covert observations but gained consent when 
necessary. Moderate participation occurs when the researcher seeks to maintain a 
balance between being an insider and an outsider, between participation and 
observation. The active participant seeks to do what other people are doing and the 
ethnographer tries to learn the cultural rules of behavior. A degree of involvement in the 
clinic was inevitable as the researcher was a known clinical figure but fortunately not 
routinely involved in any of the clinics.
Figure 3.5.4: Spectrum of participation and observation
< ^
Complete Observer Complete participant
Participant observation was chosen because transfusion practice Is heavily influenced by 
experience and it was thought to be an advantage if the researcher shared the same 
professional experience to decide what questions to ask. However, the known observer 
can disturb the natural environment, and may cause a change in normal behavior and 
consequently the researcher can record unreliable data; this should be taken into 
account during data analysis. Silverman (2006) describes the aims of observational 
research (p68):
1. Seeing through the eyes of: viewing events, actions, norms, values etc. from the 
perspective of people being studied
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2. Description: attending to mundane detail and to help understand what is going 
on in a particular context and to provide clues and pointers to other layers of 
reality
3. Contextualism: can understand events only when situated in the wider social and 
historical context
4. Process: viewing social life as involving interlocking series of events
5. Flexible research designs: open and unstructured research design which 
increases the possibility of coming across unexpected issues
6. Avoiding early use of theories and concepts (p68)
A qualitative approach using both observation and interviews and taking interpretivist 
ethnography as the philosophical and theoretical context allowed the researcher to 
explore the traditional practices of transfusion and clinicians’ and patients’ attitudes to 
transfusion. Dialogue between the researcher and the researched was essential 
(Murphy 2005); for example, the ethnographic interview would require identification of 
appropriate informants, which may follow on from the observations or may be part of the 
same process, but in this case the clinicians were approached either during the clinics or 
during separate conversations when opportunities arose. Spradley (1979) describes the 
ethnographic interview as a "speech event, which shares many similarities with the 
friendly conversation” (p58). He further describes how many ethnographers gather much 
of their data through conversations during participant observation, slowly introducing new 
elements to assist informants to yield more information. Both explicit and tacit cultural 
knowledge are revealed through speech, whether in casual comments or lengthy 
interviews and every ethnographer makes use of what people say, in seeking to describe 
his or her culture. Because language is the primary means of transmitting culture from
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one generation to the next, much of the culture is encoded in linguistic form; therefore 
the combination of interviews and participant observation was justified in this study. 
Inferences can be made from what people do, for example, in clinic, (cultural behavior) 
and by listening to the language, therefore consideration must be given as to what 
language will be used, for example, verbatim or concrete language or use of 
generalizations. Exclusive use of the ethnographic elements, or introducing them too 
quickly, would make the interviews too formal and more like an interrogation. This would 
threaten the aim of the interview, which was to find out what processes, skills and 
knowledge are used to influence the clinical decision to transfuse. Rapport would 
evaporate and cooperation may discontinue. The informants would probably perceive 
the aim of the study to reduce blood usage therefore this would influence their responses 
therefore the ethnographer had to be aware of their own influence on informants’ 
behaviour and responses. Furthermore, earlier nursing ethnographic study has revealed 
that discrepancies can occur between narratives during interviews and the reality of 
practice (Allan 2006) and therefore this adds weight to the use of ethnographic 
observation to determine the social behaviours, which culminate in a blood transfusion 
episode. In this case, the researcher did all of the observations and interviews; the 
researcher was a senior nurse in the clinical areas therefore this had to be considered in 
analysis if the interviewees described behaviours that was not observed in clinical 
practice, particularly if any behaviours were contrary to guidelines or policy. The 
relationships between the interview and observation data will be described in more detail 
in Chapter 5 (section 5.1) and how the data were integrated.
In summary, ethnographic research can help healthcare professionals to solve problems 
beyond the reach of many other research approaches, particularly in the understanding
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of patients’ and clinicians’ worlds. The ethnographic phase of this study attempted to 
make sense of transfusion practice by not only presenting the findings from the viewpoint 
of the individuals involved, but also by embedding the social context of that experience in 
the research process. The context in which experiences occur are a key strength of 
ethnography in enabling service providers, healthcare professionals and policy makers to 
use the results of research in initiating, developing or evaluating healthcare and social 
care practice or by developing further study.
3.6 Summary
The initial study design of combining qualitative and quantitative methodologies can be 
tempting because this approach would seem to give a "fuller picturê’ (Silverman 2006, 
p51), however, multiple sources of data may require more advanced data analysis skills. 
The temptation is to move between data sets and focus on one more than other when 
difficulties arise. This provided further weight to the decision to amend the original 
design, as this had not been thought through in robust way.
In summary, this research project harnessed a variety of different ethnographic methods 
to qualitatively interpret clinical practice, rather than seeking to quantify and measure its 
effects by quantitative methods. Therefore it was not value free and acknowledges the 
human contribution to the process, which would not be acceptable to the positivist 
researcher, it is these features, which make it suited to the research of the diagnosis 
and treatment of cancer-related anaemia as it has already been stated there is 
subjectivity involved in the assessment and management of this type of anaemia and 
wide variation in practice. It was an interpretivist approach whereby the researcher 
explored the symbolic interactionism in the function of the group involved in transfusion
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practice to construct an account of the transfusion culture in cancer related anaemia; 
with emphasis on the key elements involved in the clinical decision to transfuse. If there 
is to be an improvement in the understanding of clinical practice, the individual and social 
contributions, needs to be acknowledged. It is not merely treatment of a laboratory value 
but a complex decision, which is influenced by a multitude of factors, and the degree of 
influence of these factors is unknown; or alternatively, it may be a complex decision, 
which has been simplified, by focusing on laboratory values, but the fact remains the 
reality of cancer related anaemia diagnosis and treatment is relatively unknown. This 
methodology fits with this project because it was not clear at the outset what factors were 
involved in the assessment and management of cancer related anaemia. This 
methodology may also be used to help practitioners critically reflect on and examine their 
work practices and social interactions, to arrive at some sort of consensus of what kind 
of services could be provided and why they need to be provided in a particular way. it 
could be described as a critically reflexive model of research, being both practice-based 
and patient-centered in its philosophical methods. It is only following an analysis of the 
diagnostic processes and decision to transfuse that an understanding of the influencing 
factors will be ascertained and optimal transfusion strategies may be developed for 
patients.
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CHAPTER 4 
Method
This chapter begins by describing the participants in this research, including exclusion 
and inclusion criteria, and how entry was gained to the field, it includes a description of 
how the data was collected followed by the relevant ethical concerns in social and 
ethnographical research. The data collection proceeded in no fixed order and was 
subject to participant and researcher availability (Diagram 4).
Diagram 4: Chart demonstrating data collection
Observation Patient interviews
Haematology clinic
A N Haematology patients A N
Lung clinic
Vi----- 1/
Lung cancer patients )Haematology Day Unit N / N /
Oncology Day Unit
Staff interviews
Consultants 
Specialist Registrars 
Day unit nurses 
Clinical Nurse Specialists
4.1 Patient Participants and data collection
The criteria for patient selection was agreed and decided on following consultation with 
Consultant Haematologists and Oncologists; advice was also sought from the 
transfusion lead Consultant and Transfusion Practitioners and the nursing teams.
4.1.1 Patient participants
Potential participants were identified by, either the Haematology or Oncology day care 
unit staff, or medical staff in the clinics as they were in frequent contact with out-patients
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who regularly attend for blood transfusion. See Table 4.1.1a for initial inclusion and 
exclusion criteria for patients to be considered for study.
Table 4.1.1a: inclusion and exclusion criteria (patients)
Inclusion criteria
1. Male or female lung cancer out-patients or haemato-oncology outpatients who 
have cancer-related anaemia and who are supported with regular blood 
transfusion therapy. This was defined as patients who have received blood 
transfusion at least once every two weeks for the previous month or in whom it is 
anticipated blood transfusion support will be required.
2. Patients must be willing and able to complete the Functional Assessment of 
Cancer Therapy-Anaemia (FACT-An) questionnaire
3. Patients must be willing to wear the actiwatch
4. Subjects must be able to and understand and have signed the written, informed 
consent form and the written information provided therein. Appropriate time 
should be allowed for consideration and questions.
Exclusion criteria
1. Patients who are on erythropoietin therapy
2. Patients who are in any other investigational trial or therapy relating to anaemia
3. Patients who cannot read and write English because of problems of interpreting 
and completing the questionnaire
The aim for the quasi-experimental component of the study was to recruit five haemato-
oncology and five lung cancer patients to study. Potential participants were approached
by the researcher during a routine visit to the Haematology or Oncology Day Care and/or
Outpatients in a South East England NHS Acute Trust, and invited to take part in the
study. Patients were provided with the information sheet (version 2) (Appendix 3) and
actiwatch information sheet (version 2) (Appendix 4). The researcher provided an
explanation for the study at this stage and gave opportunity for any questions. The
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patients were asked to return to their next clinic appointment with a decision to enter the 
study and, if agreed, asked to complete the consent form (Appendix 5). Contact details 
for the researcher were provided. Once the consent form was completed a letter was 
sent to the patient’s GP (Appendix 6) and hospital Consultant. A copy of the consent 
and GP letter was filed in the patient case-note and with details of the research and start 
date documented in the patients’ medical records. Each patient was assigned a unique 
identification number (e.g. PH1, PH2 etc for haematology patients and PL1, PL2 etc for 
lung cancer patients) to assure anonymity.
Initially one haematology patient was recruited to the original design. Unfortunately she 
was admitted to hospital during the second 45 day period of observation and therefore 
data collection was discontinued. A second haemato-oncology patient was approached 
and he declined due to his concerns about further responsibility in addition to his 
concerns about his health and treatments. A lung cancer patient also declined for similar 
reasons. These factors contributed to the decision for the substantial amendment and 
change of research design as described In Chapter 3.
Substantial amendments were made following the closure of the quasi experimental 
component of the study, which were approved by the local research ethics committee. 
The inclusion and exclusion criteria were revised (Table 4.1.1b). The details of the data 
collection for the ethnographic interviews are described in section 4.1.3.
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Table 4.1.1b: Revised inclusion and exclusion criteria (patients)
Inclusion criteria
1. Male or female lung cancer out-patients or fiaemato-oncology outpatients who 
have cancer-related anaemia and who are being supported with regular blood 
transfusion therapy. This was defined as patients who have received blood 
transfusion at least once every two weeks for the previous month or in whom it is 
anticipated blood transfusion support will be required.
2. Patients must be willing to be interviewed
3. Subjects must be able to and understand and have signed the written, informed 
consent form and the written information provided therein. Appropriate time 
should be allowed for consideration and questions.
Exclusion criteria
1. Patients who are on erythropoietin therapy
2. Patients who are in any other investigational trial or therapy relating to anaemia
3. Patients who cannot read and write English because of problems of interpreting 
and completing the information sheet and consent form
4.1.2 Patient demographic data
Patients were interviewed in no fixed order and dependent on availability and consent 
(Appendix 7: Table 4.1.2a). Following consent of the patient participants, demographic 
data was collected on the age, sex and diagnosis and current therapy of the patient at 
entry, and whether they were working, family details as well as the timing and volume of 
blood transfusions. Demographic data was available on Electronic Patient Record and 
casenote record. Detailed information about family and work was obtained prior to 
interview. This data is shown in Appendix 7 (Table 4.1.2b; Table 4.1.2c and Table 
4.1.2d).
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4.1.3 The ethnographic interview
Potential patient participants were Identified by, either the Haematology or Oncology day 
care unit staff, or medical staff in the clinics as they were in frequent contact with out­
patients who regularly attend for blood transfusion. The aim for the patient ethnographic 
Interview component of the study was to recruit three haemato-oncology and three lung 
cancer patients to study. Potential participants were approached by the researcher 
during a routine visit to the Haematology or Oncology Day Care and/or Outpatients 
Department or day care units in a South East England Acute NHS Trust, and invited to 
take part in the study. Patients were provided with version 4 of the patient information 
sheet (Appendix 8) and an opportunity to ask questions. All the patients who were 
approached agreed to be interviewed. They signed a consent form (Appendix 5) on their 
next scheduled visit and were subsequently interviewed using a digital tape recorder in 
either the “Quiet Room” or a single room in the ward area. Patients were assigned a 
unique identifiable number (ID number) and were identifiable thereafter by their unique 
ID number only. Some interview questions were formulated in advance (Appendix 9), 
however, other questions evolved as a reaction to the patients’ responses
All Interviews were subsequently transcribed by the principal investigator and the digital 
recording removed. A sample of transcribed data is shown in Appendix 10.
4.2 Staff participants and data collection
Prior to undertaking this research, there had to be some insight and understanding of the 
processes and environments where the assessment and clinical decision making 
activities were undertaken. The potential participants needed to be considered. The
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researcher had prior experience in the management of cancer related anaemia and had 
prior knowledge that day care unit nurses, Clinical Nurse Specialists and medical staff 
were involved at various stages of the processes.
This research project required gaining consent form the multi-professional team. Key 
personnel involved included:
Nurse Consultant (Haemato-oncology)-research project lead 
Consultant Haematologist- Transfusion and haematology lead 
Consultant Haematologists 
Consultant Medical Oncologists (Lung Cancer)
Haematology and Oncology Specialist Registrars 
Clinical Nurse Specialists 
Haemato-oncology and oncology nurses 
Haemato-oncology and lung cancer patients
4.2.1 Staff participants
Clinicians (nurses and doctors) were interviewed in no fixed order and dependent on
availability and consent (Appendix 7: Table 4.2.1). The researcher approached the
directorate team via e-mail or by directly approaching clinicians for volunteers who were
involved with patients with cancer related anaemia. All clinicians were invited to
participate via letter and received an Information Sheet (Appendix 11). Each interviewee
assigned a unique number so the primary researcher could only identify them (e.g. SHI
-staff haematology 1; SL1 -staff lung 1 etc). The random numbering was due to staff
being approached and assigned an ID number but subsequent difficulty in arranging an
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interview time. They were given an opportunity to have questions answered and were 
only interviewed following signed consent to participate in this study (Appendix 12).
4.2.2 The ethnographic interview (clinicians)
The interviews were undertaken in a private facility, for example, a pre-booked seminar 
room, clinic room or single office. The interview was recorded using a digital recorder. 
Some pre-determined questions (Appendix 13) were used to attempt to ensure aspects 
of assessment and transfusion practice were discussed however the interviewer had to 
be flexible and respond to answers in an instinctive way. Nine interviews were 
undertaken and included healthcare professionals from each group: Consultant,
Specialist Registrar, Day Unit nurses. Clinical Nurse Specialists and Anaemia Clinical 
Nurse Specialist; the latter primarily cares for patients with non-mallgnant disorders 
although has experience of cancer related anaemia. The ethnographic interview was 
more like a conversation, whereby the interviewer slowly introduced new elements to 
assist informants because if the interview is too formal rapport may disintegrate and 
cooperation will cease (Spradley 1980, p59). Ail of the interviewees were previously 
known to the researcher and the implications of this will be discussed in the sections on 
ethical considerations (sections 4.4 and 4.5) and reflexive ethnographic journal (section 
7.6). All interviews were subsequently transcribed by the principal investigator and the 
digital recording removed. A sample of transcribed data is shown In Appendix 14.
4.3 Observation fieldwork
The researcher had the advantage of knowing all of the clinical areas, Including clinics 
and day care units. Access was not a problem with this research, as the relevant 
clinicians had been approached at the early design stage of the research.
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4.3.1 Gaining entry to the field
Gaining entry Into clinics was via the Consultant in charge of the clinic. The lung medical 
oncology/haemato-oncology Consultant was informed by letter and e-mail of the 
intention to commence the study and the primary investigator gained consent to 
undertake observation in their clinic (Appendix 15), although informal discussion had 
previously taken place during project design phase. Assurances of unobtrusiveness was 
described as the observer was making field notes only and was not involved in any 
assessment or decision-making behaviors. The clinics and day care units are all in a 
single centre acute Trust. The level of participation in these clinics varied as some of the 
patients and personnel were more intimately known to the investigator. Generally, 
gaining entry was not an issue as the primary investigator was known in all areas to 
varying degrees. This was perceived as an advantage in this study.
4.3.2 Observation fieldwork data collection
Initially the researcher attempted to use the pre-designed data collection form (Appendix 
16) however this was soon abandoned in preference for a small notebook as this was 
pragmatically easier to collect the data. Direct quotes and descriptions of body language 
were included as observed. The field notes differentiated between pure observations 
e.g. “the patient looked pale” from the primary researcher's opinions, e.g. “I felt the 
clinician brushed aside the patient’s complaints of tiredness”. Plans were made of the 
clinic areas in an attempt to demonstrate the complexities of the physical environment.
Data collection was undertaken according to researcher and participant availability. 
There was no pre-determined sequence of data collection as described. Observation in
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the clinical field was determined by researcher availability to coincide with clinics and day 
care activity in progress. Six clinic/day care episodes were observed (three haemato- 
oncology clinics/day care units; three lung clinics/oncology day units) in total. The 
haemato-oncology clinic and day care units are separate from the oncology clinics and 
day care units. Plans of the out-patient clinic are shown in Appendix 17 to demonstrate 
the number of clinic rooms in each area and more specifically to demonstrate the 
complexity of the oncology out-patient clinic design.
Each clinic is approximately 3-4 hours duration but the actual time spent in the clinical 
areas was variable and dependent on activity particularly as more focused data 
collection was the aim in later observations. See Appendix 7 (Table 4.3.2a) for 
observation fieldwork schedule.
Clinic and day care activity lists were obtained and the patient haemoglobin recorded. 
Following each clinic data collection episode, any gaps were filled immediately following 
the clinic to attain as accurate a field record as possible. In some clinic situations it was 
easy to record data verbatim, for example, during consultations. Other observations had 
to be completed immediately following the period of observation and attempts to 
transcribe as faithfully and accurately as possible. All filed data were transcribed into 
Word document and data on patient haemoglobin and transfusion data recorded on a 
spreadsheet. The sample of fieldnotes is in Appendix 18 and the haemoglobin and 
transfusion data is shown in Appendix 7. Table 4.3.2b demonstrates the differences in 
the size of lung and haemato-oncology clinics. Table 4.3.2c demonstrates the number of 
anaemic patients in the clinics, using the NCI criteria as described in section 2.2.1 (Table 
2 .2 .1)
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4.3.3 Managing the disruptive effect of the researcher
The roie adopted by the researcher during periods of observation was clearly defined 
from the outset It can be difficult not to volunteer opinions and a balance has to be 
achieved between establishing trust and rapport while retaining enough distance for the 
purposes of data collection. The researcher wore her clinical uniform (as is standard 
practice for this level of nurse in this Trust) and collected data in an unobtrusive way and 
evaded questions, which may have influenced the assessment and decision to treat 
anaemia; it would have been unusual to have been in the clinical areas in civilian 
clothes. Inevitably she was drawn into patient and staff conversations. There were 
some ethical issues here as the researcher was known to some participants as a 
manager and to others as a nurse consultant. This will be discussed in more detail in 
section 4.5 (ethical issues).
4.4 Managing multiple data sets
The data were managed as a continuous process during data transcription. Some 
analysis and synthesis of results of ethnographic data as it was collected revealed the 
emergence of new information, for example, the involvement of multiple people in the 
decision making process. It was not a simple interaction between a clinician and or 
nurse and a patient but a process, involving multiple players, therefore the plan changed 
slightly to include observation in the day care units as it was revealed some of the 
important patient and staff interactions occurred in this healthcare setting as well as the 
out-patient clinics. This influenced subsequent observations and interviews and the data 
collection phase merged into the analysis as the principle investigator’s knowledge and 
understanding changed. Both ethnographic interviewing and participant observation, 
whether done separately or in combination, involve a series of tasks best carried out in
131
some kind of sequence. The ethnographer for example, must locate a social situation 
and informants before doing interviews and participant observation. Some questions are 
best asked before others and observation and interviews must precede analysis of 
interview data (Spradley 1980), however, slight modifications to order of data collection 
were necessary as dependent on availability of participants and researcher. Combining 
the data will be described in more detail in the data analysis in section 5.1.
4.5 Ethical issues
Ethics will be discussed in relation to social research and more specifically the issues 
within ethnography.
4.5.1 Ethical issues in social research
Research ethics is usually concerned with issues such as the need for voluntary (not 
coerced) participation, with the right to withdraw from the study or retract consent, and 
this is stated in the patient and staff information leaflets. Participants must have 
informed consent and be protected from becoming psychologically or physically harmed 
by the research project or exploited in any way. Less obvious ethical issues include 
accurate recording and safe management of data produced by the project with adequate 
feedback and reporting of progress. Therefore both staff and patients only participated 
in the study following informed consent and were provided with a photocopy of their 
consent form. All participants were allowed time to consider their participation in the 
study. This was always more than 24 hours. All patient and staff data was anonymized 
at the point of data collection and in any subsequent presentation or publications 
including this doctorate thesis. Patient consent forms were filed in the patient case notes 
with copies held in the site file.
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All documentation, i.e. copies of consent forms, and data were kept in site files in a 
locked room within the principal investigator’s office during the active phase and later 
stored in the research office (Haemato-oncoiogy) for ease of any subsequent Medicines 
and Healthcare Products Regulatory Agency inspections and to comply with Good 
Clinical Practice (GOP) guidance. The researcher completed local GOP training in 
March 2007.
Issues of confidentiality and anonymity in clinical research can be contentious because 
projects and results are often made public in order to gain support and thus participants 
and their setting is relatively easy to identify once a report is published. Therefore, there 
was careful consideration when writing up this research project to ensure any staff and 
patients were anonymized. In summary, ethical issues had to be considered throughout 
all stages of this research project including respect of privacy if patients objected to the 
presence of the researcher.
4.5.2 Ethical concerns in ethnography
Sensitivity during the observation phase of the project was required because although it 
does not involve the patient being asked any questions directly, patients may object to 
the presence of the observer in clinic. Baillie (1995) highlights the problems of obtaining 
consent in ethnographic studies. She identifies a number of nursing studies in which the 
researchers have not explained if or how they obtained consent where the observations 
involved patients. Moore and Savage (2002) also outline more specific dilemmas in 
gaining consent in observation studies such as marginal participants and the problem of 
not being able to control who enters the field of observation. Even when the aims of the
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research have been made explicit, it is not uncommon for participants to forget this 
(Hammersley & Atkinson 2003) and this is probably more likely in this case when the 
ethnographer is known to the staff and patients in the clinical areas. It is probably further 
compounded by the fact the researcher is trying to build a rapport in an attempt to gain 
the confidence and minimise reactivity. Hammersley & Atkinson (2003) describe how 
ethnographers rarely inform all “participants” during observation and this was the case in 
this research. Anonymity would be the key to ensuring ethical principles are maintained 
particularly if controversial or poor practices are revealed. Sensitivity was required in this 
project; some of the staff participants for example, described what they believed to be 
poor practice. This was not necessarily the case as it was part of the discovery process 
and will be described in greater detail in the findings and discussion sections (section 5 
and 6).
In the introduction, the researcher described her own observations and experience of the 
management of cancer related anaemia. Awareness of this was required throughout the 
project and the researcher's own changing attitudes and opinions as the data and 
information emerged. Openness and frankness was required at the supervision 
sessions and feedback from the supervisors was used as a way of validating the 
findings. Notes were taken and the reflexive diary used. There needed to be an 
appreciation that the subsequent analysis was the researcher’s version of the reality and 
an acceptance that others may view the data differently. Furthermore, the researcher’s 
clinical background was in haemato-oncology and not lung cancer; clinical knowledge 
was greater in this area and may influence the behaviours of the researcher and the 
interpretation of the data. It is important therefore the researcher does not pre-judge, 
force interpretations of the data to fit with their beliefs but instead the researcher acts as
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a resource to make sense of the data; otherwise the risk wouid be unreliable findings. 
As Hammersley and Atkinson (2007) state:
“This requires the exercise of some anaiytic nerve, tolerating uncertainty and 
ambiguity in one’s interpretations and resisting the temptation to rush to 
determinate conclusions. " (163)
In a sense, the foundations of the analysis lies deep within the data; this necessitates re­
checking and re-visiting the data to ensure the emerging findings are an interpretation of 
the reality, and this is often not immediately apparent.
Moore and Savage (2002) summarise by stating that rather than being very prescriptive, 
researchers need to be able to respond to any changing circumstances in the field and 
deal with them in a pragmatic way. This was a problem in one of the heamatology clinics 
when a patient known to the researcher became distressed following information of a 
relapse in her disease and the researcher had to terminate the fieldwork observation 
temporarily to offer support to the patient and seek assistance. To avoid any ethical 
concerns, any patients who may be involved in the observation phase of the study were 
asked by the researcher for consent to undertake observations in clinic or sit in during 
consultations. This is recommended to clarify or avoid concerns, which may later 
emerge (Kennedy 1999) therefore an explanation to the reason for the researcher’s 
presence was explained prior to any consultations observed. The difficulty arose 
however during general observations of environment and behaviours In open areas 
when overhearing conversations in an attempt to create an image of the space and 
culture of the clinic or day unit areas. This is more significant if there is potential to
135
cause harm, distress or embarrassment to the people who have been studied. In 
summary, it is the responsibility of the ethnographer to try to act in ways that are ethically 
appropriate, remembering the aims of the research whilst balancing any problems that 
are encountered and respecting the values and interests of the people involved. The 
researcher should be able to support their actions and judgments if challenged and 
recognise that others may disagree with the arguments presented.
4.6 Conclusion
This chapter described the data collection and the ethical considerations in undertaking 
this type of research. The data are displayed in the appendices and some reference will 
be made to the demographic data in the following chapter. The data collection and 
analysis were not discrete activities; during the data collection period early ideas and a 
“sense of what was going ori’ was emerging. Some of the content of the interviews and 
observations were surprising and therefore required the researcher to think it through 
and discuss the emerging themes with the supervisors. The following chapter describes 
the findings and the process of data analysis to demonstrate to the reader how the final 
themes emerged from the different data sets.
136
CHAPTER 5 
Data Analysis and findings
This chapter describes the process of analysis; how the different data sets were 
integrated to produce the findings of the study. All the data collected were organized 
and transcribed by the researcher. The demographic data of the clinics (e.g. size of the 
clinics, frequency of anaemia) and patients (number of previous transfusions and 
haemoglobin data) are referred to in this section, as this data contributed to the overall 
analysis. The data were therefore comprised of:
Demographic patient data (Appendix 7) 
Demographic clinic data (Appendix 7) 
Patient interview data (Appendix 10)
Staff interview data (Appendix 14) 
Observation fieldwork data (Appendix 18)
Every effort was made to transcribe the interview and observation data 
contemporaneously as memory was not an adequate substitute for subsequent analysis. 
The volume of data is typically large in ethnographic studies. The raw data refers to the 
mass of Information that was gathered throughout the different phases of the project and 
will be referred to and excerpts used throughout the analysis, findings and discussion 
chapters.
The aim of the analysis was to allow the researcher to attain a clearer understanding of 
the way in which the subjects construct or views their world. Morse (1994) suggested
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four stages of data analysis including: comprehending, synthesizing, theorizing and re- 
contextualizing. Through this process the researcher built up a picture gradually of how 
the various stories fitted together and what the most important themes were within the 
clinical context. In practice, these four processes tended to occur in an iterative or 
repetitive loop, with the researcher returning to earlier stages when any new questions 
were raised by the analysis. Repeatedly the researcher visited her original thoughts and 
ideas in her reflexive diary in an attempt to make sense of what was emerging. Themes 
changed and merged; and new ones emerged throughout; and it was a process or 
activity of refinement and restructuring therefore the description of an “activity” is apt. It 
is important to recognize there is no formula for the simple analysis of ethnographic data 
and no guarantees for success hence the acceptance that others may disagree with the 
interpretation of the data. It required “thinking it through” rather than mere management 
and manipulation of the data and revisiting the data and literature review with others; 
talking and thinking about it and visiting it again.
5.1 Integrating the data sets
Different data sets were analyzed to create a version of the reality. In Chapter 3 it was 
described how meaning can be interpreted from analysis of the context, and synthesis of 
findings, from different methods (interviews and observation). This data analysis offered 
a means of holistically exploring the relationships that underpin the clinical practice of 
transfusion. The researcher had to interpret or understand the meanings attached to the 
social behaviours, by examination of the different behaviours and small scale 
Interactions between individuals that underpinned the clinical practice of transfusion. It is 
these small scale interactions between individuals that required exploration and the 
exchange of symbols in social interaction, informed by the “symbolic interactionisrrf’,
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described in section 2.8.1. In summary, the aim of the analysis was to attribute 
meanings to the social interactions in order to describe the culture of transfusion 
practice.
This raised the question of how to combine these data sets (demographic data; 
observation and interview data) and previous knowledge, to ensure the relationships 
between the data sets are explored, meanings elicited and brought together to make 
sense of the reality. Sometimes it involved “picking up a thread" for example, the 
commonality of anaemia and seeing if it was within the other data sets (Moran-Eliis et ai 
2004; p6). For example, threads picked up in one data set (e.g. interviews), for example, 
the “importance of the haemoglobin value” may be picked up in another data set (e.g. 
observations). Triangulation of data in the true sense means combining different 
research methods and Moran-Ellis et al (2006) describe how combining different data 
sets may be a form of “integratioii’ and not necessarily triangulation; and concludes:
“we came to the conclusion that integration described a relationship between 
methods brought about by decisions to operationalise and implement the 
research whilst triangulation described an epistemologicai ciairri' (p45)
By this, they mean that integration is a form of reaching an outcome of using mixed 
methodology to reach a new epistemologicai claim; In this ethnography, different data 
sets and interpretations are combined in a way to form a whole (i.e. it is not 
triangulation). The data sets are inter-dependent but retain their own paradigms and are 
not translated into one another; each equally contributing to the final analysis; and used 
to corroborate or substantiate the emergent themes. Initially, each data set was
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analyzed, for example, to contribute to the analysis, for example, to develop the 
beginnings of early themes. These were then “integrated” to form an early theme or sub­
theme; from there the sub-themes were explored again for common over-arching themes 
or in some cases contrasting sub-themes to interpret meaning from the sub-themes to 
create the final themes. This will be described in more detail in the following sections.
5.2 Aims of the analysis
The goal in ethnography is to discover the cultural patterns that influence peoples’ 
behaviours and to make sense out of their experience; the first step was to select social 
situations (the outpatient clinics and day units) and make obsen/ations and collect 
samples of behaviors, situations, events and feelings. Patterns and relationships 
emerged from the early observations and interviews. Cultural meaning not only comes 
from the patterns based on similarity but also from contrasts, for example the contrast 
between the more and less experienced and knowledgeable staff and the differences in 
haematology and oncology.
In ethnography the analysis of data is not a distinct stage as described previously; 
Including the “integration phase” as the researcher moved back and forth between the 
data sets. Previously Morton-Cooper (1980) described the aim of data analysis is that it 
“tells the story” accurately, faithfully and inteüigentlÿ' (p89). It started to take shape in 
the reflexive diary and in diagrammatic form as the researcher tried to make sense of the 
information as it came in from a variety of sources, for example the observations, 
interviews and discussions with supervisors and colleagues. This was an iterative 
process and is central to the “grounded theorizing” promoted by Glaser and Strauss in 
which theory is developed out of data analysis and subsequent data collection is
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strategically guided by emergent theory. Some describe this “theorizing” as an activity 
as opposed to a procedure (Hammersley & Atkinson 2007; p158) and involves using the 
data to illuminate ideas and then linking those ideas to other research findings and then 
bringing the ideas back to “test their f it  with further data (p158). The ideas are emergent 
from one’s experience in the field, personal experience, literature review findings and 
preliminary analytical reflections of the data as described in section 3.4.
Not all ethnography is rooted in grounded theorizing as some ethnography is directed 
more towards description and/or explanation. Analysis of routine practices such as 
transfusion practice, can lead to the analysis of rituals and a focus on routine actions and 
behaviours (Hammersley & Atkinson 2007; p169). Understanding the patterns of action 
and behaviours can also involve trying to understand the rules; this does not just mean 
the official bureaucratic rules but also the informal rules or norms that guide everyday 
conduct and behavior. This understanding of rules as guides implies the importance of 
decisions; the practicalities of decision-making are important in many organizational and 
professional contexts. In healthcare, decision making is vital to the everyday 
performance therefore a description and/or explanation of the process of decision 
making within the cultural context was an outcome from the analysis. In other words, a 
description and possible explanation for why and how the decisions are made to give a 
blood transfusion to a cancer patient In a specific culture was an outcome of this 
analysis. Embedded in this, of course, is the influence of that culture on the decision 
making behaviours. In summary, therefore this research was not aimed at developing a 
theory of transfusion culture and behaviours but to understand the culture of transfusion 
informed by the symbolic interactionism to create a holistic picture of the reality of 
transfusion practice in cancer related anaemia. From there a rational and objectively
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defined model can be developed and applied which aids the exploration and 
understanding of the social world. Further ground breaking questions may be 
developed that can be explored through other methodologies (Greenhaigh and Taylor 
1997) and this will be explored further in section 7.3 when discussing the implications for 
further research.
Ethnographic research typically has a classic “funnel structuré’ where the focus narrows 
as the research progresses (Hammersley & Atkinson 2007; p160); as the project and 
analysis progresses separate themes are examined in more detail. During this process, 
they describe how frequently, even well into the inquiry how new themes emerge, and 
not uncommonly It is completely different from what may have been expected at the 
outset. It required an openness and flexibility and acceptance that ideas can change 
throughout the enthographic journey. In other words, instead of coming to the field with 
specific questions the ethnographer analyzes the field data compiled from participant 
observation and ethnographic interviews to discover questions. The field notes required 
some preliminary analysis after each period of fieldwork, as did some of the early 
interviews, in order to know what to look for during the next period or from further 
interviews and this is part of the “tunneling” process that Hammersley & Atkinson (2007) 
describe. In this way the focus narrowed from observations and discussion about clinical 
practice to details of how the different clinical areas are organized and from there a 
further analysis on how the different cultures are organized; for example, how the 
cultures impact on activities and behaviours.
Initially demographic data were used to describe the clinical setting and the incidence of 
the clinical problem of anaemia and patterns of blood transfusion administration. The
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purpose of this was to provide a description of the clinicai setting for anaemia and it’s 
management within the sub-specialisms of oncology and haemato-oncology. 
Componential analysis was used as a distinct technique, for example, to map out the 
different components within the early themes (Appendix 17) using excerpts from the 
data. From there, a taxonomic analysis (a thought process to start grouping together 
similar themes and separating out contrasting themes) was used to explore relationships 
and contrasts in the early themes (Spradley 1980). These processes will be described 
and mapped out in detail, using the data to demonstrate their emergence. In summary, 
this section will begin by describing the final themes and demonstrate how these final 
themes were arrived at by describing the clinicai areas and practice; and thereafter early 
themes and their relationships. By "mapping out” the early themes and describing the 
components of these themes (componential analysis), relationships and contrasts 
emerged to “funnel” the early ideas into the final themes. Examples are described 
throughout the following sections of how themes merged together to create the final 
themes (sections 5.6, 5.7, 5.8 and 5.9). Therefore this research methodology and 
subsequent analysis demanded reflexivity and flexibility and a degree of creativity, which 
in was an enlightening experience for the researcher.
5.3 The clinical setting and patient demographics
Analysis of the incidence of anaemia and transfusion practice in the clinical setting was 
necessary to determine the incidence of anaemia and transfusion in the clinics and day 
units. Patient demographic data is also represented in Appendix 7 to show the patients 
clinical background and transfusion episodes. Descriptive techniques were used to 
analyze and present this data.
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5.3.1 Activity and incidence of anaemia in the clinics and day units 
The literature review had revealed that anaemia is a common and important ciinicai 
problem in cancer. It was therefore necessary to establish the reality of this problem in 
these clinical settings if the impact was to be understood. The haemato-oncoiogy and 
oncology lung clinics and day units differed in physical size, (Appendix 7) staffing and 
levels of activity (Appendix 7: Table 4.3.2b and Table 4.3.2c).
The clinics and day units were all spatially distinct clinicai areas (different wings and 
different floors within the same hospital) with separate staff. Appendix 17 for example 
maps out the clinic areas and demonstrates the different size and complexity of the 
environments. The haemato-oncoiogy day unit was smaller and essentially one physical 
space, with a separate staff and clinical preparation area, whereas the oncology day unit 
had different zones for different types of activity (e.g. a zone for supportive care; a zone 
for chemotherapy administration). In summary the oncology areas were larger; with 
more staff and more clinical activity. This may have an impact on decision making and 
behaviours in the clinical setting therefore it was important to capture this data. This 
proved to be important when it comes to the discussing and analyzing different practices 
within the sub-cultures of haemato-oncoiogy and oncology, as the environment, activity 
and people within the physical spaces influence the behaviours and cuiture of the sub­
specialisms, which is discussed later.
The data collected on clinic activity required organization, in order to demonstrate the 
incidence of anaemia in the clinical setting as this may have influenced clinical 
behaviors. It was discovered that many patients attending the clinics could be clinically 
defined as anaemic (Hb < 12g/dl), however, only a few patients, had blood ordered and
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prescribed in clinic. This was similar in the day unit areas. (See Appendix 7: Table 
4.3.2c). The fieldnotes had not captured this data, and this was obtained retrospectively 
from the clinic lists and the Electronic Patient Record (ERR). The demographic clinic 
data demonstrates that clinically defined anaemia was a common clinical issue in clinic. 
Only 22% of patients overall had a normal haemoglobin level. 22.5% in haemato- 
oncoiogy and 22.3% in the lung clinics (Appendix 7, Table 4.3.2c). This data 
demonstrated the commonality of clinically defined anaemia in the clinical areas and how 
few patients had normal haemoglobin values.
5.3.2 Demographic patient data
All of the subjects were either having chemotherapy or had been exposed to several 
cycles of chemotherapy. See Appendix 7: Table 4.1.2b for details of diagnosis and 
stage and treatment details, for example PHI and PH3 had stage IV disease which 
means they had advanced, bulky disease (descriptions of diagnosis and treatment can 
be found in the glossary of terms). None of the patients were working at the time of the 
interview due to ill health. Their work and family details are shown in Appendix 7: Table 
4.1.2c. All of the patients had been exposed to multiple blood transfusions.
The incidence of anaemia and transfusion varied between the sub-specialisms. The 
data described mirrors the literature review in that the anaemia experienced by these 
haemato-oncology patients is more frequent and severe. Therefore not surprisingly, the 
haemato-oncology patients had also experienced more transfusions. Again this may 
have an impact on the behaviours in the clinical setting, therefore provides a rationale for 
collecting and analyzing the data; and these data were integrated with the ethnographic 
observation and interview data sets as described earlier.
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5.4 Overview of themes
By undertaking this process of analysis the final themes emerged (Diagram 5.4). Final 
thematic analysis revealed that the haemoglobin was the only determinant that was 
perceived by participants to be certain, when compared to other patient factors including 
the symptoms of anaemia. The impact of the haemoglobin often meant that it was 
“separated out” from the rest of the patient factors; or assessment occurred in isolation 
from the patient and this is described as “disaggregation of the b o d f in this study 
(Diagram 5.4). The haemoglobin value was perceived as the only constant in an 
uncertain world and therefore was a powerful influence on the clinical decision to 
transfuse. There appeared to be “acknowledgement of uncertainty’ by all levels of 
clinicians (doctor and nurse) where symptoms were described as vague and the 
response to transfusion could not be predicted, however, there seemed to be a point at 
which there was less uncertainty and that was in the presence of more severe or life 
threatening anaemia and some of the transfusions fitted this category of patient. In other 
words uncertainty decreased as the severity of the illness increased.
The figure below provides a summary of the final themes however it was a complex and 
lengthy process to arrive at the concluding themes. The aim was to narrow the scope of 
enquiry to the most significant issues and this is referred to as the Iterative -  Inductive 
approach to ethnographic analysis (O’Reilly 2005). The data description, and process of 
analysis, will be discussed in more detail to demonstrate how the early themes emerged 
from the data and were combined to produce the final themes described above.
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Diagram 5.4: Final generic themes of cancer related anaemia and treatment with blood 
transfusion
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5.5 Thematic analysis and early themes
Undertaking thematic analysis is not a discrete phase but is “tangled up with every stage 
of the research proceed’ (O’Reilley 2009, p15); the data collection and analysis occur 
simultaneously. The researcher has to determine any meanings to the social 
behaviours and seek to understand the underlying motivations, thinking and ideas that 
have resulted in those behaviours developing. Secondly, the researcher has to identify 
and comprehend some of the recurrent patterns that emerge; therefore structured 
routines and relationships are used to provide a framework that might be relevant to 
understanding similar settings, which in some cases may be generalisable.
147
Data analysis did not proceed in a linear fashion and analysis and the writing up was 
constantly interspersed with periods where steps were re-traced (Ezzy 2002). It began 
by "working through" the large volume of data, to develop early themes and then work 
out how they were related or contrasted to each other. The researcher looked for 
surprises, concerns, inconsistencies, contradictions or information that were puzzling or 
demonstrated differences in opinions and in this case particularly those that related to 
anaemia and transfusion.
The early themes were established (Diagram 5.5) from the data; the researcher mapped 
these early themes out in a table and these were derived from the different components 
of each theme using the data (Appendix 19). This required re-visiting the data and trying 
to make sense of all the relationships and components as well as inter-relatedness and 
contrasts of the early themes as described in section 5.1 on integrating the data sets. 
The relationship diagram was devised in an attempt to piece together the various 
relationships that emerged. The relationship diagram assisted this process and this was 
changed on multiple occasions, and was an iterative-inductive process as described 
earlier. This was very much “a live document" for the researcher, who prefers to use 
visual representation to demonstrate process, systems or theory. This document was 
used to map out all the components and determine where overlaps and contrasts 
existed.
These sub- themes started to emerge and it was important to start to draw them together 
to create an early description of what may be going on. In addition to these sub themes, 
there were data from the clinics, for example, the incidence of anaemia. These sub
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themes have been evidenced below using excerpts from the data; these have been 
described under the sub-headings of the final themes in an attempt to map the process 
of analysis out for the reader.
Diagram 5.5: Relationship diagram demonstrating sub- themes
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5.6 The ubiquity of anaemia and blood transfusion
From the literature review it was evident that clinically defined anaemia is common in this 
population; blood transfusion is used in a variety of clinical situations and clinicians 
encounter transfusion early on in training. It is not a new or novel form of therapy, the 
public are aware of it, and many patients and staff have been previous blood donors (up 
to 3 million donations per anum in the UK). The literature review revealed that anaemia 
is common but that patients adapt and learn to live with anaemia, which can diminish its 
impact. Anaemia may be present but may be of minimal clinical consequence because it
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does not require an action or treatment and therefore a contrasting theme developed in 
that “anaemia and blood are not important', in spite of the frequency one encounters this 
in clinical practice. Diagram 5.6 demonstrates the bringing together of these components 
or early themes, to demonstrate the emergence of the final theme of ‘The ubiquity of 
anaemia and blood transfusioif by diagrammatically demonstrating the relationships 
between the components.
Diagram 5.6: Taxonomic analysis: relationship of components and early themes-Ubiquity 
of anaemia and blood transfusion
Blood transfusion 
is a common 
therapy
Living with 
anaemia
Frequency of 
anaemia
This is a form of taxonomic analysis (Spradley 1980) whereby the components or 
themes are grouped together by resemblance or related criteria or contrasting criteria. 
Some of these components arise from the demographic clinic and patient data; others
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from audit data and the literature review (high incidence of anaemia and frequency of 
blood transfusion) and others are early themes from the ethnographic data. The 
researcher’s experience and interpretation of the data is also an Influence. Each 
component will be described separately demonstrating how the data contributed to the 
development of the “ubiquity of anaemia and blood transfusion”.
5.6.1 The frequency of anaemia and blood transfusion therapy
It was demonstrated in the literature review that anaemia and transfusion were common
in the oncology setting and was further substantiated in the audit data. The demographic
patient data showed that clinically defined anaemia was frequent in the clinic setting but
that in contrast the number of patients who were transfused were minimal. Thematic
analysis of the staff interview data revealed that they viewed anaemia and transfusion as
common and familiar;
“People will always be anaemic and we are always going to need blood 
transfusions no matter what great inventions they come up with..in our acute 
setting 251)
“Oncologists use a lot of blood [  ]  I bet most of our registrars don’t have a single 
day of the week without transfusing a patient, you know I bet most of our 
registrars prescribe blood every day of the week at least once if not more than 
once and so I think a lot of oncologists use a lot of blood “ (SL1 ; 196)
The patient demographic data revealed the patients on study had been exposed to
multiple transfusion episodes, more so in the haemato-oncology population. To clarify, it
is a small proportion of patients who receive multiple transfusions, but given the large
numbers of patients who attend oncology out-patient departments every week, the
exposure to transfusion episodes is multiple. Similarly the interview data revealed that
patients were very familiar with being anaemic and having blood transfusions; they were
also familiar with the processes involved which is demonstrated in the second extract:
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"You could get the outside parameters because you know I need blood probably 
about once a week or once every 8 days and sometimes you need it twice" (PH3; 
148)
“You come into the clinic and they take your bloods, take it away and analyse, 
you might need platelets or blood and you know that you won’t get them before 
3pm anyway, because that is the delivery time. By then because you have been 
sitting there, its getting up to 3 o’clock, then you have your blood 1 unit, usually 2 
and that could last an hour and a half maybe two hours a bag and they’ll find a 
vein. They will put in a cannula in at the beginning. If they think you need blood 
rather than just take drugs they will put a cannula in at the beginning.” 66)
By combining the data sets in this way one starts getting the sense that within this
culture anaemia and blood transfusion are a given; they are embedded in day to day
practice, routinized and can be found in any oncological setting.
5.6.2 Living with anaemia
It was revealed in the literature review that the human body can adapt to anaemia; and 
section 5.3.1 revealed the majority of patients in this clinical setting had a degree of 
anaemia, however, only a few were actually treated. Importantly, even when patients 
are treated with blood transfusion, it will often be the case that they remain anaemic. It 
was revealed in the interview data that clinicians do not use the textbook definitions (NCI 
definition in literature review; Table 2.2.1) and although many cited some definitions, 
there was an acknowledgement that it was only when the haemoglobin reached a critical 
level (and this varied) that treatment would be initiated, for example:
but if they have a haemoglobin of less than lOg/dl I would refer to them as 
anaemic but I would not necessarily treat them for that “(SL1 ; 11 )
7 suppose technically anaemia is haemoglobin lower than the...the normal so it 
would be less than 11.5 in a female, less than 12.5 in a male, but we don’t act on 
these values, we only act when it is symptomatic or if the haemoglobin drops 
below eight’ (SH2; 3)
There was also an implied awareness of the adaptability to anaemia, or expectation of 
some tolerance to the anaemia, prior to initiating any therapy and it was also described 
by the patients:
152
“you get used to feeling rough anyway and you usually just put that to one side" 
(PH3;71)
The staff also acknowledged patients’ tolerance and that perhaps the other experiences
of cancer and treatment may overshadow the problem of being anaemic, for example:
“So with these patients it is not ideal, it is very difficult I think for them and I think 
that is probably why a lot of them don’t shout out about their symptoms because 
they know that they are going to have to go through all of that on top of this" 
(SL5;508)
At a fundamental level there seemed to be an acceptance by patient and staff that
cancer patients live with their anaemia and symptoms, particularly fatigue. It was only
when there was a “critical trigger” for patients or clinicians that treatment was initiated,
for example, the patient may experience an escalation of symptoms or the haemoglobin
may have decreased to a critical point.
“It is just that, when people put things in an order of importance that they could 
shift anaemia a little bit down their priority list, because they are coping with it 
until they come up to a point that they can no longer shift it down the priority list" 
(SH9;90)
“She has to work, she has to go to college, and it came to a point that she could 
no longer do her college work and that is when she decided to come in...”(SH9; 
58)
The decision to treat the anaemia was unpredictable and variable but nonetheless there 
appeared to be a point at which it switched to a clear decision to treat. This is discussed 
in more detail in section 5.7 in the discussion about uncertainty.
At a more subtle or analytical level, the “cancer-related anaemia” may have had a 
different meaning for different clinicians and patients or it may have a different meaning 
than when “anaemia” is used isolation. For example one of the patient extracts 
demonstrates that in spite of multiple blood transfusions he did not consider himself to 
have anaemia:
“You use the word anaemic. I don’t use the word anaemic, because I don’t 
perceive myself as anaemic. But maybe I should." {PH3; 39)
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This was also reflected in the different definitions in the interview data. The meaning of a 
diagnosis is an important factor in how a disease is managed, and may be an influence 
on the culture of transfusion practice, and will be explored in more detail in Chapter 6.
5.6.3 Anaemia and blood transfusion in the hierarchy of clinical issues 
Despite the frequency of anaemia it emerged from the data to be unimportant in terms of 
continuing education of the management of anaemia; this was evidenced by statements 
in the interviews, for example, one of the Consultants when asked about his transfusion 
training stated:
"Well nobody has trained me since I was at medical school..I probably should 
have bee/?"(SH1 ;312)
And he commented further:
7 know that medical students get an appalling lack of education about blood 
transfusion these days" (SH1 ; 326)
The management of anaemia did not appear to be discussed in clinical practice; It did
not pose a clinical issue that warranted discussion between colleagues; for example
where one of the Consultants described how anaemia the management of anaemia is
learned in the clinical setting ‘7 am treating it as a given, it is something they (the doctors)
learn by osmosis, (SH1;336). The following excerpt by the other consultant similarly
demonstrates the low priority of transfusion decisions in clinic, but alternatively it may be
due to the prioritizing of other issues in the clinic:
7 guess what it comes down to is that most of our clinics are very busy and who 
gets a blood transfusion and who doesn’t is not something that is necessarily 
discussed with the consultant ...whereas any chemotherapy change has to be 
discussed with the consultant we don’t mandate that for blood transfusions...and 
so therefore I guess the message that gives out is that this is a less important 
decision and so therefore the registrars or clinical fellows don’t feel that they have 
to come and talk to us about it they will make the decision and because they are 
not talking to us about it and because we are not talking to them we are probably 
not educating on the job about blood transfusion" (SL1 ;28)
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The lack of discussion about anaemia and transfusion was also evident in the fieldwork 
data, whereby a long consultation with a known anaemic patient was largely based 
around the disease and plan, and the anemia was not discussed until the end of the 
consultation and the patient described how he received his blood results as an 
outpatient:
"The patient explains that he gets the blood results from the nurse anyway..and 
he doesn’t think the GP even iooks at it”. (H.11.3.08;91 )
This demonstrated the patient’s awareness of the professional’s priorities of care and
links to the clinician’s description of priorities in the clinic described in the earlier excerpt;
the primary disease and therapy is the focus and not the anaemia or the quality of life
issues. In summary, the important decision making discussions focused on the disease
and treatment and the management of anaemia seemed to be given low status or
priority; at most a brief discussion around the technical/logistics of the transfusion as
demonstrated in one of the fieldnotes:
"They discuss her need for blood first-"your Hb is 7.2-how are you feeling-it was 
8.5 last week-shall we transfuse you?” [  ]  They discuss the plan for today-maybe 
she could fit in blood today-go up to the day unit to discuss with them first "If you 
think you can have blood today then do it”-"sounds good-lt’s a p/an” (HC1 ;35)
The low priority or status of anaemia and transfusion decisions was demonstrated
elsewhere, for example, one of the Specialist Registrars described how she could not
remember if her decision making had been over-ruled by another healthcare professional
and she described this as "none scar me so much” (SH2;479). In addition, it may be
linked to the “meaning of cancer related anaemid’, whereby although anaemia was
common it was not until it reached a critical level that it warranted a diagnostic label and
treatment. In summary, the management of mild or moderate cancer related anaemia
sits relatively low in the hierarchy of clinical issues for cancer patients and this is
reflected by the lack of discourse and education. The hierarchy of the clinical issues will
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be discussed in more detail in section 6.2.1 where the relationships between the 
hierarchies of clinical task and knowledge will be explored in more detail.
The important elements of transfusion practice seemed to be primarily related to safety,
and process issues to avoid making transfusion errors, rather than decision making as
demonstrated in the following extract:
“my main recoiiection of mandatory training was about labeling the bottles 
correctly and storing them in the right place and getting the blood from the right 
place as opposed to when to transfuse and why” {SL1 ;256)
“we were taught how to check a patients ..you know, when you are taking a 
sample and also when you are putting a sample up how to check the patients 
details and check the blood group and the expiry date and that sort of thing, so 
apart from that I can’t think of any..” {SH2;306)
Therefore, the safety aspects of transfusion sit high in the hierarchy of training and
education. This may be related to national mandates about transfusion safety and the
financial risks to the Trusts for not complying with mandatory training measures. In
summary, the education systems in place, in the form of mandatory training were not
focused on clinical decision making, but on the processes involved once the decision to
transfuse had been made and this may be related to the institutional priorities of ensuring
safety and compliance.
5.6.4 Summary
This section (5.6) demonstrated how the different components and emerging themes, 
derived from the different data sets were combined and integrated to produce the theme 
of “The ubiquity of anaemia and blood transfusiori’ (shown in Diagram 5.6). It is an 
interpretation of the reality; for example, the researcher had to acknowledge her interest 
in transfusion and that the participants appeared to find this a new experience to be 
asked about their transfusion practice. For example, one of the Consultants commented,
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during the interview: “you are being very chalienging.... it is very interesting' (SH1;337). 
However, by continually re-visiting the data and questioning the content of the data it 
emerged that there was an acceptance of the commonality of anaemia and transfusion, 
that patients lived with anaemia and transfusion, but that in contrast to the cancer and 
therapy it did not warrant education; debate and careful decision making. The multiple 
facets of this theme will be discussed in more detail in Chapter 7, because it has 
implications for the sharing of knowledge; decision making and transfusion training and 
practice.
5.7 Acknowledging Uncertainty
As described in the literature review, there was an acknowledgment that the symptoms 
of anaemia were unpredictable. The haemoglobin was an absolute value that all 
participants referred to as defining anaemia, however, it was universally acknowledged 
that uncertainty exists, particularly if the anaemia was moderate or mild, and the 
haemoglobin levels that were used to define anaemia varied among patients and 
professionals. This may be related to the indeterminacy of the anaemia; or alternatively 
related to the difficulty of separating out the symptoms of disease and side effects of 
treatment from the symptoms of anaemia.
The literature review also revealed there were unpredictable responses to transfusion 
and the benefits of transfusion may not be clear; therefore the professional has to decide 
how to balance the benefits against the risks. It was felt that some of this uncertainty 
could be relieved if the anaemia was contextualized or assessment and treatment 
decisions could be improved if the professionals who “knew” the patient were the key 
decision makers. It was implied that the quality of that decision could be improved if the
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decision was contextualized and therefore was a contrast to the other themes or 
components that resulted in the uncertainty. Therefore although uncertainty existed; by 
contrast the uncertainty could be reduced if the decision was placed in context for if the 
patient was known to the clinician. Diagram 5.7 demonstrates how individual early 
themes or components were combined to produce the overarching theme. As in the 
previous section, each early theme will be described in detail using extracts from the 
data sets to demonstrate the researcher’s thematic analyses.
Diagram 5.7; Taxonomic analysis: relationship of components and early themes - 
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5.7.1 Uncertainty
It was demonstrated in the literature that a wide variation in practice exists in spite of
clinical guidelines. It was described how symptoms could be attributed to anaemia but
fatigue levels In particular did not always correlate with anaemia. This uncertainty was
revealed in the data and related to assessment and diagnosis of anaemia, for example
the Specialist Registrar acknowledged the uncertainty of anaemia:
"It’s an individual thing, definitely. I don’t think there is a level for anyone” 
(SH2;42)
Another level of uncertainty existed in relation to the uncertainty of response to the
transfusion, for example:
../ Just can’t remember a time when I was saying” I definitely think this person 
needs a transfusion " (SH2;515)
(when asked about response to transfusion) “most of the time..they are very 
vague., very vague descriptions really...Just feeling more energy or just feeling a 
bit better but is that a change due to transfusion or due to something else that is 
going on otherwise with them..it is very difficult to say” (SH4; 156)
“..you will feel so much better after two units of blood..and often they 
don’t...”(SH4;244)
The patient data revealed similar findings in that they acknowledged the uncertainty of
confirmation of anaemia as well as the uncertainty of response to transfusion. Patient
PH3 described this eloquently early in his interview:
“At times you couldn’t tell whether you felt awful because you were low in the 
blood states or you felt awful because you ... because of the chemotherapy. And 
even when you had the blood you were obviously better because you’re going 
about ..but you could still feel awful...but that was no reflection on the blood going 
in. Sometimes for example, about 3 or 4 weeks ago, I had blood on the Friday 
and I had the best weekend I had had for about 5 months. I had a good period of 
for three days and then I went downhiil and for that one weekend I felt really 
brilliant and that was down to the blood”. (PH3;5)
PHI described her tiredness but this was unpredictable and not necessarily related to
the haemoglobin level, for example early in the interview when asked what she thinks
she feels like when she is anaemic she stated:
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7 feel fatigue I just want to like., .erm... get some rest, everything that I do, I do
very slowly. Simple things like washing the dishes take longer for me, because I 
feel very fatigued".(PHI ;4)
But conversely when asked about her haemoglobin level when she comes to the hospital
and being able to predict the anaemia she responded:
“Yes very surprised...actually last time it was 7.6 and I wasn’t feeling so 
tired....like I think it was yesterday....yes Thursday... yes... and I wasn’t feeling so 
tired. I was feeling tired but as normal as I had been before but this was the 
lowest level that I had been....’’(PHI :45)
The patients were therefore uncertain about the relationship between how they were
feeling with the presence of anaemia and described in their interviews how they used the
haemoglobin value about confirming or rejecting the presence of anaemia, for example:
“It is sometimes the other way around because sometimes you just feel awful 
because of just the mixture of what is happening to you and you can just feel 
awful and in fact your bloods are all right. You know they couid be 9.4 or 
whatever it is. ’’ (PH3;45)
In summary, “uncertainty" was described by both clinicians and patients; to some degree
this had been expected, however, it is interesting that patients themselves could not
“read their bodies" and their symptoms did not always correlate with the haemoglobin
level. When this happened the haemoglobin level was frequently used as the deciding
factor whether to transfuse or not. This demonstrates the importance of the haemoglobin
result in the decision making which will be discussed in further detail in section 5.9.1.
5.7.2 Separating the symptoms
This theme started to emerge early in the patient interviews where it was described how 
difficult it was to define the anaemia and separate the symptoms of anaemia from 
symptoms of disease or side effects of treatment; and is closely linked to the previous 
theme. Without being able to clarify the symptoms of anaemia, it is difficult to treat;
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treatment can easily result in either over or under-transfusion. Examples from the data
that demonstrate this difficulty of separating out the symptoms; include the following:
7 suppose the most common things are, the tiredness, the fatigue which again is 
a tricky one because it could be cancer-related fatigue and chemo-related fatigue 
that we talk about..again it may not be associated with the anaemia” (SH5;65)
I would normally say ...are you any more tired than normal..are you any more 
breathless than normal and if I think they might be then I would perhaps go Into 
some more detail about that to try to determine if they had a symptomatic 
anaemia as opposed to symptoms of their disease... .and of course symptoms of 
disease can be very much overlapping with symptoms of anaemia.. ”(SL1;27)
To combat the uncertainty, it appeared the haemoglobin was used to define and
diagnose the anaemia. For example:
“We know they are anaemic already, because we have got a blood count in front 
of them" (SH2;133)
It may be the clinicians did not therefore feel the need to confirm the symptoms of
anaemia, particularly as there was uncertainty about the symptoms; the symptoms may
then become inconsequential and may not even be pursued with the patient. For
example when asked about symptoms of anaemia one of the clinicians stated:
The questions I am asking myself is ...do I need to? ...and by that I mean if the 
haemoglobin has fallen (SH1 ;417)
In summary, at the early stages of analysis this was described as “separating the 
symptomd’ whereby there seemed to be attempts to ask about symptoms but the 
questions to patients were also vague and non-specific for example, questions about 
being tired or breathless, which may have been related to the uncertainty as described 
earlier. Conversely, there appeared to be faith in the haemoglobin value as described in 
the last two excerpts; further analysis was required to unpick the detail of how the 
haemoglobin value was interpreted by the clinician as it appeared the symptoms were 
not able to be interpreted in a robust way.
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5.7.3 Risks vs Benefits
As described earlier, the uncertainty also existed as to whether the patient would benefit
from the transfusion and whether all the risks and benefits could be applied in cancer
related anaemia. The benefits might be that one may expect some symptomatic
improvement or improvement in quality of life parameters but from the earlier analysis
this was perceived to be unpredictable by the patients themselves. It also implies there
may be difficulty in assessing response (i.e. measuring the benefit) by clinical staff and
this was acknowledged in the interviews, for example;
“..in fact so there is not very good continuity in assessment of response to blood 
transfusions I think something in which we should and could improve but we don’t 
robustiy assess response [  ]..we have no robust mechanism of assessing 
response of a transfusion which means that there is a risk and I am sure it 
happens that people do get repeat transfusions who are not necessarily 
benefiting from them”. (SL1;130)
This has implications for practice in that there may be a tendency to over-transfuse,
thereby increasing or causing unnecessary risk. The risks of transfusion are part of
mandatory training (as described earlier) but surprisingly, this did not seem to be of a
concern to the medical team who tended to view it as no harm or minimal harm of
administering blood transfusion. For example:
“..because when I do transfuse people at that level some of them feel better and I 
rarely don’t, ...I don’t see people being worsd’ (SL1 ;424)
I am thinking we can and probably do transfuse people who don’t need to have it 
or who maybe don’t need to have a transfusion, the consequences of that seem 
potentially less catastrophic than giving the wrong chemo or the wrong chemo 
dosage to the wrong person (SL1;299)
It could be that the medical clinicians do not have the “hands-on” experience to balance
the risks with the benefits because they are not present at the point of care delivery, i.e.
at the point of transfusion. This may be related to earlier discussions about the hierarchy
of clinical issues or concerns in that a transfusion decisions are of less clinical
consequence than other decisions in the clinicians “hierarchy of concerns”.
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It was also revealed that decisions to transfuse had been made in clinic or later when
blood results became available or that a nurse had asked for a prescription to be written
or for a decision to be changed, which will be explored in the section on “shared
responsibility” in section 5.8.3. The nurses are the actual administrators of the blood
however, and this may result in the nurses being more cognisant of the risks of
transfusion, for example:
“Possibly, whether they (doctors) are just not thinking about it or think they are 
doing the nurse a favour by just prescribing the blood, yes., it could be any of 
those things but they haven’t thought enough about it ...they haven’t had a 
scare...”(SH5;355)
“....yes so people being made aware if you have never seen a reaction or you 
know a bad transfusion related event you are not really going to think twice about 
prescribing ....you know for any drug,...if you see a bad effect or side effect it 
really scares you and you think ..god and you think twice” (SH5;361)
“and in fact transfusing them is putting them at risk and you don’t want to over- 
..transfuse... ”(SH4; 116)
Patients may also consider the risks and some may wish to avoid transfusion but the
patients described how they had to receive blood in order to survive therefore in relation
to this the risks seemed inconsequential, for example PH1 describes:
PH1: “I just sometimes get scared because I know that sometimes I can get 
some illness, even knowing that they do tests for ail kinds....there is always the 
possibility that something goes wrong...so of course I have had lots of blood and I 
think “oh my god” how many chances of getting something, some illness, so of 
course I am really scared... it just keeps in my mind”
PI: “Do you worry about it?”
PH1: “Yes of course, I do worry about it you think about in the future I could 
develop another kind of illness like...erm...hepatitis so obviously I do worry.”
PI: “And how do you see blood transfusion now?”
PH1: “In my situation right now because of the leukemia and because of the 
chemo and how it reacts for me and for me and how it makes me feeLl need the 
blood..for me now it’s very good' (PH1 ;69)
In summary, the benefits appear to be unpredictable and the risks do not seem to be 
considered at the point of decision making; the reasons for this may be complex and will
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be discussed further in subsequent sections. Furthermore there may be something 
about the immediacy of blood transfusion; it is a transient treatment with a transient 
effect and can have a limited impact, therefore the long term risks are not important. 
This can influence decision making particularly if the patient has poor prognostic disease 
where the short term benefits outweigh the long term risks; therefore the risks may be 
inconsequential. This was implied in SH1 interview where he described a reluctance to 
transfuse children because of the long term risk. The patients also seemed to accept the 
risks as the blood is a life saving treatment for them at that moment in time; but 
recognised the benefits were not sustainable as in PH3 comments in 8.8.2 where he felt 
good following a transfusion for one weekend only.
5.7.4 Contextualizing the anaemia
The uncertainties have been described; however. It was revealed in the data that some
strategies are employed in an effort to reduce the uncertainty. This is about
contextualizing anaemia; it involves thoughts about the speed of onset of the anaemia;
the type and intensity of therapy; stage and type of disease and previous response to
transfusion and individual patient characteristics. Therefore the context of anaemia and
the ability to have some degree of prediction had an influence on assessment and
decision making. For example, the day unit sister described how she contextualized the
anaemia trying to take into account their disease and treatment and whether the patient’s
blood counts were recovering or not:
“(you) take into account where they are in their treatment, their disease status, 
their age...''{SH4;Q9)
“If you have got someone who you know is recovering their counts from 
chemotherapy but their haemoglobin is maybe lagging a little bit behind..! would 
often try and not transfuse them because you know that the bone marrow is 
beginning to work again” {SH4] 187)
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Similarly, one of the Consultants described this behaviour as an attempt to contextualize
the anaemia and relate it to the pathway:
...but often you can..sometimes you can tie it to what’s happened to the 
haemoglobin over time..and see in fact they’ve been tired for ages and they’ve 
only become anaemic since you started chemotherapy and they are no more 
tired than before..so that’s not the anaemia (SL1;72)
Therefore there is a suggestion here that some of the uncertainty can be reduced by
linking the anaemia more closely with the other patient factors such as disease and
treatment detail, and timing of anaemia in relation to treatment pathway. This may have
implications for clinical decision making in practice as it implies that the clinical staff who
have most knowledge about the Individual patient may be best placed to assess,
diagnose and treat cancer related anaemia.
5.7.5 Summary
The section has demonstrated how the sub-themes are linked together, for example, 
uncertainty is related to the difficulty of separating the symptoms of anaemia from the 
symptoms of cancer. The risks and benefits of transfusion are also uncertain and it was 
described how patients did not always Improve post-transfusion. This uncertainty was 
acknowledged and various strategies were described that could improve the decision 
making, for example, previous knowledge of the patient. The final contrasting theme of 
contextualizing the anaemia may give some insight into how improvement into the 
management of anaemia can be made and this has implications for practice which will 
be explored further in the discussion chapter (Chapter 6) and the implications for practice 
section (Section 7.2).
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5.8 Socialization in practice
It was not clear at the outset of the study how transfusion practice is learned, but it was 
recognized in the literature review that despite clinical guidelines, transfusion practice 
varied. Some of this may be due to the uncertainty in diagnosis and treatment as 
described, however, as the data analysis progressed other themes emerged which may 
provide some further explanation of variation in practice. Furthermore, there was 
evidence from the data that traditional practices existed in different clinical settings; that 
practice varied according to institution and sub-specialty; that shared or collective 
decision making was acceptable practice and therefore all of these may be described as 
forms of socializing the various players (doctor, nurse or patient) into the accepted 
behaviors of that culture (Diagram 5.8). It appeared that clinicians are socialized into 
anaemia practice depending on where they are and in what institution. For example, it 
was evident that clinicians changed their practice because that was acceptable in the 
new department or institution and that was the traditional practice in that particular 
clinical setting. It was demonstrated in the previous section that uncertainty existed 
therefore institutions use transfusion guidelines in an effort to control the practice and 
prevent over or under-use of blood products. This research demonstrated how small 
communities of practice actually controlled the use of blood more so than by 
implementation of guidelines. This was further substantiated by the evidence that 
showed multiple clinicians may be involved in making the decision to transfuse; the 
decision sometimes appeared to be shared or mutually agreed, or changed at the point 
of care delivery (the day units) and therefore the decision making could be described as 
a social behaviour.
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The behaviours seemed to be different for the different sub-specialisms of haemato- 
oncology and lung cancer and this gave further evidence for the socialization in practice. 
However, individuals bring their own experiences, knowledge and attitudes to the 
different social communities and these are influenced by the environment and these 
have been collectively referred to here as “internal and external influenced'. As for the 
previous sections, each theme will be discussed separately to explain how these were 
derived from the different data sets.
Diagram 5.8: Taxonomic analysis: relationship of components and early themes-
Socialization of practice
Internal and 
External 
influences
Shared
responsibility
m .
Traditions
Socialization 
of practice
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5.8.1 Traditional practice
Traditional practices were implied in many of the interviews in relation to blood
transfusion practice. These were described as "habits” or reference to the fact that blood
has been a long standing form of therapy and that “old evidence” was used to dictate
practice. For example one of the Consultants commented:
“The reason that we tend to give two at a time I am sure is affected by 
practicalities and habits as it is by logic” (SH1;171)
“because other therapies you get updated in but bloods been around a long time 
you know you just use i t ... ”(SH1;318)
“so., there is clearly a body of very old scientific evidence to show that getting 
your haemoglobin level above ten doesn’t really help you terribly very much” . 
(SH1;113)
Similarly the Oncology Consultant acknowledged the existence of traditional practice in
the following extract, and more specifically in relation to the two unit transfusion:
“Obviously we give two unit transfusions far more often than any other amount for 
I have no idea what reason. I do know and this is historic when I was a medical 
SHO both general medical and in oncology which I was in the same place we 
were told that we should never give a one unit transfusion to anybody ever 
because there was never an indication for that ...people needed two or three 
units or they didn’t need it at all... ”(SL 1;445)
Conversely, it was acknowledged that practice had changed over time, with
acknowledgment that a lower trigger was now used:
I haven’t a clue ..I would suspect that they are better at that now than they were, 
you know in the olden days you used to throw blood around... (SH1;269)
“..and I think also doctors are more reluctant to prescribe whereby initially when I 
think back years ago when your haemoglobin was 9...9.5 you know you could 
have a couple of units of blood and It was prescribed willy-nilly... “ so yes there 
has been a huge change in practice” (SH5;154)
It was demonstrated in the literature review that medical behaviours and clinical decision 
making can be entrenched (Firth-Cozens 1997) and these data demonstrated that 
perhaps this is the case in relation to transfusion prescribing practice.
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5.8.2 Internal and external influences
This broad term was used to describe the early theme of what influenced the clinician in
making decisions about transfusion; these could be practitioner attitudes or external
influences on their behaviours such as practices within the institution or clinical setting.
For example, the Specialist Registrar described her experiences in other hospitals:
“while I have been here no patient has ever commented that they feel that they 
are not being transfused often enough or that they feel tired at home and that 
maybe just that they haven’t communicated that to me, but...erm..I would 
certainly..in X hospital it was commented ..oh it’s a bit cruel to let them go til its 
below 8 before transfusing them but I’ve certainly ..its never been communicated 
that patients feel we are being cruel to them not to transfuse them before..I don’t 
know (SH2;97)
“Erm ..I don’t think we are meant to but certainly at my last hospital we would, if 
somebody was about to be discharged we would transfuse them up to a higher 
haemoglobin” (SH2;55)
The second extract demonstrates how the doctor followed the routine practice in that
area in spite of it being against those hospitals guidelines; in other words, clinicians may
tend to be influenced by the "transfusion culture” in the particular clinical setting rather
than practice independently and this may contribute to the variation in practice described
earlier. For example, she also described the practice on the wards:
“All the things you are saying about what the triggers to transfusion and when you 
should ..transfusing are ..I don’t think that is clear I don’t think we have particular 
training...all we know is on the ward is when someone’s haemoglobin drops 
below 8 you should transfuse and that’s what the SHO’s know but more formal 
training we haven’t had .”.(SH2;423)
Similarly the Clinical Nurse Specialists explained their experiences of this setting in
comparison to other clinical settings:
Yeh... I suppose that is what they are used to...just different trusts they have 
different ways of doing things (SH4;106)
I mean I was taught here to look at the 10, but whereas before I probably 
wouldn’t have worried til about 9 (SL4;356)
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It was also related to what education they had experienced; some of the participants 
made reference to the erythropoietin literature, as demonstrated in the following 
excerpts:
"... I know because the manufactures of erythropoietin have banged this into us 
over the years that patients feel better if they are on erythropoietin and they have 
got high haemoglobins and that’s very good.. erm... ” (SH 1;92)
“Well... up until a couple of weeks ago or ten days ago then you would say there 
is good evidence to use to use erythropoietin to maintain haemoglobin in those 
circumstances and ..em..with clinical benefit but now in the last week to ten days 
you can say erythropoietin might be harmful..em..and may impair survival 
outcome from malignancy so I think the jury is still out on erythropoietin and 
ESA’s (SL1;220)
As described earlier where the clinics were busy and there was no time to dedicate to 
decision making (section 5.6.3), the practicalities of transfusion influenced the 
transfusion decision making, for example, resource availability, as demonstrated in the 
following excerpt:
“a lot of this has got to do with space, we can’t just transfuse everyone who’s 
haemoglobin is below 10. We haven’t got the bed space or the staffing to do it .it 
depends what it is, if it is below 9 and we are giving them chemotherapy, we 
know it is going to be lower again next week...if they are really feeling quite 
rough, tired and short of breath and things, before we give them treatment we will 
still give them the chemotherapy, but probably give them the blood transfusion 
the next week, if we car?" (SL4;96)
7 think the resources are considered with the ....where are they going to have 
this blood, where can we fit them in and how can they have it in a timely fashion 
before or after chemotherapy so from a resource point of view that is at the 
forefront of my mind how and where am I going to give them this 
blood. ..ehm... "(SH5;211 )
One of the nurses described how medical clinicians do not think the decision through
because they may not have witnessed transfusion reactions:
.. It could be any of those things but they haven’t thought enough about it ...they 
haven’t had a scare... (SH5;355)
The nurses are at the point of care delivery and therefore witnessed transfusion
reactions may negatively influence their decision to transfuse. Also, as they are the
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administrators of blood they may associate transfusions with additional workload and the
day unit nurses are responsible for managing the resources within the day unit. This
may mean nurses would be less likely to want to transfuse patients than medical staff
and therefore challenge the medical decision as was evident in the day unit sister
interviews, where they prioritized treatments or changed medical decisions:
“but I have just said we just can’t do it, we have got a list on the board now of 
people, prioritising them and we look at their symptoms more, it is a bit 
harsh. “{S\4; 115)
Alternatively, medical clinicians may not be giving transfusion decisions much thought as 
described earlier and this may be related to the hierarchy of the task (the decision to 
transfuse). From a junior doctor perspective it may be acceptable for nurses to make the 
transfusion decisions because they do not consider this to be an important decision, as 
they do not discuss their decision making with the Consultant as described in section 
5.6.3. In summary, this section demonstrates the complexity of influences on the 
individual clinicians in making clinical decisions and begins to describe how the culture of 
the organization and other internal factors may influence decision making.
5.8.3 Shared responsibility
This sub-theme is related to the previous theme where it was emerging that multiple 
clinicians may be involved in the ultimate decision to transfuse. It seemed that no single 
professional group owned this clinical issue; and the patient was also involved in the 
decision therefore this sub-theme was described as “shared responsibility”. For 
example, one of the Specialist Registrars described how this shared responsibility 
worked in practice:
. / mean certainly if the consuitant said “actually I don’t think they need blood “ 
they are perfectly within their rights to say, no they don’t need blood it is their 
patient and as long as they explained why then that would be fine I think..and
171
normally when I worked on the day unit, the nursing staff would tell me..because 
they knew the patients a lot better than me and they knew how likely they were to 
be symptomatic..how quickly they would come back, whether they could wait, in 
their opinion for another day and manage without blood.. “. (SH2;479)
The Consultant Haematologist also described the shared responsibility and like the 
Registrar viewed this as a positive experience:
7 get questioned you know...does someone really need that transfusion? I mean 
I can’t think of specific instances but you know I would not be put out if I had a 
phone call saying somebody has come up for their transfusion and actually their 
haemoglobin is not that low or actually maybe they should have three units rather 
than two and I would take that as being good teamwork’ (SH1 ;364)
Conversely some perceived this behaviour as negative, although it was fully
acknowledged this practice also occurred:
“Yep em if the doctor that saw the patient is around ,if the consultant is around 
they will come back to the person that saw the patient, othenfl/ise they may not 
and they may go to the Reg and....I’m trying to think when I was that Reg, and if
somebody came to me em then.. I don’t know, its sounds too horrific for
words...I’m trying to imagine if it could possibly happen....that the person who 
prescribes the blood never sets eyes on the patient.em..I think that does 
happen....I think it does” (SL1 ;383)
“just blood being prescribed by a registrar as a favour to a nurse for a patient that 
they have never seen and they know nothing about and it is quite frightening and 
it happens and I see it happening most weeks, and that is something that needs 
to be addressed” (SH5;397)
“but you would hope when someone is taking responsibility for prescribing the 
drug they would see them, but I see it in clinics most weeks where random 
registrars have been asked to prescribe blood for patients they have rarely or 
never seen and I think it Is wrong and perhaps it needs to be brought to their 
attention. But if there is no-one chasing it and if people aren’t taking responsibility 
for it then it is difficult.it does happen, in clinics especially... ”(SH5;345)
In these latter excerpts the shared responsibility is not viewed as teamwork but more
lack of responsibility or ownership of the prescribing. Perhaps at a deeper analytic level
the key word is “prescribing”; as was demonstrated in the literature, blood components
are not subject to the same rules as medicines yet the word “prescribing” is used
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routinely when referring to transfusion; it may also be related to the status of the task as 
described earlier in that it is not perceived as of high importance therefore not subject to 
the same rules as prescribing medications. It may be the principles of prescribing 
medications may not need to be applied to the principles of prescribing blood therefore 
this would have implications for practice which will be discussed in Chapter 7.
5.8.4 The influence of the sub-specialist culture
Of further interest was the way in which the sub-specialisms of haematology and 
oncology differed, which may give insight into how anaemia is managed in the clinical 
setting. Haemato-oncology cancers are rare, treatments can be intense and 
relationships between individual patients and clinicians form along the way. This was 
evident in the observations, whereby patients and medical nursing staff used first name 
terms to address each other. Conversely, lung cancer is a common cancer with 
typically short survival and poor prognosis. This is perhaps an observation that is not 
typically acknowledged but may be important in determining the culture of the sub­
specialty. The differences in sub-specialisms may be related to the nature of disease 
and treatment or the volume of patients or patients having poor prognosis disease within 
the lung clinics. This will require further discussion in Chapter 7 as to how this 
influenced the differences in behaviours and management of anaemia between the two 
sub-specialisms.
The environment seemed to also have an impact on the behaviors, for example, the 
oncology clinic was larger and more complex and appeared more chaotic, for example 
there were larger numbers of patients (see Table 4.3.2b). The haemato-oncology clinic
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was more self contained and quiet. This was an important feature as it may have 
affected the time available for patients-clinidan consultations. Appendix 17 shows the 
layout of the clinics. One of the registrars described the oncology out-patient clinics as a 
"warren” and many of the conversations were concerned with the functionality of the 
clinic rather than discussions about patients or educational discussions. For example, 
see LC1 fieldwork notes (Appendix 18) where much of the energy in clinic was 
consumed in process of how the clinic was functioning, for example, were the computers 
working and how difficult it was to secure a clinic room as evidenced in the following 
excerpt:
Another SpR comes in “/ haven’t a hope in heft’..she is talking about finding a 
clinic room. What is more important is finding a room with a computer that is 
working
The Consultants walk in....he introduces the new Consultant and then she is 
escorted to a room. There is also a visiting doctor with the senior Consultant. 
The senior Consultant starts complaining about the room with the broken 
computer..’7/76 computer department need to come and apologise to the patients!’ 
(LC1;34)
These clinics were busy, with more patients and less time. The junior doctor aspired to 
be like the Consultant because he complained he had taken an hour to explain a 
diagnosis. This implied the culture of the clinic was about efficiency and speed. Another 
important feature may be the poor prognosis of these patients and the emphasis being to 
improve symptoms rather than cure, for example the Lung Consultant was efficient when 
explains the prognosis to the patient and it was over in a matter of a few minutes, for 
example:
“we cannot cure this disease..you haven’t got a lot of cancer but it can’t be 
surgery”. Again the patient asks how long she has got. He explains he cannot 
be definite but approximately a year-he explains some people go on for a lot 
longer and others do not. He explains that in some people it can prolong life ..by 
3 months..it is designed to improve symptoms and make you feel better. They 
repeat again the conversation around what she can do..can she leave the house
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and again she mentions her pain. He states there are “no prizes for grinning and 
bearing it" 169)
This may impact on the management of anaemia. It may be that the team over­
compensates treatment of symptoms in an effort to improve quality of life if quantity of 
life is not optional. This was implied in some of the interviews, for example, SL1 
explained:
7 treat alot of lung cancer where it’s very difficult because lung cancer patients do 
get breathless because of their disease and often because of other co-morbidities 
they have associated with their malignancy....such as chronic airways disease 
and sometimes they have a degree of cardiac disease as well.. Having said that 
in some ways in a lung cancer patient.lf their breathlessness is a significant 
feature and they almost have a lower threshold ..even though I know that 
anaemia may not be the sole or maybe even the most important reason for their 
breathlessness and their breathlessness often to my mind ...their breathlessness 
is multifactorial in aetiology I would almost perhaps have a lower threshold for 
transfusing such a patient because if it happens to help they can be patients who 
symptomatically can be very difficult to treat...so I would...”(SL1 ;44)
Conversely the haemato-oncology clinic was calm; it was a smaller more contained
environment. The relationships between the patient and the team seemed closer and
there was a familiarity between the patient and clinician. A further example which
demonstrated the differences in the sub-specialisms was the observation of how patients
were informed of diagnosis and treatment plans. For example, when taking notes during
a patient consultation, one of the Consultants’ asked what the observations had to do
with anaemia. This was the first period of observation, where the researcher was
attempting to get a feel of the clinic culture as opposed to focusing on anaemia. The
researcher explained that perhaps not directly but the way in which he managed that
patient did, for example, he explained her laboratory results and showed her them in
graph form on the computer. This was an example of the general impression of that
clinic in that the medical staff may have had more time to “educate” the patient about
their disease and progress, than in the oncology clinic. This was further substantiated
175
during the more focused patient interviews, where the haemato-oncology patients
appeared more knowledgeable about their disease and treatment and frequently used
the same language as the professionals for example:
...if my neutrophils are low,... like....In two days or three days I have to have more 
blood .... if my neutrophils are coming up..yes if my neutrophils are coming up 
and I don’t feel tired anymore (PH1;100)
Well I know because I am allergic to platelets in that I have developed antibodies 
because I have had so many different platelets.. (PH3;418)
Conversely, the lung patients did not use medical terminology or seem so informed for 
example:
7 don’t know..l don’t know really. I just see the doctor and he says I need blood. 
He then books it on the phone....(PL 1; 122)
The reasons for this are probably multiple as described but have implications for how the 
sub-cultures may influence transfusion practice, in that if the patient is informed they may 
be more involved in the decision making process. However, it also implies that the 
nature of the clinics and the pressures within the clinical setting may mean that is some 
clinical settings this “education of the patient” may not be possible, either due to time 
constraints or the way in which the clinics are organized and structured, it may also 
mean the patients are socialized into the practice of that sub-culture.
Another significant difference In the sub-cultures was the different haemoglobin levels
used to describe anaemia and frequently referred to in the interview data. The oncology
clinicians described anaemia by using a higher haemoglobin level, for example in the
following excerpts. The first excerpt is the haemato-oncology example; the second
excerpt is the oncology example:
"anaemia is anything that’s abnormal but in our patients we would probably have 
a lower threshold than some sectors would....and of course you have to assess
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each patient individually ...em.Jn our case..some patients with a haemoglobin of 
8 [ ]  ...AgainJts very difficult to say.jfs usually around 8 or 8’ish”. (SH4;4)
“if I’m honest.J don’t separate particularly for males and females so I would say a 
haemoglobin of less than 10g/dl is anaemic or is anaemic as far as I am 
concerned although that on it’s own would not be my trigger for 
transfusion.. .(SL1 ;3)
This higher trigger used in oncology was revealed in the audit data, but not in the actual 
transfusion triggers used in the oncology patients in this study. This may be a reflection 
of the impact of radiotherapy, whereby there is clinical evidence for use of a higher 
trigger. Oncology departments have radiotherapy and chemotherapy patients and this 
may influence the oncologists when describing what they define as anaemia, however, 
there was no evidence in this study that in the lung oncology setting that higher triggers 
are actually used either in how the clinicians described when they would transfuse or in 
the lung clinic data. The second excerpt is revealing in that it describes a definition of 
anaemia, but they would not transfuse at this level. This will be discussed in more detail 
in Chapter 7.
5.8.5 Summary
Some sub-themes within the “socialization in practice” may help to explain the wide 
variation in practice described in the literature review; this contribution to knowledge 
about transfusion practice has not been previously acknowledged. The variation in 
practice has been described but not the influences on behavior within the clinical setting 
of haemato-oncology and oncology, which can be summarized as:
• The influence of the local community of practice 
The low priority and status of anaemia management 
The shared responsibility
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• Habitual behaviours which in this research has been described as traditional 
behaviours
Optimal transfusion behaviours may be developed if the cultural influences on 
transfusion are acknowledged and different strategies are developed. Furthermore, 
socialization of practice may have implications for how training and education in 
transfusion practice is to be developed; more emphasis needs to be placed on evidence 
and efficacy of transfusion rather than merely the safety aspects.
5.9 Disaggregation of the body
The haemoglobin value, widely and frequently referred to by participants, seemed to be 
the trigger for action but there was a great deal of discussion about the symptoms in the 
interviews (perhaps because the researcher asked about symptoms); yet the reality was 
many of the actual behaviours were a response to the haemoglobin, and very little 
assessment seemed to occur in practice, other than a few brief questions. It was also 
demonstrated in previous sections how assessment may not be necessary if the 
haemoglobin result was available. This implies the haemoglobin is used in isolation, 
and decisions may be made when all the information is not available. The ease and 
universality of the haemoglobin test (virtually every patient who attends the outpatient 
areas has their Hb tested) relates to availability heuristics described in the literature 
review, whereby a clinician will base a decision on the ease of availability of information. 
The shared decision making described earlier, sometimes meant that decisions were 
changed or made in absence of the patient, therefore not ail the information would be 
readily available, for example, the patient would be unable to contribute to the 
assessment and provide the subjective information. For example, when the doctors
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wrote on the charts to give blood if the haemogiobin was less than lOg/dl as described in
the foilowing excerpt:
...because that when it (prescription chart) normally comes to us is when it has 
been circled and a note put at the bottom of the page to give them a blood 
transfusion whereas they may not have been assessing for that before, they have 
just got the result (SL4;222)
The overarching general theme is that sometimes the assessment and decision making 
are made either without knowing the patient or having ail of the information available. 
Conversely, it was acknowledged that the assessment and decisions were improved if 
the patient has a relationship with the clinician, or the low haemoglobin was 
contextuaiized as described in section 5.7.4.
Diagram 5.9: Taxonomic analysis: relationship of components and early themes - 
Disaggregation of the body
The impact of the 
haemoglobin
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5.9.1 Importance of the haemoglobin
It was described earlier how the symptoms cause uncertainty when assessed in 
isolation. This was further consolidated in the interview with SL4 (Oncology Day Unit 
Sister) who stated when asked what would prompt them to ask the patient questions 
about the presence of the symptoms of anaemia;
“ ...and you have got the results in front of you or if you notice that they looking 
really pale and they are Just not quite themselves. I think it is because we have 
got the resuits in front of us ..it doesn’t happen that often unless it is really low 
that you actually look at someone and go ..your anaemic...it is more that we 
have got the results first and then we see them, if you know what I mean’’ (SL4; 
79)
The idea started to form for the researcher that the impact of the haemogiobin level has
profound effect; a low haemoglobin level would stimulate the clinician to ask about
symptoms or how the patient was feeling. In an uncertain world perhaps the
haemoglobin value is the only constant and therefore the major influence on the
decision. Alternatively it may be that the influence of the culture is another "certainty “
and therefore this drives the clinical behaviour to conform to what is the usual practice in
these clinical settings. The level of haemoglobin was important, so for example, clinically
defined mild anaemia (10-12g/dl), was tolerable, however, it appeared the haemoglobin
was the primary determinant for the ultimate diagnosis therefore the holistic assessment
did not seem of importance:
“Ok I think we are quite spoilt because we get full blood counts on everyone, so if 
I am sitting in a leukaemia ciinic I won’t actually bring the patient in until they 
have had a full blood count so that I know that they are anaemic” (SH2;128)
“...but again you would still have to have the blood count in front of you so you 
wouldn’t have to do anything clever....in order to ...you would Just have to assess 
how the anaemia was affecting them symptomatically...and so again you would 
ask for oedema, chest pain shortness of breath, how it impacted on their walking 
distance, whether they got chest pain going up hills, that sort of thing” (SH2;161 )
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The literature revealed that generally when making a diagnosis, one uses the history and 
symptoms followed by laboratory investigations to confirm or refute a diagnosis. In the 
case of cancer related anaemia it appears to be the opposite in that the laboratory value 
implies a diagnosis and the presence of symptoms may be used some of the time to 
confirm or refute the diagnosis; sometimes the laboratory value was used in isolation. 
This phenomenon has not been previously described in relation to cancer related 
anaemia and may be related to the culture of organization and/or of resources, for 
example, there may not be the time to explore the other effects of the cancer related 
anaemia.
In this study, there was no evidence that systematic or holistic assessment was 
undertaken to confirm the diagnosis, other than the anaemia nurse specialist who 
acknowledges that diagnosis and management of non-malignant associated anaemia 
differs from cancer patients because “they (cancer patients) are a different group in the 
sense that some of them have got problems with their bone marrow and that is the 
factory “{SH9]320), which means the production of red blood ceils is affected. There was 
also evidence that in non-malignant cases holistic assessment was undertaken:
When those patients come in they are put through a full assessment The full 
assessment will be ...first get the full story from the patient when they come and 
let them tell their story. From that you could actually start to make sense. From 
what they are telling you their story. [  ]  That compromises the oxygen circulation 
that is happening in their body. So putting all of that together, all of that 
information from asking the patients questions , doing a physical assessments 
and then taking vital signs. (SH9;125)
This was a more thorough approach, however, in a sense this is making a primary 
diagnosis with an attempt to find out the cause of the anemia, for example, iron- 
deficiency or vitamin B12 or folate deficiency. One could argue that the management of
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cancer related anaemia is different because the underlying cause is known; it is 
secondary to the cancer or therapy, and is an accepted consequence of disease and 
treatment, it may be related to the hierarchy of the task in that if the management of 
anaemia is perceived as a low status decision because it is regarded as a symptom of 
the cancer as opposed to a disease entity in its own right. It is not a primary diagnosis, 
but merely a consequence of the disease and therapy; therefore the clinical attitude and 
approach may differ for these reasons and this will be discussed in more detail in section 
7 in relation to assumptions that can be made about making a diagnosis.
5.9.2 Knowing the patient; knowing anaemia
This theme initially emerged as “knowing the patienf, because it emerged that the 
relationship with the patient was important in transfusion decision making and it was 
described how knowledge of the patient improved the quality of decision making. 
However, not surprisingly it also emerged the more experienced clinicians seemed to be 
more discerning in their assessment and decision making. Therefore this theme was 
developed from the data that demonstrated or described how improvements could be 
made when assessing anaemia.
Earlier it was described how it was acknowledged by the clinicians that by 
contextuaiizing the anaemia (the low haemoglobin level), assessment and decision 
making could improve. Simiiariy the sub-theme of "knowing the patient" emerged; and 
that by not reviewing the haemoglobin value in isolation, assessment and decision 
making could improve. It may appear obvious, but direct interaction with the patient is an 
important part of the process and may actually improve practice. The patient-clinician
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interaction was described in the interviews frequently as a series of questions about
tiredness and shortness of breath. Appearance included how the patient walked and
their colour. Both patients and clinicians acknowledged that knowing the patient was an
advantage in the assessment process and was the preference for assessment. For
example the Specialist Registrar described her experience of working in the day unit:
..and normally when I worked on the day unit, the nursing staff would tell me 
because they knew the patients a lot better than me and they knew how likely 
they were to be symptomatic..how quickly they would come back, whether they 
could wait, in their opinion for another day and manage without b/ood...(SH2;479)
But when you have a key person liaising with the patient and working with the 
patient, it is quite easy to put “your finger on the pulse” and decide whether to 
transfuse or not because you know your patient better and you can get the facts 
for your assessment quite easily (SH9;479)
This knowledge of the patient may prevent the disaggregation of the body whereby the
haemogiobin is used in isolation and relates to the patient being involved in the decision
to treat the anaemia, for example, patients described how the team interacts with them:
Ves some take more part, some get more involved in how I feel when... erm...do I 
feel symptomatic more..what do I think..they listen and we talk [  J.some get 
Involved and some doesn’t, some prefer not to get involved as much with the 
paf/enr (PH1;186)
Or based on their experience based on a whole print out and see what it looks 
like. I would think that it is their decision. I have never ever said “ I want blood “ 
and they said “ no you don’t J “and I said “I do!” I ’ve always felt very comfortable 
with how we work it out (PH3; 301 )
However, it was also likely that clinical decisions were improved by more exposure over 
time. It may because of the uncertainty of diagnosis and treatment that experiential or 
tacit knowledge may improve decision making. For example, in the following excerpt by 
a Consultant;
“my response to that as junior registrar would have been, they are telling me they 
need a blood transfusion, somebody who has been doing this job for years is 
telling me that this person needs a blood transfusion, they probably do so I will 
just prescribe it... whereas now i might challenge that I would not have
183
challenged that 6, 7 or 8 years ago so I know myself it is not a conversation that I 
have had with any of the registrars and so I have to say I don’t know what my 
response would be but I suspect it would be, like mine, initially you would do it 
and then maybe over time you sort of work out that not everybody needs a blood 
transfusion” (SL1 ; 171 )
However, it was aiso observed that it has taken many years to become more discerning, 
and this may be hampered by the reality that within the culture of blood transfusion; there 
is limited discussion and discourse about this clinical issue and one could argue that 
because of this; tacit knowledge may take longer to accumulate. In summary, “knowing 
the patient and knowing anaemia" may have a positive impact on transfusion practice, 
but this will be discussed in greater detail in Chapter 6.
5.9.3 Summary
The haemoglobin value was a powerful influence on assessment and decision making 
behaviours; both patients and healthcare professionals made reference to it. It may be 
related to availability heuristics as described in the literature review, whereby the 
haemoglobin is accessible and reliable. The NCI classification of anaemia also uses the 
haemoglobin value to define anaemia but In contrast the symptoms and holistic 
assessment are described as important in the literature, with many studies focusing on 
quality of life. The relative unimportance of the task of deciding to transfuse and the 
balance between the factual evidence (the haemoglobin level) and the tacit knowledge 
(knowing the patient) demonstrates the complexity of the decision; this will be described 
in more detail in Chapter 6 where the relationship between hierarchy of task and 
disaggregation will be explored. The reality is that holistic assessment did not seem to 
occur in practice; the haemoglobin was obtained to diagnose the anaemia although 
conversely it was recognized knowing the patient and discussing the anaemia with the 
patient was the preferred option; with decision making improving with experience.
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5.10 Summary of analysis and findings
The ethnographic cycie has been described by Spradley (1980; p 29), however, the 
primary researcher did not technically adhere to this. She adapted the original to include 
“asking question^’ not only of oneself but supervisors and colleagues as well as the 
participants themselves. There seemed to be a point where the same issues and 
themes were recurring and no new themes or data was emerging (Diagram 5.10) and 
the researcher described this as “saturation”.
Diagram 5.10: The ethnographic cycle (author version of cycie)
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This analysis process may not adhere to true ethnographic methodology as one could 
argue that saturation is never reached and cultures could be observed ad infinitum and 
new themes would emerge. The researcher would argue that this research explored a 
specific aspect of decision making within the wider culture and therefore there came a 
point that saturation was reached.
From the early themes, the data was re-visited on multiple occasions. Further analysis, 
resulted in appreciation that some of the initial themes had the same meaning or 
underpinning behaviors as described during the componentiai analysis. In this way, new 
categories or sub categories emerge and there was a considerable amount of 
reassignment of data among the categories (Boeije 2002). Final analysis revealed fewer 
themes, although it was essentially an extension of the analysis as opposed to separate 
discovery. The aim was to search for universal cultural themes, and a description of the 
larger relationships among the early themes. The overall analysis phase was lengthy, 
iterative and could be described as a fluid process, constantly moving and changing until 
the researcher was satisfied that all elements of the data had been interpreted and 
organized into some sort of meaning that would underpin the clinical practice In the 
broadest sense. The different data sets were utilized to substantiate common threads of 
thoughts and ideas. In other words there was an attempt to bring generality to the 
findings in order for the possibility of transferability to other transfusion cultures. The four 
different influencing themes emerged, following working through and thinking about the 
data:
• Ubiquity of anaemia and blood transfusion
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• Acknowledging uncertainty
• Socialization of practice
• Disaggregation of the body
These phenomena have not been described previously in the management of cancer 
related anaemia with blood transfusion. The findings suggest that anaemia and 
transfusion are commonplace; but the management of cancer related anaemia may differ 
from other types of anaemia. It was complicated by the fact that presenting symptoms 
could not be attributed to anaemia as confounded by symptoms of cancer and side 
effects of therapy; which made confirmation of diagnosis uncertain. The haemogoiobin 
was used almost universally, (and sometimes in isolation) to diagnose the presence of 
cancer related anaemia, but it was described how the assessment and management of 
this type of anaemia could be improved if the anaemia and treatment was contextuaiized 
and if the professional had prior knowledge or was familiar with the patient. Treatment 
decisions were heavily influenced by the clinical culture through socialization into the 
cultural practices, probably more so than by guidelines, knowledge and even experience. 
The culture of anaemia and transfusion practice, and clinical decision making in the 
wider sense, in relation to the literature will be discussed in more detail in the following 
chapter (Chapter 6).
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CHAPTER 6 
Discussion
This chapter discusses the findings and foilows a similar structure to Chapter 5 as each 
major theme is discussed in further detail and in relation to existing knowledge and the 
literature review. This exploration of the culture of anaemia management used a variety 
of ethnographic methods to illuminate how this clinical problem is managed in the clinical 
setting. Blood transfusion is the traditional approach to treating anaemia but, despite 
guidelines and mandatory training, in all clinical settings wide variation of practice is 
reported (Salem-Schatz et al 1993). It was a combination of this variation in practice, 
and observation that many patients did not appear to improve post-transfusion, which 
motivated the researcher to explore this subject further. Exploring actual practice using 
ethnographic methods has provided an explanation for why uncertainty and variation 
exists In clinical settings.
The analysis and findings section described the culture and the chronicle of events In the 
clinical settings, however, ethnographic methodology takes this a step further and there 
was an attempt to interpret what was happening in reality; to make sense of it and 
explain it as a form of “constructing an account". To do this the researcher employed 
analytic categories that presumed general patterns but with the recognition this does not 
"fix” the phenomenon under study; by this it is meant there may be deeper understanding 
of the clinical problem but it may require further research, education or service 
developments to begin to tackle any issues that emerged from the findings.
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It should be remembered, however, that cultures are not homogenous; one cannot make 
broad generalizations without taking into account differences amongst the group 
members. However, this “construction” although it may not be validated or 
generaiisabie, does not mean elements cannot be used elsewhere in other clinical 
settings to make sense of what is happening; otherwise the research would only have 
value for the culture that was explored. Rigor has been applied to this research by 
integrating the data sets and using the evidence from the data sets to validate the 
findings. Therefore from the findings, tentative associations can be inferred and by close 
examination of the detail of the processes involved in decision making, some causal 
mechanisms may be developed. Schofield (1990) elaborates how by this means, 
ethnographers can make reasonable judgments and assumptions about the 
transferability of findings that can be applied to other settings. The clinical usefulness of 
this construction lies in the ability to use it to change practice or increase awareness in 
the social world of medical care, and in this case, of cancer related anaemia, where 
complexity In its management has been demonstrated; with the recognition that barriers 
exist, which prevent insight by clinicians. Therefore, the foilowing is a discussion of the 
findings and is a product of the ethnography; the primary researcher’s interpretation and 
use the literature to understand of the process of assessment and management of 
cancer related anaemia and blood transfusion.
6.1 The ubiquity of anaemia and blood transfusion
This study suggested the reality is that clinically defined anaemia is ubiquitous in the 
cancer care setting. The important issue here is “clinically defined”, in that this term 
encompasses ail patients who have a haemoglobin of “less than within normal limité’ 
(NCI criteria; Groopman & Itri 1999). The ciinic data revealed it was not until the
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anaemia became moderate or severe by NCI criteria that treatment was initiated. The 
implication here is that cancer patients live with their anaemia; and healthcare 
professionals and patients seem to accept this as a normal consequence of disease and 
therapy; treatment is not initiated until a critical point is reached. Although a small 
proportion of patients are transfused, the large numbers of patients and the increased 
frequency of anaemia in some patient groups mean that healthcare professionals are 
frequently involved in blood transfusion decisions and this was revealed in this study. 
Transfusion is a common therapy for cancer related therapy and frequently delivered 
form of treatment in cancer day unit settings; there was familiarity with this subject and 
all participants could tell their "stories". Blood transfusion is also used in the treatment of 
non-malignant anaemia (e.g. peri-operative anaemia; sickle cell anaemia etc) but it may 
be that cancer related anaemia differs in some way from other types of anaemia, 
because of the context of the anaemia and the inextricable relationship with the cancer 
and treatment. The patients learn to live with the symptoms of cancer and anaemia and 
the side effects of treatment and it is only when the haemoglobin level falls to a critical 
level, or symptoms reach a critical point that treatment is initiated. This difference will be 
explored by discussing the meaning of cancer related anaemia and how patients live 
with their anaemia.
6.1.1 Biomedical assumptions about cancer related anaemia
Anaemia is defined as having a lower than normal haemoglobin; and it fits a classical 
biomedical definition. Winkeiman (2009) describes how western society and scientific 
medicine, views illness primarily as disease, which is understood as biological 
abnormalities in the body’s structure, chemistry or function. This assumption of 
biological disease is so deeply engrained in the thinking of most health professionals that
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they may make assumptions. For example, in making a diagnosis and assigning a 
biomedical labels provide a universal valid system of classification but the assumption is 
that medical practice is culture free and scientifically neutral and objective (Winkeiman 
2009). The findings of this study supported this claim in that the haemoglobin value 
(biomedical value) was used to define the presence of anaemia but the participants 
acknowledged that sometimes the degree of anaemia did not correlate with the 
symptoms or patient experience. In defining disease, the biomedical approach is to 
focus on the results of laboratory results; but may neglect the patient experiences, 
therefore the haemoglobin level was used to define and treat the anaemia however, this 
had different meanings and experiences for the participants, which will be explained in 
more detail below.
The processes whereby particular disease labels are attributed can be ambiguous in 
some cases, and they may not be determined solely by naturally occurring categories 
and phenomena. For instance in the literature review it was described how Hunt (1985) 
uses the example of hypogiycaemia to show a degree of indeterminacy in the attribution 
of that biomedical term. She argues that contrary to a commonsense view of a diagnosis 
as a description of facts, a term such as hypogiycaemia expresses the physicians’ 
concepts of “anomaly” or “dysfunction”. Furthermore, Winkeiman (2009) describes how 
he has been with clinicians measuring blood glucose levels and some levels were so low 
that the patient should have been unconscious, but was functioning normally; he 
summarized by stating “ the biological condition is not the sole determinant of a disease, 
but, rather, how the condition relates to the social context’ (p42). In summary, the 
attribution of the disease label is highly variable among clinicians, and Hunt concludes
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that one must regard such diagnostic labels as cognitive constructs and as such are 
subject to the influence of culture and context.
This approach could be applied to the concept of anaemia. It is not simply a biomedical 
term; it has different meanings for different heaithcare professionals, which are subject to 
culture and context. For example anaemia was frequently described in the classical 
sense as haemoglobin of less than 12g/dl by the participants, yet the definition of 
anaemia requiring treatment in the clinical setting was much lower than this, and varied 
between individuals. Furthermore this differed between haemato-oncology and oncology 
clinicians. Haematology clinicians frequently talked about a haemogiobin of less that 
8g/dl however, oncology clinicians tended to use a higher trigger in discussion, usually 
10g/dl. The higher trigger used for describing anaemia in the oncology setting did not 
necessarily translate into treatment (as demonstrated in the ciinic data where only those 
with haemoglobins of less than 8.5g/di were treated), it may be this is the description 
used in that sub-culture to describe anaemia, but not necessarily the trigger to treat the 
anaemia.
A vivid demonstration of the variety of meaning of cancer related anaemia was the 
statement by PH3 (in section 8.7.3) who stated that he did not see himself as having 
anaemia, despite multiple transfusion episodes. The label of anaemia, however, may be 
necessary for the clinicians in order to describe a clinical situation. Lave and Wegner 
1991 (in Atkinson 2005) describe how this "is as much a matter of apprenticeship as any 
other culture specific way of knowing and telling” {p47y, there needs to be a production of 
reliable (that is reproducible) clinical descriptions otherwise there would be no 
organizational control. However, this study demonstrated that despite the universality
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and ubiquity of anaemia in the cancer setting; and the use of the biomedical diagnostic 
label of anaemia, cancer related anaemia had a different meaning for different sub­
cultures and even for different individuals within the sub-cultures. If the definition was 
variable, this could contribute to the indeterminacy and uncertainty of treatment as 
individuals are socialized into the meaning of anaemia for their particular sub-culture. 
The definition of anaemia aiso relates to the disaggregation of the body; as the defining 
criteria is the haemoglobin level and not necessarily what the patient feels or 
experiences. Finally, this aiso demonstrates how the ubiquity of aneamia and blood 
transfusion relates to the other themes {acknowledging uncertainty; socialization of 
practice; disaggregation of the body) as they are all inextricably linked to each other as 
part of the wider culture of cancer related anaemia practice. In other words it is about 
the context of the anaemia, how it presents in clinic, what it means for patients and 
clinicians, and how it is diagnosed and treated in the individual clinical setting.
6.1.2 Adapting to anaemia
In the preceding section it was described how in defining the disease, normal values are 
used, but this can be problematic, because the concept of “normal” can be variable. For 
example, many cancer patients could have been anaemic prior to their cancer diagnosis 
and this would be their norm. Furthermore, many cancer patients remain anaemic for 
many months or even years despite transfusion; and the degree of anaemia may 
fluctuate. Therefore, the patient may continually be anaemic throughout therapy, by 
biomedical criteria; however they adapt or learn to live with their anaemia.
The literature review described the physiological adaptation to anaemia and how it may 
not be until there is a degree of oxygen debt that the patient becomes symptomatic. This
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physiological trigger is undetermined and therefore many patients adapt to a degree of 
anaemia; some to a trigger as low as a haemoglobin of 7g/dl (Hébert et a /2004; Morisaki 
and Sibbaid 2004; Madjdpour and Spahn 2005). This is why clinically defined anaemia 
may be common, but why it is not always evidenced in behaviours or symptoms in 
patients. This study demonstrated how staff participants could all remember patients 
who had surprised them by adapting to their anaemia; and more interestingly the 
patients themselves could not predict their fluctuations in haemogiobin to correlate with 
how they were feeling. This study replicates the physiological findings demonstrating the 
unpredictability of cancer related anaemia and of the finding in the patients’ poor 
predictions of their symptoms, which implies the level of oxygen debt trigger may be 
variable within individuals at different times on the treatment pathway. However, this has 
already been demonstrated in the literature review that patients’ symptoms and side 
effects of chemotherapy fluctuate during the treatment pathway (Richardson et al 1998) 
and it may be these symptoms overwhelm and confound both patient and clinician as to 
what are cancer-related symptoms and what are anaemia-related symptoms. This may 
have been the reason for the situation where patients received blood despite having 
relatively high haemogiobin (PH2 received two unit transfusion when his haemogiobin 
was 9.8g/di). This will be discussed in more detail in the discussion about symptoms 
(section 6.2.1); but the difficulty in separating the symptoms may be further confused by 
this adaptability. In summary, the degree of adaptability appears to be highly variable 
and unpredictable and as ubiquitous as the anaemia itself.
6.1.3 Conclusion
It has been demonstrated that the dividing line between “normal” and abnormal is not 
nearly as sharp as one would assume at first glance; even when using distinct
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biomedical markers. The meaning of the haemoglobin ievel appears to be different in 
different sub-cuitures and even within individuals, it is a subjective assessment of 
anaemia; even in the presence of the haemoglobin, and therefore may be influenced by 
all the experiences and knowledge and culture of the clinical setting. The ubiquity of the 
aneamia may also mean that it is not viewed as an illness. If a disease at the time of 
diagnosis causes no pain or suffering or disability, even if it precedes or accompanies a 
more serious (“real”) disease such as cancer; especially if it is frequently encountered, it 
will not be viewed as an illness (Eddy 1999). This may contribute to why participants in 
this study did not always perceive the anaemia to be important.
6.2 Acknowledging uncertainty
This section develops further some of the uncertainties described in the previous 
sections. The literature demonstrated the definition of anaemia using the NCI criteria 
(Groopman & Itri 1999) and the pragmatic transfusion trigger guideline developed by the 
BOSH (1999) of 8g/dl; both of which are used in clinical settings. However, given the 
uncertainties about what constitutes a disease, it appears these definitions and 
guidelines may be arbitrary. Similarly, the literature review described the classical 
symptoms of anaemia, (Ludwig and Strasser 2001; Vogeizang et al 1997) but it was not 
always demonstrated in this study that assessments or decisions fitted ail the criteria. 
Correlations between haemoglobin levels and quality of life were also reported (Celia 
1997; Holzner et al 2002; Lind et al 2002) but these studies fail to describe the reality in 
that this may be unpredictable, and for this reason cancer related anaemia may not 
always be easy to clinically manage. Despite many studies on cancer related anaemia, 
the reasons for this variation in practice has not been clearly defined. There are 
descriptions of the difficulty In managing this clinical problem but limited explanation
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other than recommendations that more comprehensive assessment of the patient is 
required. This section will discuss uncertainty further in relation to making assumptions 
about the symptoms as weil as making assumptions about response to transfusion.
6.2.1 Assumptions about assessing the symptoms of cancer related anaemia 
The findings of this study demonstrated that the symptoms did not always mean the 
patient was suffering from their anaemia. This study showed the symptoms of disease 
and side effects of treatment may create such a degree of indeterminacy that there 
would be no rationale in trying to assess the haemogiobin with the symptoms in a robust 
way. For example, this study revealed that patients themselves were frequently “wrong” 
when they assessed how they were feeling with their haemoglobin. They could be 
feeling well, with no symptoms and have a clinically defined severe anaemia (Hb 6.5- 
7.9g/di); or the reverse where they were feeling extremely fatigued yet their haemoglobin 
level could be 9-10g/dl. This is an important feature of cancer related anaemia. The 
literature describes how a full systems review assessment is required to assess anaemia 
(Foubert & Wujcik 2005), however, this study’s findings suggests that the uncertainty 
should be acknowledged as it may be that even if a full assessment was undertaken, the 
outcomes may be no different. This study revealed the actual practice of diagnosing 
anaemia, that required treatment, was usually a response to the haemoglobin; and the 
trigger for treatment was culturally influenced.
It is known from the literature that few clinicians make use of the complete history and 
systems review (Hoffbrand 1989). In the assessment of anaemia the literature stresses 
the importance of systems assessment however; actual practice in this study reveals this 
was not undertaken. The reasons for this are unclear from this study and warrant further
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discussion. The assessment appears to be based primariiy on the laboratory values with 
or without conversation with the patient. It was described in the findings how the 
clinician described a lack of time in the clinic, which suggests if clinicians had more time 
perhaps their assessment and decision making may be more thorough. A Cochrane 
Review of the effects of interventions aimed at changing the length of time for 
consultations revealed that longer consultations did not necessarily have benefits or 
resulted in change of clinician behaviours, but did result in patients’ taking more 
responsibility for their problems (Wilson and Childs 2006). The assessment may be brief 
or non-existent, and the decision to transfuse made in response to the haemoglobin level 
however, the physicians’ priority in ciinic may be to focus on the cancer in the hierarchy 
of clinical concerns as described in section 5.6.3. This hierarchy of task and knowledge 
can be summarized in diagram 6.2.1.
Diagram 6.2.1: Hierarchy of knowledge and task
Physician
Factual (biomedical) knowledge
Disaggregation
High status Cancer and its treatment
Low status
Hierarchy of knowledge V & task
Nurse
Tacit knowledge 
“Knowing the patient" 
Anaemia and its treatment
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The physicians focus of concern on the task of treating the cancer may not need to 
change or indeed should it change because cleariy the cancer should be the clinicians 
focus, however, it has implications for how anaemia couid be managed. If the 
responsibility were to shift to the nurses for example, because their clinical priorities may 
differ from the physicians' priorities, they may place greater emphasis on quality of life 
issues and therefore give the treatment of anaemia more consideration. This will be 
discussed in more detail in Chapter 7.
The literature demonstrated frequently encountered, low risk clinical conditions are 
frequently assessed using pattern recognition (Del Mar et a /2006). Clinicians attempt to 
match the presentation within their internal “schema” (Coderre ef a/2003) but there is a 
risk that too much emphasis is placed on pieces of evidence, for example, laboratory 
values or if the patient has too many problems at once (Del Mar et ai 2006). This study 
has revealed the latter may occur when the haemoglobin is the evidence and the patient 
has not only multiple symptoms but unpredictable symptoms further confounded by the 
fact the symptoms may not be attributable to the anaemia. It was also revealed in the 
literature review that more experienced clinicians gain more information from the history 
rather than systems review i.e. it is the conversations that reveal the most information 
(Del Mar et a! 2006; Hampton et al 1975; Hoffbrand 1989) and the more difficult 
decisions require a full history (Del Mar et al 2006). It may be that the assessment and 
treatment of cancer related anaemia is over-simplified because of its frequency and 
complexity or because it is not a primary diagnosis but a consequence of cancer and 
treatment; it is iikeiy in the out-patient setting that parsimonious behaviors ensue 
because of the lack of time to dedicate to this common but complex problem and
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therefore limited time is dedicated to questioning patients. The time factor may also be 
related to the priorities of the different professional groups as described earlier.
The literature review described how learning in the social world incorporates knowledge; 
skills and practices; personal understanding of people and situations; accumulated 
memories and episodic events (Eraut 2000;2004). In summary, personal knowledge 
mainly comes from observations and this implies a holistic rather than fragmented 
approach to knowledge. It may be the day unit nurses are in the best position to learn 
the skills of anaemia and transfusion practice as they will have “accumulated memorled’ 
of patients who attend for blood transfusion; they are more likely to be in a position to 
observe changes over time and may be related to the findings of the importance of 
“knowing the patient, particularly if the clinic process remains unchanged where patients 
are reviewed by different physicians.
In summary, it would be easy to be critical of the behaviours in clinic however, in a sense 
it can be understood how these behaviours have evolved. The behaviours may have 
developed because of the clinical priorities of physicians and this has implications for 
practice, which will be discussed in more detail in Chapter 7.
6.2,2 Assumptions about response to transfusion
Despite the frequency of cancer related anaemia and blood transfusion to treat it in the 
UK, there has been limited research in this area. The bulk of research activity in cancer 
related anaemia as described in the literature review has been the erythropoietin studies. 
Multiple erythropoietin studies have demonstrated improved quality of life with an 
increase in haemoglobin (Boogaerts et al 2003; Osterborg et al 2002) and the earlier
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studies showed improved survival outcomes (Antonadou et al 2001 ; Littlewood et al 
2001 ; Vansteenkiste et al 2002). However more recent published trials have raised the 
concern regarding the Impact of erythropoietin agents on survival in oncology patients 
and these have reported increased mortality in patients treated with erythropoietins in 
some tumour groups (Leyiand-Jones 2003; Henke et al 2003; Overgaard et al 2006; 
Wright et al 2007). These studies may be a powerful influence on perceptions about 
cancer related anaemia and transfusion practice; and the influence of the pharmaceutical 
industry was described in the literature review (Bekelman et al 2003; Kjaegard and Als- 
Nielson 2002). The findings in this study demonstrated clinicians were aware of the 
early positive impact of erythropoietin and there may be assumptions that a concomitant 
increase in haemoglobin by transfusion, may improve quality of life. There are two 
criticisms of this assumption. Firstly, the rise in haemoglobin with erythropoietin is 
sustained, constant and generally, patients' haemoglobin rises up to within or near 
normal limits (Demetri et al 1998; Glaspy et al 1997; Littlewood et a /2001); treatment 
with blood transfusion results in peaks and troughs of haemoglobin. Secondly, the 
benefits of erythropoietin may be greater because it results in a rise in homologous 
haemoglobin; as opposed to allogenic blood in the form of a blood transfusion. There is 
risk in transference of findings from erythropoietin studies. Blood transfusion and 
erythropoietin are different forms of treatment therefore outcomes cannot be 
comparable; this study revealed the clinicians were knowledgeable about the 
erythropoietin literature, perhaps because there was no comparable blood transfusion 
literature in this clinical setting. The clinicians may assume patients’ quality of life will 
improve post-transfusion, yet this study revealed patients and clinicians could not 
consistently describe benefit following a blood transfusion, and the risk would be a 
tendency to over-transfuse.
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This study revealed the response to transfusion was described by participants as 
unpredictable. Some other specialties have started to research outcomes from blood 
transfusion in more robust ways; presumably derived from a similar hunch to this 
researcher that sometimes patients seem to have no benefit from transfusion 
whatsoever, in terms of improved quality of life or that blood transfusion can adversely 
affect outcome. If one thinks about what a blood component contains; it contains not 
only red blood cells but white blood cells and foreign proteins and this may have 
immunomodulatory effects (Landers 1996); and It was described in Chapter 2 how 
properties of the transfusion itself may contribute to variable responses. The Koch 
(2008) study in the literature review revealed how cardiac patients did significantly worse 
following transfusion of “old blood”. It may be that the age of the blood, patients receive 
in oncology, has the same negative effect; or result in the patient feeling no benefit 
following transfusion as red blood cells only have a finite life span. This study revealed 
how in this clinical setting participants (patients and professionals) described 
unpredictable responses to transfusion, but it was beyond the scope of this study to 
explore the age of the transfused blood. The age of blood is not considered in oncology 
and haemato-oncology and this may have implications for future research which will be 
discussed in Chapter 7.
A further uncertainty exists; Wigton et al (1999) described how physicians and medical 
students use and interpret evidence in individual ways; and this does not seem to 
change even amongst the most experienced physicians. This was observed in this 
study where evidence was cited from the erythropoietin studies and different 
interpretations used. Furthermore, when a clinician is unable to turn to a definitive body
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of clinical research, they use a variety of bodies of evidence including clinical 
observations. The individual nurse or clinician may be most impressed by observations 
made in his or her own individual practice. This source of evidence is notoriously 
vulnerable to bias and error (Eddy 1999), who states:
"What a clinician sees and remember is biased by the types of patients who 
come in; by the decisions of a patient to accept a particular treatment and return 
for follow up; by a natural desire to see good things; and by a whole series of 
emotions that charge one’s memorÿ’{p52).
In this study, the nurses described "scared’ associated with transfusion and in the 
analysis chapter it described how this may be related to the fact that nurses were at the 
point of care delivery and hence more likely to have witnessed transfusion errors or 
adverse reactions. The physician may not have these vivid memories and therefore may 
perceive blood transfusion as being a form of low risk therapy; for example, it was 
described how frequently they would prescribe blood without having any contact with the 
patient. The way in which the clinics were set up also meant that different clinicians 
would be assessing the response to the blood transfusion; which may add further 
inconsistency. Alternatively, this casual approach to transfusion could be related to the 
“shared responsibility” theme and the physician may be trusting of the nurses decision 
making as in SHI statement where he described this as "good teamwork’ (Section 
5.8.3). This will be discussed in more detail in section 7.3.
6.2.3 Conclusion
In summary, there is indeterminacy in the definition of the diagnosis of cancer related 
anaemia and the treatment with blood transfusion. It is difficult to know what the most 
powerful influences on the responses to uncertainty are and although they are most
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likely to be a combination of the multiple phenomena described. Typically, the final 
decision about how to manage a patient requires synthesizing ali the information about a 
disease, the patient, signs and symptoms and the effectiveness of tests, outcomes of 
treatment and values. In the management of cancer related anaemia decisions may be 
undertaken without actuaiiy knowing the impact on the patient; with uncertainty about 
signs and symptoms, risks or benefits and with incomplete and biased information about 
outcomes and this seems to be acceptable in the culture of transfusion practice in 
oncology. Furthermore there may be inadequate communication due to lack of time in 
the clinics and inconsistency of review as patients are reviewed by different clinicians. In 
summary, it may result in a tendency to oversimplify and use the haemoglobin value as a 
basis to treat the patient.
Another influencing factor is the available evidence, which demonstrates that different 
tumour groups may respond differently or have different treatment needs. Yet cancer 
related anaemia was researched in the early years as a disease entity rather than within 
context of the tumour type; as demonstrated by the fact that it can be a prognostic 
indicator in some disease groups (Hasenclever et al 1998). It may be the benefits of 
transfusion differ between patients with different tumour types for multiple reasons for 
example; the oncologist described how perhaps a more liberal approach to transfusion 
may be required in lung cancer patients because of their breathlessness (Section 5.8.4).
it is likely that variation in practice is inevitable and in fact may be desirable. Eddy 
(1999) describes how some variation in practice is appropriate; "the differences in 
patient’s risks, signs and symptoms, responses to treatment and vaiues are reai’’ (p59). 
There are also differences in clinician talents and different facilities, resources and
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environment. Alternatively, Eddy (1999) also describes how uncertainty can harm the 
quality and cost of medical practice; and most of the simplification of uncertainty pushes 
in the direction of overutiiization. If this is the case, the amount of uncertainty which 
exists in this clinical area would tend to explain the over-utilization of blood components 
as described by participant SL1 in section 5.7.3. This has implications for practice and 
again raises the question as to who is best placed to create individualized and holistic 
assessment and treatment of cancer related anaemia and this will be discussed further 
in section 7.2.
6.3 Socialization In practice
This section will focus on the influence of the culture on the assessment and decision 
making processes. In the end given all the uncertainties, incentives and heuristics 
described in the previous sections, the clinician may do what is most comfortable, i.e. 
treat rather than not treat. If there is no way to identify what is best for certain, or prove 
that blood transfusion has no benefit or have a deleterious outcome, then the safest and 
most comfortable position is to do what others are doing. A physician or nurse who 
follows the practice of others is safe from criticism, and free from having to defend 
oneself, as defended by the concurrence of colleagues. This tendency to succumb to 
the cultural and environmental influences is likely to be the most single important 
explanation of regional variation in practice and even within the same institution. This 
has not been described previously in relation to the management of cancer related 
anaemia.
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6.3.1 The ethics of resource availability
The impact of the resources in the day care unit to administer blood was shown in this 
study to change the decisions to transfuse. This is likely to be a component of 
“socialization in practice” but the findings related to use of resource and lack of impact of 
the implications of cost warrant more detailed consideration. The day unit staff 
influenced the decision to transfuse by working within the constraints of the available 
transfusion slots; If they had time the transfusion would take place and if not the decision 
was deferred or changed. The cost of transfusion was shown in the literature review to 
be massive and yet in this clinical setting it was given minimal consideration; when 
clinicians were questioned about resource and cost, the financial implications were not a 
consideration.
It may be resource availability is a powerful influence on the final decision and why 
clinicians do not object to a change in plan of care. There may be an acceptance that if 
there are finite resources then there is reduced questioning behaviours leading to an 
increase in acquiescing behaviours. This may contribute to the socialisation in practice 
as it is accepted that decisions may be changed by others. It may be new clinicians 
adapt to new departmental or institutional behaviours depending on resource availability 
as this would be outside their sphere of influence, particularly for the junior clinician, 
especially if there is limited resource. It could explain why the day unit nurses are in a 
powerful position to question decision making as they control the resource. It was not 
clear from this study if there were unlimited day unit resources that this would lead to a 
more liberal transfusion practice, but it may be a factor for national variation in 
transfusion practice, for example, the experience of SH2 who described a more liberal 
transfusion strategy at her previous hospital, as they had capacity to transfuse patients
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prior to discharge. It is perhaps morally repellent to acknowledge that resource 
availability, influences decisions but this may be a consideration in the clinical setting 
and needs to be acknowledged.
In a wider sense there is an acceptance that resources for the provision of healthcare 
are scarce, in that it is likely there "never will be enough resources to satisfy human 
wants completel/ (Drummond 1999, p436). This was described in the literature review 
with reference to the donated blood supply and the future risk of new pathogens impact 
on supply. Blood components do not appear to be subject to the same cost scrutiny as 
drugs; it has the potential to become scarce, and a scarce resource should be used 
carefully, therefore it was surprising this was not an influence. In this study, local day 
unit facilities were however viewed as a limiting resource and this may require future 
examination, for example, how frequently are decisions changed and what is the impact 
on outcomes, if there is a limited resource in a clinical setting and what is the cost of 
ensuring adequate resources are available.
6.3.2 Clinical intuition and the cognitive continuum
It has been shown in the literature review the kind of task the clinician is working on 
influences their thinking (Hamm 1999); and when an expert clinician reviews a patient 
sometimes it can appear that no reasoning has been used at all. In the literature review 
(section 2.7) Hammond (1980; 1981; 1986) described the concept of the cognitive 
continuum and how clinicians use different ways of thinking when faced with different 
problems; ranging from analysis through to intuition Inducing decision making; these 
features included: the complexity of the task; the ambiguity of the task and the form of 
task presentation. If the diagnosis and management of cancer related anaemia is
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applied to Hammond’s cognitive continuum, by the nature of the clinical problem 
(pertinent cue of haemoglobin; relationship between the cues; linear principle; limited 
response time) it leans towards intuitive thinking. However, these are not isolated 
thoughts as it has been shown the social and institutional context can also be expected 
to have a role in determining the mode of cognition a clinician uses (Hamm et a /1984). 
Much medical reasoning for example, takes place in discussion, with different clinicians 
and skill mixes; and such groups will accept some kinds of thinking, that which seems 
familiar, competent and eliminates uncertainty, (Bursztajn et al 1981); hence as 
demonstrated in this study the faith of the biomedical value of the haemoglobin.
The institution also affects the prevailing mode of cognition used through the kind of staff 
training and the amount of time it allows for reasoning about each patient and the 
rewards or outcomes (Hamm 1999); for example if efficiency in clinic is highly valued this 
will push towards intuitive thinking. This was evident in the oncology clinics where the 
Specialist Registrar aspired to be as efficient as the Consultant, because of limited time 
availability, intuitive thinking can lead to error if the practitioner Is a novice as described 
in the literature review (Dreyfus and Dreyfus 1986: theory of expert cognition); as the 
novice must think more analytically, or at a minimum obey the rules (in this case the 
transfusion guidelines). This may relate to the observation by the Consultant that the 
day unit nurses are in a sense the “gatekeepers of transfusion” \n that he described how 
they are more likely to adhere to guidelines. Alternatively, it may be the day unit nurse Is 
an expert as described in chapter 2 and uses his/her intuitive knowledge to make 
discerning decisions. In summary, it is probably a combination of the cognitive theories 
that explain the practice of transfusion; some of the decision making is influenced by the 
nature of the task, some by the experience, knowledge and skills of the clinician and
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some by the institutional and cultural factors that influence the cognitive mode used in 
the clinical setting.
6.3.3 Learning the skills: storytelling and rhetoric
There is an implication in the findings that even if research evidence should be available 
much of what was learnt in actual practice about transfusion practice was by experience 
or by working in the particular culture. Mandatory training had little impact and was 
about process not the decision making. Therefore it could be argued the most 
experienced clinicians, in terms of repeated exposure to cancer related anaemia and 
treatment with blood transfusion, may have superior decision making skills; as discussed 
in the previous section. However, the everyday accomplishment of medical work is 
dependent on a wide range of skills and in large part they are gained through tacit 
acquisition as part of an apprenticeship into the specialism. “These tacit skills are often 
indeterminate and are rarely explicit but are largely rhetorical” (Atkinson 1995, p91) 
therefore it requires more than just exposure to the task in hand; it requires consideration 
and discussion. The competent practitioner translates the skillful work of clinical 
investigation and laboratory tests, into plausible and persuasive accounts that justify past 
actions, current understandings and future plans as evidenced in some of the 
professional participants' stories about transfusion. Medical knowledge is grounded in a 
great deal of talk and enacted within an oral culture, however, this study revealed the 
management of anemia escaped the rhetoric in clinical practice and the consequences 
of this was that there was lack of these informal systems for learning the craft of 
managing cancer related anaemia. The experienced Consultant for example, described 
how she did not discuss transfusion decisions with her junior teams. It may be that one 
learns their skills by being exposed to the clinical scenarios as it was described the skills
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were “learned by osmosid’, therefore it may be assumed the more experienced or those 
who have had the most exposure to cancer related anaemia, would have the more finely 
tuned skills to assessment and decision making skills; as described in the previous 
section when discussing “experts”. It may be that some of the discussion and learning 
would be with the patients themselves, rather than with colleagues; for example the day 
unit nurses who frequently treat all cancer patients with blood transfusion. The quality of 
their pattern recognition as described in the literature review (Del Mar et al 2006), should 
be greater and as a consequence their decision making more discerning, but this would 
require further testing in future research.
The problem with tacit knowledge is that it is not easily shared, and it was evident from 
the interviews that the clinicians found it difficult to express their knowledge and rationale 
for decision making; which makes it difficult to share expertise. This may because of the 
tacit nature of their knowledge, however, it may have implications for who is best placed 
to assess and treat cancer related anaemia and this will be discussed in implications for 
practice in Chapter 7.
6.3.4 Teamwork and shared decision making
There is a tendency to focus on the patient and clinician interaction as a determinant of 
quality of care (Atkinson 1995), and therefore this was initial reason responsible for the 
research to focus on the clinic as it was assumed that this was where ail the assessment 
and decision making was undertaken. However, it became apparent as the data was 
collected the decision making could occur anywhere, for example, in the day units or via 
telephone conversations or at the end of clinic or when laboratory results became 
available. This study revealed that an analysis of the doctor-patient interaction in clinic
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cannot capture the full extent of care systems In place in the case of this clinical problem.
The consultation if viewed sociologically is a very complex social construct but is only a
partial view, and the author would argue, only a miniscule part of medical work (Atkinson
1995). This study demonstrated the management of cancer related anaemia is a
collective problem which is socially managed and whether this can be transferred to
management of other clinical problems could be debated. This team-working was
implied by the Consultant Hematologist who fully supported the contribution by the day
unit nurses in their assessment and decision making skills:
“..once they (day unit nurses) have been trained up they are not only extremely 
competent and motivated but there is an atmosphere where they are encouraged 
to question what the doctors are doing" (SHI ;361 )
The practice of assessment of cancer related anaemia and decision to treat with blood
transfusion has been shown in this study to be a collective, organizational activity; the
decisions may be subject to, negotiation and revision, based on the talk within and
between groups or teams of practitioners. This demonstrates that medical decisions
may not involve just one nurse or doctor but may also bring into play more than one
group of professionals, members of which contribute different views of expertise and
different organizational interests. The silent isolated single handed decision-making is,
therefore, is probably not the model for the assessment and treatment of cancer related
anaemia with blood transfusion; there may be many actors and the social setting in the
organization of the clinic will generate Its own information. The quality of decision
making may therefore be dependent on the communication within the team rather than
the individuals within the team; or the degree and quality of communication with the
patient. This will be discussed in more detail in section 6.4.
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6.3.5 Organizational sub-cultures
The findings demonstrated differences between the sub-cultures of haemato-oncology 
and oncology; for example, although both disciplines gave weight to the haemoglobin, 
there was a tendency for them to differ in their description of the definitions of anaemia. 
This is substantiated in the literature where there may be different discourse and 
language used In different settings and Atkinson (1995) makes a distinction between 
“information” and “decisions” (p53). All too often information (such as laboratory results) 
is treated as given, while the exercise of judgment or decision-making is applied to that 
information; so for example, although the definitions of anaemia were different in the 
sub-cultures the point at which they initiated treatment was similar.
The management of the distressing symptom of breathlessness for the lung team was 
particularly problematic and they described this in their interviews. Breathlessness 
whether due to anaemia or disease appeared to be the most problematic symptom to 
manage for clinicians and patients, therefore, this may lower the threshold to treat the 
anaemia, in an effort to do something to relieve it. This was alluded to in SLTs interview 
when she described how blood transfusion would be unlikely to make her patients feel 
worse but may help improve their breathlessness, although there was a recognition and 
acceptance that it may not. Conversely, this was not an issue for haemato-oncology.
Atkinson’s work of the culture of the haematology clinic demonstrated that medical 
students are progressively socialized into the culture of the clinic (Atkinson 1995). This 
study demonstrated the different cultures of the haematology and oncology clinics. The 
haematology clinics provided a focused learning and education environment for staff and 
patients. Patients were shown their results in graphical form for example on the
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computer and complex disease parameters such as cytogenetics were discussed. 
Although the culture of the clinics In haemato-oncology was educational and academic, 
this was not translated into the management of anaemia and the reasons for this are 
likely to be multiple as described In previous chapters. However, there did seem to be 
more patient involvement and the “knowledgeable patient” was evident. This was 
further evidenced by the patient interviews where patients frequently described their 
blood results. Including differential counts and genetic changes. This could have been 
attributed to increased exposure to clinical situations and blood transfusions; but is likely 
to be a product of the culture of the clinic in that it was usual for patients to have complex 
Issues explained to them.
6.3.6 Conclusion
Clinical decisions are not isolated cognitive events; the significance of making decisions 
in the context of the clinical settings is emerging as important. In this study it was 
demonstrated that the assessment and decision making in cancer related anaemia can 
be socially and spatially disparate, meaning that transfusion decisions are influenced by 
the different social interactions in different clinical settings therefore this inevitably results 
In variation in practice. This was described in section 2.8 whereby decision making is 
not made in isolation but through Interactions between individuals which take place 
through symbols and the interpretation of meanings and events (Giddens 2008). He 
described how It is the small scale interactions that can influence behaviours and by 
trying to understand these interactions in this study, it became increasingly evident as 
this thesis progressed that the context of the assessment and decision is important; 
whether in relation to resource or the unique qualities of the culture or how knowledge 
and skills develop In the culture. If improvements are to be made In transfusion practice,
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it may be prudent to reflect on elements within this section regarding exposure to 
transfusion; controlling the resource and how expertise can be developed. This will be 
discussed with implications for practice in Chapter 7.
6.4 Disaggregation of the body
Analysis revealed that the haemoglobin was frequently the only determinant that was 
expressed by the participants as reliable and typifies the biomedical model as described 
earlier. The impact of the haemoglobin often meant that it was “separated out” from the 
rest of the patient factors or assessment occurred in Isolation from the patient and this 
was collectively described as “disaggregation of the body”. Atkinson (1995) used this 
term in his ethnography of haematologists whereby a diagnosis was made using various 
samples and evidence, for example:
“with each of these techniques and others like them -  the haematologist heips to 
disaggregate the body into finer and finer discriminations” (p65).
He was referring to the diagnostic material including various biopsies, morphology and 
other test to make a conclusion about diagnosis and stage of disease. In the context of 
this research finding, the haemoglobin is separated out perhaps because of the 
unreliability of symptoms and signs or because the patient was not always available to 
confirm the presence of symptoms in the presence of the haemoglobin. The 
haemoglobin value may have been perceived as the only constant in an uncertain world 
and therefore was a powerful influence; and there was evidence that the laboratory 
values were used in isolation to diagnose and treat the anaemia, in the absence of the 
patient, therefore this terminology is being adapted to adopt a different meaning.
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6.4.1 Disaggregation of practice
The separation of medical knowledge from the social setting warrants further discussion. 
Berg (1992) cited in Atkinson (1995, p46) describes how medical sociologists have too 
often separated out the medical and social in order to explain particular aspects of 
medical knowledge. He described how in such sociological work:
“it is simply biomedical knowledge that directs the physician, through logical 
steps, from individual findings towards the right diagnostic and therapeutic 
decisions. The “cognitive” domain of medical action was thus regarded as self 
explanatory, not needing and defying sociological scrutin/ (Berg 1992, pi 53).
The view that Berg criticizes fails to do justice to the social organization of everyday 
knowledge production and reproduction. For example, anaemia and blood transfusion 
practice can be seen as routine knowledge but this research has demonstrated it is not 
managed merely as a biomedical event but is influenced by the social world. In 
Atkinson's work it was not uncommon for haematologists to request an action in a 
patients chart (1995, p56), only for the request to be ignored or not perfectly complied 
with. This behavior was evident in this study whereby the oncologist would write on the 
chart to give blood if the haemoglobin was less than lOg/dl and expected the nurse to 
act accordingly. The social and technical division of labour in hospital often results in 
teams or individuals working at cross purposes; therefore the term “disaggregation” 
could be used more widely to describe the various pockets of activity and decision 
making in the clinics and day units. Action and knowledge do not necessarily dovetail 
smoothly together to produce a seamless web of decision-making, especially if agendas 
are different. For example, the quick action in clinic in response to a haemoglobin may
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be to decide to give a transfusion, however, to those in the day unit it could mean 
organizing another blood sample; patient transport; a phone call to Blood Bank; a phone 
call to the patient; cannulation of the patient; collecting the blood; finding a doctor to 
prescribe the blood and so on. SL4’s interview (Day Unit Nurse) demonstrated this 
perfectly, whereby requests for transfusion were changed at the point of care delivery, in 
the day unit, and it may be related to the volume of work a single transfusion episode 
entails.
Similarly, although not evidenced in this study, it is not uncommon practice for the blood 
bank department to question and challenge a transfusion decision depending on a 
haemoglobin level, which is the only clinical information they would have available; 
further reinforcing the importance of the haemoglobin in the clinical setting but also 
demonstrating it is a significant amount of work for them that may be influenced by the 
same resource pressures as the day units (e.g. short staffing levels). In summary, 
different specialists define their work and their interests in quite contrasting ways, and 
hence may define the clinical problem (anaemia) differently and they may also be 
working with different competing timetables in the wider clinical setting.
6.4.2 Knowing the patient
Another use of the theoretical concept of “disaggregation” could be in the context of the 
growing sub-specialism in medicine; the body is not stable, nor whole. Each 
professional group fragments the body into their specialty; laying claim to a distinctive 
knowledge to that part, e.g. haematologists claims the blood, bone marrow and lymph 
nodes, the lung oncologist to the lungs and breathing. The body is represented in 
various departments, divisions and laboratories and the body may be discussed without
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actually “knowing the patient”. In other words, the modern body has been appropriated 
and reconstituted by a diverse group of experts and healthcare professionals. In this 
system of medical inspection and surveillance, the integrity of the body is dissolved into 
a series of more or less discrete domains of knowledge (Atkinson 1995). Important 
clinical decisions can be made in the absence of the patient; and this is may be a 
frequent and acceptable occurrence. This has been recognized as a feature of medical 
practice in that a considerable volume of medical work is away from the patient and the 
consultation (Atkinson 1995). Medical staff are familiar with the concept that decisions 
are made about patients following consultation with other professionals; the 
Multidisciplinary Team decision making Is a perfect example whereby the clinician and/or 
nurse relays the patient history. The pathologist displays the histology and provides a 
summary and the radiologist provides a summary of the imaging. The diagnosis is 
confirmed and treatment planned based on a summary of histology and imaging and 
resultant staging. The Consultant treating the patient has the final responsibility but 
he/she must trust the pathologist/radiologist and other professionals for example, 
cytogenetisist; immunophenotyping scientist. They seem to do this unwittingly. This is 
an example of shared decision making and demonstrates the complexity and social 
behaviors involved. It also demonstrates the “disaggregation of the body” (Atkinson 
1995) into various parts which then come together again in the MDT to form a cohesive 
summary of what is going on for that patient. It may be the only way medical work can 
function in that clinicians have to trust other’s decisions on a regular basis; therefore 
there may be acceptance of change of decisions as demonstrated in this study.
This is further substantiated in this study when the Consultant Oncologist was “horrified” 
when she described how decisions were made by staff when they had not “laid eyes” on
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the patient; however, one could argue far more important decisions are made in absentia 
of the patient and this is culturally acceptable. In fact the shared decision making is 
preferred and is borne out of the “Improving Outcomes Guidance” for all tumours (DoH 
1995). The other Haematology Consultant in contrast welcomed the shared decision 
making and liked the fact that transfusion was being controlled by experienced nurses as 
described earlier, who he described as “Gatekeeperd’. The literature review, reported 
Saiem-Schatz et al (1993) study that demonstrated improved transfusion practice (81% 
vs 48%); the former group having more knowledge but also more receptive to input from 
colleagues. In summary, it could be argued that it should be a shared responsibility with 
opportunities for those to challenge and question the original decision based on either 
their own skills or knowledge or their knowledge of that particular patient. Conversely, as 
most of the symptoms are subjective and unpredictable it could be argued improved 
decision making could be made by the clinician with the most intimate knowledge of the 
patient as they would be the best equipped to recontextualize the haemoglobin value 
with the person standing before them. Atkinson (1995) describes how the clinical gaze is 
no longer "anchored to the bedside itself (p61), however, it could be argued as this 
study shows that decision making is thought to be improved if the clinical gaze 
encompasses the patient and all the available information about that patient to enable a 
bedside decision, which would have the advantage of involving the patient in the 
decision.
6.4.3 Conclusion
Improved decision making requires knowledge of the patient and preferably the 
assessment and decision making is in conjunction with the patient to avoid the 
“disaggregation of the bod f that occurs if the haemoglobin is evaluated in isolation.
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Reconstitution and recontextuallzation of the haemoglobin either with symptoms e.g. 
breathlessness, or signs, such as fatigue or patient dialogue could improve decision 
making; and involving the patient in the decision may be helpful. In this sense the 
phenomena of haemoglobin and signs and symptoms are constructed together to make 
sense of what is going on, and a patient-centered decision can ensue. Patient centered 
care is a term used to “describe the therapeutic relationships between care providers 
and service users, and between the care providers themselved’ (Manley and 
McCormack 2008; p12). The preferred option is for the team to work with the patient to 
make the most appropriate decision. In summary, whilst some decisions may be 
possible in absentia of the patient; it may be advantageous if there is more patient 
involvement in the clinical decision to administer blood, because off the vast amount of 
uncertainty, and cultural influences; and this decision should certainly not be made on 
the basis of the haemoglobin In isolation.
6.5 Summary
This chapter discussed the findings in relation to the literature and the reality of clinical 
practice in cancer related anaemia and its management with blood transfusion. The 
management of this problem has been over-simplified for a multitude of reasons 
described. Firstly there is a lack of evidence and education (both formal and discourse 
in practice) and assumptions have developed based on the belief that cancer-related 
anaemia may be the same as other types of anaemia; which may be related in part to 
the commonality of anaemia. Secondly, assumptions have developed about transfusion 
practice; for example that by increasing the haemoglobin patients wili benefit, but be at 
no more risk. Thirdly, faith in the biomedical value of the haemoglobin level is highly 
valued and clinical decisions are frequently made on the basis of this knowledge alone.
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The reasons for this are complex and based on a multitude of unpredictable measures or 
application of generic anaemia and transfusion and/or erythropoietin study evidence. 
However, the overwhelming influence of the culture was unexpected and was evidenced 
in the starkest way by seemingly automatic and unquestioning change of decision 
making behaviours depending on where the participants worked. These elements will be 
brought together in the conclusion to suggest implications for practice and further 
research; in addition to making recommendations for the future.
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CHAPTER 7
Conclusion
This chapter concludes the thesis and presents a summary of the findings of the 
ethnography of the the culture of anaemia and blood transfusion practice in the haemato- 
oncology and oncology settings. The strengths and limitations of the study are 
discussed together with suggestions for research into cancer related anaemia and blood 
transfusion practice. Whilst this study was concerned specifically with anaemia in 
haemato-oncology and lung cancer, the relevance of findings may have broader 
implications for patients with different tumours and therefore most of the discussion and 
conclusions are generic to patients with cancer related anaemia.
This chapter will summarize the analysis, findings and discussion chapters and 
recapitulate the key issues and their implications for practice and future research. It 
should be clear from the data that variation in professional or clinical practice in this area 
is real and the differences in patients’ risks, signs and symptoms, responses to treatment 
and values are real. Differences in nurses or clinician skills, knowledge and area of 
expertise are real, as are the availability of resources. Therefore it could be argued 
variations in clinical decisions are inevitable, and desirable in many instances, if 
treatment is tailored to the individual. However, it is not clear if the variations in practice 
are appropriate. The problem is that uncertainty clouds every aspect of cancer related 
anaemia that many of the appropriate variations may not occur and many of the 
variations in the management of anaemia do not appear to be motivated by logic but 
rather because it is the common practice in the particular clinical setting. More
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importantly perhaps there appears to be lack of the involvement of the patient in the 
decision. Much of the practice of transfusion appears to be based on tradition and 
practices within the specific culture and this is further confounded by the difficulty in 
being transparent and accepting of uncertainty in that it goes against the values placed 
on evidence based practice and the certainty of medical knowledge. It should be 
accepted that it may not be easy to be precise about defining the clinical problem and 
that “one size fits alt' approach may need to be abandoned, for example, the use of 
definitive transfusion triggers. The decision making should be tailored to the unique 
individual and perhaps the only way to do this is by involving the patient in that decision.
7.1 Summary of the study
The aims of the study were to explore the impact of cancer related anaemia and how 
decisions were made to treat the patient with blood transfusion, using an ethnographic 
methodology (Chapter 3). Data were collected over a nine month period using fieldwork 
observation and interviews with clinical staff and patients. Thematic analysis was used 
to analyze the data (Chapter 5) based on an adaptation of Spradley’s framework (1980).
The findings fall into four main areas. First, they suggest that anaemia and transfusion 
are commonplace in the clinical setting; and this is related to fact that many patients live 
with anaemia and it may not be viewed as an Illness. Second, the findings suggest that 
there is a great deal of uncertainty surrounding the diagnosis and management of this 
clinical problem; but this uncertainty is acknowledged by both patients and clinicians. 
Third, the findings suggest that clinicians, and to some extent patients, are socialized 
into the practice of the culture of transfusion practice; and fourth that the haemoglobin
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level Is used as a distinct fragment of information on which to assess for the presence of 
anaemia and base the decision to treat with blood transfusion.
7.2 Implications for practice
This section brings together the literature, the findings and the discussion points to make 
recommendations for clinical practice in the management of cancer related anaemia and 
offer suggestions to potentially influence the culture of practice.
7.2.1 Managing cancer related anaemia
This study has shown cancer related anaemia may differ from other types of anaemia 
and is therefore not a distinct disease entity; it should probably be assessed, treated and 
researched in context of the cancer and the treatment, by making transparent what is 
invisible in clinical practice for example, the transfer of knowledge, uncertainty and 
socialization of practice. Managing cancer related anaemia may be improved if likened 
to monitoring a chronic condition. The essence of monitoring a chronic or recurrent 
condition is periodic measurement; followed by adjustment of the management. Factors 
that should be considered include what needs to be monitored, (for example Hb, fatigue 
and breathlessness); the frequency of measurements and how to adjust treatment. For 
example, the subjective opinion of the patient could be monitored in a self report tool and 
represented in graph form not dissimilar to the fatigue diary (Richardson 1994). This 
may give more control over to the patient resulting in more patient-centered decision 
making. However there are also several common errors of monitoring to avoid: 
rechecking to soon, over-reacting to chance fluctuations and over adjusting therapy, for 
example, the clinician response to fluctuating haemoglobin levels may result in over­
responsiveness to the low haemoglobin. In this way trends rather than one off
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assessments and responses to transfusion could be monitored. Monitoring (and 
adjustment of treatment) can be then thought of as a form of external homeostasis: 
bringing the average level and fluctuations back to more tolerable levels.
This study demonstrated how patients live with anaemia, and from the insights the aim of 
transfusion would be to maintain a haemoglobin to a level at which symptoms can be 
tolerated. Graphical representations may be helpful in monitoring levels of fatigue and 
the haemoglobin; and breathlessness in the lung patient population. Chronic care can 
potentially be improved (and at reduced costs) if for each chronic disease patients were 
more involved in their care (Del Mar et al 2006: p98) and more patient centred models of 
care were developed. In summary, some chronic diseases are effectively self-managed 
by patients, e.g. blood pressure, asthma and anticoagulation. It may be this model could 
be applied to the management of cancer related anaemia or at least involve the patient 
to a greater extent in the assessment and decision making processes, with the 
acceptance that there has been a tendency to over compensate and treat the anaemia 
unnecessarily.
Finally, it was also demonstrated in the literature review that the ability of the task feature 
to influence the mode of cognition is influenced by the knowledge of the practitioner on 
the task (Hamm 1999). Generally the greater the knowledge; the more analysis occurs; 
this has implications for practice in that the staff participants described how they had no 
further education on transfusion making decisions. At a basic level, mandatory training 
could be changed for cancer clinicians to incorporate some of the elements in this study; 
for example, to increase awareness of the influences on decision making; to achieve 
patient concordance and to encourage more discussion in practice about this subject. In
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addition to formal education the functions of the clinic need to be considered as these 
influence learning and practice; for example how to change the clinics to facilitate patient 
and clinician learning through discussion and rhetoric. This may need consideration of 
the physical environment as well as process, for example, how to facilitate 
communication between the professionals and how to ensure patients are reviewed with 
all the information available.
7.2.2 Changing the culture
In healthcare today in the UK, using evidence based practice is considered to be best 
practice and traditional practice is not viewed as legitimate. However, this study 
demonstrated practice was entrenched because of the cultural influences, including the 
processes and structures of the clinical settings, professional relationships and the ways 
in which transfusion practice is learned. Traditional practices existed because of the tacit 
knowledge and intuitive behaviours demonstrated and described by practitioners. For a 
change to occur in the transfusion culture may take a radical shift in work practices which 
may be disruptive as transfusion has always been done in a certain way. If there is to be 
a change in practice; it would require a continuous development rather than a series of 
one off changes and involvement of everyone involved. Successive reforms typically 
focus too closely on changing structures and processes, and too little on changing 
patterns of behaviour and relationships in care settings (Manley and McCormack 2008). 
Reform of the culture of care would be necessary if the patient-centered approach to the 
management of anaemia is to be implemented.
The literature review, findings and discussion chapter described the theoretical basis for 
recommending a change of practice. Firstly, the literature review described the
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importance of the small interactions; the exchange of different symbolic meanings in the 
form of “symbolic interactlonism”. Secondly, this provided the basis for exploring 
transfusion practice using ethnography to study the social interactions that influenced 
transfusion behaviour. Third, the findings demonstrated that transfusion behaviours 
were influenced by the culture and relationships and interactions in the clinical setting; 
the decisions were not made in isolation.
The findings have implications for change of practice. It will therefore require a long 
term plan and a series of changes and strategies to engage the whole clinical team. 
One cannot be too prescriptive at this stage as it probably requires a flexible approach 
as each change may inform or influence another; it would be an iterative process. 
Examples could include focused education for the clinical teams as described in the 
previous section but this alone may not be influential If most of intuitive knowledge is 
passed on by rhetoric. Therefore, the clinical environments and processes would need 
to be considered as described earlier, to facilitate a learning environment for improved 
decision making. Another radical approach would be to formalize the nurses’ 
responsibility for transfusion decisions; legalize and legitimize their involvement in the 
process in the same way as non-medical prescribing of medication. It could be argued 
that nurses would be more discerning in their transfusion decision making than 
physicians as they would be a clinical priority as opposed to the physicians whose 
priority is to diagnose and treat the cancer; this is related to the hierarchy of clinical 
priorities as described In the findings in section 5.6.3 and discussed further in section 
6.2.1. Unlike non-medical prescribing there is legally no barrier to this change and in 
theory an institution could manage this change independently, however, it would be 
advantageous to changing the culture if a national change occurred; otherwise,
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traditional practices may persist is to if it did not become a widely practiced behavior. 
This does not mean exclusively a nurse decision but just empowering the decision­
makers and hopefully formalizing and improving the teamwork. Furthermore it would 
allow the clinical group (the nurses) who has the problem of the management of anaemia 
as high priority of their clinical issues, as they directly deliver the treatment and control 
the resource. It could also facilitate the patients and the day unit nurses to make patient- 
centered decisions based on the patient held diary as above, in the clinical environment 
that is the point of care delivery.
These are merely the researcher’s opinion on how the culture could begin to change; but 
with the understanding of the much wider involvement of all the players including 
laboratory staff; all the clinical teams; the transfusion practitioners and transfusion 
committee and the Trust as a whole. Success or failure of change will be dependent on 
the researcher’s ability to persuade others of the value of this study as a starting point.
In summary, the assessment and decision to treat should be put into context; the 
conversations between patient and clinician should be in relation to where the patient is 
on their treatment pathway and perhaps the decision to transfuse not be solely based on 
what is culturally acceptable. Ideally, there should be discussion and concordance 
between the patient and the clinician. However, one has to consider the cultural barriers 
to this; consider the time allowed to make the decision in the clinical setting and the low 
priority of anemia and its’ management. The clinics are busy and many of the patients 
are on treatment; this study has shown anaemia is low on the list of priorities for 
clinicians and patients. The researcher has produced an ethnography of transfusion 
practice and has provided a foundation on which to base change in clinical practice and
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one of these changes may be to legitimize nurse prescribing of blood components. Of 
course, equally nurses do not work in isolation and would be subject to the cultural 
influences on practice, however, by legalizing prescribing of blood components, decision 
making would be a clinical priority in this professional group, which by virtue of 
contextualizing the task; the meaning of the decision for the nurse; and the influence of 
their experience implies that prescribing behaviours would improve.
7.3 Implications for further research
Discussion and progressive focusing of this research also resulted in a shift from 
concern with describing social events and behaviors towards starting to test any 
explanations of behaviour and/or theories that have been developed; with the aim of 
recommending future research activity. In summary the aims of the research were to 
explore the culture of transfusion practice and determine the influences on clinical 
decision making. This was congruent with the MRC (2008) guidance to explore the 
influences on interventions in an effort to determine what could optimize the outcomes of 
well established Interventions, in this case, blood transfusion. It was discovered was that 
uncertainty was acknowledged and decision making was based on the culture of 
transfusion practice in the organization. The next steps would be to test interventions 
that could tolerate uncertainty for individual patients but within that is the understanding 
that variation exists because of the nature of cancer related anaemia. For example, to 
explore the benefits of nurse prescribing and patient centered decision making as 
described in 7.2. Expanding this research methodology into other clinical settings with 
patients with other cancers may be useful to determine if any other types of cancer 
patients have different issues with cancer related anaemia and symptoms. In summary, 
the uncertainty of the benefits of transfusion in the population with mild or moderate
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anaemia surely warrants further research, for example, longitudinal research to 
determine if maintaining low or high haemoglobin, using blood transfusion impacts on 
tumour growth, outcomes or infections. The unpredictability of response to blood 
transfusion may also warrant further research for example to determine if patients have 
less response when “old” blood product is used, although it is acknowledged this did not 
form part of this study.
The effects of the culture on transfusion practice were surprising. This research has not 
fully answered the impact of the transfusion guidelines and if different strategies can be 
used to implement guidelines or measure the impact of different education strategies, 
other than mandatory training; the latter has been shown to be futile in terms of making 
an impact on the clinicians decision making. The lack of consideration of cost of blood 
transfusion was an intriguing finding for the researcher; this is probably not a unique 
attitude and belief that blood is of minimum cost for example a recent excerpt from a 
journal demonstrates:
"Speaking about the standard use of transfusions, Mr Foubert says: 
‘Transfusions rapidiy raise the biood ceii count and haemoglobin concentration 
and are effective in virtually ail patients at limited cost” (Davis 2008; p12)
A robust cost analysis of the real cost of blood transfusion in cancer related anaemia 
may be useful. The real world is such that resource has to be considered and it should 
only be those patients with clinical need and benefit who should receive transfusion. A 
transfusion episode requires a great deal of resource as well as the cost of the product 
itself and if 2.5 million units are used per anum in the UK; the lack of consideration of 
cost may push towards over-utilization of blood and this would have massive financial 
implications. Other clinical specialties are already exploring alternative strategies to
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transfusion successfully and perhaps oncology and haematology are behind in this area 
of research with the exception of the erythropoietin research.
Finally, and perhaps most importantly, there was the assumption the patient’s 
haemoglobin may be representative of the degree of suffering by the patient; the 
haemoglobin was used in isolation to influence the decision to treat. However, it may be 
that a low haemoglobin value is not representative of the impact of anaemia on the 
patient. A unique finding of this study was that even the patient’s “got it wron^’ in that 
they were surprised by the haemoglobin result as it did not always correspond with how 
they were feeling, for example, they may be assymptomatic (e.g. no shortness of breath 
or fatigue) with a low haemoglobin, but they would be treated with blood transfusion. 
This may result in the tendency to over-transfuse. Is the hypothesis that the 
management of anaemia is classic case of disaggregation of the body? It is proposed 
here that the unique difference of cancer related anaemia (as opposed to other types of 
anaemia) is that the classical signs and symptoms of anaemia are not applicable in the 
assessment of this type of anaemia. A future study could include a longitudinal study 
mapping the symptoms of this type of anaemia and quality of life with haemoglobin 
levels. It is suggested here this may be useful to undertake in patients with different 
tumour types as the impact of anaemia may vary between cancers, for example, the lung 
cancer patients may have a lower tolerance of the symptoms of anaemia because of the 
impact of their breathlessness.
7.4 Summary of recommendations for practice and research
The preceding sections have described implications for practice and suggestions for 
changing practice in addition to describing possible future research studies. This study
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has contributed to the knowledge of cancer related anaemia and transfusion practice 
however this requires translation into improving practice. It also poses further questions 
and these should also be translated into action, by generating further research studies. 
These are summarized below in Table 7.4.
Table 7.4: Recommendations for practice and research
Recommendations for practice
Issue Recommendation Action
Cancer related anaemia is 
not a primary diagnosis 
Patients live with their 
anaemia
Uncertainty in determining 
impact of anaemia
Manage cancer related 
anaemia like a chronic 
condition
Patient centred decision 
making
Develop self management 
tools (patient information, 
patient diary, patient held 
record)
Anaemia management is 
low priority in the clinics
Shift the professional 
decision making 
Legitimize nurse prescribing 
of blood components to 
allow decision making to 
occur at point of care
Develop curriculum and 
competencies for 
prescribing blood 
components
Learning the skills of 
anaemia management are 
not facilitated in the clinical 
or educational environment
The learning environment 
should facilitate tacit 
learning
Clinic remodeling to create 
environment conducive to 
learning
Redesign mandatory 
training
Recommendations for research
Issue/hypothesis Recommendation
Lack of research in different 
tumour groups
Expanding this methodology into other cancer populations
Lack of research into the 
benefits of transfusion for 
patients with mild/moderate 
anaemia
Longitudinal research to determine if maintain a low or 
high haemoglobin with blood transfusion has an impact on 
tumour growth, infections or outcomes
The classical symptoms of 
anaemia
(breathlessness/fatigue etc) 
or haemoglobin are not 
useful in assessing cancer 
related anaemia
Longitudinal study mapping the symptoms of this type of 
anaemia and quality of life with haemoglobin levels.
Lack of cost benefit 
analysis of blood 
transfusion
Cost analysis of blood transfusion in cancer practice
Lack of research into the 
unpredictability of response 
to transfusion
Physiological studies to determine if the age of blood 
transfused has an impact on infections and outcomes in 
the cancer population
230
7.5 Strengths and limitations of the study
The strengths of this study include its original contribution to the understanding of cancer 
related anaemia and its management with blood transfusion; and the use of this 
methodology to explore the culture of transfusion practice. Whilst the findings cannot be 
generalized because of the nature of the methodology (Chapter 3), they undoubtedly 
offer a range of insights into the practice of blood transfusion in the oncology setting. 
This contributes to the understanding of why there is variation in clinical practice in 
different clinical settings. Much previous research concerning cancer related anaemia 
was quantitative, where the researcher(s) would typically isolate symptoms of anaemia 
and use different quality of life tools to measure it; which offered some objectivity but 
failed to perhaps tease out the uncertainties of the assessment and management of this 
type of anaemia. The weaknesses of those studies is that certain generalizations have 
been made about cancer related anaemia that fail to take into account the unique 
individuals' unpredictability of their anaemia in terms of it’s impact as well as unique 
responses to individual blood transfusion episodes. This ethnographic approach to the 
study of this clinical problem has enabled a deeper understanding of how anaemia 
impacts on cancer patients, from the patients’ perspectives and indicated ways in which 
different aspects of anaemia and transfusion relate to each other. The findings 
demonstrate the intricacies that exist in cancer related anaemia management, and how 
different sub-cultures within institutions influence decisions. In this way this study has 
enabled a more holistic understanding of this clinical problem, which in turn will inform on 
possible ways to improve the management of cancer related anaemia.
The study contributes to knowledge about how clinical teams function (Atkinson 1995) 
and demonstrates clinical decision making theory in practice. The findings suggest that
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clinical knowledge about anaemia and transfusion develops in accordance with theories 
about tacit knowledge and intuitive knowledge. The study shows that by contextualizing 
the anaemia and by having the patient at the centre of decision making, it may improve 
the management of cancer related anaemia. It has demonstrated the power of the 
cultural influences; and If the desired outcome is to change practice then it may require a 
huge cultural shift for this to occur. This is perhaps unrealistic considering the deeply 
entrenched transfusion practices that exist, but would go beyond mere manipulation of 
processes and systems.
A further strength of the study was the use of different data sets to develop the 
ethnography; the findings emerged by finding threads or Ideas in one data set then use a 
different data set to corroborate or verify the emerging theme. This added robustness to 
the findings, rather than if a single data source had been used.
A limitation of the study is that, as an ethnographic study, it represents the researcher’s 
interpretation of reality and that there may be other possible interpretations of reality, 
although the participants’ voices are represented in the final thesis. Furthermore, it could 
be argued that a limitation of this study was that there were not extensive periods of time 
spent in the field; this study was limited to fieldwork observation in six clinics. Therefore 
this study could not be considered to be an in-depth ethnography but rather an 
exploratory study adopting an ethnographic approach. It could also be argued the 
researcher was an experienced nurse in the sub-specialism of haematology and less so 
in the sub-specialism of lung cancer; this may have influenced the researcher’s 
interpretations of the observations during the fieldwork and therefore may have 
influenced the findings. The familiarity of the researcher within the organization is
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acknowledged here and this will be discussed in greater depth in the following section, 
which reflects on the researcher’s journey.
Finally the study was based in two cancer sub-specialisms therefore there may be limits 
to transferability of findings to other tumour group patients and staff populations or 
different types of anaemia and their management. Furthermore, this study was confined 
to relatively small samples within two sub-specialisms and this may have skewed the 
data, and it Is acknowledged this is a limitation of this study. Equally, it may not be 
transferable to paediatric settings, whereby there is a greater reluctance to expose 
children to transfusion, because of the long term risks of transfusion combined with their 
better outcomes from cancer, which would influence the culture of transfusion practice.
7.6 The reflexive ethnographic journal
it was described in Chapter 1 and in the previous section how the researcher is integral 
to interpretive ethnographic methodology and combines the perspectives of both the 
researcher and the researched (Savage 2000). The essence of this was captured in my 
reflexive ethnographic journal and used throughout the research from inception to 
completion. This is described as “ethnographic refiexMtÿ' (Allan 2006; p404) and the 
final thesis therefore could be described as my interpretation of the truth, in that I have 
contributed to the final product. My experiences, imagination. Inspiration, motivation and 
intellect influenced this research and without it I would argue that an original contribution 
to knowledge would have been unlikely. I have worked in haematology and cancer for 
many years and have cared for many “anaemic patienté'; I have made thousands of 
“transfusion decision^' and therefore have formed attitudes about clinical practice, which 
influenced my interpretation of the data and this is acknowledged here.
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My journal formed the foundations of the reflexivity in this research and I used it 
throughout the data collection and data analysis phases where I would write myself 
notes and further questions. For example, early excerpts described visits to the lung 
clinic “very busy, packed waiting room, people afraid to get up from seats in case they 
lose their slot” and observations from the day care unit “a patient wants a newspaper to 
read whilst he is waiting for his cannula to be put in and his biood to start'. Both of these 
observations were from December 2007 prior to formal observation and interview work 
but formed part of the ethnography in that I was beginning to formulate a picture of what 
was happening. Also interspersed throughout the journal were notes I had taken during 
supervision, in addition to thoughts and questions to myself; these included sudden and 
random thought processes whilst writing or following some of the observations and 
interviews. I also took notes when I met with key people who informed or assisted with 
this project (these are identified in the research log. Part 2). For example, I wrote the 
following when I met with an experienced ethnographer:
What do I want to observe in the clinic?
Are all the patients relevant?
What is the structure of the consultations?
Who is present in the Consultations?
What are the things that are shaping the clinic and how it functions? 
Where do they (patients and clinicians) sit?
What took place?
What were the behaviours?”
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These notes assisted me during the subsequent observations in clinic and helped me to 
understand that it was not possible to record every consultation and every aspect of the 
clinic, but learn to focus on the important elements of the behaviours and environment 
within the clinical settings.
Looking back through the annotations it could be demonstrated how my thoughts 
changed and evolved as the project developed, for example, “uncertainty” was noted 
early on in the journal as was “the educated patient'. These early notes taken following 
some of the interviews and observation fieldwork revealed the beginnings of the sub­
themes within the final research findings. These are described here as “analytic memos" 
and included notes made on the “role of uncertainty’ and “knowing the patient: are 
relationships important?”. Such notes demonstrated my formulation of ideas and during 
the analysis the reflexive journal helped me to bring these ideas together and develop 
themes; notes were taken when re-reading the data and diagrams sketched to try to start 
making sense from the large volume of data. It was an iterative process whereby I would 
move between the data and take notes then repeatedly re-visit other data to verify my 
thoughts and ideas.
The content of the reflexive diary demonstrated the shift in my understanding; firstly was 
my realization that the management of this clinical problem was influenced by the 
cultural practices, which were in turn dependent on the social interactions in that culture. 
Secondly, I had an increased understanding that uncertainty clouds all assessments and 
decisions from an early belief that the haemoglobin was infallible. Thirdly, I recognized 
the importance of contextualizing the anaemia in the presence of the patient, in an 
attempt to prevent the disaggregation of the body and that this, in combination with the
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other cultural practices, may result in less than optimum transfusion practice. Finally, I 
recognized that different professional groups (physicians and nurses) may have different 
clinical priorities and this may influence the decision making behaviours and interactions.
Finally, this project took me four years to complete, although undoubtedly the last six 
months were the most intense. However, during this four year period not only had my 
understanding of cancer related anaemia and transfusion practice developed but the 
change of research design represented a personal ontological struggle for me. Originally 
it could be described that I had a natural leaning towards a positivist ontological 
perspective but that I shifted to an interpretive perspective with a determined attempt to 
see the world through the eyes of others and I attempted to represent this truthfully and 
faithfully by using reflexivity and the data. I found this a difficult but rewarding process 
especially as new information emerged from the data. Having gone through this 
ontological shift I would argue, based on my personal experience of undertaking this 
research, that any researcher could undertake ethnography, if it is the most appropriate 
methodology to explore the reality of practice. There is no robust argument that any 
individual’s version of reality is not valuable even if it requires a paradigm shift, if one 
keeps true to the data. I would argue that if one is dismissive of any standpoint 
epistemology, not only could it be perceived as disrespectful but there would be a 
tendency to not appreciate, understand or assimilate different types of research 
evidence, whether qualitative or quantitative. In summary, this ethnographic study not 
only acknowledged my personal contribution but also required me to use reflexivity 
throughout the research from the early ideas through to study completion to create the 
final thesis.
236
7.7 Summary
This study has shown that the culture of a specialism is a powerful influence on 
behaviours, which may result in less than optimal blood transfusion for a multitude of 
complex reasons which have been outlined in chapters 6 and 7. Some 
recommendations from this study relate to the practical aspects of how transfusion 
decisions should be made in clinical practice; others relate to how patients could be 
empowered to take control of their “symptoms of anaemia”. There may be no reason 
why patients cannot begin to manage their chronic condition in the same way as other 
patient groups manage their diabetes or heart disease; with the appropriate support and 
information. They are in the best position to know what level of anaemia is tolerable.
There has been recent debate about nurses prescribing blood components and this 
study supports and endorses nurse prescribing of blood in this clinical context. This 
study showed that nurses already make decisions about transfusion; are experienced 
and exposed to transfusions; and therefore a recommendation of this study would be to 
legitimize this and develop training and education to support to nurses to undertake this 
extended role; not dissimilar to non medical prescribing. This is further supported by the 
evidence that nurses may be in an ideal position for the social learning in that they are 
frequently exposed to anaemic patients who are undergoing blood transfusion and 
quality of life issues may be their clinical priority. This would be a radical shift in practice 
and would potentially disrupt the culture of transfusion practice; the decision making 
base would be shifted away from the medical team and would be shared with the group 
who control the resource and more importantly, who have more opportunity to negotiate 
with the patients as they attend the day units for therapy. Although some transfusion 
nurses have proposed this (Pirie & Green 2008), this is the first research evidence which
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has suggested there is a rationale and theoretical basis for supporting this radical 
change and this is a unique contribution to the study of transfusion practice.
Local systems change is recommended to change the responsibility of assessing cancer 
related anaemia and the “prescribing’ of blood components by the day unit nurses, for 
reasons described earlier (quality of life priorities; point of care delivery). For this 
innovation to be successful, it is acknowledged that such change is most effective when 
it involves the key stakeholders (Kitson 2009). Healthcare organizations do not work in a 
logical organized manner and therefore the “systems” involved in blood transfusion 
practice need to be understood first. This study has provided some insight into the 
systems and it is recognized that the “purposeful integration of systems theory with 
knowledge translation theories and models may enable the application of research and 
new knowledge to practice be speeded up" (Kitson 2009 ,p225). In other words it may 
take more than a change in responsibilities, but engagement of the teams in 
understanding the Interactions and behaviours, and additional knowledge, engaging the 
whole team in the process, may facilitate change.
By combining the empowerment of patient and nurses in this way, the shift towards a 
nurse-patient partnership in anaemia management may provide a way forward to 
reducing the uncertainty, although it is acknowledged that uncertainty may continue to 
exist and indeed may be desirable. However, another strategy to improve decision 
making would be recontextualization of the anaemia. Anaemia should be put back into 
the body, and treated accordingly. It should not be viewed as a separate symptom and 
should be re-contextualized into the rest of the disease and treatment pathway. This 
would bring robustness to those indications where blood is absolutely necessary, and
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when not to transfuse, for example, when there is only mild or moderate anaemia and 
the blood counts are recovering. It would also mean that any research or practice should 
be related to the patients with different cancers. The problem is that much of the 
research is related to anemia and transfusion as a clinical entity whereas it may be more 
prudent to undertake research in specific tumour populations as outcomes related to 
anaemia and transfusion may vary between patients with different tumour types; and the 
patient’s transfusion needs may vary in relation to quality of life. What may be best 
practice for one type of cancer patient may not be for another; therefore any guidance 
would need to reflect this and perhaps tumour specific guidelines need to be developed; 
with the flexibility of patient partnership working reflected in those guidelines. If these 
factors were considered the decision to administer a blood transfusion is more likely to 
be discerning and there may be less likely tendency to over-transfuse. If the decision 
makers were the key clinical staff in the best position to do this; it Is likely the 
socialization of practice would remain a powerful influence over the behaviors, however 
the outcome would be closer to optimal transfusion practice as the patient would be at 
the centre of the decision to transfuse, which should surely be the ultimate aim.
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Appendix
Appendix 1 : FACT-An anaemia and fatigue subscale (version4)
By circling one number per line, please indicate how true each statement has been true 
for you during the past 7 days
Additional concerns
Not at A little Some- Quite Very
all bit what a bit much
1 feel fatigued 0 1 2 3 4
1 feel weak all over 0 1 2 3 4
1 feel listless ("washed out”) 0 1 2 3 4
1 feel tired 0 1 2 3 4
1 have trouble starting things because 1 
am tired 0 1 2 3 4
1 have trouble finishing things because 
1 am tired 0 1 2 3 4
1 have energy 0 1 2 3 4
1 have trouble walking 0 1 2 3 4
1 am able to do my usual activities 0 1 2 3 4
1 need to sleep during the day 0 1 2 3 4
1 feel lightheaded (dizzy) 0 1 2 3 4
1 get headaches 0 1 2 3 4
1 have been short of breath 0 1 2 3 4
1 have pain in my chest 0 1 2 3 4
1 am too tired to eat 0 1 2 3 4
1 am interested in sex 0 1 2 3 4
1 am motivated to do my usual activities 
1 need help doing my usual activities 0 1 2 3 4
1 am frustrated by being too tired to do 0 1 2 3 4
the things 1 want to do 
1 have to limit my social activity 0 1 2 3 4
because 1 am tired
0 1 2 3 4
Below is a list of statements that other people with your illness have said are important. 
By circling one number per line, please indicate how true each statement has been for 
you during the past 7 days.
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Functional Well-Being
Not at A little Some- Quite 
all bit what a bit
I am able to work (include work at 0 
home)
My work (include work at home) is 
fulfilling 0
I am able to enjoy life 0
I have accepted my illness 0
I am sleeping well 0
I am enjoying the things I usually do 
for fun 0
I am content with the quality of my life 
right now 0
1
2
2
2
2
Very
much
4
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Appendix 2: Blood transfusion audit
Table 3.3a: Transfusion triggers (Haemato-oncology and oncology)
Number of 
transfusion episodes
Mean Hb transfusion 
trigger
Range
Haemato-
oncology
54 7.8g/dl 5.1-10.3g/dl
Oncology 202 9.1g/dl 5.8-12.8g/dl
Table 3.3b: Single vs. Multiple Unit Transfusions (Oncology only)
Number Percentage
Single unit 14 6.9
2 unit transfusion 162 80.2
3 unit transfusion 21 10.3
> 4 unit transfusion 5 2.5
Total 202
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Appendix 3: Patient information Sheet (version 2) (on headed notepaper)
REC Number: 07/H0802/96 
Principal Investigator: Liz Bishop
Introduction
You are being invited to take part in a research study, which is part of a Doctorate study 
being undertaken at Surrey University by the Haematology Nurse Consultant, Liz Bishop, 
and <name of acute trust>. Before you decide, it is important for you to understand 
why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with friends, relatives and your GP if you 
wish. Ask us if there is anything you do not understand of if you would like more 
information. Take time to decide whether or not you wish to take part. Should you 
decide to take part in the study, you should keep this document in a safe place in case 
you need to look at it again.
Thank you for reading this
1. What is the purpose of this study?
The main purpose of this study is to find out if blood transfusion has an impact on your 
quality of life and fatigue and activity levels.
Haemoglobin, which carries oxygen from the air that we breathe, is found In the red 
blood cells in your bloodstream. The red blood cells are responsible for carrying this 
oxygen to your tissues. As a result of your condition, or treatment, you may develop a 
low red blood cell count and consequently a low haemoglobin level. Together, these 
may cause anaemia. Common symptoms of anaemia are fatigue (tiredness), lack of 
energy and shortness of breath. In some cases these symptoms can also interfere with 
your ability to perform daily activities, such as bathing, shopping, working or hobbies so it 
is important for us to understand the impact of anaemia on your activity levels.
Blood transfusion Is routinely used to correct anaemia, but it is not known how it impacts 
on fatigue and activity and quality of life in the outpatient setting. We would like to do 
further research to measure quality of life and activity over a period of 90 days whilst 
maintaining your haemoglobin with blood transfusion. We may observe your 
consultation in clinic but we do not interfere with the decision as to whether to give you 
blood transfusion or not. In a separate part of the study we are also interviewing 
doctors and nurses to examine in more depth how they assess and treat anaemia and 
observing their behavior in clinic.
2. Why am I being invited to take part?
You have been invited to join this research study because you have anaemia and you 
sometimes receive blood transfusion to maintain your haemoglobin levels. You would, if 
you decided to take part, be 1 of 10 patients to enter the study in this hospital.
3. Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form, if you
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decide to take part you are still free to change your mind or withdraw at any time and 
without giving a reason. This will not affect the standard of treatment or care you 
receive.
4. What will happen to me if I take part?
The study lasts for a total of 90 days. If you decide to take part in this study you will 
have to attend clinic at the beginning of the study but this can be co-ordinated with one 
of your usual visits to clinic. Your fatigue levels will be measured at visits at the clinic 
every four weeks (4 times in all) by completing a brief questionnaire. This takes 
approximately 10 minutes and you will be asked to complete it before your blood results 
are available. The study nurse will explain how to complete the questionnaire. If the 
timing of the questionnaire does not coincide with your clinic appointment you will be 
posted your questionnaire and asked to return it by post in the Stamped Addressed 
Enveiope provided.
Activity levels will be recorded by a technique known as actigraphy. This involves 
wearing a device called an actiwatch (worn like a wristwatch) and this records your 
movement and sleep. It is waterproof but it is best to take it off whilst bathing, showering 
or swimming. The actiwatch is worn throughout the 90-day study period. See the 
attached sheet “instructions for wearing the Actiwatch”
5. What do I have to do?
For this study to be successful, it is important you complete the questionnaire and wear 
the actiwatch continually (apart from when bathing). Throughout the study period you 
can take your medications as usual. Throughout the 90-day period you will attend the 
hospital as dictated by your doctor. We will also record how often and how much blood 
transfusions you receive.
6. What is the procedure that is being tested?
Blood transfusion is routinely used to increase patients’ haemoglobin levels. It is 
necessary to maintain the haemoglobin to enable oxygen to each the tissues and for this 
reason we tend to transfuse patients when the haemoglobin level fall to 8.0g/dl or below 
or when you have symptoms of anaemia. However, there is some uncertainty as to the 
benefits of blood transfusion in terms of patients' quality of life, namely fatigue and 
activity levels.
Throughout the study period you will be given blood transfusion according to standard 
practice, i.e. when your haemoglobin falls. The blood will be dripped into your arm via a 
cannula (a fine tube inserted into a vein) during your out-patient visit. This study will 
examine how often you have blood transfusions and if this impacts on your quality of life, 
specifically your fatigue and activity levels. The researchers will not influence the 
decision to give you blood. This wiii remain the decision of the doctor looking 
after you.
7. Are there other ways of treating my condition?
Sometimes patients who are anaemic are treated with a drug called erythropoietin but it 
is not routinely available. Not all patients respond to this drug and your doctor may 
decide it is not an appropriate way to manage your anaemia.
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8. What are the possible side-effects?
There are risks of receiving blood transfusion. The main risks are infection and 
transfusion reactions but this study is not influencing the decision to treat the anaemia. 
This is the decision of your doctor.
9. What are the possible disadvantages and risks of taking part?
There are no disadvantages or risks to you directly because we do not interfere with your 
treatment. The only inconvenience of this study is having to wear the actiwatch 
throughout the study period and complete the questionnaire.
Before agreeing to take part in the study you should check that any private medicai 
insurance you have will not be affected by you taking part.
10. What are the possible benefits of taking part?
There are no direct benefits of this study to you. The information we get from this study 
may benefit future patients who have anaemia.
11. What if new information becomes available?
Sometimes during the course of a research project, new information becomes available 
about the treatment/drug that is being studied. If this happens, your doctor or nurse will 
tell you about it and discuss with you whether you ant to continue in the study. If you 
decide to withdraw, your treatment will continue as before. If you decide to continue in 
the study you will be asked to sign an updated consent form and the new information 
would be explained to you. Also, on receiving new information your research nurse or 
doctor might consider it to be in your best interests to withdraw you from the study. 
He/she will explain the reasons and arrange for your care to continue.
12. What happens when the research study stops?
When you have completed the 90-day study period you will continue with routine care 
and attendance at the hospital as before. This means you will have blood transfusions 
dependent on your symptoms and haemoglobin level at each visit as before.
13. What if something goes wrong?
If you have any complaints about treatment you have received you should inform your 
study nurse or doctor. If there are complaints about something serious happening during 
or after your participation in the study you should inform your study doctor/nurse 
immediately. The research supervisors at Surrey University may also be contacted < 
insert supervisors name and telephone numbers>. Any transfusion reactions will be 
recorded and foilowed-up as usual practice. Your legal rights are not affected by giving 
your consent to take part in this study. Your right at law to claim compensation for injury 
where you can prove negligence is not affected. This should not affect any private 
medical insurance you have.
14. Will my taking part in this study be kept confidential?
Yes-all information, which is collected about you during the course of the research, will 
be kept strictly confidential. Any information about you, which leaves the hospital for 
data analysis, will have your name and address removed. A letter will be sent to inform 
your GP that you are participating in this study. The questionnaires that you complete 
will be kept confidential within the study.
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15. What will happen to the results of the research study?
The results of the study when completed, will be analysed, reviewed by the study team, 
and published in a research journal in due course. The results will also be published as 
a Doctorate study at Surrey University. Neither you, nor anybody else who see the 
results from the study will be able to identify anyone from the study. The results of this 
study are likely to be available December 2008. If you would like a summary of the 
results when available please inform the research nurse.
16. Who is organising and funding the research?
This study is organised and funded by the <name of acute trust>.
17. Who has reviewed the study?
This study has been reviewed and approved by the National Ethics Committee, Surrey 
University ethics committee and the local ethics committee of <name of acute trust>. .
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Appendix 4-Actlwatch Information Sheet (version 2)
Instructions for wearing the Actiwatch
Please put on the Actiwatch and wear it as you would a wristwatch. The webbing strap 
can be pierced at any point according to your personal fit. The Actiwatch is a device 
used to measure movement and determine your sleep-wake cycle.
The Actiwatch must be worn continuously, on your non-dominant wrist, (i.e. the one 
that you don’t write with).
It is essential that you do not remove it when you go to bed.
Although the Actiwatch is waterproof, please remove it when washing-up and showering 
and if you are going swimming or taking a bath.
Remember to attach the Actiwatch immediately afterwards.
To press the event button, press in the circle on the top of the Actiwatch, you will hear a 
click.
Event Button
Press the event button at night when you go to bed and turn the lights out to go to 
sleep.
Press the event button when you wake up In the morning to start getting up.
Please call me if you have any queries
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Appendix 5: Patient Consent form (version 1 ) (on headed notepaper)
Date given to patient:___________________________
Ethics protocol number: 07/H0802/96
Patient identification No: P
Name of principal investigator: Liz Bishop
Please tick box
1. 1 confirm that 1 have read and understand the information sheet dated
..............  ( version...... ) for the above study and that 1 have had an
opportunity to ask questions
2. 1 understand that my participation is voluntary and that 1 am free to 
withdraw at any time, without giving a reason, and my medical care 
and legal rights will not be affected.
3. 1 am willing to allow access to my medical records to check that the 
study is being carried out correctly. 1 have been assured that strict 
confidentiality will be maintained.
4. 1 agree for my GP to be notified of my participation in this study
5. 1 agree to participate in the above study
6. 1 would / would not like to be informed of the results of this study {please delete 
as appropriate)
Name of patient: Date:
Name of person obtaining consent:
(If different from principal investigator)
Principal investigator: Date:
Date:
Signature:
Signature:
Signature:
(1 copy for patient, 1 copy for principal investigator, 1 copy for hospital notes)
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Appendix 6-GP letter (version 2) (on headed notepaper)
Patient name:
Hospital Number:
DOB:
Address:
Telephone number:
Date:
Study Title: A study to determine the impact and assessment of cancer-related anaemia 
in lung and haematology cancer patients and the decision to treat with blood transfusion
REG Number: 07/H0802/96 
Principal Investigator: Liz Bishop 
Anticipated study start date:
Dear Doctor ...............
The above patient has agreed to participate In a study at <insert acute NHS Trust> It is 
a study examining the impact of blood transfusion on the fatigue and activity levels of 
patients with cancer-related anaemia. The study period Is 90 days. Their fatigue and 
quality of life will be measured at baseline and 4-weekly intervals using a questionnaire, 
which takes approximately 10 minutes to complete (Functional Assessment of Cancer 
Therapy-Anaemia Questionnaire). Activity will be measured continuously by wearing an 
actiwatch on their non-dominant wrist-a technique known as actigraphy. Patients will 
receive blood transfusion as directed by their doctor. Patients will attend the hospital 
as directed by their team throughout the study period.
If you require more information regarding this study please do not hesitate to contact me, 
in the department of haematology.
Yours sincerely,
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Appendix 7: Demographic Data 
Patient Data
Table 4.1.1a: Patient interview schedule
Patient ID Date of interview
PHI 20.8.08
PH2 22.8.08
PH3 27.8.08
PL1 18.8.08
PL2 25.8.08
PL3 1.9.08
Table 4.1.2b: Demographic, diagnosis and treatment details
Patient
ID
Age Sex Diagnosis and stage Treatment to date
PH1 32 Female Stage IV lymphoblastic 
lymphoma
3 cycles COPDM 
chemotherapy
PH2 62 Male Acute Myeloid Leukaemia 3 cycles of ADE 
chemotherapy followed 
by cord blood stem cell 
transplant
PH3 28 Male Stage IV Diffuse Large B cell 
Non Hodgkin’s Lymphoma
6 cycles CHOP 
chemotherapy; relapsed 
and underwent 2 cycles 
DHAP chemotherapy 
followed by autologous 
stem cell transplant
PL1 67 Male Squamous cell carcinoma left 
lung
(T4 N2 MO)
Radical
chemoradiotherapy to 
left lung, 3 cycles of 
vinorelbine and cisplatin. 
Completed 64Gy in 32#
PL2 59 Female Non small cell lung cancer left 
lower lobe 
(T2 N2 MO)
Completed chemo­
radiotherapy, 4 cycles 
vinorelbine and cisplatin 
Completed 64Gy in 32#
PL3 52 Male Adenocarcinoma right lung 
(T3 N2 MO)
3 cycles of vinorelbine 
and cisplatin
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Table 4.1.2c: Patient family and employment details
Patient
ID
Marital status Dependents Previous employment
PHI Married 2 children; aged 5 and 8 None; housewife
PH2 Married 2 children; independent 
adults
Engineer
PH3 Single but long term 
partner
None Graphic designer
PLI Divorced 3 children; independent 
adults
Retired
PL2 Married 1 child; independent Office clerk
PL3 Single None Unemployed
Table 4.2.1: Clinician interview schedule
Staff ID Designation Date of 
interview
SHI Consultant Haematologist 4.2.08
SH2 Specialist Registrar (Haematology) 28.2.08
SH4 Day Care Unit Sister (Haematology) 6.12.07
SH5 Clinical Nurse Specialist (Haematology) 28.1.08
SH6 Clinical Nurse Specialist (Anaemia) 6.6.08
SL1 Consultant Oncologist (Lung) 19.12.07
SL4 Day Care Unit Sister (Lung) 17.3.08
SL5 Clinical Nurse Specialist (Lung) 28.1.08
SH9 Anaemia Clinical Nurse Specialist 12.4.08
Table 4.3.2a: Observation and fieldwork schedule
Clinic/Day Care 
Unit ID
Date of fieldwork Time spent In clinic
HC1 28.2.08 4 hours
HC2 11.3.08 3.5 hours
HC3 23.5.08 4 hours
LC1 1.2.08 5 hours
LC2 28.3.08 4.5 hours
LC3 22.5.08 4 hours
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Table 4.3.2b: Clinic size contrasts: Oncology and haematology
Oncology Haemato-oncology
OPD
Consulting
rooms
Day Unit 
Bed or chair 
spaces
OPD
Consulting
rooms
Day Unit 
Bed or chair 
spaces
SIze-number of 
rooms/bed spaces
18 35 6 20
Patient numbers 25-65 45-55 25-35 25-35
Nurse numbers 3 10 1 5
Table 4.3.2c: Haemoglobin values of patients in clinical areas and transfusions
administered from clinic/day care decisions (anaemia is defined using the NCI criteria; 
Table 2.2.1; p34)
No./% of patients with Hb HC1 HC2 HC3 LOI LC2 LC3
WNL(>12g/dl) 7 7 2 6 5 11
Mild (10g/dl-12g/dl) 11 12 10 22 16 18
Moderate (8g/dl-10g/dl) 6 3 5 4 5 6
Severe (6.5-7.9g/dl) 1 1 2 1 0 2
Life threatening (<6.5g/dl) 0 1 0 0 0 0
Total 25 24 19 33 26 37
Number of patients treated 
with blood transfusion
1 2 1 1 1 0
% of patients WNL 28% 29% 10.5% 18.8% 18.5% 29.7%
% of anaemic patients ,. 72% 71%-. 89.5% 81.2% 81.5% 70.3%
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Appendix 8: Patient Information Leaflet (version 4)
Version Number: 4; 9.8.08
Research Ethics Committee Number: 07/H0802/96
Principal Investigator: Liz Bishop
Introduction
You are being invited to take part in a research study, which is part of a Doctorate study 
being undertaken at Surrey University by the Haematology Nurse Consultant, Liz Bishop, 
and <insert name of acute NHS trust>. Before you decide, it is important for you to 
understand why the research is being done and what it will involve. Please take time to 
read the following information carefully and discuss it with friends, relatives and your GP 
if you wish. Ask us if there Is anything you do not understand of if you would like more 
information. Take time to decide whether or not you wish to take part. Should you 
decide to take part in the study, you should keep this document in a safe place in case 
you need to look at it again.
Thank you for reading this
1. What is the purpose of this study?
The main purpose of this study is to find out if blood transfusion has an impact on your 
quality of life and fatigue and activity levels.
Haemoglobin, which carries oxygen from the air that we breathe, is found in the red 
blood cells in your bloodstream. The red blood cells are responsible for carrying this 
oxygen to your tissues. As a result of your condition, or treatment, you may develop a 
low red blood cell count and consequently a low haemoglobin level. Together, these 
may cause anaemia. Common symptoms of anaemia are fatigue (tiredness), lack of 
energy and shortness of breath. In some cases these symptoms can also interfere with 
your ability to perform daily activities, such as bathing, shopping, working or hobbies so it 
is important for us to understand the impact of anaemia on your activity levels.
Blood transfusion is routinely used to correct anaemia, but it is not known how it impacts 
on fatigue and activity and quality of iife in the outpatient setting. We would like to do 
further research to measure quality of life whilst maintaining your haemoglobin with blood 
transfusion. We may observe your consultation in clinic but we do not interfere with the 
decision as to whether to give you blood transfusion or not. In a separate part of the 
study we are also interviewing doctors and nurses to examine in more depth how they 
assess and treat anaemia and observing their behavior in clinic.
2. Why am I being invited to take part?
You have been invited to join this research study because you have anaemia and you 
sometimes receive blood transfusion to maintain your haemoglobin levels. You would, if 
you decided to take part, be 1 of 10 patients to enter the study in this hospital.
3. Do I have to take part?
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It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to change your mind or withdraw at any time and 
without giving a reason. This will not affect the standard of treatment or care you 
receive.
4. What will happen to me if I take part?
The study involves being interviewed by the principle investigator, Liz Bishop. She will 
arrange a convenient time to interview you, which coincides with a routine hospital visit 
to the hospital. In a quiet and private location she will ask you a series of questions 
about anaemia and blood transfusions. The questions will be about how you are feeling 
and about your symptoms. Other questions will be about the blood transfusions. The 
interview will be tape recorded, but your identity will not be revealed. The interview will 
last no longer than 1 hour. The tape recording will be transcribed by the principle 
investigator and annonymised. In other words, the copy of your transcript will be named 
PH1 ; PH2 and so on and not be identifiable other than by the principle investigator. No- 
one other than the principle Investigator will have access. You can have a copy of the 
transcript at your request. The recording will be removed from the digital recorder 
following transcription.
5. What do I have to do?
The only requirement for you is to have the interview. It is very informal.
6. What is the procedure that is being tested?
Blood transfusion is routinely used to increase patients’ haemoglobin levels. It is 
necessary to maintain the haemoglobin to enable oxygen to each the tissues and for this 
reason we tend to transfuse patients when the haemoglobin level fall to 8.0g/dl or below 
or when you have symptoms of anaemia. However, there is some uncertainty as to the 
benefits of blood transfusion in terms of patients’ quality of life, namely fatigue and 
activity levels.
Throughout your treatment period you will be given blood transfusion according to 
standard practice, i.e. when your haemoglobin falls. The blood will be dripped into your 
arm via a cannula (a fine tube inserted into a vein) during your out-patient visit. This 
study will examine how often you have blood transfusions and if this impacts on your 
quality of life, specifically your fatigue and activity levels. The researchers will not 
Influence the decision to give you biood. This will remain the decision of the 
doctor looking after you.
7. What are the possible disadvantages and risks of taking part?
There are no disadvantages or risks to you directly because we do not interfere with your 
treatment. The only inconvenience of this study is having to be interviewed.
Before agreeing to take part in the study you should check that any private medical 
insurance you have will not be affected by you taking part.
8. What are the possible benefits of taking part?
There are no direct benefits of this study to you. The information we get from this study 
may benefit future patients who have anaemia.
9. What if new information becomes available?
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Sometimes during the course of a research project, new information becomes available 
about the treatment/drug that is being studied. If this happens, your doctor or nurse will 
tell you about it and discuss with you whether you want to continue in the study. If you 
decide to withdraw, your treatment will continue as before. If you decide to continue in 
the study you will be asked to sign an updated consent form and the new information 
would be explained to you. Also, on receiving new information your research nurse or 
doctor might consider it to be in your best interests to withdraw you from the study. 
He/she will explain the reasons and arrange for your care to continue.
10. What happens when the research study stops?
When you have completed the interview you will continue with routine care and 
attendance at the hospital as before. This means you will have blood transfusions 
dependent on your symptoms and haemoglobin level at each visit as before.
11. What if something goes wrong?
If you have any complaints about treatment you have received you should inform your 
study nurse or doctor. If there are complaints about something serious happening during 
or after your participation in the study you should inform your study doctor/nurse 
immediately. The research supervisors at <insert name of university> may also be 
contacted <lnsert supervisor names/telephone numbers>. Any transfusion reactions will 
be recorded and followed-up as usual practice. Your legal rights are not affected by 
giving your consent to take part in this study. Your right at law to claim compensation for 
injury where you can prove negligence is not affected. This should not affect any private 
medical insurance you have.
12. Will my taking part in this study be kept confidential?
Yes-all information, which is collected about you during the course of the research, will 
be kept strictly confidential. Any information about you, which leaves the hospital for 
data analysis, will have your name and address removed. A letter will be sent to inform 
your GP, that you are participating in this study. No-one other than the principle 
investigator will have access to the data. You can have a copy of the transcript at your 
request. The recording will be removed from the digital recorder following transcription.
13. What will happen to the results of the research study?
The results of the study when completed, will be analysed, reviewed by the study team, 
and published in a research journal in due course. The results will also be published as 
a Doctorate study at Surrey University. Neither you, nor anybody else who see the 
results from the study will be able to identify anyone from the study. The results of this 
study are likely to be available December 2008. If you would like a summary of the 
results when available please inform the research nurse.
14. Who is organising and funding the research?
This study is organised and funded by the <insert name of acute NHS trust>.
15. Who has reviewed the study?
This study has been reviewed and approved by the National Ethics Committee, Surrey 
University ethics committee and the local ethics committee of <insert acute NHS 
Trust>.
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Contact for further information
If you need any further information or have any questions regarding the study, or your 
participation, please contact
Thank you for considering to take part in this study; you will be given a copy of this 
information leaflet and signed copy of the consent form to keep.
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Appendix 9: Sample Patient Questions
1. What do you feel like when you are anaemic
2. When do you think you feel anaemic?
3. What are your sleep patterns?
4. How do you think you can tell you are anaemic?
5. Why do you think you are so tired?
6. Can you predict when you might be anaemic?
7. Do you have any concerns about having blood transfusion?
8. How do you feel once you have had a blood transfusion?
9. If there is any benefit how long does this last?
10. How are you involved in the decision to have blood?
11. How much do you know about your other blood counts and results?
12. Do the nurses and doctors ask you enough about how you are feeling-can you 
describe some times?
13. What do you think we could do better?
14. What do you know about blood transfusions?
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Appendix 10: Sample of patient transcription data
1 If perhaps, first of all can you think back to a time when you were anaemic and tell
2 me what it felt like?
3
4 The difficulty I have. ..is with the kind of chemotherapy I had. At times you couldn’t
5 tell whether you felt awful because you were low in the blood states or you felt awful
6 because you ... because of the chemotherapy . And even when you had the blood
7 you were obviously better because you’re going about but you could still feel awful
8 ...but that was no reflection on the blood going in. Sometimes for example, about 3 or
9 4 weeks ago, I had blood on the Friday and I had the best weekend I had had for
10 about 5 months. I had a good period of for three days and then I went downhill and
11 for that one weekend I felt really brilliant and that was down to the blood.
12
13 But sometimes it didn’t make you feel brilliant?
14
15 No
16
17 And were there times when it didn’t have any impact at all?
18
19 I had blood yesterday, two bags and I couldn’t tell the difference afterwards. But the
20 difficulty I have here is you are on treatment.. and then you are on this and that and
21 you are lying in bed or sitting in a chair like your level is low now., but if I go back 5
22 weeks ago prior to all, you know, in between treatment and starting this one I can
23 obviously feel the difference.
24
25 And so, what sort of things do you feel when you feel low? What are your main
26 symptoms?
27
28 Tired... I don’t get breathless. I just feel tired, actually I can sometimes tell when I am
29 getting low on blood.
30
31 You can? If your haemoglobin level is low yes? How can you tell?
32
33 You start to slow down and I can remember sitting at home thinking I am beginning to
34 feel really draggy and you come in and you go to the day unit and you say I think I
35 am going to need blood today, and they go and check and they say yes. So you get
36 quite a good idea when you think back to your question at the beginning, when do
37 you feel anaemic? You use the word anaemic. I don’t use the word anaemic ,
38 because I don’t perceive myself as anaemic. But maybe I should. I could say yes I do
39 need a top up.
40
41 So you would generally know that yourself and say or sometimes would it be the
42 other way around?
43
44 It is sometimes the other way around because sometimes you just feel awful
45 because of just the mixture of what is happening to you and you can just feel awful
46 and in fact your bloods are all right. You know they could be 9.4 or whatever it is.
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47
48 Do you know what levels it gets to when you start to feel really washed out?
49
50 Well 1 think it gets about ....well it’s not below 8 but it is very difficult to judge,
51 because it is not just that. I am sure the platelets I get, infections , so it is a
52 combination of things...but there are instances when I can say, yep I have had blood
53 and I feel really great.
54
55 Like that weekend?
56
57 Like that weekend.
58
59 So sometimes you feel good after blood, sometimes it doesn’t make an impact. What
60 ratios is that roughly, what do you think? Out of the times that the benefits are there
61 and not there?
62
63 Obviously the benefits are there...but sometimes I still feel bad
64
65 At a physiological level?
66
67 Yes because obviously without it I would feel worse than I did erm.. I think probably it
68 perks me up in a sense that I can walk more upright, you know what I mean? I can
69 trot along and you..you get used to feeling rough anyway and you usually just put
71 that to one side...erm ratio....the thing is I can remember when I feel really, really bad
72 and I have blood, it does me good and I can remember like that weekend when I had
73 it and I was surprised how perky I was . and like all the other periods like I had blood
74 last night, actually I feel quite good today but I actually felt quite good yesterday, but
75 that maybe is because I am just lying in bed, not doing anything because if I am up I
76 am walking and straining and kind of pushing myself along .
77
78 And if you were to describe how much better it makes you feel, you know percentage
79 wise, what would you say?
80
81 Oh sometimes I can think 200% better,.but other times nothing. I was in XX hospital
82 and I had three bags of blood, I don’t know why they just did go on with the bloods. I
83 was really feeling awful .you know I was thinking I just don’t know what is going
84 wrong with me. I had about 6 hours in blood transfusion and I perked up . yes I can
85 really remember it.
86
87 Can you remember how low you were then?
88
89 Yes really low I was really feeling ....
90
91 And can you remember how low your haemoglobin was?
92
93 No but it must have been pretty low to have 3 pints of blood. I shouldn’t say this but 1
94 think they cocked up the ordering actually
95
96 Do you think so?
97
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98 Well you see XX is different from here. If you order blood you get it today. In XX If
99 you order blood today you get it tomorrow.
100
101 All right then you have got to come back?
102
103 Because it is not an emergency I mean obviously if it was an emergency you would
104 get it straight away. But mine wasn’t an emergency. I think I just got totally out of
105 kilter. I should have had blood earlier at that weekend.
106 So you can remember when it does you really good, it perks you up. It’s a kind of
107 tonic
108
109 And the times when you have felt really good about it can you remember if any
110 significance in time or a relationship to your chemotherapy. Was it when you were
111 recovering or immediately afterwards...do you think that is linked?
112
113 The weekend that I hadn’t had any chemotherapy I was just coming up to the day
114 unit to have blood when necessary, and I just needed to be monitored until they
115 found another donor. The blood I had last yesterday could well be related because I
116 don’t..there is no obvious ....erm no obvious ginormous pick up but I think that is
117 related because I am having chemotherapy which I am finding very difficult to
118 handle. So you are having other things pushed in at the side when you are feeling
119 slightly ill and therefore your perky level actually doesn’t go up, if I can put it like that.
120
121 Levels of perkiness vary?
122
123 Obviously you are better because you have had blood. You must do , but it is not
124 noticeable. When I am away from all the chemotherapy and I have blood I can feel
125 the difference. As soon as you start putting other influences into the mix the
126 difference becomes less marked.
127
128 Do you think you can predict when you are anaemic or is that related to just the
129 tiredness?
130
131 It is quite interesting because when I was coming up to the day centre during the
132 week.. I came in on a Thursday and then I didn’t come in again until the Tuesday. So
133 you actually had to worry over the weekend whether you were going to run out of
134 platelets and whether you were going to run out of blood. So you would actually
135 watch you r results quite closely to see if you could actually predict them. Platelets
136 were easier to predict than blood interestingly. You could say like I am sure I will
137 need platelets, its down and you track back and you know you need platelets?
138 Therefore I can calculate that I need them before the weekend and he would say
139 something stupid like I should..and therefore say no..it was more difficult because
140 you couldn't work out. There seemed to be no correlation between what was
141 happening before and what is happening now..
142
143 So there is no pattern is there?
144
145 You could say with the... I mean within a certain period I am going to need blood
146 anyway but within that period it was very difficult to work out. You could get the
147 outside parameters because you know I need blood probably about one a week or
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148 once every 8 days and sometimes you need it twice and sometimes you would go
149 out like that and much to my annoyance I couldn’t work out why that happened/
150
151 That’s ok I think that is a recurrent theme. And do you have any worries about having
152 blood, does that bother you?
153
154 No no
155
156 You don’t have any concerns or thoughts about it?
157
158 No
159
160 When you make that decision or when that decision is made to have blood, you
161 touched on it briefly, so you are in the clinic or the day unit. Describe that process ,
162 you come Into the unit or you come into the clinic and what is it that, how do you get
163 to the outcome that you are having blood ?
164
165 You come into the clinic and they take your bloods, take it away analyse, you might
166 need platelets or blood and you know that you won’t get them before 3pm anyway,
167 because that is the delivery time. By then because you have been sitting there , its
168 getting up to 3 o’clock , then you have your bloods 1 un it, usually 2 and that could
169 last an hour and a half maybe two hours a bag and they’ll find a vein. They will put in
170 a cannula in at the beginning. If they think you need blood rather than just take drugs
171 they will put a cannula in at the beginning.
172
173 So is that because you have had a discussion, is it, with somebody ?
174
175 Yes because I was feeling really tired today.
176
178 So you say that?
179
180 Yes they say, how are you and I say I feel really tired, I need to have some blood. So
181 he puts in a cannula which is sensible then they can take the bloods. So they are
182 very efficient, you know I lie on a bed or sit in a chair.
183
184 And have there been times when you have gone in and said I think I need blood and
185 then it turns out you don’t , or do they always do what you ask?
186
187 No no no I think what they don’t want to do is to keep putting needles into you...and I
188 have had a cannula put in then they have done their thing then taken it out and that
189 is fine. You try and make an assessment, they make an assessment and it is all very
190 fair and logical and they take it out because actually you don’t need blood or
191 platelets.
192
193 And is that ok. When you have come in and said you feel tired?
194
195 Yes I am quite happy with that because I might feel tired for other reasons, because
196 this is the difficulty with, and that is when I was neutropenic. It is difficult because you
197 can be tired anyway.
198
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199 Do you think your tiredness is related to your neutropenia?
200
201 I think it must be related to blood as well, not to platelets erm I mean I suppose when
202 one is low , I think the difficulty you have is I can operate quite a long time without
203 feeling tired and then because I have gone through all the chemotherapy and I have
204 gone through all the transplant thing , then back here again, you are actually quite
205 tired. Your life is “being tired”.
206
207 You live with it?
208
209 You live with it erm
210
211 Has that been cumulative?
212
213 I think it has, but if you ask me do you feel tired now, I don't feel too tired .
214
215 So it fluctuates?
216
217 Yes
218
219 So how does it feel?
220
221 I find I get tired in the evening. I am tired earlier if you know what I mean and I can
222 have bad days, like last week I had a really bad week and I just felt tired and awful all
223 the time. This week I actually don’t fee l i feel tired but...
224
225 Do you sleep all right?
226
227 I doze really because I have this on my mind..lots going on I guess..
228
229 What about since your diagnosis?
230
231 Not bad but I haven’t slept particularly brilliantly. I mean in hospital it doesn’t really
232 matter quite honestly because you doze during the day. At home I will get up, get
233 dressed have breakfast and go and do something and if you are tired, you just go to
234 bed early because what you don’t want to do is just sit in a chair feeling tired ,
235 because you feel even worse.
236
237 So one of your strategies is to get up and do things?
238
239 Yes, I always get up and get dressed, eat wander around the house, sometimes go
240 out sometimes don’t. I don’t like lying in bed, I can’t cope with that.
241
242 And when you have blood and you say you are a bit more perkier does it help you do
243 more?
244
245 It makes the quality of what you are doing better. That weekend, we had people in for
246 coffee and tea. You could for a moment, you were actually having a normal life, you
247 know you were discussing politics, you were discussing financial things with friends
248 and talk about anything but cancer. And all of a sudden you felt this is you know, it
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249 just makes things normal for a moment.
250
251 How sustainable is it?
252
253 It had gone by Monday afternoon
254
255 And is that something you generally find with blood transfusions...sustainability?
256
257 I think it wears off ..,yes . ..the difficulty is to judge that, though I have never thought
258 about it in those terms because if you go downhill, I am not quite sure if you go
259 downhill gently or all of a sudden you go like that then level off. Or you just feel, just
260 ‘Tm feeling a little bit grotty today because I haven't got any blood, you know I need
261 blood. You might just say I feel grotty today because you do. ..you don’t always relate
262 it to, I need something. You are likely to think about it when you come up to the out
263 patients.
264
265 How do you think the doctors and nurses decide when you need blood? What do
266 you think makes them think that you do?
267
268 Well I presume they look at your print out, which I get a copy of as well, and from that
269 they decide whether to do it or not
270
271 Just from that lab result?
272 Or do you think they look at you, or talk to you?
273
274 There were two instances when I felt really tired and I needed to have blood. And
275 there have been instances when I felt ooh I might need blood, but I didn’t need blood
276 but that didn’t worry me. You know you come in and I feel tired and your blood is
277 something like 9.8 or something and you think..oh 9.8 is all right.
278
279 And did you think that or did they think that?
280
281 They thought that. But when you see 9.7 you could see. You know people ask why
282 and they are very good at explaining ...but if you see 9.8 you think oh that’s all right.
283 That is a level that I am sustainable at quite happily.
284
285 So what level do you want, if I was to say to you, what level do you want your blood
286 at ?
287
288 I would judge it by how I feel
289
290 Right
291
292 I mean if I walk in without seeing these results I can’t say I am 9.9 today or I am
293 whatever. I can just say I am feeling really tired and I think I will probably need blood.
294
295 So is it just a mutual agreement, how would you describe it?
296
297 No I don’t think it is a mutual agreement at all. I think it is the doctors who decide.
298
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299 Based on the labs?
300
301 Or based on their experience based on a whole print out and see what it looks like. I
302 would think that it is their decision. I have never ever said “ I want blood “ and they
303 said " no you don't J “and I said “I dol” I’ve always felt very comfortable with how we
304 work it out.
305
306 And thinking about your relationship with them, how would you describe your
307 relationship with the team members and is there some relationships that are different
308 or better or..?
309
310 I think within any team within any organisation, there are some you relate to more
311 quickly, more easier than others and some you find easier to talk too. They might find
312 it easier to talk to you because they have to form a relationship as well. ..so you can
313 see it. I mean it is quite fascinating to sit and watch as part of my job at work, but it
314 doesn’t worry me. If I had somebody who I really didn’t like, but they were good, I
315 would just say that they were good. I would rather have somebody who had no
316 bedside manners and was brilliant, than someone who had brilliant bedside manners
317 but was awful. I would rather go for the medicine than be brilliant and I am quite
318 happy with that. I mean I can accept that quite happily but that doesn’t happen. But
319 there is a difference between people? Yes there has to be, that is the nature of the
320 beast.
321
323 What’s good then, what’s good sort of interaction, what do you think that is?
324
325 I think some people you just relate to more easier than others. I think they are all
326 good. I can actually say we get on with them all, but the pure nature of the beast, in
327 that some people you feel more relaxed with, maybe that is the wrong word erm...but
328 if I come in ...in the morning to the outpatients on the ground floor we don’t know
329 exactly who we are going to see and actually I don’t care who we see.
330
331 Do you think it is better to see the same person?
332
333 I don’t know
334
335 How well do you know the team?
336
337 We know them all now, it is something we have talked about, wondering that, but the
338 feeling that I get is that it is a team effort, so by seeing everyone on the team you are
339 actually broadening their knowledge of you and that could well be to my advantage
340 and anything that comes to my advantage is fine by me.
341
342 Do you think it is anything to do with how the team functions then?
343
344 I haven’t got any experience about how other teams in the hospital work. If you asked
345 me before I came in I would have thought I was seeing one person. Obviously not the
346 same person what with leave and all that. But I thought the people you see the
347 numbers would have been slightly narrower, but they are slightly narrower
348 anyway..1....2...3...4...5......5 different we see maybe 6. So it’s not a great number
349 erm no J (wife) and I have discussed this and wondered. We feel the advantages
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350 outweigh the disadvantages. And they are actually all nice, they are all concerned
351 and in that sense I have no worries
352
353 Thinking about the nurses now, do you think, have they been involved in discussions
354 to give you blood do you think?
355
356 I don’t know, because when you go into the day unit, it disappears into the office and
357 then one of the nurses will come out and say yes you have to have blood today J. So
358 you don’t know who is making the decision. I assume it is the doctor.
359
360 Do you feel involved in it?
361
362 Not particularly but I don’t think it is something I need to be..its not my expertise so ..
363
364 And if, thinking about the discussions you have had with your wife and whatever is
365 there things you think we could do better in terms of managing your period as an out-
366 patient particularly I am thinking?
367
368 No I don’t think so erm ..
369
370 You said you sometimes worried over the weekend or there was a gap, you know
371 ..will I get through to the next period when I am back or... was that an issue, or I
372 wonder if I can last until then ?
373
374 No I don’t think so. It is something I thought because obviously ..my wife worries
375 because when you are at home you can’t get it and we are actually quite a long way
376 from the hospital. Because last time I got an infection we had to go to X hospital and
377 that is the nearest hospital I can get to quickly so you are only worried about distance
378 so you are really trying to see if you can get everything topped up. It is just so It
379 means you won’t get an infection over the weekend. It is usually my platelets
380 because you.. I can last quite long on blood cant you. But I have been down really,
381 really low on platelets and you don’t want those too low because you start to bleed.
382 So only in that sense really I don’t spend my time worrying at home otherwise I’d be
383 a nervous wreck.
384
385 Is there anything else you want to ask or say?
386
387 I think since we have been here I think everyone has looked after me beautifully. Yes
388 if I take it as a 95% level and my biggest contact is opposite In the S ward and they
389 have been really good. But everywhere you go, I mean I went down for a CAT scan
390 yesterday and they were lovely there, I have been surprised how lovely people are.
391 So I think we were very lucky to come to X hospital.
392
393 Because it is not easy being a patient is it?
394
395 No it is rotten
396
397 Do you think you learn how to be a patient? Is it difficult to learn or is there a way you
398 have to be?
399
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400 No I think you have to be yourself. I think you certainly get institutionalised by the
401 very nature of the beast, how long I have been here, but you know the nurses don’t
402 treat you as an institutionalised person. They treat you as a human being, they are
403 very courteous and they try really, really hard (talks about last Christmas) they went
404 out of their way to help
405
406 Anything else you want to say about blood?
407
408 Just that I have had alot...and I get resistant
409
410 How do you know that?
411
412 They told me
413
414 So you know all about antibodies and things?
415
416 Well I know because I am allergic to platelets in that I have developed antibodies
417 because I have had so many different platelets..you know if I was to have a bad lot
418 ...when my face has gone up like a football.
419
420 Just going back to what you said..do you think the haematologists want to avoid
421 giving you the blood or platelets..is that the sense you get?
422
423 I think quite correctly they want to give you the right medicine at the right time. They
424 don’t want to over prescribe and they don’t want to under prescribe It., they want to
425 give you blood at the appropriate moment rather than just give you blood because
426 you are 8.9.1 think the process is thought about,., it is certainly done with care. I think
427 that everything they do they think about it, it is approached with the patients best
428 interests at heart.
429
430 Do you think what they are doing is balancing the risks and the benefits
431
432 Yes but I think if you are needing blood then you would get it. If I need platelets I get
433 it, if I need blood I get it. But if there is a question...is it necessary today? Maybe
434 there thinking is maybe we can leave can leave it for another couple of days and
435 then over a period of time the number of transfusions you will have to have is less
436 and therefore that must be better for him. So overall you would get slightly less
437 transfusions. So if they were having 10 you would be having 9 therefore you have
438 saved one transfusion which could help you and obviously blood Is a resource you
439 don’t want to waste but you don’t want to be too liberal with i t .
440
441 And is that the sense you get?
442
443 That is the sense I get...
444
445 Anything else?
446
447 No (interview terminated)
448
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Appendix 11: Staff Information Sheet (version 1) (on headed notepaper)
REC Number: 07/H0802/96 
Principal Investigator: Liz Bishop 
Introduction
You are being invited to take part in a research study, which is part of a Doctorate study 
being undertaken at Surrey University by the Haemato-onclogy Nurse Consultant, Liz 
Bishop, and < insert acute NHS Trust>. Before you decide, it is important for you to 
understand why the research is being done and what it will involve. Please take time to 
read the following information carefully and discuss it with colleagues if you wish. Ask us 
if there is anything you do not understand of if you would like more information. Take 
time to decide whether or not you wish to take part. Should you decide to take part in 
the study, you should keep this document in a safe place in case you need to look at it 
again.
Thank you for reading this
1. What is the purpose of this study?
The main purpose of this study is to examine the culture and practice of assessment of 
cancer-related anaemia and the key elements you use when deciding to treat the 
anaemia with blood transfusion. There is also a patient component to this study to 
examine if blood transfusion has an impact on patient's quality of life and fatigue and 
activity levels. Following exploration of these elements it is hoped that we can determine 
the most appropriate strategies to ensure optimal transfusion prescribing behaviours in 
the treatment of cancer-related anaemia
Blood transfusion is routinely used to correct anaemia, but it is not known how it impacts 
on fatigue and activity and quality of life in the outpatient setting. It is known that 
different clinicians/nurses make different decisions in the assessment and treatment of 
cancer related anaemia in spite of the presence of clinical guidelines. The reasons 
behind this are unclear. One way of establishing the influences on the decision to treat 
cancer-related anaemia Is to interview a variety of grades and type of clinical staff in an 
attempt to discover what factors are involved. In a separate part of the study we are also 
observing the behaviors of clinical staff how they assess and treat anaemia because 
there may be other factors Involved, e.g. lack of availability of beds or it may be the 
patient-clinician interaction is an important feature.
2. Why am I being invited to take part?
You have been invited to join this research study because you are a clinician/ nurse who 
cares for patients with cancer-related anaemia and are frequently involved in treating 
patients with blood transfusion. The aim is to interview 8-10 staff and undertake 
observation in six clinics (three haemato-oncology and three lung clinics).
3. Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you
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decide to take part you are still free to change your mind or withdraw at any time and 
without giving a reason. This will not affect your post.
4. What will happen to me if I take part?
You will be interviewed by the primary investigator of the study (Liz Bishop, Nurse 
Consultant, Haemato-oncology). The interview will be tape-recorded. It will take place in 
a private office/location of your choice. The tape recording will be transcribed and 
subsequently analyzed by the primary investigator. Your identity will not be revealed.
5. What do I have to do?
You will be interviewed by the primary investigator. It is not clear at this stage how long 
this interview will be but it will be no longer than one hour. It will be very informal and 
there will be no fixed questions.
6. What is the procedure that is being tested?
There is no procedure as such being tested, however, it is an exploratory study 
examining what signs and symptoms (if any) you feel are important in diagnosing 
cancer-related anaemia. In addition, it is an attempt to also define what factors 
influence you in your decision to order a blood transfusion to correct the anaemia.
7. What are the possible disadvantages and risks of taking part?
The main disadvantage is the impact on your time
8. What are the possible benefits of taking part?
There are no direct benefits of this study to you. The information we get from this study 
may benefit future patients who have anaemia and inform clinical practice.
9. What happens when the research study stops?
When you have completed the interview the recording will be transcribed. Your details 
will not be revealed to the transcriber as you will be assigned a unique study number. 
The primary investigator will analyse your transcription. The study will be reported as 
part of a doctorate study at Surrey University and subsequently as a published original 
paper. It may also be presented at Trust wide meetings or national or international 
conferences, however, your identity will not be revealed.
10. What if something goes wrong?
Your legal rights are not affected by giving your consent to take part in this study. Your 
right at law to claim compensation for injury where you can prove negligence is not 
affected. This should not affect any private medical insurance you have.
11. Will my taking part in this study be kept confidential?
Yes-all information, which is collected about you during the course of the research, will 
be kept strictly confidential. Any information about you, which leaves the hospital for 
data analysis, will have your name and address removed.
12. What will happen to the results of the research study?
The results of the study when completed, will be analysed, reviewed by the study team, 
and published in a research journal in due course. The results will also be published as 
a Doctorate study at Surrey University. Neither you, nor anybody else who see the 
results from the study will be able to identify anyone from the study. The results of this
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study are likely to be available December 2008. If you would like a summary of the 
results when available please inform your research nurse.
14. Who is organising and funding the research?
This study is organised and funded by the < insert acute NHS Trust>.
18. Who has reviewed the study?
This study has been reviewed and approved by the National Research Ethics 
Committee, Surrey University ethics committee and the local ethics committee of < 
insert acute NHS Trust>.
Contact for further information
If you need any further information or have any questions regarding the study, or your 
participation, piease contact
Thank you for considering to take part in this study; you will be given a copy of this 
information leaflet and signed copy of the consent form to keep.
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Appendix 12: Staff Consent Form (version 1) (on headed notepaper) 
Date given to staff volunteer:___________________________
Ethics protocol number: 07/H0802/96
Staff identification No: S
Principal Investigator; Liz Bishop
Please tick box
1. 1 confirm that 1 have read and understand the information sheet dated
.............. ( version........ ) for the above study and that 1 have had an
opportunity to ask questions
2. 1 understand that my participation is voluntary and that 1 am free to 
withdraw at any time, without giving a reason, and my legal rights will 
not be affected.
3. 1 have been assured that strict confidentiality will be maintained.
4. 1 agree to participate in the above study
5. I would / would not like to be informed of the results of this study {please delete 
as appropriate)
Name of staff: Date: Signature:
Name of person obtaining consent: Date: Signature:
(If different from principal investigator)
Principal investigator: Date: Signature:
(1 copy for patient, original copy for principal investigator)
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Appendix 13: Sample clinician participant questions 
Questions about anaemia and cancer
1. How would you define anaemia?
2. What are the main symptoms of anaemia?
3. At what level of haemoglobin do you think your patients develop symptoms of 
anaemia-can you give examples?
4. What are the main symptoms/signs that patients with cancer have?
5. What are the main symptoms of cancer-related anaemia-are there any 
differences form other types/causes of anaemia?
6. Why are your patients anaemic?
7. What do you think is the clinical course of anaemia?
8. What strategies can be used to improve a patient’s anaemia?
Questions about the assessment of anaemia
1. Describe to me how you assess anaemia?
2. Can you give me examples of questions you ask patients?
3. Have you ever decided to treat the anaemia without asking the patient any 
questions or doing any physical assessment-if yes-can you describe?
4. What physical or objective signs/symptoms do you use in your assessment?
5. What subjective or patient reports do you use?
6. Does your assessment of anaemia change dependent on where you think the 
patient is on their disease or treatment pathway?
7. Who do you think should assess anaemia and what skills and knowledge do they 
need?
8. What do you think are the main contributing factors to a cancer patient’s 
symptoms?
9. How can you separate the symptoms of disease/side effects of chemotherapy 
from symptoms due to anaemia-what techniques/strategies do you use?
10. What do you think contributes to a patient’s fatigue levels-start with the most 
influential?
Questions about blood transfusion
1. What are the risks of blood transfusion?
2. Do you think patients are aware of the risks-if yes which ones are they most 
aware of?
3. What do you think is the main risk?
4. What are the benefits of blood transfusion?
5. What benefits do patients describe to you-think what they actually say?
6. What proportion of patients describe a benefit to you?
7. What do you think is a reasonable transfusion trigger?
8. What is the Trust’s transfusion trigger?
9. How many units of blood do you mostly order?-Why and in what situations do you 
use different numbers of units?
10. Do you ever order single unit transfusions? If yes-when and why?
11. Do you think single unit transfusion would be good-describe pros and cons?
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12. How much is a unit of blood?
13. Do you ever consider the cost of the transfusion?
14. Do you ever consider the resources required-does this influence your decision to 
treat-if yes-can you describe?
15. How would you like to treat a patient with anaemia-e.g. more blood transfusion
Questions about attitudes towards anaemia and biood transfusion
1. Do you ever feel any pressure to treat a patient's anaemia?
2. Do patients ever request a blood transfusion?
3. Can you think of situations when a patient has received a blood transfusion 
because they wanted it but you would have withheld blood transfusion?
4. Do you think patients see blood as an expensive or scarce resource-describe?
5. Do you think staff see blood as an expensive or scarce resource-describe?
6. Have you observed any changes in the treatment of anaemia with blood 
transfusion over the years?
7. Who do you think should request blood transfusion-e.g. any doctor, level of 
doctor, experience etc
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Appendix 14: Sample of clinician interview transcription data
1 PI So how would you define anaemia in one of your patients?
2
3 SL1 I think there are different definitions of anaemia... em..l think with a ..if I’m honest..I
4 don't separate particularly for males and females so I would say a haemoglobin of
5 less than 10g/dl is anaemic or is anaemic as far as I am concerned although that on
6 it’s own would not be my trigger for transfusion...clearly there are laboratory
7 definitions of anaemia with laboratory normal variables.. em..l think treating solid
8 tumour oncology patients..many of whom are receiving cytotoxic chemotherapy..
9 em... I guess practically speaking because the vast majority of them have a
10 haemoglobin lower than the lower limit of normal on laboratory variables that in itself
11 is not sufficient for me in my head to determine them as being anaemic..so., but if
12 they have a haemoglobin of less than lOg/dl I would refer to them as anaemic but I
13 would not necessarily treat them for that
14
15 PI How would you explain that to a patient?
16
17 SL1 Em..I will say your blood tests show you are mildly anaemic and that’s probably partly
18 because of your cancer and partly because of the treatment we are giving you but its
19 only very mild and we don’t need to do anything about it now..having said that
20 whatever somebody’s haemoglobin is I would look back at the first haemoglobin we
21 have recorded for them for example before we have given them chemotherapy or if
22 we are giving them chemotherapy..em... or the earliest date which I have known
23 them so I have some idea of what the change has been for that person over their
24 disease course ..I mean obviously if they have been a long standing patient for many
25 years I might look back at their haemoglobin 6 months or a year ago..so I can see
26 whether I think that represents a change or if it has been a dramatic change or a
27 recent change..em..and em..if somebody is anaemic In my mind then I will also ask
28 them.. I would normally say ...are you any more tired than normal..are you any more
29 breathless than normal and if I think they might be then I would perhaps go into some
30 more detail about that to try to determine if they had a symptomatic anaemia as
31 opposed to symptoms of their disease....and of course symptoms of disease can be
32 very much overlapping with symptoms of anaemia..say if somebody to my
33 mind..em..has a haemoglobin of say 9.8g/dl i would probably tell them that they were
34 mildly anaemic and that we would keep an eye on that and ask them about
35 symptoms that could develop that we didn’t necessarily need to do anything about
36 that now other than watch it...em...l suppose remembering that most of my patients
37 will be returning to clinic at least every three weeks so we have ample opportunity to
38 watch that..to look at that and watch it.
39
40 PI What sort of things do patients tell you about their symptoms and how can you
41 separate that out?
42
43 SL1 Em..lt’s..there are differences depending on which disease type I am treating..and I
44 treat alot of lung cancer where its very difficult because lung cancer patients do get
45 breathless because of their disease and often because of other co-morbidities they
46 have associated with their malignancy....such as chronic airways disease and
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47 sometimes they have a degree of cardiac disease as well.. Having said that In some
48 ways in a lung cancer patient..if their breathlessness is a significant feature and they
49 almost have a lower threshold ..even though I know that anaemia may not be the
50 sole or maybe even the most important reason for their breathlessness and their
51 breathlessness often to my mind ...their breathlessness is multifactorial in aetiology I
52 would almost perhaps have a lower threshold for transfusing such a patient because
53 if it happens to help they can be patients who symptomatically can be very difficult to
54 treat...so what I would...What I would say..I haven’t quite answered your question
55 yet..I will do that in a minute..what I would say to a patient is...If I do feel we need to
56 intervene with a blood transfusion..then I would say to the patient it may help your
57 breathlessness..this may help with your tiredness and fatigue..but it may not and I’ll
58 need you to monitor and think yourself..three days after the transfusion, a week after
59 the transfusion, ten days after the transfusion is my breathlessness any different than
60 normal...is my tiredness any different than normal ...to try and decide whether
61 anaemia was the cause of their symptoms and whether transfusion actually
62 alleviated them or whether it didn’t...em..because otherwise in the lung cancer
63 population you could be transfusing repeatedly and regularly without actually any
64 symptomatic gain on behalf of the patient because actually the anaemia is not the
65 reason that they are feeling unwell.
66
67 In terms of what patients say to me... if you ask most patients are you tired-the
68 answers yes because they’ve got cancer and maybe because they’re anaemic...so I
69 am sure if I was to ask most of the non-anaemic patients if they are tired..the
71 answers yes..if you say are you a little bit anaemic-are you tired-are you breathless,
72 usually the answer is yes 1 am a bit tired ...but often you can..sometimes you can tie
73 it to what’s happened to the haemoglobin over time..and see in fact they’ve been
74 tired for ages and they’ve only become anaemic since you started chemotherapy
75 and they are no more tired than before..so that’s not the anaemia ..sometimes you
76 don’t know, .quite often you have a patient with a malignancy who is or not having
77 chemotherapy who is anaemic and if you ask them directly ..is a bit tired, sometimes
78 feels a bit breathless..and it can be very difficult to determine whether anaemia is
79 one of or the cause for that
80 
81
82 PI Do you think patients expect transfusions and do you ever feel any pressure to give a
83 blood transfusion?
84
85 SL1 I think patients..there are patients who expect treatment, whatever that may be but
86 there are also patients who, particularly if they haven’t had transfusions in the past,
87 are quite scared of transfusion so they are not necessarily looking for you to
88 transfuse them..some are and some are not and some are looking for an intervention
89 and they talk about iron tablets..and so...will iron tablets they make me feel better but
90 we don’t usually give them iron tablets
91
92 PI Do you routinely check for other causes of anaemia?
93
94 SL1 Iron, transferrin..no we don’t...so clearly you don’t know whether someone has an
95 iron deficiency anaemia or whether..most typically... obviously we do have a full
96 blood count profile we can see whether it is normocytic anaemia or whether it is
97 normochromic anaemia and most frequently it is and it’s not a sudden drop in
302
98 haemoglobin with an iron deficiency picture..em.. and certainly if I was going to give
99 somebody an iron supplementation I would want to check a ferritin level but just
100 because somebody is anaemic..no I don’t typically check their ferritin routinely..but I
101 also don’t give them iron-no I don’t ever..I don’t think 1 ever do.... and not in the
102 patient cohort I treat currently anyway-l don’t treat them with iron- at all
103
104 PI If you can describe the patients who do get benefit and those who don’t -is there
105 anything distinguishable between them?
106
107 SL1 I would say some patients who are more profoundly anaemic feel better..usually get
108 some benefit..it is less obvious and predictable..so if someone has a haemoglobin
109 level of 6/7 per decilitre I think they universally feel pretty shocking..em.. and usually
110 feel better because most of my patients are not actually bleeding..em.. and although
111 ,1 rarely see patients with anaemia that profound, when I do and it usually a disease
112 related phenomenon, I think they almost universally feel terrible and blood
113 transfusion does make them feel better, whereas if someone has a haemoglobin
114 between 9 and 10 grammes per decilitre,! rarely transfuse, I’m not saying never but 1
115 rarely transfuse these people. Or if you do have a haemoglobin between 8 and 9 I do
116 think there are some patients who... I know there are patients who feel very little
117 difference having had a blood transfusion and I personally don’t find I can predict
118 who they are
119
120 Pi But say if somebody has had a haemoglobin of between 8 which is our guideline and
121 you have transfused them because they are giving you a report and they don’t have
122 a significant benefit would you automatically stop transfusing them?
123
124 SL1 I think our response to that..em..my response and I think myself as part of a team,
125 our response to that is..em..is not ideal and is not robust .because what I know is
126 that there is ...I guess in clinical practice what will happen is I might tell someone
127 that I am going to arrange a blood transfusion and see what happens in terms of their
128 symptoms but actually the way actually the way that our clinics are set up if what we
129 rarely I may not see them next or I may see somebody that someone else has
130 transfused and so ..em.. I rarely will see them next time in fact so there is not very
131 good continuity in assessment of response to blood transfusions I think something in
132 which we should and could improve but we don’t robustly assess response so
133 although if I am going to give someone a blood transfusion or considering ordering a
134 blood transfusion to someone who has previously been transfused I will ask them if It
135 helped last time..em..l don’t robustly ..we have no robust mechanism of assessing
136 response of a transfusion which means that there is a risk and I am sure it happens
137 that people do get repeat transfusions who are not necessarily benefiting from them.
138
139 PI Could you argue that that might impact on you how you assess anaemia in the first
140 place?
141
142 SL1 Yes it does because...
143
144 Pi You’ve not been able to see a change in time?
145
146 SL1 Eh., yes., there is that and also I do think that I am aware, now that I work more
147 closely with haematoiogists that the process most haematologists go through when
303
148
149
150
151
152
153
154
155
156
157
158
159
160 PI
161
162 SL1
163
164 PI
165
166 SL1
167
168
169
170
171
172
173
174
175
176
178
179
180
181
182 PI
183
184 SL1
185
186 PI
187
188 SL1
189
190
191 PI
192
193 SL1
194
195
196
197
198
they transfuse is quite different than the process that I think a lot of oncologists go 
through in that..em..if the haem,..what I grew up with is the haemoglobin is less than 
10g think about transfusing them if the haemoglobin is less than 10g they are having 
chemotherapy they definitely should have a transfusion without..and that was 
that....that was that without any additional consideration of what was how chronic 
was the anaemia what was the patients symptoms, would they benefit erm and 
although my approach to that has changed over time that is certainly the approach I 
started with pretty much everyone with a haemoglobin of less than 10 grammes 
should have a conversation about blood transfusion and if they were on 
chemotherapy they definitely needed the blood transfusion with a haemoglobin of 
that level
Is that for all solid tumours or just lung cancers
That was all solid tumours,now
Do you think that is still the case for juniors ...doctors
I think..em..l think it can be the case for some definitely and I think it is also the case 
for... I think it is I don’t know whether it is in protocols actually or I don’t know any 
protocols where It is written but..em..pharmacy and chemotherapy nursing where a 
lot of them come back saying “don’t we need to transfuse them first, the haemoglobin 
is 9.8 and so what I suspect happens is..my response to that is, if I have an 
oncology pharmacist or senior oncology chemotherapy nurse coming to me with that 
request, my response to that as junior registrar would have been ,they are telling me 
they need a blood transfusion ,somebody who has been doing this job for years is 
telling me that this person needs a blood transfusion, they probably do so I will just 
prescribe it. whereas now I might challenge that I would not have challenged that 6, 7 
or 8 years ago so I know myself it is not a conversation that I have had with any of 
the registrars and so I have to say I don’t know what my response would be but I 
suspect it would be, like mine, initially you would do it and then maybe over time you 
sort of work out that not everybody needs a blood transfusion
Why do you think that that is the case?
Why do I think that not everybody need it?
No why do you think that it is different in oncology than haematology?
We have no transfusion teaching, we have a lot of anaemic patients we have a lot of 
patients who’s treatment makes them anaemic
But you could argue that haematology does as well
Yeh ...I know to a greater extent...absolutely, but..em..but transfusion medicine is a 
branch of haematology It is where I think haematologists know more about 
transfusion medicine than oncologists and therefore know more about actually know 
more about the risks and resource limitations and the appropriateness of selecting 
for blood transfusion. Oncologists use a lot of biood but have no training in when to 
transfuse, when not and why not, and yet I bet most of our registrars don’t have a
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199 single day of the week without transfusing a patient, you know I bet most of our
200 registrars prescribe blood every day of the week at least once if not more than once
201 and so I think a lot of oncologists use a lot of blood but have no training in it ...and
202 there has been, I suppose to be fair there are situations in oncology for example in
203 radiotherapy brain cell cancers where there is evidence that maintaining an adequate
204 haemoglobin helps tissue oxygenation and therefore improves delivery of treatment
205 and therefore improves outcome and ..em.. anecdotally I saw someone today who
206 was going to have their next cycle of chemotherapy and their haemoglobin was 9.7.
207 He obviously wasn’t particularly symptomatic from it..em..l told him he was mildly
208 anaemic but I wasn’t going to do anything about it...we will just keep an eye on it and
209 if it got much worse or we got a lot of symptoms he might need a blood transfusion
210 later but nothing to worry about now, it is a normal part of cancer and cancer
211 treatment. He then went off to see the radiotherapists who says we are going to give
212 him radical radiotherapy he can’t have a haemoglobin level of 9.7 we better get that
213 up by giving him 2 litres of blood .Try and get his haemoglobin to 12, and of
214 course..em.. there is evidence now in a number of cancers now that outcome is
215 better if you maintain the haemoglobin level around 12 grammes per decilitre
216 throughout treatment particularly with squamous cell cancers. I think that is fine I
217 think that is a research driven rational for transfusion which I think..
218
219 PI As opposed to a ...?
220
221 SL1 Well... up until a couple of weeks ago or ten days ago then you would say there is
222 good evidence to use to use erythropoietin to maintain haemoglobin in those
223 circumstances and ..em..with clinical benefit but now in the last week to ten days you
224 can say erythropoietin might be harmfui..em..and may impair survival outcome from
225 malignancy so I think the jury is still out on erythropoietin and ESA’s..em..but I think
226 that blood transfusion in order to maintain haemoglobin at a given level because
227 research has should that treatment is more likely to be successful in cancers it is
228 going to be better to maintain a haemoglobin. I think in that situation clearly you may
229 want to discuss costs and resources and like you do with any new drug intervention
230 where needs improve survival but at least that has a rational behind it whereas I
231 know myself and I really do think throughout a lot of oncology that the rational for
232 prescribing a blood transfusion is that the haemoglobin is a bit low on paper
233 and..em..you know and there is a wide held belief that the trigger is less than ten...I
234 think that is a wide held belief
235 PI
236 What about the impact on clinical guidelines?
237
238 SL1 Minimal
239
240 PI Why do you think that?
241
242 SL1 Because people don’t read them or don’t realise that they are there and they have
243 entrenched practice and so they work according to their habit and entrenched
244 practice and unless a new guideline or new rational Is widely, well not widely
245 publicised but repeatedly told so someone is aware of it I don’t think that will lead to a
246 change of practice I think maybe if a new guideline is emailed to everybody and
247 everyone is told it is available on the intranet these are the guidelines
248
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249 PI Oh course you could argue that every hospital has transfusion guidelines as we do
250 and with that we all do mandatory training so our guidelines are 8 currently or is it
251 because they are not evidence based or is there any other reasons why?
252
253 SL1 I am assuming that they are evidence based I don’t know that they are not. I suppose
254 I am aware of the guidelines because I go to mandatory training....but actually
255 mandatory training which you can rattle off in ten minutes on line doesn't...doesn’t
256 really address what you do now and is that correct and how could it be different and
257 er...its better than nothing but I have to be honest my main recollection of mandatory
258 training was about labelling the bottles correctly and storing them in the right place
259 and getting the blood from the right place as opposed to when to transfuse and why.
260
261 PI Going back to the culture of the clinic and the assessment of anaemia in clinic, do
262 you think there is things that could be changed or improved that might make you
263 think...
264
265 SL1 Yes I do.. I think that we could..if I talk about the non lung cancer patients as
266 opposed to ..I think actually it would not be difficult to have a basic anaemia
267 symptoms of anaemia assessment that maybe you had yourself, maybe you even
268 give It to the patient and ask them to monitor symptomatic response, which of these
269 symptoms do you have, comment 48 hours... 5 days a week, 10 days..I don’t know I
270 don’t think it would be that hard to do because we are all used to assessing toxicity
271 from and clinical benefit from chemotherapy so we give a clinical, we give a
272 therapeutic intervention, we see the patient a couple of weeks later and we assess
273 the benefit they have had from that both clinically and also the toxicity they have had
274 from that but yet we don’t do that with blood transfusions and actually it wouldn’t be
275 difficult to do....you’d have a set list of possible symptoms that someone might get
276 from anaemia and assess the clinical benefit from that and document that in a robust
277 and rigorous way....if there is a paper proforma trigger these are the questions, this
278 is the date of the transfusion, what is the assessment, then you might actually look at
279 this and use it as a tool I can quite easily imagine tools that might help I think lung
280 cancer patients that Is needed but what is a also needed for lung cancer patients is a
281 more robust assessment of breathlessness as a whole..em.. when lung cancer
282 patients are breathless a segment of anaemia comes in to what is required but it is
283 not the whole thing. I think it would be easy to do but I think it could be ..I guess what
284 it comes down to is that most of our clinics are very busy and who gets a blood
285 transfusion and who doesn’t is not something that is necessarily discussed with the
286 consultant ...whereas any chemotherapy change has to be discussed with the
287 consultant we don’t mandate that for blood transfusions...and so therefore I guess
288 the message that gives out is that this is a less important decision and so therefore
289 the registrars or clinical fellows don’t feel that they have to come and talk to us about
290 it they will make the decision and because they are not talking to us about it and
291 because we are not talking to them we are probably not educating on the job about
292 blood transfusion and I say that in as far as a oncology consultant can educate
293 about blood transfusion but I expect most of us have learnt some thing about over
294 the time and what I have said to you is that my use of blood has changed over the
295 years that I have been in oncology and it has reduced..em.. in that I am less likely to
296 transfuse now than I was before but actually I rarely have that conversation with my
297 juniors
298
306
299 PI Do you think it is seen as not important then?
300
301 SL1 I think it is seen as less dangerous than chemotherapy, and..em..yes I think it is seen
302 as less dangerous than chemotherapy so although talking now 1 am thinking we can
303 and probably do transfuse people who don’t need to have it or who maybe don’t
304 need to have a transfusion, the consequences of that seem potentially less
305 catastrophic than giving the wrong chemo or the wrong chemo dosage to the wrong
306 person, and I am not taking it lightly...but I guess we, on the wards allow SHO’s to
307 decide who needs a transfusion and not where we have never let a SHO decide who
308 gets chemotherapy or not...I think a lot of the transfusing happens without even my
309 knowing i.e. I see a patient I don’t have their blood results with me ...the blood results
310 are not back when I see the patient so..em...they go on a list to be checked later and
311 that never comes back to the consultant, that goes from the clinic
312 nurse/chemotherapy nurse directly to the clinical registrar who decides whether to
313 transfuse or not
314
315 PI Oh I didn’t know that
316
317 SL1 And so I will sometimes know that the patient I see is anaemic but I maybe won’t
318 even know that and some of that will go direct to the registrar
319
320 PI Going back to the assessor you mentioned males and females and that you didn’t
321 think that you looked at that particular area are there any other....
323
324 SL1 Well I guess it is true if I have a 6 foot 5 strapping bloke with a haemoglobin of 8.5
325 and a tiny little woman with a haemoglobin of 8.5 I am more likely to presume that
326 the great big bloke is going to be symptomatic at the same level of haemoglobin as
327 the tiny little woman is. So in my head I don’t have a cut off for males and a cut off for
328 females but I do think about size, sex and comorbidities when I am deciding to
329 transfuse
330
331 PI What skills and knowledge do you think a person needs to assess anaemia and to
332 decide to give blood transfusion and who do you think is best placed to do it?
333 Sorry I know that is two questions.
334
335 SL1 Ok that’s fine in terms of skills and knowledge..em..l think that the person who is
336 making the decision first of all needs to understand what are the potential causes of
337 anaemia and not to assume in outpatient care cohort that it is all because they have
338 got cancer and make sure that they have not had an acute drop in haemoglobin, that
339 they are not bleeding so we need to know what the causes are of anaemia and how
340 to assess for acute changes in haemoglobin and symptoms and signs of blood loss.
341 They need to have an understanding of what is likely to happen to that patient in the
342 future with or without a blood transfusion in terms of cancelling their treatment
343 because that may impact on the appropriateness of transfusion or not and I think you
344 should always have an understanding that blood is a limited resource and not
345 everyone with low haemoglobin needs to have a biood transfusion so I think we
346 should have some understanding of the symptoms of anaemia are and actually have
347 a written assessment and documentation of what those are so that if., .so that when
348 so that there is the possibility of assessing whether or not that the patient has
349 symptomatic benefit from it. Although before I had any mandatory training...when I
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last did mandatory training it’s the first training in blood transfusion that I recollect 
although it can't actually be the first training I’ve ever had in blood transfusion but I 
don't remember ever having had any other, but of course people need to understand 
the risks of blood transfusion but you wouldn’t prescribe any other treatment without 
considering the side effects of that treatment might be or what the risks might be
You’d look up the BNF to see what the risks are
Yes you would
But do you think junior doctors could rattle off all the risks of transfusion?
Probably not I doubt it 
And what the risks are?
I don’t think they’d be able to do that with any precision...I am not sure I can do that 
with precision...em..I think they would be able to, I think they would understand that 
the reasons for needing, to provide matched blood..em..to match blood and I think 
they would know., maybe an infection risk. I would assume they would know that 
blood donors are screened..em.. I don’t know exactly
Do you think they would know about the other things like TRALI?
No... no, I don’t because I don’t know if it forms a regular part of general education 
particularly
Just going back, to so ideally in an ideal world somebody would have all that 
knowledge, but going back to your clinic, what you are describing to me is that 
actually the person who makes that ultimate decision might not have even seen that 
patient.
Yes that’s true, I think that probably Is the case......
In some of the cases you don’t have the blood results that the chemo nurse goes 
back and asks the Reg..?
Yep em if the doctor that saw the patient is around ,if the consultant is around they 
will come back to the person that saw the patient, otherwise they may not and they 
may go to the Reg and....I’m trying to think when I was that Reg, and if somebody
came to me em then.. I don’t know, its sounds too horrific for words...I’m trying
to imagine if it could possibly happen....that the person who prescribes the blood 
never sets eyes on the patient..em..l think that does happen....! think it does
Going back to what you described blood as a limited resource.what do you mean by 
that?
I suppose what I mean by that is..em.... Well that biood is available through 
donation, and whilst there maybe biood banks but actually it is possible for them to 
run out of blood..em..you know biood is not manufactured in pharmacy....or you
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400 know by some pharma company it’s a donated product, and although there are a lot
401 of donors and there is and., er.. there is actually..hospital units only have a certain
402 amount of blood in store and the country has a certain amount of blood available and
403 if it’s overused there is a possibility for resources to become more limited or stretched
404 or for the blood to run out completely, so that is what I mean that it’s....
405
406 PI Do you think people think about that when prescribing blood or do they think about it
407 in the same way as you might think about an expensive drug?
408
409 SL1 I don’t know, I think it is... 1 do know that for example when I was a surgical house
410 officer and you have to cross match blood and it is your responsibility to match sure
411 blood is cross matched for patient X before they turn up for their operation and is it a
412 group and save? Do you cross match and how many units do you cross match? .1
413 really remember then being made very aware not to over cross match all the patients
414 who were going for surgery because it wasn’t necessary and because blood was
415 limited and it was a waste for example you would never cross match 8 units for
416 everybody..em..you wouldn’t cross match blood for some people at all and so I was
417 definitely aware that as a surgical trainee that blood was limited and that has stayed
418 with me a bit..em.. in oncology if I think, why do I sometimes not transfuse people?
419 So 1 have got someone who’s haemoglobin is 8.9 and they are a bit under the
420 weather, why do I not transfuse them? Is it because that is not the policy, is it
421 because the blood scarce and that is the policy, or is it because the risks outweigh
422 the potential benefits? I don’t think in my mind. I think it is because I am not
423 convinced they need it but i...so I do think that is one reason why I sometimes don’t
424 transfuse people, I think you shouldn’t transfuse everybody and they don’t all need it
425 anyway and but I don’t often think, but if someone has a haemoglobin between 8
426 and 9 I actually don’t believe that the risks outweigh the benefits. Now there may be
427 very good medical evidence to tell me that I am wrong but I don’t believe the risks
428 outweigh the benefits...em.. and I think the reason I think that is ..because when I do
429 transfuse people at that level some of them feel better and I rarely don’t, ...I don’t
430 see people being worse and it maybe that the side effects are rare, but if they are
431 and they get them they can be severe I suppose. But I rarely see people having or
432 knowing that they have had a transfusion reaction with a fever or a rigor but that has
433 been self-limited so I rarely see people having seriously sequelae from having a
434 blood transfusion...almost never... so I suppose in my mind ...so therefore I am
435 saying ..I don’t not transfuse because of the risk even though I know there can be
436 side effects from risks of transfusion I don’t think it is that that stops me...I think the
437 thing that stops me is either I know from that patient from past experience that they
438 are unlikely to get clinical benefit or that I am not convinced that they will get clinical
439 benefit at this stage and they don’t meet the guidelines any way... em.. and built into
440 that there maybe something about resource and the fact that the resource is scarce
441 and I don’t want to overuse blood for people who I am not convinced are particularly
442 symptomatic from their anaemia and therefore i think in my mind I wouldn’t waste
443 blood on someone who I wasn’t convinced was symptomatic so that would be an
444 issue more than the risk i think.
445
446
447 And do you have any thoughts about two unit transfusions
448
449 Yes I do my view on two unit transfusions are that....obviously we give two unit
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450 transfusions far more often than any other amount for I have no idea what reason, i
451 do know and this is historic when I was a medical SHO both general medical and in
452 oncology which I was in the same place we were told that we should never give a
453 one unit transfusion to anybody ever because there was never an indication for that
454 ...people needed two or three units or they didn’t need it at all...em..and most people
455 could get away with two because they would feel better enough with two so that was
456 a good amount to give. I remember once wanting to give somebody one unit of
457 blood and I may have been wrong but the rational had all packed out .The team
458 rational was, it was a patient who’s cardiac failure was very severe but they were
459 anaemic and we wanted them to have more than one unit of blood but we wanted to
460 give it very slowly so that we knew that overnight we probably wouldn’t give them
461 more than one unit and we might give a bit more after a bit of time and probably no
462 evidence for that either but we were told that unless we were giving him more and
463 more quickly he shouldn’t be having blood at all. So that is the teaching I had as a
464 junior, was there was never any indication for a single unit transfusion. Everybody
465 was given two units or more and most people felt better with two, so start with two
466 and see what happened...em..I don’t know whether other people had other specific
467 teaching but I do know that we managed to give two units transfusions. I do
468 sometimes give 3 units, I only give more than 3 if someone’s haemoglobin is 5 say or
469 less than 5
470
471 And why three sometimes?
472
473 Erm..erm I guess if someone’s haemoglobin is between 6 and 7 i ‘d probably
474 prescribe three units,I don’t know why I would. Two units wouldn’t feel like quite
475 enough. Desperately unscientific.
476
477 Going back to the benefits what do patients describe to you and ...
478
479 Some patients are very clear, it was like Lazarus I was resurrected it was amazing, I
480 felt so much better, everyone told me I looked better. I had so much more colour in
481 my cheeks...and the partner is sitting there and said they looked so much better it
482 was brilliant it was a miracle miracle....em...very quickly within a few hours 1 was a
483 new man. New woman it was fantastic....em..and sometimes you’d say how did you
484 feel afterwards? and they’d say dunno really., much the same really or are you
485 breathless? Yes and it is clear it has’nt made a very big difference. I would say
486 myself its only probably within the last 18 months- 2 years that I am rigorous about
487 asking those questions if I know somebody has had a blood transfusion and then
488 documenting those responses...em.. and it is really quite a recent think, you know
489 relatively recent thing that I have been rigorous about doing that..em..but yes some
490 patients I think benefit really well and sometimes people don’t’ and I think at the
491 moment I cannot predict necessarily in advance who that patient is going to be
492
493 And in hindsight can you think....
494
495 I sometimes wonder whether ....erm...sometimes in hindsight ok.. I mean It might be
496 different because we are looking at different patient groups for me I would say
497 sometimes in hindsight they have got terrible CPD and that was going to be such a
498 large component of their breathlessness that I was never going to make that better
499 by giving them two units of blood which more often than not would be exactly what
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500 they have had...and two units of biood was not going to take away 60 years of
501 smoking and dreadful emphysema...em..you know., in some of those patients it
502 does make an incremental difference and it makes there multi factorial
503 breathlessness more manageable
504
505
506 Do you ever think about where they are in their treatment or disease pathway?
507
508 Yes I do I was about to say
509
510 Or in relation to their cycles of chemotherapy
511
512 Err yes..em.. in terms of where they are ...I think that somebody who is
513 symptomatically anaemic with limited season early in their chemotherapy actually is
514 more likely to feel better because the reasons that they are tired and/or breathless
515 are more limited and anaemia is more likely to be a large part of that or a major part
516 of that. Where as some of my patients who are very near to the end of their disease
517 or to the end of their life particularly if ...I think the impact Is actually less
518 particularly...if they are only moderately anaemic as opposed to profoundly
519 anaemic I think the people who are profoundly anaemic which for me is few and far
520 between .Profoundly anaemic I think it usually does makes some degree of
521 difference. And people who have very advanced disease erm again every symptom
522 of which anaemia is a part is then again multi factorily caused and so I think treating
523 the anaemia is never a miracle or is rarely miraculous
524
525
526 And do you then consciously decide to not transfuse or is that a difficult decision in
527 oncology?
528
529 Em...rarely unless somebody is truly terminal or pre terminal so in the very last week
530 or couple of weeks of life but I think of someone in the last three months of life I don’t
531 think that on its own would stop me from transfusing I don’t know, and I guess it then
532 becomes a balance actually... hmm I think we do quite often say to people, I don’t
533 know that we are right. ..for example if we decide that they are not having any more
534 active chemotherapy treatment and so the treatment is supportive care and palliative
535 care measures but we can still do other things such as painkillers and blood
536 transfusion as though it is some kind of panacea you know “ don’t worry your not
537 having chemo but you can still have blood “ and it feels like a sort of..an intervention
538 and I think we sell it to the patients as such a bit .without necessarily always having
539 much fore thought about whether it will help . and I suppose I wouldn’t want
540 to....again I mind be wrong and it may be a lack of knowledge on my part but I am
541 not sure I would want to just decide that patients can have blood transfusions
542 because hopefully I have the knowledge and evidence that it might not palliate them,
543 but again it does come down to .if you do transfuse someone in an attempt to palliate
544 symptoms we ought to be much more robust at assessing a response to that
545 palliative intervention and therefore making a decision whether it is worth repeating
546 in the future or not, and I really don’t think we do that
547
548 What do you think could improve the treatment of anaemia?
549
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550 ! think what could improve the treatment of anaemia in oncology, is actually erm I am
551 quite sad I wont be there when you come into the clinic. I suppose you are there to
552 observe but I would quite like to have you there to teach almost and to challenge,
553 and to say” are you sure you’re going to give this blood transfusion and why” and I
554 think it would improve treatment of anaemia if we did have a .. if we., all of us in
555 oncology could stand a bit of education from a blood transfusion physician or a
556 haematologlst or someone who knows more about it than we do and to let us know
557 how you would approach this in haematology and I guess maybe a lymphoma
558 haematologlst or somebody who is not too many miles away from what we do but
559 also knows about transfusion medicine as well and to actually learn that approach or
560 to have someone challenge us and say “ but why are you transfusing this person
561 that’s against the guidelines " nobody ever challenges us. If any of us prescribes a
562 blood transfusion we are never told that contravenes guidelines ever....em..or at
563 least I never have been...so I think it is ... .and I doubt. ..so...
564
565 What sort of information would you want because....?
566
567 i’d want...first of all I would want to know is what somebody who knows more about
568 transfusion medicine than I do would do in the same situation. What would they do . I
569 suppose what I would want to know is what questions do you ask when you are
570 deciding whether to transfuse and how do you monitor response to that and what are
571 your triggers for someone who is anaemic who is on chemo or not on chemo and are
572 those different from each other and does the fact they are on chemotherapy make a
573 difference to the decision to transfuse? And should it or should it not and why or why
574 not? Em., and what would be the frequency of repeat? I don’t know., .how would you
575 assess responses is it symptoms alone or is it other laboratory measures or....?
576
577 What do you think our differences are the ?
578
579 My impression is probably that you transfuse less than we do. At the same level i
580 think the threshold for a haematologlst to transfuse ,1 think they would have a higher
581 threshold to transfuse so ie they wouldn’t transfuse for all indications that we
582 do....that is what I think is the difference. But I rarely ..rarely spend this much time
583 thinking about it, so in clinic I ask them a few questions very quickly and I’ll decide
584 whether to transfuse or not..and I might say to them have you had a transfusion
585 before, and also did it help?
586
587 What do you think about educating patients?
588
589 Going back to something we said ages ago. You asked whether patients expect a
590 blood transfusion if I tell them they are anaemic I do try and educate patients at that
591 point where I consider education to tell them that they don’t necessarily need a
592 transfusion or they don’t necessarily need intervention right now. I mean I guess
593 patients need to know what. I also wouldn’t like to think that somebody has been
594 struggling at home for weeks on end and is clearly profoundly anaemic and very
595 symptomatic and we didn’t know about it and we could have made them better very
596 simply or made them feel better simply with a transfusion if we had known, I think
597 patients need educated in both ways... this is what to look out for and we might need
598 to check your blood count but not everyone with anaemia needs a transfusion ail the
599 time. I guess they don’t need to know they need a blood transfusion every time.
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600
601 And what if you had more access to EPO?
602
603 Again if we disregard the latest concerning data that EPO may lead to worse to
604 malignancy outcomes possibly...if we disregard that completely..em.. if we had more
605 access to EPO I would have used it ...to maintain haemoglobin in patients having
606 undergoing cancer treatment on the basis that there is some evidence that doing that
607 leads to improved cancer outcome...and the other reason that I would use it if I had
608 access to it I mean clearly there are side effects of EPO and if someone does get
609 pure red cell aplasia...then that is a dreadful thing and they become life long
610 transfusion dependant and so that is a very significant risk and catastrophic for the
611 person if it does happen. Clearly it is not common but if it does happen it is
612 catastrophic. Having said that for most patients and chemotherapy units EPO
613 injections are far simpler and quicker than biood transfusions..so Yes.
614
615 Is there anything else you wish to add? Are there any burning issues?
616
617 No...I don’t think so...I can’t think of any. Is that OK?
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Appendix 15: Request to observe clinic (version 1) (on headed notepaper)
<insert Consultant details>
<lnsert Date>
Dear Dr
Re: Research study 
REC Number: 07/H0802/96 
Principal Investigator: Liz Bishop
There are several phases to the above research study. One of the phases is to 
undertake ethnographic observation study in six cancer clinics (3 lung cancer; 3 
haemato-oncology clinic) to identify the key elements, which clinicians and patients use 
to assess and treat cancer-related anaemia and explore the culture of transfusion 
practice. Both the observation and field notes will be undertaken by myself. Please see 
the attached fieldwork data collection sheet. No staff or patients will be identifiable on 
completion of the study and all data will be annonymised. If you agree to this you will be 
contacted via e-mail to confirm the date of the proposed observation and which of us will 
be attending your clinic. Results of this study will be made available to you at your 
request.
Thank you for consideration in participating in this study. Please do not hesitate to 
contact me should you require more information.
Yours sincerely,
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Appendix 16: Field note data collection sheet (version 1)
Date: Time clinic 
starts
Name of clinic Time clinic 
finishes
Doctors present 
(including grade)
Number of 
clinic rooms
Nurses present 
(Including grade)
Number of 
patients
Others present
Hb results of all 
patients
Consultation times 
recorded and grade 
of staff
Details of anaemic 
patients (Hb <8g/dl)
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Details of how 
patients are booked 
for Tx
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Field notes: (Codes: P=patient; D=Doctor; N=Nurse; C=Cierk) 
Time:
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Appendix 17: Haemato-oncology Out-patient Department
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Appendix 18: Sample of observation fieldwork data
3 clinics running concurrently
• Lung clinic (7 rooms)
• Palliative care clinic (1 room)
• Radiotherapy ciinic (2 rooms)
Other clinics (round the corner but shared waiting room and phlebotomy)
• Anticoagulant clinic
• Chest clinic
11 doctors in clinic
• 3 Lung Consultants (2 first day for one of them-one only there for half the clinic)
• 1 PC Consultant
• 1 RT Consultant
• 7SpR’s
Medical Staff for lung clinic
3 Consultants
4 SpR’s
Nurses
• 1 staff nurse (to run the clinic)
• 2 HCA (to assist with running the clinic)
• 2 Lung CNS
• 2 Lung research nurses
• 1 RT Nurse
Admin staff (at reception)
• 2 clerks (Lung/PC/RT clinic)
• 1 clerk (Anticoag clinic)
Cancer Information Centre
1 information officer
Patient Numbers Booked
• 9 patients RT (radiotherapy) clinic
• 8 patients PC (palliative care) clinic
• 37 patients for Lung Clinic
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1 0945 I arrive in the clinic at 0945. The clinic is due to start at 0950.
2 There are windows in the waiting room
3
4 The waiting room is already % full-a mixture of patients for the anticoagulant ciinic
5 and the lung clinic. There is a lot of noise. It is a mixed population; ethnically
6 diverse and ages vary but first impression is an elderly population. There are 3
7 patients in the doorway in the big hospital wheelchairs which are bulky and taking
8 up a lot of space in the entrance towards the clinic rooms
9 There is a ? confused/demented lady talking loudly to herself near the desk
10 The Cancer Information Office door is open but there is no-one there
11
12 Three clinic clerks are sitting at the desk
13
14 I go into the communal room
15 “Poor D” is there-he is the first doctor in clinic. I had been introduced to him when I
16 had a previous visit to the clinic as “Poor D”. He is a Medical Oncologist SpR. I
17 said good morning. He said the other doctors were still in the MDT. He said he
18 had seen the first patient already..another SpR came in. He started talking to her
19 about a patient who had not been prescribed GCSF and had become unwell-she
20 should have had GCSF. He asks her “shall we do an audit-it would be good..bet
21 there are lots of patients".
22
23 SN comes in and interrupts them-“can one of you see this patient (she is holding
24 the notes)..she is not very well..can she be seen by a doctor soon?” She hands the
25 notes the female SpR and walks out.
26
27 The RT nurse is on the phone talking loudly about a patient-describing her
28 symptoms. One of the lung CNS’s comes in with a set of casenotes, picks up the
29 phone and dials someone and starts speaking about a patient. One of the research
30 nurses comes in and sits at one of the PC’s and logs onto the EPR and looks up
31 blood results. The CNS and the Lung RN do not speak-everyone is busy-there is no
32 time for pleasantries-everyone is busy with their problems.
33
34 Another SpR comes in “I haven’t a hope in heH’’..she is talking about finding a clinic
35 room. What is more important is finding a room with a computer that is working
36 The Consultants walk in....he introduces the new Consultant and then she is
37 escorted to a room. There is also a visiting doctor with the senior Consultant. The
38 senior Consultant sees me and starts complaining about the room with the broken
39 computer..’’the computer department need to come and apologise to the patients”.
40 There are other discussions going on “lets see if there is a room here..is Dr X in
41 there?..no good..come on let’s go and have a look”
42
43 I walk out Into the corridor-it is narrow and winding and the scales and height
44 measurement device is in the corridor. Patients and family members are milling
45 about. Some are being escorted to Consulting Rooms-others are being weighed.
46 One of the doctors is asking a patient in the corridor “Did you get your letter?”
47
48 i walk into the waiting room-it is now full and some people are standing-1 do a head
49 count-there is now 77 people waiting. The confused noisy patient has gone-there
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50 are still 2 wheelchairs. Some are waiting at the desk-someone is asking the clinic
51 clerk about congestion charges. A doctor comes out into the waiting room and
52 shouts a patients name. A patient with four ? family members stand up and follow
53 the doctor towards the consulting rooms. I overhear a person saying ‘Tve not seen
54 10.30 it so busy here..standing room only..I only came up for a blood test”. I leave the
55 waiting room and go back down the corridor..I can overhear conversations “not
56 even Carbo-etoposide” and another doctor can be heard doing a dictation in the
57 first clinic room. She has scans up on the PC. There are other conversations
58 between another doctor and the staff nurse “can you give someone an inhaler?
59 She has just started chemotherapy..she just needs a quick script
60
61 I then go into a clinic room with a new patient and the SPR and the Lung CNS. The
62 doctor makes the introductions-l explain I am just observing. She is 77 years old
63 and with her daughter in law. She looks very well. The doctor asks her when she
64 saw the surgeons and what did they say to her. She said she had a lot of pain and
65 rubbed across her chest where she had felt the pain..”it is still there-l can’t wear my
66 usual bras..I have got to wear my old ones”. What did the surgeon explain to you
67 asked the doctor. The patient said “he said he could get rid of the fluid..and the
68 pain would get better but I still have the pain...he wasn’t very nice..he said I had the
69 cancer but not much.. .surgeons are a funny bunch.”
71 The SpR then explained it was lung cancer and it was a solid lump on the right side
72 but it also was on the other lung, which was why there was fluid on her lung.
73 The SpR and CNS then start talking about the CT scan-its not on PACS because it
74 was done elsewhere.
75 The patient says “I have lots of questions”
76 The doctor wants to know more
77 “1 have patches for the pain”..Were these given by your GP?”
78 The patient talks continuously..”l wasn’t very well and he gave me some painkillers.
79 My doctor said ..you shouldn’t be in pain..That’s what we said..we said we would
80 ask all the questions today because they (the surgeons) didn’t say very much..it’s
81 cancer they said..it was a shock. So why is the pain still there..that’s what I want to
82 know..
83 The doctor asks about the painkillers and the patient continues talking whilst
84 rummaging in her handbag for the list of tablets she is on..she hands a piece of
85 paper to the SpR. He examines it and asks her if she is still taking the co-dodamol
86 because she shouldn’t be if she is also taking the paracetamol because they both
87 have paracetamol in them. The doctor explains to the patient that she shouldn’t be
88 in pain and he tells her “we can sort that out today as well”. He goes onto explain
89 the reason for her pain that it is pleurisy which just means inflammation and he
90 draws her a picture of her lungs explaining that they are in a casing and every time
91 she breathes in and out they are rubbing and this is why you are getting the
92 pain...He also draws her a picture of where the cancer is-that it has been on both
93 sides of the chest and caused some fluid to accumulates. The CNS and SpR talk
94 about trying to get the scans again..
95
96 “This isn’t good” says the patient. The SpR states that they have seen the scans in
97 the MDT ..and discussed them but that we haven’t physically got them or the
98 written report. They return to a discussion about the operation. The SpR states the
99 first part of the operation was to have a look and suck some of the fluid out..The
100 patient interrupt again-“Can’t they cut it out?”
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101
102 The SpR shakes his head...’’what we know is that you have a primary lung cancer
103 and it has spread into the pleura-cutting out the primary tumour won’t cure the
104 cancer..cancer starts with one abnormal cell then doubles to 2 cells..then 4..then
105 8..then 16..but not very quickly..your type is slow growing..but we can treat it with
106 chemotherapy..”
107
108 “Why have I still got the pain?..my breathing is alright..that’s what I can’t
109 understand.”
110
111 “You still have the whole of one and half of the other.. .what would you be doing
112 now if you weren’t in the clinic..do you go out..do you still go to the shops..do you
113 go out shopping or do you need a lift?
114
115 “Yes..I go out a lot..no..I walk,.I do a lot of hoovering”
116
117 It sounds like you could cope with chemotherapy..
118
119 What does this involve?..will I lose my hair..”
120
121 The SpR and CNS explain the chemotherapy regime and how often the patient has
122 to come to hospitaL.they also stop and talk to each other...confirming the day of
123 treatment and how many courses they think she will have..whilst they are doing this
124 and explaining to the patient the daughter writes the probable dates in her diary.
125 The patient and daughter sometimes get it wrong and appear confused but the SpR
126 reassures them..explainlng that it is quite complicated and that they will write it all
127 down for them.
128
129 The patient asks “What Is the success rate?” and the doctor explains that “we have
130 to hope it takes the pain away and improves your symptoms..we also want to
131 increase your quality of life and for longer..but we won’t know what until we have
132 given you your first few doses and check the CT again..we can get good
133 results..and you are fit and well to start with..”
134
135 The patient asks “would you carry on after 4 lots?” and the response is “most
136 people don’t cope with too much..the patient looks disappointed but not tearful.
137 She says that some people have told he they can have tablets..”if I had a tablet I
138 wouldn’t need to come up?...I get a lot of indigestion..I get confused..some with
139 food..she gets the list out again and the SpR looks at it..he points at the list and
140 says she can take two of those (for her indigestion)..’’we’re not doctors..we don’t
141 know..”
142
143 The SpR tries to cheer her up..you are still hovering? You look very well..apart
144 form the glaucoma you have been well..we think you will be able to cope with
145 chemotherapy. The CNS and SpR taik together again-reassuring each other
146 throughout their discussion, muttering in low voices about the stage..T4 and Ml..
147 The SpR tells the patient he is going to get his boss-“the guvner” to come and see
148 her. (all new patients see the Consultant)
149
150 Whilst he is out of the room the CNS sits next to the patient and takes her hand.
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151 She also opens the patient booklet she has in her hand and shows it to the patient.
152 (The team use the Roy Castle Charity patient information leaflet because it has
153 space to write the specific diagnosis, stage and team etc-). The patient asks the
154 nurse when the treatment will start-she is told it will be within a fortnight-she also
155 asks if she can have a drink whilst she Is having therapy as she likes a “Scotch of
156 an evening”. The CNS also informs her she will have another CT scan as it has
157 been some time since her first scan and they will want to repeat it before she has
158 therapy to provide a baseline. The patient didn’t look very happy about this and
159 explained that she didn’t like the scanner and found it claustrophobic. The patient
160 also asks what will happen if she doesn’t have any treatment. The CNS answers
161 honestly and informs the patient it will spread..but turns the conversation Into the
162 advantages of chemotherapy..for example it works on the whole body therefore
163 may prevent it spreading. The conversation is interrupted by the Consultant
164 coming back into the room with his visiting doctor and the original SpR..
165
166 Introductions are made and the Consultant sits down closely to the patient. He
167 controls the conversation-the overall impression is serious, very polite but
168 confident. It is very controlled and unlike the SpR and CNS conversation he does
169 all the talking and does not allow them to interrupt. If they do he stops them politely
170 and states he will cover that in a minute. He informs them very clearly that “we
171 cannot cure this disease..you haven’t got a lot of cancer but it can’t be surgery”
172
173 Again the patient asks how long she has got. He explains he cannot be definite but
174 approximately a year-he explains some people go on for a lot longer and others do
175 not. He explains that in some people it can prolong life ..by 3 months..it is designed
176 to improve symptoms and make you feel better. They repeat again the
178 conversation around what she can do..can she leave the house and again she
179 mentions her pain. He states there are “no prizes for grinning and bearing it” and
180 that the pain relief can be increased ..the patient asks about radiotherapy but she is
181 told “lets not go there too much information”. He states his goodbyes and shakes
182 their hands and wishes them the best and leaves the room with the other two
183 doctors.
184
185 Again the patient looks a bit shocked..she shrugs her shoulders and looks at us and
186 says ’’You can’t live forever..” The CNS reminds the patient that the Consultant was
187 talking about the average patient and that some patients do very well-The patient
188 started asking about hair loss and she is reassured the treatment will not cause hair
189 loss,
190
191 The SpR comes back in and yet again there is movement around the desk. It is like
192 musical chairs. The patient is distressed-she is fidgeting and is repeating hersif
193 about the hair loss. The SpR sits down again and explains the other side effects -
194 he explains that taking chemotherapy is not like taking penicillin and side effects
195 include things like becoming anaemic and risk of infection. It Is explained that she
196 will be given another week to read all of the information and return to clinic the
197 following week to ask any further questions and make a final decision regarding
198 treatment. He also explains that he will give her something else for the pain and he
199 writes another prescription for her. He spends some time explaining that he will not
200 increase the dose of the patch as this would give her a “funny head”. Eventually he
201 and myself leave the room as I want to allow the patient sometime with the CNS in
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202 case she is upset.
203
204
205 I return to the communal room-the other CNS is on the phone about another patient
206 -1 hear her saying she is worried about him and she wants the palliative care team
207 to see him-she is saying he is non-compliant, he is not well and he has
208 haemoptysis. A research nurse is looking up patient laboratory results on one of
209 the computers. The new Consultant comes in and picks up another set of
210 casenotes-the casenotes are in a note trolley in order to be seen-there are about 8
211 sets of notes waiting. I ask the Consultant if he tries to see the same patients each
212 time. He states they don’t. I ask him if he thinks it would be more efficient and
213 improve continuity of care if the patient mostly saw the same doctor at each visit.
214 He disagrees, saying it’s probably not possible and the patient benefits from seeing
215 different doctors with different skills. I disagree and explain it may be easier to see
216 the subtle changes in patients and although difficult to ensure seeing the same
217 doctor each time -  maybe it would be possible 70% of the time. He shakes his
218 head and he is not keen for this continuity. I wonder if it is related to the size of
219 these massive clinics and/or the poor prognosis of the patients or if it is the culture
220 to see different patients in oncology.
221
222 The SpR comes into the communal room again. He feels he did not do a good job
223 informing the patient about her lung cancer and treatment. I say I am sure he did.
224 He said he should be able to do it like the Consultant and I get the impression he
225 wanted to be able to deliver the message quicker and more efficiently. He also
226 asks me about giving a patient some platelets. I ask him what the patient’s platelet
227 count is. The patient’s platelet count is 15 x 10^ 9/1. I explain our guidelines.
228 Patients should have platelets if their count is less than 10 or if the patient is unwell
229 with a fever or actively bleeding then they should be administered if between 10
230 and 20. We establish the patient is not and I ask him when she is due
231 chemotherapy. He explains it is the following week and I suggest that probably her
232 count is on its way up and he will find it recovers on it’s own. He agrees and
233 decides not to give a platelet transfusion.
234
235 I observe more communications in the corridor-patients are still being shepherded
236 through to be weighed and then returned to their seats. One of the patients is a bit
237 shaken and doesn’t look very well-there are 2 healthcare assistants with her and
238 they are guiding her into one of the Consulting rooms as she appears to have
239 soiied herself in the toilet. I hear the staff nurse saying to them that she will speak
240 to the Site Nurse Practitioner to arrange a bed to be booked. There is also a foul
241 smell throughout the clinic-it is because there is a palliative care patient with
242 fungating lungs and the Palliative Care Consultant has been with him and his family
243 in a room for over an hour and it is pervading the clinic area. One of the HCA’s is
244 spraying air freshener.
245
246 I go into another consulting room with another patient about to be seen. Another
247 SpR is seeing this patient. He has small cell lung cancer with bone métastasés.
248 He has had 2 cycles of chemotherapy (Carboplatin/Etoposide). The SpR asks how
249 he has been. He says he is feeling better and states “I guess it’s working”. He also
250 informs the doctor he has put on 4 kg and that his appetite is better and that he is
251 eating properly. The doctor asks about his hair-its not falling out. The doctor
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252 confirms what the patient believes in that it is a good sign that the patient is feeling
253 better. They have a discussion about the CT scan that the patient should have had
254 the week before-the patient did not receive an appointment letter but on further
255 examination it is revealed the patient’s address has changed and he had not
256 informed the hospital. The doctor re-books one on the computer and
257 simultaneously calls the CT scanning department to book a scan. She writes the
258 appointment down for him on his appointment card. They confirm the next
259 appointment date for chemotherapy and the patient leaves
260
261 The impression of the clinic is that it is busy and there is a lot of movement and
262 discussions In different places-for example-patients have their first encounter at the
263 booking in desk and then they take a ticket (like a delicatessen ticket) for the blood
264 test queue. They then sit in the crowded waiting room for a long time waiting to be
265 called In by the doctor. The Cancer Information Room is in the corner of the waiting
266 room but no-one seems to want to go in. Maybe they are afraid they will lose their
267 seat. It is not very inviting-its name is on the glass window-but it is not easy to see
268 what it is or what it is there for. Also if you were to go in other patients would see
269 you-and what would that be like if you started to cry and the waiting room full of
270 people could see you. It is a bit like a gold fish bowl.
271
272 In addition, there is an anticoagulation clinic running alongside the cancer clinic
273 which probably does not help the patients relax. It is a chaotic environment with
274 several clinics running at the same time-staff coming and going, names being
275 shouted out. Perhaps patients are afraid they will miss their turn. The clinic clerks
276 are busy at their computers, booking patients in and out, occasionally there is a
277 small queue at the desk (3 or 4 people) and how do the patients know which clerk
278 to go to (one is for the anti-coagulant clinic) if it is there first time visiting the clinic.
279
280 The phlebotomy area is behind the desk-you go in a separate door. There are 3
281 phlebotomists-two for the anticoagulant clinlc-the other is for the lung clinic and
282 chest clinic. There are two systems for calling patients through to phlebotomy-
283 anticoagulant patients have their names called and the other clinic patients take a
284 delicatessen type ticket and wait for their number to be called out. There is no way
285 for the patients to understand this unless they have been there before. I hear the
286 clerks repeating the systems to new patients. There are 2 white boards on display
287 to inform patients. The waiting time is displayed on the oncology board but the
288 anticoagulant board is 3 days out of date. The anticoagulant board Is scruffy and
289 has been written with a dry pen so can’t be seen unless quite close. The oncology
290 board is neat.
291
292 The doctors and CNSs appear quite stressed -  as if they have a lot on their minds.
293 They have to move from one situation or conversation to another quickly-
294 sometimes on the telephone, sometimes in clinic rooms or the corridor. They are
295 ail working hard. A lot of time is taken up with process and system management
296 rather than discussing cases or research or discussion about individual patients.
297 Perhaps this clinic has been busier than normal-also the technical issue of one of
298 the precious clinic rooms being unavailable (no computer) seems to be having a
299 very negative impact. There is no lunch break-the clinic runs until 3pm. There is
300 biscuits and drinks and the usual tray of fruit which is provided by the Trust for all
301 oncology areas which is laid out in the communal room. People eat on the hoof but
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302 don’t seem to expect anything else. However, the atmosphere is good-people are
303 friendly and smiling. There is laughing and joking-in spite of the difficult and
304 complicated environment.
305
306 Clinic finishes at 3.30pm
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Appendix 19: Componential analysis
Early Themes Componential analysis Evidence
The impact of the haemoglobin The Hb was the primary determinant for diagnosis and 
management of anaemia for 
patients and clinicians
The Hb seemed to be equally 
important in haematology and 
oncology, however,
haematology use a lower 
transfusion trigger of 8g/dl and 
oncology had a tendency to 
discuss using a higher trigger of 
10g/dl.
We know they are anaemic already, because 
we have got a blood count In front of them so I 
am not at all good at assessing for that sort of 
thlng..(SH2;131)
I suppose obviously you look at the blood 
results and If someone’s haemoglobin Is less 
than 8 and then you are thinking about them 
being anaemic (SH5;3)
“ Its very mechanical you know Its below 10” 
Its not It’s not a holistic overview of how 
outpatient Is feeling .It was just...Rlght ok If It Is 
below 10....(SL5;444)
Separating the 
symptoms The problem of separating symptoms of anaemia from 
symptoms of their disease and 
side effects of chemotherapy.
The impact of breathlessness in 
lung cancer patients and the 
difficulty of separating this from 
symptoms of anaemia.
Related to experience, skills and 
knowledge of the HOP- the day 
unit nurses see the patient as a 
whole
Related to uncertainty
Its not going to be just the fact that they are 
anaemlc..they have so many other symptoms 
so dealing with that more than just saying your 
haemoglobin Is 8.5...you will feel so much 
better after two units of blood..and often they 
don’t...(SH4;244)
non- cancer related anaemia may not be as 
symptomatic because they are not receiving 
cytotoxics. (SH5;45)
I suppose the most common things are, the 
tiredness, the fatigue which again Is a tricky 
one because It could be cancer-related fatigue 
and chemo-related fatigue that we talk about 
.again It may not be associated with the 
anaemia (SH5;65)
.. I would normally say ...are you any more 
tired than normai.are you any more breathless 
than normal and If I think they might be then I 
would perhaps go Into some more detail about 
that to try to determine If they had a 
symptomatic anaemia as opposed to 
symptoms of their disease....and of course 
symptoms of disease can be very much 
overlapping with symptoms of 
anaemla..(SL1 ;27)
If you ask most patients are you tired-the 
answers yes because they’ve got cancer and 
maybe because they’re anaemic...so I am 
sure If I was to ask most of the non-anaemic 
patients If they are tired..the answers yes. 
(SL1;67)
The disease..In most cases people that are 
really fatigued It has got a lot to do with the 
disease and the type of cancer that they have 
got (SL4;295)“Knowing’
patient the Seeing patterns and changes over time; having a relationship 
with the patient. Related to 
experience of the clinician 
and/or nurse and who has the
.and normally when I worked on the day unit, 
the nursing staff would tell me because they 
knew the patients a lot better than me and they 
knew how likely they were to be 
symptomatic..how quickly they would come
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opportunity or patient contact to 
make the assessment and 
decision.
Access to all the information-the 
haemoglobin and the patient
Decisions made in absence of 
patient is acceptable, however 
acknowledges knowledge and 
relationship with the patient is 
important
back, whether they could wait, in their opinion 
for another day and manage without blood.. 
.(SH2;479)
..obviously nurses can’t prescribe blood so at 
the end of the day you have to get a doctor, a 
doctor has to prescribe It but.ehm... I think 
from a time point of view and knowing a patient 
on an Individual basis It’s more of a nurse... in 
my opinion a nurse could do more effectively 
perhaps.. (SH5; 106)
But when you have a key person liaising with 
the patient and working with the patient. It Is 
quite easy to put "your finger on the pulse’’and 
decide whether to transfuse or not because 
you know your patient better and you can get 
the facts for your assessment quite easily 
(SH9;479)
Yes some take more part, some get more 
involved in how i feel when... erm...do I feel 
symptomatic more..what do I thlnk.they listen 
and we talk (PH1;186)Contextualizinganaemia Acknowledgement of the patient treatment and disease pathway
Importance of not assessing the 
Hb in isolation
Holistic assessment
take Into account where they are in their 
treatment, their disease status, their 
age...(SH4;89)
If you have got someone who you know Is 
recovering their counts from chemotherapy but 
their haemoglobin Is maybe lagging a little bit 
behind..! would often try and not transfuse 
them because you know that the bone marrow 
Is beginning to work again (SH4; 187)
..but you can usually tell the patients up front 
who are going to need blood because they are 
usually the patients with heavy disease bulk or 
bone marrow infiltration and with those 
patients I usually say, look It Is very likely that 
you are going to need blood so they are 
prepared so that It’s not sprung on them 
(SH5;225)
I got those patients that are known to me, I 
know what they were like at diagnosis..and It Is 
kind of, you are wanting to Improve their 
quality of Hfe...erm without ..I ‘d be looking at 
their performance status ..how well they are, 
how well they would be to come up here, what 
stage of their disease they are....if they are 
very palliative, what we are going to achieve 
by that If they have been feeling that way 
throughout because of their disease or 
symptoms arising from their dlsease..(SL5;93) 
...but often you can..sometlmes you can tie It 
to what’s happened to the haemoglobin over 
time..and see In fact they’ve been tired for 
ages and they’ve only become anaemic since 
you started chemotherapy and they are no 
more tired than before..so that’s not the 
anaemia (SL1;72)
So in my head I don’t have a cut off for males 
and a cut off for females but I do think about 
size, sex and comorbidities when I am 
deciding to transfuse (SL1;323)
Oh yes definitely...! can predict yes...even
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when.... erm...when the chemo is finished., if I 
start a five days of chemo, on the fifth day I will 
know already that I am going to need blood.... 
It Is predictable... and then after two days 
again and until my neutrophils drop..then I feel 
tired and need blood..until they all get higher 
again...(PH1;60)Uncertainty Lack of clarity in diagnosis; 
Indeterminacy; Hesitancy; no 
definitive treatment; lack of 
clarity in knowing the 
effectiveness of the treatment 
(the blood transfusion). The 
uncertainty exists at a level of 
haemoglobin (mild or moderate 
anaemia). Further analysis is 
required to explore if in the 
presence of severe anaemia 
there is less uncertainty.
,./ just cant remember a time when I was 
saying” I definitely think this person needs a 
transfusion " (SH2;515)
So..alot of time the Registrar on the day unit 
may say their haemoglobin Is 8.9 we’ll 
transfuse them..0K..lf you ran that sample 
again It could just as easily be 9.2 (SH4;123) 
most of the time..they are very vague..very 
vague descriptions really...just feeling more 
energy or just feeling a bit better but Is that a 
change due to transfusion or due to something 
else that Is going on otherwise with them..lt Is 
very difficult to say (SH4; 156)
It’s an Individual thing, definitely. I don’t think 
there Is a level for anyone (SH2;42)__________Balancing the risks and the 
benefits
Recognition that there may be 
benefits. Knowledge of risks, 
but benefits outweighing the 
risks. Not all patients benefited. 
Immediacy of treatment. Belief 
that there was no harm in giving 
blood
..In fact so there Is not very good continuity In 
assessment of response to blood transfusions 
I think something In which we should and could 
improve but we don’t robustly assess response 
[  ]..we have no robust mechanism of 
assessing response of a transfusion which 
means that there Is a risk and I am sure It 
happens that people do get repeat 
transfusions who are not necessarily benefiting 
from them. (SL1;130)
If It Is end stage and they are dying then If the 
haemoglobin keeps dropping then there Is not 
going to be any benefits In keep giving them 
blood transfusions, but end stage, but god If 
they have still got six months but If they are In 
the last month or I can’t see much point to be 
honest (SL4;660)
No ..I mean unless someone Is physically very 
short of breath In front of you or very pale or 
whatever, and If they are not really describing 
their benefit it Is often hard to say that there 
has been a benefit (SH5;143) 
because when I do transfuse people at that 
level some of them feel better and I rarely 
don’t, ...I don’t see people being worse and It 
maybe that the side effects are rare (SL1;424) 
Yes either a third to 50 (benefit from blood 
transfusion) (SL4; 176)
erm.. the ones with the worst performance 
status It Is more difficult to determine, or that Is 
my experience anyway, as to whether It has 
been a benefit to them. (SL5;219)
Yes of course, I do worry about It you think 
about In the future I could develop another kind 
of Illness llke...erm...hepatltls so obviously I do 
worry. (PH1;78)
In my situation right now because of the 
leukemia and because of the chemo and how 
It reacts for me and for me and how It makes
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me feeI.J need the blood.Jor me now it’s very 
pood (PH1;83)Living with 
anaemia (fatigue and other symptoms)
Patients tolerate symptoms of 
anaemia. Anaemia Is not 
serious; Healthcare
professionals assume patients 
to tolerate a level of 
symptomology; not all symptoms 
or side effects can be treated
Linked to the frequency of mild 
or moderate anaemia in the 
clinical setting
Oh it Is low , I think nausea and vomiting and 
neutropenia and things like that are much 
higher up the scale .that would be the bottom 
one ..mm.m (SL4;596)
So with these patients It Is not Ideal, It Is very 
difficult I think for them and I think that is 
probably why a lot of them don’t shout out 
about their symptoms because they know that 
they are going to have to go through all of that 
on top of this (SL5;508)
At no point does he ask the patient if he Is tired 
or how he Is feeling or any assessment of the 
Impact of his anaemia (H. 11.3.08;47)
I feel fatigue / just want to like., .erm... get
some rest, everything that I do, I do very 
slowly. Simple things like washing the dishes 
take longer for me, because I feel very 
fatigued. (PH1;4)
I don't sleep well...I ] l don’t sleep very well 
during the night. I haven’t slept well since I had 
the leukaemia (PH1;10)
It Is just that, when people put things In an 
order of Importance that they could shift 
anaemia a little bit down their priority list, 
because they are coping with It until they come 
up to a point that they can no longer shift It 
down the priority list (SH9;90)
..well over a quarter of the human race Is 
suffering from anaemia at any given time. So I 
think it Is a big problem, but because of the 
way that It affects Individuals, people adjust to 
the symptoms, people adjust to their way of 
life. . That they only come up to seek help for 
severe health and medical help when it Is 
really very, very severe. (SH9;74)
She has to work, she has to go to college, and 
It came to a point that she could no longer do 
her college work and that is when she decided 
to come ln...(SH9; 58)
If one’s got a patient who Is on chemotherapy 
and Is one of the regular patients then I am 
much less searching about their symptoms, 
partly because there Is a sort of set 
pattern.... (SH1;30)
Traditions The importance of “what has 
always happened in practice”
Anaemia is common. Blood is 
ubiquitous
Change of practice over time as 
experience is gained-not by 
evidence or guidelines
“Word of mouth”
....two units of blood is what we always 
transfuse..I know I always thought earlier In my 
career ..I always thought one unit of blood 
won’t do anything but It will raise your 
haemoglobin by a gram...(SH4; 199)
It was always just automatically two units and 
no-one really ever you know..I was always told 
one unit won’t really do anything so what was 
the point in giving lt.(SH4; 235)
That Is what I was told when I came, by the 
registrar on the ward and so on...(SH2;441) 
..and I think also doctors are more reluctant to 
prescribe whereby initially when I think back 
years ago when your haemoglobin was 9...9.5
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you know you could have a couple of units of 
blood and it was prescribed wllly-nllly... “ so 
yes there has been a huge change In practice 
(SH5;154)
The reason that we tend to give two at a time 
I am sure Is affected by practicalities and 
habits as It Is by logic (SH1;171)
I am much less enthusiastic about transfusing 
them up to a target haemoglobin than I used to 
be If they are comfortable with their lower 
haemoglobin ...that Is probably the biggest 
change.(SH1;183)
I haven’t a clue ..I would suspect that they are 
better at that now than they were, you know In 
the olden days you used to throw blood 
around... (SH1;269)
Well nobody has trained me since I was at 
medical schooL.I probably should have been 
(SH1;312)
I would have thought that anyone In a hospital 
who Is using a significant amount of blood 
should be updated because It Is..you know that 
Is actually Interesting Isn’t It because other 
therapies you get updated In but bloods been 
around a long time you know you just use I t ... 
(SH1;318)
..and I really do think throughout a lot of 
oncology that the rational for prescribing a 
blood transfusion Is that the haemoglobin Is a 
bit low on paper and..em..you know and there 
is a wide held belief that the trigger Is less than 
ten...I think that Is a wide held belief (SL 1;230) 
obviously we give two unit transfusions far 
more often than any other amount for I have 
no Idea what reason. I do know and this Is 
historic when I was a medical SHO both 
general medical and In oncology which I was In 
the same place we were told that we should 
never give a one unit transfusion to anybody 
ever because there was never an Indication for 
that ...people needed two or three units or they 
didn’t need It at all... (SL 1;445)
(Who taught you a trigger of 10) I don’t 
know, It has just been a standard practice, I 
don’t know If that Is related to the radiotherapy 
because that Is what they come back to look at 
anything below 10, yes It Is not one particular 
person (SL4;344)
you know that Is actually Interesting Isn’t it 
because other therapies you get updated In 
but bloods been around a long time you know 
you just use It ...(SH1;319)
Internal and Current practice in the clinicalexternal setting as a major Influence;
Influences personal attitudes; impact of
unique clinical environment; lack 
of impact of mandatory training 
in transfusion; impact of 
erythropoietin research; lack of
Erm ..I don’t think we are meant to but 
certainly at my last hospital we would. If 
somebody was about to be discharged we 
would transfuse them up to a higher 
haemoglobin (SH2;55)
Yeh... I suppose that Is what they are used 
to...just different trusts they have different 
ways of doing things (SH4;106)_____________
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education
The impact of different
institutions-staff base decisions 
on the practice within the 
particular institution or 
department-staff very quickly 
accepting of local practice. Non 
questioning.
Socialization of practice
The Impact of resource
availability
/ mean I was taught here to look at the 10, but 
whereas before I probably wouldn't have 
worried til about 9 (SL4;356)
All the things you are saying about what the 
triggers to transfusion and when you should 
transfusing are ../ don’t think that Is clear I 
don’t think we have particular training...all we 
know Is on the ward Is when someone’s 
haemoglobin drops below 8 you should 
transfuse and that’s what the SHO’s know but 
more formal training we haven’t had I don’t 
know whether It Is ..(SH2;423)
... I know because the manufactures of 
erythropoietin have banged this Into us over 
the years that patients feel better If they are 
on erythropoietin and they have got high
haemoglobins and that’s very good..
erm...(SH1;92)
so., there Is clearly a body of very old scientific 
evidence to show that getting your
haemoglobin level above ten doesn’t really 
help you terribly very much . (SH1;113)
Well nobody has trained me since I was at 
medical school..I probably should have been 
(SH1;312)
Somebody who has been doing this job for 
years Is telling me that this person needs a 
blood transfusion, they probably do so I will 
just prescribe It. whereas now I might
challenge that I would not have challenged that 
6, 7 or 8 years ago so I know myself It Is not a 
conversation that I have had with any of the 
registrars and so I have to say I don’t know 
what my response would be but I suspect It 
would be, like mine. Initially you would do It 
and then maybe over time you sort of work out 
that not everybody needs a blood transfusion 
(SL1;169)
..em.. there Is evidence now In a number of 
cancers now that outcome is better if you 
maintain the haemoglobin level around 12 
grammes per decilitre throughout treatment 
particularly with squamous cell cancers. I think 
that is fine I think that Is a research driven 
rational for transfusion which I thlnk..(SL1;213) 
,.em..wlth clinical benefit but now In the last 
week to ten days you can say erythropoietin 
might be harmfuh.em..and may impair survival 
outcome from malignancy so I think the jury Is 
still out on erythropoietin and ESA’s..em..but I 
think that blood transfusion In order to maintain 
haemoglobin at a given level because 
research has should that treatment Is more 
likely to be successful In cancers It Is going to 
be better to maintain a haemoglobin. 
(SL1;222)
my main recollection of mandatory training was 
about labelling the bottles correctly and storing 
them In the right place and getting the blood 
from the right place as opposed to when to 
transfuse and why. (SL1;2S6) ______________
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/ would quite like to have you there to teach 
almost and to challenge, and to say" are you 
sure you’re going to give this blood transfusion 
and why’’ and I think It would Improve 
treatment of anaemia If we did have a .. If we., 
all of us In oncology could stand a bit of 
education from a blood transfusion physician 
or a haematologlst or someone who knows 
more about It than we do and to let us know 
how you would approach this In haematology 
(SL1;547)
I mean honestly I wouldn’t want It, I mean I 
know It Is checked and everything but still the 
thought of having someone else’s blood In 
your body (SL4;318)_______________________Anaemia and 
blood
transfusion is not important
In comparison to the impact of 
the diagnosis and side effects of 
cancer therapy; the 
chemotherapy is more 
important; decisions made In 
absentia of patient
Linked to the frequency of mild 
and moderate anaemia in the 
clinical setting.
Blood transfusion is ubiquitous
The patient explains that he gets the blood 
results from the nurse anyway..and he doesn’t 
think the GP even looks at it. (H. 11.3.08;91) 
Possibly, whether they are just not thinking 
about It or think they are doing the nurse a 
favour by just prescribing the blood, yes.. It 
could be any of those things but they haven’t 
thought enough about It ...they haven’t had a 
scare... (SH5;355)
Just blood being prescribed by a registrar as a 
favour to a nurse for a patient that they have 
never seen and they know nothing about and it 
Is quite frightening and it happens and I see it 
happening most weeks, and that Is something 
that needs to be addressed (SH5;397)
I know that medical students get an appalling 
lack of education about blood transfusion 
these days (SH1;326)
I am treating It as a given ,lt Is something they 
learn by osmosis, (SH1;336)
I guess what It comes down to Is that most of 
our clinics are very busy and who gets a blood 
transfusion and who doesn’t Is not something 
that Is necessarily discussed with the 
consultant ...whereas any chemotherapy 
change has to be discussed with the 
consultant we don’t mandate that for blood 
transfusions...and so therefore I guess the 
message that gives out Is that this Is a less 
Important decision and so therefore the 
registrars or clinical fellows don’t feel that they 
have to come and talk to us about It they will 
make the decision and because they are not 
talking to us about It and because we are not 
talking to them we are probably not educating 
on the job about blood transfusion (SL1;281) 
..what I have said to you Is that my use of 
blood has changed over the years that I have 
been In oncology and It has reduced..em.. In 
that I am less likely to transfuse now than I 
was before but actually I rarely have that 
conversation with my juniors (SL1;291)
I am thinking we can and probably do 
transfuse people who don’t need to have It or 
who maybe don’t need to have a transfusion, 
the consequences of that seem potentially less
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catastrophic than giving the wrong chemo or 
the wrong chemo dosage to the wrong person 
(SL1;299)_______________________________2. Shared
responsibility No single healthcareprofessional owns the clinical 
problem; shared clinical decision 
making
Linked to who is most 
experienced and who is best 
placed to assess and treat 
cancer related anaemia
Linked to earlier work by 
Atkinson (1995) -decision 
making a collective,
organizational activity
I am sure there are situations but none stick In 
my mind, none scar me so much. I don’t think 
I’d mind, I mean certainly If the consultant said 
“actually I don’t think they need blood " they 
are perfectly within their rights to say, no they 
don’t need blood It Is their patient and as long 
as they explained why then that would be fine I 
think..and normally when I worked on the day 
unit, the nursing staff would tell me .because 
they knew the patients a lot better than me and 
they knew how likely they were to be 
symptomatic..how quickly they would come 
back, whether they could wait. In their opinion 
for another day and manage without blood.. . 
.(SH2;479)
Yep em if the doctor that saw the patient is 
around ,if the consultant Is around they will 
come back to the person that saw the patient, 
otherwise they may not and they may go to the 
Reg and....I’m trying to think when I was that 
Reg, and if somebody came to me
em then.. I don’t know, its sounds too
horrific for words...I’m trying to Imagine If It 
could possibly happen....that the person who 
prescribes the blood never sets eyes on the 
patient..em..l think that does happen....I think 
It does (SL1;383)
More than skills and knowledge.... Yes 
absolutely. Experlence..yes..l think so...yes 
and people accepting responsibility for It as 
well...they just don’t seem to do it...people 
prescribe ....yes so people being made aware 
If you have never seen a reaction or you know 
a bad transfusion related event you are not 
really going to think twice about prescribing 
....you know for any drug,...if you see a bad 
effect or side effect it really scares you and you 
think ..god and you think twice (SH5;381) 
just blood being prescribed by a registrar as a 
favour to a nurse for a patient that they have 
never seen and they know nothing about and It 
Is quite frightening and It happens and I see It 
happening most weeks, and that Is something 
that needs to be addressed (SH5;397) 
but you would hope when someone Is taking 
responsibility for prescribing the drug they 
would see them, but I see It In clinics most 
weeks where random registrars have been 
asked to prescribe blood for patients they have 
rarely or never seen and I think it Is wrong and 
perhaps It needs to be brought to their 
attention. But If there Is no-one chasing It and If 
people aren’t taking responsibility for It then It 
is difficult..it does happen, in clinics
especially... (SH5;345)
I get questioned you know...does someone 
really need that transfusion? I mean I can’t 
think of specific Instances but you know I
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would not be put out If I had a phone call 
saying somebody has come up for their 
transfusion and actually their haemoglobin Is 
not that low or actually maybe they should 
have three units rather than two and I would 
take that as being good teamwork (SH1;364)
I think a lot of the transfusing happens without 
even my knowing I.e. I see a patient I don't 
have their blood results with me ...the blood 
results are not back when I see the patient 
so..em...they go on a list to be checked later 
and that never comes back to the consultant, 
that goes from the clinic nurse/chemotherapy 
nurse directly to the clinical registrar who 
decides whether to transfuse or not (SL1;305)
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Abstract
Background: Clinically defined cancer-related anaemia is common in cancer patients but 
the impact of mild/moderate anaemia is undetermined, when combined with cancer 
symptoms and/or the side effects of therapy. Blood transfusion is the standard 
treatment; however there are significant risks and costs and considerable variation in 
practice. It is Important that the decision to give blood is carefully considered and it is 
not clear how these decisions are made.
Obiectives: To explore the cultural practices which shape the culture of transfusion; and 
to identify the key elements, which influence clinical decision making in blood transfusion 
in haemato-oncology and lung cancer patients.
Methods: The assessment and decision making processes for blood transfusion were 
explored using six patient and nine clinician interviews; and observation based on 
ethnographic methodology. Data were analyzed using thematic analysis.
Findings: The findings fell into four main areas. First, the findings suggested that 
anaemia and transfusion are commonplace in the clinical setting; and because many 
patients live with anaemia and it may not be viewed as an illness {The ubiquity of 
anaemia and transfusion). Second, there is a great deal of uncertainty surrounding the 
diagnosis and management of this clinical problem; but this uncertainty was 
acknowledged by both patients and clinicians {Acknowledgement of uncertainty). Third, 
clinicians and to some extent patients, are socialized into the practice of the sub­
discipline {Socialization of practice)', and fourth that the haemoglobin level was used as a 
distinct fragment of information on which to assess for the presence of anaemia and 
base the decision to treat with blood transfusion {Disaggregation of the body).
Conclusion: The classical symptoms of anaemia may not be useful in the assessment of 
this type of anaemia because confounded by symptoms of the cancer and side effects of
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therapy. The management of anaemia is not a priority in this setting however by 
understanding the complexity of factors for variation in practice in the clinical context, 
new models for learning transfusion skills can be developed. Furthermore, different 
collaborative groups could be organized to develop optimal transfusion practices, for 
example to include nurse-prescribing of blood components.
Keywords
Anemia
Blood transfusion 
Cancer, neoplasms 
Culture
Decision making
What is already known about the topic?
• Anaemia is common in the cancer population and blood transfusion is the 
standard therapy
• Transfusion practice varies considerably and the reasons for this are unclear
• it is not known how transfusion behaviours are learned or how the decisions to 
treat with blood transfusion are made in the clinical setting.
What this paper adds?
• This study demonstrates that transfusion practice is heavily influenced by the 
culture or sub-cultures within an organization
• The classical symptoms of anaemia may not be useful in the assessment of the 
impact of anaemia but this hypothesis requires further research
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• Anaemia is not a priority in the ciinical setting and therefore there is a lack of 
informal systems for learning transfusion decision making
• New ways of learning and new models of care are suggested to develop optimal 
transfusion practices, for example introduction of nurse prescribing of blood 
components and patient centred decision making.
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introduction
Clinically defined cancer related anaemia is reported as a common problem in patients 
with a incidence of 52% and 38% respectively (Ludwig et al 2004). The pathogenesis of 
cancer-related anaemia Is variable, but may involve bleeding, erythroid hypoplasia, 
reduced red cell survival, nutritional deficiencies, decreased erythropoietin levels, 
haemolysis and poor iron re-utilisation by bone marrow (Bokemeyer 2005; Estrin et a! 
1999). Furthermore, cancer related anaemia is exacerbated by myelosuppressive 
chemotherapy and may be aggravated by radiotherapy (Barrett-Lee et a! 2000). The 
presence of cancer reiated anaemia probably decreases patients' quality of life, and may 
impact on fatigue (Demetri 2001; Giaspy 2001; Ludwig and Strasser 2001) and is 
associated with shorter survival times in some cancer patients (Caro et a! 2001). 
However, the body is uniquely capable of adapting to anaemia, which allows more 
oxygen to be released to the tissues (Morisaki and Sibbald 2004) thereby some patients 
can function to near normal levels with haemoglobin levels of 7g/dl,
Blood transfusion remains the standard therapy for cancer related anaemia for the 
majority of patients in the UK, but there is considerable variation In transfusion practice. 
There are risks to transfusion such as transmission of infectious diseases, transfusion 
reactions and allo-immunisation, over transfusion and immune modulation (Goodnough 
2003). However, improved survival, and the use of more intensive chemotherapy 
regimens supported by growth factors, means the requirement for blood transfusions has 
increased while the donor supply has diminished (Williamson et a! 1999). Most clinical 
practice guidelines adopt the British Society of Haematology recommendations and use 
a transfusion trigger of 8g/dl (BOSH 2001), but this numerical trigger ignores individual 
patient factors and the underlying pathophysiological consequences determining each
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patient’s individual tissue oxygen demands. Furthermore, there may be also be a unique 
physiological response to transfusion, which is dependent on a degree of oxygen debt 
(Madjdpour and Spahn 2005), therefore the decision to transfuse blood needs to be 
carefully considered and it is not clear how these decisions are made in the cancer 
setting.
There are many influences on decision making but studies evaluating relationships 
between physician background characteristics and quality of care have found few 
consistent associations in decision making (Wigton et al 1999). Site of practice variables 
have been better predictors of quality than have characteristics of individual physicians. 
In addition, tasks occur in unique clinical contexts and clinical judgments and decisions 
are not isolated cognitive events. A study explored the relationship between physicians' 
knowledge and attitudes regarding the use of blood products, and the quality of their 
transfusion practice, based on in depth physician interviews and medical record reviews 
(Salem-Schatz et al 1993). Large baseline differences were observed between the two 
hospitals; 48% of transfusions in Hospital A were justified compared with 81% in Hospital 
B. At the physician level, knowledge of transfusion indications and receptivity to input 
from colleagues were significantly associated with higher quality transfusion practice (p = 
0.01 and p = 0.02 respectively). Decision-making can therefore be a collective 
organisational activity, subject to debate and question, and therefore may be more 
reiated to social, interactional and situational factors.
It was not clear if cultural factors influenced cancer related anaemia practice; therefore 
an ethnographic methodology was used to study the interactions and individual 
characteristics using a combination of interviews and observational fieldwork.
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Ethnography is concerned with people’s behaviours in everyday contexts rather than 
under unnatural or experimental circumstances and it is argued here that ethnography 
was particularly valuable not only because of the attention to context; but also because it 
offered a holistic way of exploring the relationships that support transfusion practice 
(Savage 2006).
Methods
Ethical approval was obtained and nine medical and nursing clinicians were interviewed 
and included Consultants, Specialist Registrars, Clinical Nurse Specialist and Day Unit 
Nurses. Six patients were also interviewed; Table (i) shows patient inclusion and 
exclusion criteria and Table (ii) shows patient demographic details.
Table (i): Inclusion and exclusion criteria
Inclusion criteria
4. Male or female lung cancer out-patients or haemato-oncology outpatients who have 
cancer-related anaemia and who are being supported with regular blood transfusion 
therapy. This was defined as patients who have received blood transfusion at least once 
every two weeks for the previous month or in whom It is anticipated blood transfusion 
support will be required.
5. Patients must be willing to be interviewed
6. Subjects must be able to and understand and have signed the written, informed consent 
form and the written information provided therein. Appropriate time should be allowed for 
consideration and questions.
Exclusion criteria
4. Patients who are on erythropoietin therapy
5. Patients who are in any other investigational trial or therapy relating to anaemia
6. Patients who cannot read and write English because of problems of Interpreting and 
completing the information sheet and consent form
Table (ii): Patient demographic data
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Age Sex Diagnosis and stage Treatment to date
32 Female Stage IV lymphoblastic 
lymphoma
3 cycles chemotherapy
62 Male Acute Myeloid Leukaemia 3 cycles of chemotherapy followed by 
cord blood stem cell transplant
28 Male Stage IV Diffuse Large B cell 
Non Hodgkin’s Lymphoma
6 cycles chemotherapy; relapsed and 
underwent 2 cycles salvage 
chemotherapy followed by autologous 
stem cell transplant
67 Male Squamous cell carcinoma left 
lung
Radical chemoradiotherapy to left lung, 
3 cycles of vinorelbine and cisplatln. 
Completed 64Gy In 32 fractions
59 Female Non small cell lung cancer left 
lower lobe
Completed chemo-radiotherapy, 4 
cycles vinorelbine and cisplatln 
Completed 64Gy in 32 fraction
52 Male Adenocarcinoma right lung 3 cycles of vinorelbine and cisplatln
All participants gave informed signed consent Ail interviews were digitally recorded and 
later transcribed by the researcher. Six focused fieldwork observations were undertaken 
in outpatient and day care clinics. The data were analyzed using thematic analysis; 
initially, each data set was analyzed separately, to develop a sub-theme and then 
integrated to create the final themes.
Results
Early in data analysis, sub- themes started to emerge from the data, which were related 
to each other (Diagram i); these sub-themes came together to form the main themes. 
Final thematic analysis revealed there were four main themes (Diagram ii).
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Figure (I): Relationship diagram demonstrating sub- themes
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Ubiquity of anaemia and transfusion
The demographic clinic data demonstrated that clinicaiiy defined anaemia was a 
common clinical issue in clinic and day care units; only 22% of patients overall had a 
normal haemoglobin level, however, only a few patients, had blood ordered and 
prescribed in clinic and the day unit areas (Table iii). This was also evidenced in the 
staff interview data which revealed that they viewed anaemia and transfusion as a 
familiar occurrence:
“Oncologists use a lot of blood [  ]  I bet most of our registrars don’t have a single 
day of the week without transfusing a patient
However, it was recognised that patients tolerated their anaemia, for example:
“So with these patients It Is not Ideal, It Is very difficult I think for them and I think 
that Is probably why a lot of them don’t shout out about their symptoms because 
they know that they are going to have to go through all of that on top of this’’
Despite the frequency of anaemia it emerged from the data to be unimportant in terms of
education of the management of anaemia; this was evidenced by statements in the
interviews, for example, one of the Consultants when asked about his transfusion
training stated:
“Well nobody has trained me since I was at medical school..! probably should 
have been”
Furthermore, the management of anaemia was not discussed between colleagues, for 
example:
7 guess what it comes down to Is that most of our clinics are very busy and who 
gets a blood transfusion and who doesn’t Is not something that Is necessarily 
discussed with the consultant. . . [ ]...and so therefore I guess the message that 
gives out Is that this Is a less Important decision and so therefore the registrars or 
clinical fellows don’t feel that they have to come and talk to us about It they will 
make the decision and because they are not talking to us about It and because 
we are not talking to them we are probably not educating on the job about blood 
transfusion”
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In summary, the management of mild or moderate cancer related anaemia sits low in the 
hierarchy of issues for cancer patients and this is reflected by the lack of education and 
lack of discourse in the clinical settings.
Table (iii): Haemoglobin values of patients in clinical areas and transfusions
administered from clinic/day care decisions (HC=Haematology clinic/day unit; LC=Lung 
clinic/day unit)
No./% of patients with Hb HC1 HC2 HC3 LC1 LC2 LC3
Within normal limits 
(>12g/dl)
7 7 2 6 5 11
Mild (10g/dl-12g/d!) 11 12 10 22 16 18
Moderate (8g/dl-10g/dl) 6 3 5 4 5 6
Severe (6.5-7.9g/dl) 1 1 2 1 0 2
Life threatening (<6.5g/dl) 0 1 0 0 0 0
Total 25 24 19 33 26 37
Number of patients treated 
with blood transfusion
1 2 1 1 1 0
% of patients within normal 
limits
28% 29% 10.5% 18.8% 18.5% 29.7%
% of anaemic patients ^ 72% 71% 89.5% 81.2% 81.5% 70.3%
Acknowledging Uncertainty
Uncertainty in diagnosis was universally accepted, for example the Specialist Registrar 
acknowledged the uncertainty of anaemia:
"It’s an Individual thing, definitely. I don’t think there Is a level for anyone”
The patient data revealed similar findings in that they acknowledged the uncertainty of 
anaemia as well as uncertainty of response to transfusion as one patient described in the 
following excerpt:
“At times you couldn’t tell whether you felt awful because you were low In the 
blood states or you felt awful because you ... because of the chemotherapy. And 
even when you had the blood you were obviously better because you’re going 
about ..but you could still feel awful...but that was no reflection on the blood going
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in. Sometimes for example, about 3 or 4 weeks ago, I had blood on the Friday 
and I had the best weekend I had had for about 5 months. I had a good period of 
for three days and then I went downhill and for that one weekend I felt really 
brilliant and that was down to the blood"
The clinicians also acknowledged the uncertain response to transfusion:
“..In fact so there Is not very good continuity In assessment of response to blood 
transfusions I think something In which we should and could Improve but we don’t 
robustly assess response [  ].. I am sure It happens that people do get repeat 
transfusions who are not necessarily benefiting from them”
However, it was described how uncertainty couid be reduced if the anaemia was
assessed in the context of the patient pathway for example the day unit sister described
how she contextualized the anaemia:
“(you) take Into account where they are In their treatment, their disease status, 
their age...If you have got someone who you know Is recovering their counts 
from chemotherapy but their haemoglobin Is maybe lagging a little bit behind..I 
would often try and not transfuse them because you know that the bone marrow 
Is beginning to work again”
Socialization In practice
Traditional practices were described in many of the Interviews in relation to blood 
transfusion practice, for example:
“because other therapies you get updated In but bloods been around a long time 
you know you just use I t ... ”
“The reason that we tend to give two at a time I am sure Is affected by 
practicalities and habits as It Is by logic” 
it emerged that clinicians are socialized into anaemia practice depending on what 
institution and department, for example, the Specialist Registrar described her 
experiences in other hospitals:
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“Erm ..I don’t think we are meant to but certainly at my last hospital we would, if 
somebody was about to be discharged we would transfuse them up to a higher 
haemoglobin”
Yeh... I suppose that is what they are used to...just different trusts they have
different ways of doing things
Sometimes the clinics were busy and there was no time to dedicate to decision making,
and the practicalities of transfusion influenced the transfusion decision making, for
example, resource availability, as demonstrated in the following excerpt:
7 think the resources are considered with the ....where are they going to have 
this blood, where can we fit them In and how can they have It In a timely fashion 
before or after chemotherapy so from a resource point of view that Is at the 
forefront of my mind how and where am I going to give them this blood... ”
It seemed that no single professional group owned this clinical issue, for example, one of
the Specialist Registrars described how this shared responsibility worked in practice:
I mean certainly if the consultant said “actually I don’t think they need blood “ 
they are perfectly within their rights to say, no they don’t need blood It is their 
patient and as long as they explained why then that would be fine I thlnk..and 
normally when I worked on the day unit, the nursing staff would tell me..because 
they knew the patients a lot better than me and they knew how likely they were to 
be symptomatic..how quickly they would come back, whether they could wait. In 
their opinion for another day and manage without blood..
Conversely some perceived this behaviour as negative, although it was fully
acknowledged this practice also occurred:
“just blood being prescribed by a registrar as a favour to a nurse for a patient that 
they have never seen and they know nothing about and It is quite frightening and 
It happens and I see It happening most weeks, and that Is something that needs 
to be addressed”
A significant difference between oncology and haematology was the variation in 
haemoglobin levels used to describe anaemia and frequently referred to in the interview 
data. The oncology clinicians described anaemia by using a higher haemoglobin level,
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tending to describe a trigger of 10g/dl, whereas the haematology specialists tended to
describe anaemia in the context of 8g/dl but this did not appear to result in more
transfusions in oncology. However, the sub-specialism influenced the decision making,
for example, the Lung Consultant explained:
“I treat alot of lung cancer where it’s very difficult because lung cancer patients do 
get breathless because of their disease and often because of other co-morbidities 
they have associated with their malignancy....[  ]  I would almost perhaps have a 
lower threshold for transfusing such a patient because if it happens to help they 
can be patients who symptomatically can be very difficult to treat...so I would...”
In summary, the practice was heavily influenced by the sub-culture, whether this was the 
influence of the sub-specialism or the individual department or institution.
Disaggregation of the body
Most of the transfusion decisions were based on the haemoglobin; minimal assessment 
seemed to occur in practice, other than a few brief questions to the patient, which were 
often prompted by the haemoglobin value, for example:
“ .... / think it is because we have got the results in front of us ..it doesn’t happen 
that often unless it is really low that you actually look at someone and go ..your 
anaemic..,it is more that we have got the results first and then we see them, if 
you know what I mean”
This phenomenon of separating out clinical information has been described by Atkinson 
(1995) as “Disaggregation of the b o d f and can be used to understand this clinical 
situation whereby the haemoglobin value was used in isolation to make the transfusion 
decision.
Both patients and clinicians acknowledged that knowing the patient was preferred, for 
example the Specialist Registrar described her experience of working in the day unit:
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“ ..and normally when I worked on the day unit, the nursing staff would tell me 
because they knew the patients a lot better than me and they knew how likely 
they were to be symptomatic..how quickly they would come back, whether they 
could wait, in their opinion for another day and manage without blood...”
Clinicians were engaged with patients to varying degrees:
“Yes some take more part, some get more involved in how I feel when... erm...do 
I feel symptomatic more..what do I think..they listen and we talk [  ]  some prefer 
not to get involved as much with the patient”
It may because of the uncertainty of diagnosis and treatment that experiential or tacit
knowledge may improve decision making, for example, in the following excerpt by a
Consultant:
"my response to that as junior registrar would have been, they are telling me they 
need a blood transfusion, somebody who has been doing this job for years is 
telling me that this person needs a blood transfusion, they probably do so I will 
just prescribe it... whereas now I might challenge that I would not have 
challenged that 6, 7 or 8 years ago so I know myself it is not a conversation that I 
have had with any of the registrars and so I have to say I don’t know what my 
response would be but I suspect it would be, like mine, initially you would do it 
and then maybe over time you sort of work out that not everybody needs a blood 
transfusion”
In summary, transfusion decisions were based on the haemoglobin value, but it has 
been demonstrated here that the haemoglobin value does not always correlate with how 
the patient is feeling. Uncertainty exists but experiential learning and knowing the patient 
were acknowledged as improving the decision, however, because transfusion decisions 
are sometimes made in absence of the patient and because decision making is not 
debated in practice, sub-optimal transfusion practices exist.
Discussion
This study showed the symptoms of disease and side effects of treatment are
indeterminate and there may be no rationale in trying to assess the haemoglobin with the
symptoms In a robust way. The literature describes how a full systems review
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assessment is recommended to assess anaemia (Foubert and Wujcik 2005), however, 
this study’s findings suggests that it is likely that variation in practice is inevitable and in 
fact may be desirable, for example, Eddy describes how some variation in practice is 
appropriate; “the differences in patient’s risks, signs and symptoms, responses to 
treatment and values are real” (Eddy 1999, p59). However, Eddy also describes how 
uncertainty can harm the quality and cost of medical practice; and most of the 
simplification of uncertainty pushes in the direction of overutilization. If this is the case, 
the amount of uncertainty which exists in cancer related anaemia would tend to result in 
over-utilization of blood components.
Medical work is dependent on a wide range of skills and the majority are gained through 
tacit acquisition as part of an apprenticeship into the specialism; “ these tacit skills are 
often indeterminate and are rarely explicit but are largely rhetorical” (Atkinson 1995, 
p91), and therefore require discussion and debate. Discrete cultural knowledge is 
acquired informally through participation in working practices and much of this is 
unconscious; “it is implicit learning normally associated with the concept of socializatiori’ 
(Eraut and Hirsch 2007, p5). Giddens describes how socialization is the process 
whereby an individual gradually becomes knowledgeable and skilled in the ways of the 
culture in which they exist and how societies have “structural continuity over timê’ 
(Giddens 2006, pi 63), which perpetuates values, norms and social practices. The 
interactions between individuals take place through symbols and the Interpretation of 
meanings and this has been described as “symbolic interactionism” (Giddens 2006, 
pi 07), for example the different haemoglobin values that were described between 
oncology and haematology. Symbolic interactionism emphasizes the small-scale 
interactions of individuals, not society as a whole, however this study revealed the
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management of anaemia escaped the rhetoric in clinical practice and the consequence 
of this was a lack of informal systems for learning how to manage cancer related 
anaemia.
The significance of the interactions implies the quality of decision making may be 
dependent on the communication within the team; or the degree and quality of 
communication with the patient. The silent isolated single handed decision-making is, 
therefore, is probably not the model for the assessment and treatment of cancer related 
anaemia with blood transfusion. Ideally, because of the risks of transfusion the patient 
should be consulted and together the clinician(s) and patient make sense of what is 
going on, and patient-centered decisions can ensue. Patient centered care is a term 
used to “describe the therapeutic relationships between care providers and service 
users, and between the care providers themselved’ (Manley and McCormack 2008, 
p12). However, this study revealed the importance of the haemoglobin and this may be 
either a reflection of the uncertainty of symptoms or alternatively it may be related to the 
limited time to dedicate to cancer related anaemia in the out-patient setting; 
parsimonious behaviours may ensue whereby a quick decision based on the 
haemoglobin value is made because of the value placed on the haemoglobin result. 
Therefore anaemia sits low In the hierarchy of clinical concerns, because the physicians' 
priority in clinic is to focus on the cancer and treatment. This lack of priority for anaemia 
may also be influenced by the meaning of anaemia; if a disease at the time of diagnosis 
causes no pain or disability, even if it accompanies a more serious (“real”) disease such 
as cancer, it will not be viewed as an illness especially if it is frequently encountered 
(Eddy 1999) and will therefore be given low status. These elements are summarized in 
Diagram 3.
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Diagram 3; Hierarchy of knowledge and task (cancer related anaemia)
High status
Low status
Physician
Factual (biomedical) knowledge
Disaggregation
Cancer and its treatment
Hierarchy of knowledge &task
Nurse
Tacit knowledge 
“Knowing the patient" 
Anaemia and its treatment
In summary, the unique difference of cancer related anaemia (as opposed to other types 
of anaemia) may be that the classical signs and symptoms of anaemia are not applicable 
in traditional assessment because they are confounded by the symptoms of cancer and 
treatment; this hypothesis would require further investigation. It is likely that socialization 
of practice will remain a powerful influence over behaviors, however, if nurse-prescribing 
of blood components were legitimized transfusion decisions could be optimized as day 
unit nurses may be best placed to prioritize anaemia, through repeated exposure to 
transfusion and by knowing the patient. Optimal transfusion practice should be the aim 
and the decision making should be tailored to the unique individual and perhaps the only 
way to do this is by involving the patient in that decision.
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1.0 Introduction
This paper is a summary of the integration of knowledge; research and practice over the 
four years of doctorate study; providing the reader with an understanding of the taught 
eiements, the research journey, and the impiicatlons for clinical practice for the author. It 
will begin by describing the development of self; and will be followed by the development 
of the research project including a description of the change in the ontological position of 
the researcher. It will conclude by describing any deficiencies in learning, as well as 
conclusions and recommendations for the future doctorate programmes.
2.0 Development of self
Undertaking the taught eiements of the doctorate programme highlighted shortfalls in 
knowledge and experience; particularly in the critical thinking of designing and 
undertaking a research project. In addition, professional development and a greater 
understanding of the wider strategic and political themes continued concurrently in order 
to fulfill the aims of the course. The taught elements of doctoral studies and advanced 
research methods provided the foundations for developing and refining the research 
project; and the communities of practice, leadership and innovations in organizations 
were the most instructive in contributing to professional development, however all 
modules contributed to successful completion of the doctorate. The taught eiements of 
the programme were relevant to the professional development as the author moved to a 
new post in October 2005 as Nurse Consultant in haemato-oncoiogy and in December 
2007 moved to Head of Nursing for Oncology and Haematology. The move to a more 
influential role as Head of Nursing and managing a team of 180 nurses with an annual 
budget of £7.5 million required advanced leadership skills to manage at a clinical level
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but was lacking in some essential skills for a senior nursing management position, the 
latter of which will be described later in section 5.
Relationship diagrams are a useful and effective way of organising and identifying links 
between concepts, topics and variables (Finn 2005). They are also helpful in 
maintaining an overview of the different components of a complex topic and help to 
convey information that would be difficult to achieve in a written passage alone, allowing 
the complexity to be appreciated, but still allowing the individual components and their 
connections to be viewed. Therefore a relationship diagram was developed to 
demonstrate the links between knowledge, theory and clinical practice both in 
professional practice and the development of the research question (Appendix 1)
As the research journey progressed, the researcher changed and developed novel 
thoughts and new ways of thinking at several levels. Firstly, the understanding of the 
reality of cancer related anaemia and transfusion practice changed, for example, it was 
the uncertainty and Inconsistency surrounding the management of the clinical problem 
that led to the research however, it emerged the socialization of transfusion behaviours 
was the major influence in this inconsistency and this had not been anticipated. 
Secondly, the fundamental ontological and epistemological positions changed as the 
project evolved, which was a difficult journey for the researcher, who was new to 
reflexive ethnography, and this will be described in more detail in the following section.
3.0 Knowledge and research development
Throughout the programme it was essential to improve critical thinking and theory 
development skill through extensive reading and thinking. An aspect of study, which
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was crucial to the success of the research project, was the challenge of narrowing down 
a topic of study in a logical and coherent fashion to produce a realistic and feasible 
project. In other words, taking an idea from its inception through the various highs and 
lows and learning and using creative skills to recognize and/or develop originality to 
develop a project was the key to success. Chapter 1 of the research thesis 
demonstrates the origins of the research project and describes how the project changed 
to an ethnographic methodology; however, the shift of ontological position was not an 
easy journey because the researcher had a positivist approach at the outset of the 
project. In summary, this ontological shift was difficult to accept and using the 
ethnographic methodology to explore the messy nature of the social world in depth, 
including an acceptance that a more positivist approach would not be able to answer the 
research questions.
Previously a reductionist approach had been taken with regard to the science of method 
or “methodology”, for example, during the researcher’s MSc project. The development of 
the methodology in the doctorate research required an open approach, and by using a 
combination of extensive reading, critical thinking and discussion with supervisors and 
other experienced researchers, and medical colleagues, a final research methodological 
approach evolved to underpin the final project design. This was an iterative process and 
interviews and observations commenced, however, the literature had to be re-explored 
and advice sought from experienced ethnographers as to how to improve these data 
collection phases (see Research Log, Part 2). Although the willingness to change the 
methodology was driven by the need to answer the research questions in a more robust 
way it was difficult and highlighted the need for flexibility and creativity for successful 
research,
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The data analysis phase was the most time consuming component of the research but it 
was the most rewarding and creative part of the four years, requiring culmination and 
integration of all the skills and knowledge gained from undertaking the doctorate. In 
summary, the research was an attempt to study the reality of the culture of anaemia and 
transfusion practice in the clinical setting. Denzin (1997) quotes Malinowski (1922) who 
was a founding father of ethnography summarized the purpose of ethnography;
“Find out the typical ways of thinking and feeling, corresponding to institutions 
and culture of a given community and formulate the results in the most 
convincing way” {xv)
The researcher attempted to do this within the sub-speciaiisms of haemato-oncoiogy and 
lung cancer. A cultural model (4 main themes; chapter 5) was developed from the 
findings to bring some meaning to the actual practice and although not generalizabie, 
“they may be relevant to other groups at other times and placed' (O’Reilly 2009, 82). In 
summary, the aim was to Inform and influence transfusion practice and the communities 
of practice module was reflected on as group knowledge and behaviours were important 
in influencing the decision making.
4.0 Professional Development
The emotional change in the shift of ontological position form a positivist to an 
interpretive epistemoiogy described in section 3 and in Chapters 3 and 7 of the thesis 
also resulted in a change of professional behavior. A more open and less reductionist 
viewpoint and more critical stance has developed although it is acknowledged this was a
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fluid change, with some resistance along the way. There are different ways of 
developing clinical practice and there has been a recognition that human behaviours and 
relationships massively influence the quality of care and this is not solely to do with an 
individual’s skills and knowledge.
The emotions and leadership module was the most influential in facilitating my 
professional development, for example, the Myers-Briggs Personality Type Inventory 
(MBTI) assisted examination of personal strengths and weaknesses as a leader and this 
was developed further in the clinical setting by applying it to my senior team (Team 
MBTI). Subsequently, this was used in staff appraisals (including 360 degree appraisal 
methods) which then facilitated the team to improve teamwork, by improving behavior, 
individual development and communications. Recognizing that emotions were important 
and required to be controlled and/or harnessed to improve functionality and productivity 
not only in oneself but in others influenced my leadership and management skills.
Strategic development and the policy review and service development projects 
contributed to overall professional development, specifically in relation to the Nurse 
Practitioner role and Nurse Consultant role. Research demonstrates that nurses can do 
some of what doctors do and often to the greater satisfaction of patients (Shum et al 
2000; Venning et al 2000). Whilst undertaking this doctorate I moved from Nurse 
Practitioner to Nurse Consultant and finally to Head of Nursing. This was a natural 
development from being a medical substitute in the Nurse Practitioner role to leading 
clinical aspects of a service, for example the rapid access lymphadenopathy service and 
late effects clinics in the role of Nurse Consultant, to leading a team and facilitating team 
development and improving nursing services and standards in the Head of Nursing role.
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The success of each of these roles was greatly influenced by the doctorate programme, 
facilitating initially improvement in self but more long-term improving others by 
influencing on a larger scaie, as I moved towards leading a team of 185 nurses. This 
may not have been achievable or certainly less successful if the Doctorate in Clinical 
Practice had not been undertaken.
On a broader scale, one of my expectations and needs from undertaking this doctorate 
was to improve interdisciplinary debating skills to help reduce boundary disputes and 
work towards capitalizing on the wealth of skill that all the team can bring to bear on 
solving health problems. As confidence improved throughout the four years, these 
perceived restrictions to behavior dissolved and the ability to put one's point across on a 
convincing and coherent way improved as did critical analysis skills. This not only 
enhanced my personal strengths but influenced the local and wider nursing workforce.
Therefore in summary, the key components of my professional development were:
• Understanding my personality type and using my strengths to develop myself and 
other team members; and managing my weaknesses to improve productivity and 
performance
• Development of verbal communication skills, participate in group-discussion. 
Intervene in meetings and present cases and deal with criticism, demonstrating 
greater analytical and critical thinking skills
• improved critical thinking and reasoning skills and using evidence appropriately 
to persuade organizational teams to explore and develop innovative practice
• Development of strategic knowledge and using this knowledge to enable 
implementation of novel practice and bring about change.
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• Exploration and greater insight of my personal ethical framework and broadening 
my ontological perspective to apply it both in practice and research
• Development of advanced team working skills In order to implement “the leaning 
organizatiori’ (Garside 1999; 211) in practice. Garside (1999) describes the 
difficulties in challenging the norms so systems and practice can be unlearnt and 
re-learned. In relation to the research project, this was and continues to be a 
challenge in changing the management of anaemia, where blood transfusion 
practice is influenced by the culture of the clinical setting.
5.0 Limitations and recommendations
Healthcare systems and policy is constantly changing and there is the need to measure 
and be able to eloquently describe what it is that nursing contributes to the healthcare 
systems to ensure efficiency and efficacy of the nursing workforce. The deliverables and 
outputs of nursing have to be measurable and quantifiable and In more recent years 
nursing metrics and Key Performance Indicators are being developed. If the outputs are 
measurable this empowers nurse leaders, but nurses need to be equipped how to 
develop these and use these systems to benefit nursing and patient care. How to 
develop and use these measures as well as how to develop the skills to financially 
manage a budget were not incorporated into the doctorate programme. The lack of 
knowledge and skills about the economics of healthcare (e.g. commissioning; drug 
expenditure etc) weakens the post-doctorate healthcare professional as this information 
is learned by default and therefore limits the nurse leader. In being able to communicate 
or challenge other professionals to the required standard. The doctorate programme 
would be strengthened if the economics of healthcare systems were incorporated into 
future programmes.
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6.0 Conclusion
In summary, undertaking a Doctorate in Clinical Practice was more a process of “adding 
to” a well established portfolio of knowledge and skills and fine tuning what was already 
in existence, but more importantly it resulted in a shift of attitudes and critical analytic 
skills. Undertaking a doctorate program was a continuation therefore, albeit a more 
intense period, of lifelong learning and development. It required hours of reading and 
more importantly, hours of creative thinking and reflection, to achieve the end product, 
but this would not have been achievable in isolation and the contribution of the 
supervisors and taught elements of the programme are acknowledged (see Research 
Log, Part 2). Although it included seif-direction and motivation as well as seif-discipiine, 
resilience and tenacity and the ability to prioritize and juggle a number of tasks at once, 
to essentially project manage the research; the support and advice of the supervisors 
was essential.
In summary, fulfillment of learning and development was successful and resulted in an 
increased confidence to design, undertake and implement high quality research in the 
field of clinical haematology and the skills to hold one’s own in the wider field of 
oncology. It has also given me the confidence to write and publish more as well as 
contribute to assisting others with project development and management, and my 
publication portfolio has increased in the last four years. Furthermore, it has made me 
more, weii-equlpped and therefore more powerful to anticipate, influence and lead 
change in an ever-changing world and more prepared to question one’s own practice as 
well as that of others.
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Appendix 1; Development of self: Integration of eiements of the program pius learning 
that has resulted in integration of knowledge, research and practice
Taught Modules Formative and summative Professional
Introduction to doctoral projects Development
studies
Professional ethics in a Review of learning and
risk society development needs Supervision sessions with
Topic review research supervisors
Advanced research Policy review
methods for the reflective Annual reviews 1:1 with nurse manager
practitioner Research proposal and clinical lead/ \ Log book f \
Policy, politics and power \i J Academic paper \---/ Cancer strategy teamN r Overview of the integration N K
Communities of practice of knowledge, research and Operational meetings
practice
Emotions, leadership and Portfolio Leading on projects, e.g.
innovations in Viva voce developing nurse services
organisations
Developing the clinical
team
Clinical supervision
Publications
r
Book chapters
Peer review
papers
Conferences
Development of self
Increased knowledge of policy 
and strategic planning
Contemporary practice 
Advanced practice 
Innovative practice
1 Personal
Relationships
The team
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Introduction
Part two of the thesis incorporates the policy review, service development project and 
the research log. The policy review describes the NHS Knowledge and Skills 
Framework (KSF) under the Agenda for Change (2003), followed by an exploration into 
the evolution of the policy, with reference to the socio-economic and political 
environment, and workforce influences. The policy review also explored the Knowledge 
and Skills Framework with reference to advanced nursing practice roles. At the time of 
undertaking the doctorate in clinical practice the author was an Advanced Nurse 
Practitioner and moved into a Nurse Consultant post in Haemato-oncoiogy and therefore 
had an interest in how “medical work' undertaken by nurses was integrated into the KSF 
framework; particularly as the KSF excludes the medical profession. The research 
project described In Part 1 led to greater understanding of learning skills and knowledge 
in the clinical setting, and it is now appreciated that the KSF does not easily incorporate 
the tacit-intuitive learning and shared knowledge between professionals. The KSF is 
inflexible and does not accommodate easily the assessment of practitioners’ holistic 
skills and knowledge acquisition and therefore it does not solve the problem of blurred 
professional boundaries, and this is described here. Finally, the policy review concludes 
with a description of the limitations of this policy implementation.
The second section of Part 2 describes the service development project, which included
the audit of blood transfusion practice in oncology and haemato-oncoiogy; this
demonstrated a difference in practice between these sub-speciaiisms. The audit was
described in the research thesis (Chapter 3, section 3.3) and revealed that variations in
transfusion practices existed, but it was assumed at the early stages of the doctorate
programme that the variation was due to different levels of skills and knowledge between
the oncology and haematology clinicians. The research has demonstrated the
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complexity of transfusion practice and argued that the decision making was shaped by 
the culture of the clinical setting. Therefore, the service development project conclusions 
that using strategies to increase the skills and knowledge of the clinicians did not reflect 
the reality of transfusion practice. The four year doctorate journey therefore started with 
a narrow view of skills and knowledge, reflected In the KSF policy review, which had not 
explained the complexities of clinical practice; the service development project started to 
generate some further questions and the research contributed to the understanding of 
how clinical behaviours develop in the clinical setting, albeit in the narrow field of 
transfusion practice.
in the third section, the research log maps out the pathway learning for the author of the 
clinical doctorate. It was a convoluted pathway with substantial amendments to the 
project and as described earlier from the early view of skills and knowledge it emerged 
that healthcare behaviours, including the development of expertise, is shaped by the 
culture and not merely absorption of biomedical knowledge and skill acquisition. The 
research log demonstrates the time frames for the researcher’s journey and should be 
read in conjunction with the “Overview of the integration of knowledge, research and 
practicd’ paper in Part 1, which brings together all of the elements of the clinical 
doctorate.
Finally, Part 2 concludes with a conclusion of the integration of the two parts of the final 
thesis and describes how the different elements of the doctorate programme fit together 
to provide a unique contribution to the practice of transfusion, and more generally to 
learning skills and knowledge in the clinical setting.
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The NHS Knowledge and Skills Framework 
(NHS KSF): A Policy review
1.0 Introduction
in 1999 the government published a paper “Agenda for Change-Pay Modernization in 
the NHS" and this initiated the largest radical shake up of NHS payment systems since 
the evolution of the NHS in 1948, applying to over a million NHS staff (DOH 1999a). As 
part of the process, the NHS Knowledge and Skills Framework (NHS KSF) policy was 
developed which lies at the heart of the career and pay progression strand of the 
“Agenda for Change” and applies to ail healthcare professionals with the exception of 
doctors, dentists and some board level and other senior managers (DOH 2004). The 
NHS KSF attempts to describe the knowledge and skills, which NHS staff need to apply 
in their work in order to deliver quality services. The challenge is to bring coherence to a 
chaotic and fragmented healthcare system, maximizing the contribution of ail the 
different professional groups, with the over-arching purpose to facilitate the development 
of services so that they better meet the needs of the users and the public by investing in 
the staff. In summary, the KSF was developed with the intent to bring fairness and 
equality to the education and training and promotional systems within the NHS.
The NHS KSF is designed to support the healthcare workers and facilitate their learning 
and provide every member of the service with the same developmental framework 
thereby producing high quality services for the public indirectly. With current concerns of 
staffing the NHS, the KSF (and Agenda for Change) is an attempt to prepare the future 
healthcare workforce by providing fairness, equity and a formal structure for staff
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development. Previously, many healthcare institutions have attempted this at local level 
but there has been a pressing need to develop policy at macro level. This has resulted 
in the development of national, competency-based assessment systems, culminating in 
the NHS KSF policy. However, the implementation of this relatively new policy was 
always going to be contentious, as the different professional groups have historically 
resisted the notion of cross-professional, competency-based assessment systems 
(Masterson 2002). The national programme is not yet fully rolled out and it may take 
some time to establish if implementation has resulted in the aims that it was designed to 
achieve.
A feature of many health policy documents is the recognition of a pressing need to 
redesign the workforce. This is not a new phenomenon but until relatively recently, 
redesign was formulated by single professional disciplines. Little regard was given to the 
impact of change by one discipline on rest of the healthcare professionals, however, this 
is starting to change and a range of documents have been published which acknowledge 
that unless workforce design is undertaken in an integrated manner across ail 
disciplines, it is unlikely that any solutions will provide the highest quality of service with 
the limited financial and human resources available (Benton 2003). The Waniess 
review (Waniess 2002) takes this further by stating:
“Changing skill mix and increasing workforce capacity cannot happen
quickly; it needs to be planned and actively managed But before the
end of the decade, there needs to be considerable progress on skill mix 
and pay modernization to avoid capacity constraints” (para 5.57).
372
While the NHS KSF attempts to unite the workforce, there continues to be a range of 
policy threads in the form of pay modernization that seem to be inadequately connected, 
for example the Consultant contract Framework (DOH 2002) and the NHS Plan (DOH 
2000). The interdependence of disciplines is real and any action taken by one 
professional group in terms of role redesign or workload transfer will have an impact on 
other groups and the reality is that cross-professional knowledge and consideration of 
these changes is rarely found. For example, do medical colleagues support, or even 
understand, the changes involving non-medical prescribing? Was the impact of 
reduction in junior doctors' working hours integrated into the other healthcare workforce 
plans prior to implementation? The KSF has attempted to unite the workforce and 
integrate the healthcare professions but in reality how successful will this be? This paper 
will address how far the KSF has worked towards preparing the future workforce for the 
effective running of the NHS and undertake a thorough policy analysis of the KSF in an 
attempt to determine the origins and meaning of this policy in particular relation to 
redesigning future roles in advanced nursing practice.
2.0 Policy Analysis
Policy analysis involves a detailed process of examination, dissection, evaluation and 
research of a specific policy and it contains three central ingredients: “ the policy making 
process, its context and the use and development of theorÿ' (Harrison 2001). The NHS 
requires adaptation and reform if it is to survive the increase in demand therefore a 
policy analysis framework examining future requirements and preparation of the 
workforce of the future would be appropriate for detailed examination of the KSF. The 
Human Resources Development Policy Formulation: A Framework for Analysis (WHO 
Health systems 1998) will be used to facilitate the in-depth analysis of this policy with 
detailed study of the political context in which it evolved and the major influences in
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shaping this policy (WHO 1998) (Diagram 2.0). The context of policy development in 
diagram 2.0 refers to the overarching political and socio-economic environment, disease 
patterns and the involvement and degree of influence of various stakeholders. The 
policies refer to the macro-economic policies and major government organizational 
reforms for example, the labour government’s intention to modernize the welfare state 
system when they came into power in 1997, as well as inclusion of the policies 
themselves. The support systems refer to information technology; human resources and 
financial planning that are required for planning and implementing workforce planning 
scenarios.
Diagram 2.0: Human Resources Development Policy Formulation: A Framework for 
Analysis (WHO Health systems 1998, p6)
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The relationships between each component within each factor and their individual or 
cumulative effects on policy development are complex and highly interconnected. Many 
may have indirect effects, and their influence is mediated through other factors and 
dynamics, for example the historical power of the medical profession. This makes it 
difficult to isolate the precise impact of any one of the factors and although the tool 
provides a basic framework to facilitate policy analysis. It does therefore mean there are 
limitations. For example, not all of the above have shaped the development of the KSF 
and some have been more powerful influences than others, for example, future 
workforce capacity has had a major impact, yet some of the professional bodies have 
not. In addition, some players have not been considered, for example, the private 
sector. The wider issues of traditional practice and staff attitude are not Incorporated into 
this model yet this has a major impact on how the KSF policy rhetoric will be translated 
into practice. The NHS and its various professions have a long history of tradition, 
particularly medicine and nursing, and this undoubtedly influences policy evolution. 
Furthermore, the strength of the professional bodies may also hinder implementation of 
the .NHS KSF by contributing to gaps and slippages In the accurate implementation of 
this new policy. A form of critical or discourse analysis of the KSF policy will reveal the 
motivation and politics involved, as well as an interpretation of the conditions behind this 
policy, to allow a comprehensive review of this new policy. In summary, a critical 
analysis using this framework as a policy analysis tool, recognizing the above shortfalls, 
and an exploration of the relevant forces, will culminate in a theory of development of the 
NHS KSF.
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3.0 Description of the KSF
Undoubtedly the NHS is a knowledge-based service but despite the critical importance of 
knowledge and skills, historically there has been a general and persistent failure to 
provide the NHS with information about, how the service runs and knowledge transfer 
between the different services sectors, which are central to the effective running of the 
service. There appears to have been a lack of basic information about “what is going ori' 
and a wide range of technical issues, many of which had been recognized since the 
early days of the NHS, but which had not been tackled systematically. The need for 
information and understanding in these areas is growing rather than declining and in 
addition, there now seems a desire to prepare for the future rather than the traditional 
NHS approach to change, which tended to be reactive. It could be argued the 
development of the KSF is required to guide the service in whatever is the chosen 
direction. The focus of the NHS KSF is not to describe what attributes a worker has, but 
rather on how they apply their knowledge and skills to meet the demands of the work of 
the NHS. It seeks to describe what people actually do and focuses on the application of 
knowledge and skills, rather than individual talents. The KSF is a key tool for describing 
and redesigning future roles and this framework has been designed especially for the 
NHS and is capable of describing a wide range of current roles. It is made up of 30 
dimensions with six core dimensions which are relevant to every post in the NHS: these 
are communication, personal and people development, health, safety and security, 
service improvement, quality and equality and diversity. The other 24 dimensions are 
specific and apply to some but not all jobs in the NHS. For each dimension the 
government has provided a brief summary and all dimensions, whether core or specific, 
have a number of levels. Most dimensions have four levels, but there are a few that 
extend to five. For every level there is a more detailed description that helps to explain 
what is required in terms of the knowledge and skills associated with that dimension at
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that particular level. In addition, further indicators that help assess whether a particular 
competence is being met are given alongside examples of their application and how they 
relate to previously published benchmarks.
The NHS KSF claims several long-term benefits for patients, public and the NHS 
workforce and can be summarized as follows;
• Improving the quality of care through embedding the principles of good patient 
care in the development and review of staff and linking the KSF to policy 
imperatives
• Improving recruitment and retention by embedding good human resource 
management Into the service
• Improving teamwork
• Greater innovation in the deployment of staff by providing a tool for role design
• Improving equality of opportunity and diversity. The NHS KSF introduces for the 
first time an NHS wide framework applied equally for all staff in development, 
review and career progression
• Improving career development by providing an integrated service-wide framework 
that shows progressive levels of application of knowledge and skills that can be 
used flexibly to careers In the NHS
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• Improving morale by providing an open, explicit and fair development
• Improving pay
In summary, for every post in the NHS a post outline based on the NHS KSF will be 
developed, with the exception of medics and some senior management roles. Outlines 
must reflect the requirements of the post and not the abilities or preferences of the 
person who is employed in that post. This describes a rather pragmatic approach, 
however, a wide range of professional and non-professional groups of workers are 
involved, which inevitably will lead to conflict when trying to manage such a vast and 
diverse work population. It is these issues, as well as the context of KSF development, 
which will be described In the following sections, with particular reference to advanced 
practice nursing roles.
4.0 The evolution of advanced practice nursing roies
The NHS Plan, published in 2000 (DOH 2000), outlined the government’s strategy to 
modernize the NHS and set out a programme for reform, identified performance targets 
for the service and detailed the government’s plan for investment in the NHS. In relation 
to nursing, it was the aim to enhance the skills of the workforce and remove professional 
boundaries. Alongside of this policy, healthcare restructuring and increase In demand 
for some services, for example, patient support and information, has led to substantial 
increases in different types of advanced practice roles, for example the Clinical Nurse 
Specialist (CNS), Nurse Practitioner and Nurse Consultant roles. The Nurse Practitioner, 
typically undertakes some medical tasks and can “diagnose, refer, prescribe and provide 
complete episodes of care for clients with undifferentiated healthcare problems “(Stillwell 
1985), Alternatively, the CNS role has not been regulated and in the past there has
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been no specific educational or experiential requirements resulting in wide variation of 
services offered. The Nurse Consultant, on the other hand, is closely linked to explicit 
NHS priorities and expected to establish cross-boundary inter-agency creative solutions 
but may be used inappropriately as some Trusts employ consultants because it may be 
a more attractive role and thereby aiding recruitment, rather than arising out of clearly 
defined organizational goals. The lack of consensus on how to define advanced practice 
and the variety of nursing roles that exist has contributed to the latest policy development 
with higher levels of practice, (although not finally defined yet), to be registered on a 
separate section of the NMC register. The competencies will be revised to align them 
with the KSF, and the nursing committee will develop a registration system and propose 
a process for accommodating existing practitioners (due September 2005). Despite it 
being a primary aim, it is unlikely that introducing these new standards will reduce the 
excess of titles that currently exist, although work will continue with this (Walter 2005). 
This formal recognition and registration of advanced practice should be welcomed as it 
has been devised to protect patients from nurses who adopt such titles but without the 
necessary education, skills and knowledge.
There is general consensus, in several models, that clinical practice is the primary focus 
of these advanced practice roles (Bryant-Lukosius et al 2004) but the evolution of these 
advanced practice roles has probably arisen under a variety of circumstances as 
described earlier. For example, some argue that advanced practice nursing roles have 
arisen out of an emphasis on reducing costs and is in fact experimentation and nothing 
more than a stopgap for the shortage of doctors (Castledine 1995). Not surprisingly 
therefore, role conflicts and role negotiations are a way of life for advanced nurse 
practitioners (Dowling et al 1996). How role domains are defined varies depending on 
the model, for example Manley (1997) identified four integrated roles related to direct
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and indirect expert practice, education, research and consultation with knowledge and 
skills related to transformational leadership, collaboration and organizational 
development. The Synergy Model (Maloney-Harmon 1999) identifies eight domains of 
practice for clinical nurse specialists and these relate to clinical judgement, clinical 
inquiry, teaching/learning, collaboration, systems thinking, advocacy/moral agency, 
caring practices and response to diversity. The Strong Model identifies five domains for 
the acute care nurse practitioner, including direct comprehensive care, support of 
systems, education, research, publication and professional leadership (Ackerman et al
1996). Whatever model is applied these are all fairly generic competencies, which can 
be applied to both medical and nursing domains but do not explore in-depth the concept 
of specialism. Specialism, and indeed sub-specialism, is increasing as treatment and 
care becomes increasingly complex; nursing and medicine and some of the other allied 
healthcare professionals use some generic skills and specialism usually follows 
thereafter, whereby the professional focuses on either a particular practical or theoretical 
branch of their profession. Some of these skills are not easily transferable and some 
skills developed by advanced nurse practitioners have expanded into areas traditionally 
seen in the medical domain. Equally, however, some doctors have developed particular 
interest in counselling and support, which would have been traditionally viewed as 
nursing activities. This “blurring of boundaries’ suggests skills and knowledge should not 
be categorised into nursing or non-nursing or medical activities and the labelling of 
procedures into “medical” or “nursing” must be considered to be historically dated in the 
current climate and conflicts with the modernising of the NHS which, has been high on 
the political agenda for many years now.
Essentially the KSF and Agenda for Change were driven by this need to modernize the 
healthcare workforce systems and pay systems. One approach to solving this problem
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would be to establish “Ideal” requirements, for example, appropriate technology and 
resources with professionals being motivated to change (Harrison 1994). Rushing and 
Smits (2005) developed a framework analysis for creating the ideal workforce in their 
work in various countries setting up new workforce systems (see Table 4.0). The KSF 
incorporates some of these systems, for example, the fundamental principles of lifelong 
learning and competency based practice. However, one could argue some of the major 
players have been excluded from the KSF policy, such as the medical professional 
bodies therefore there is not flow and progression amongst the healthcare workforce. 
These and other Issues will be discussed in more detail when examining the political and 
social context of policy development of the KSF.
Table 4.0: Criteria for the ideal workforce training and education system (Rushing FW 
and Smits 2005)
Be customer driven-organized around the needs of students, workers and employers
Be easy to find and enter, and be designed so that people can move easily between 
programs and the workplace.____________________________________________
Meet the needs of all learners. Including those who have under-served in the past 
because of racial, ethnic or cultural differences, gender, disability or learning style
Provide support services such as career counseling, childcare and financial aid to 
those who need them
Be competency-based so that all students are able to master the skills and 
knowledge they need in as much or as little time as they need to do so
Be staffed by people who are prepared to teach a diverse student body and who 
have relationships with employers that help them to stay up-to-date with changes in 
their own fields
Be co-ordinated with private sector programmes, with social and other services and 
with economic development strategies
Be based upon full partnerships between business, labour, and training and 
education
Rely on the best labour market information, so that people acquire skill that local 
industries need
Provide students and workers with a foundation of basic skills to equip them to be 
lifelong learners
Be accountable for results and committed to using outcome measures to 
continuously improve programme_________________________________________
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It may be that advanced nurse practitioners are evolving as a discrete professional 
group, outside of the traditionally accepted definitions of nursing and medicine (Barton et 
al 1999) but it may not be ideal to create another separate group if one were to apply the 
above Rushing and Smits model. It will be interesting to see how these new roles can 
be integrated into the KSF because medicine is not included.
Clear boundary definition cannot be based on knowledge alone because both medicine 
and nursing draw from the same core academic disciplines. As Barton et al (1999) 
states: “preventing or limiting movement of occupational boundaries, by rigidly defining 
particular skills lacks insight into the very evolution of occupations and professions’ 
(p59). In theory the KSF seeks to unite the professions, however, the exclusion of 
medicine does not fit with the emerging philosophy of a needs based service irrespective 
of professional boundaries. For example, how are the competencies of medics 
assessed? Is there a separate framework for skills assessment or is it still working on the 
traditional “watch one, do onS’ principle? In addition, if the Rushing and Smits model is 
applied, the KSF does not allow easy migration of the workforce: a healthcare 
professional may have the necessary skills and knowledge but still has to remain within 
their professional body. This will inevitably lead to conflict and lack of definition for 
advanced practice roles.
In summary, there is now a driving force to reconfigure healthcare systems, largely 
driven by the need to provide quality healthcare with limited resources and a situation 
where the NHS is making the most of what staff it currentiy has because in the current 
climate it is unlikely many more staff with the necessary skills and knowledge will be 
readily available. In the interim period there has been considerable scope for making 
better use of nursing staff in specialist roles but this has been hindered by rates of
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recruitment and retention. There is a need for improved education and training for non­
medical staff, who could take on the functions of doctors but the standards are variable 
and services patchy and some doctors are unwilling to delegate functions when they are 
unsure of the skills of the staff. In addition some nurses have been trained to perform 
tasks but are reluctant to continue performing; there may be many reasons for this, for 
example, they may feel unsupported or have been inadequately prepared, it may be that 
nurses are struggling to reconcile the tension between advancing their technological 
skills and retaining their caring role. Perhaps nurses and medical staff should share 
responsibility for these activities rather than transferring them wholesale to the nurses’ 
domain (Cahill 1996). Cahill further explains one of the criticisms of advanced practice is 
that it is aimed at conserving the expensive energies of doctors, particularly when one 
examines the emerging roles of Surgical Assistant and Nurse Practitioner. The National 
Association of Theatre Nurses is uneasy for example about the way in which the surgical 
assistant is developing: “(we)... must be clear why these roles are being introduced and 
ensure they improve the quality of patient card’ (NATN 1996, p49). It could be said one 
of the major driver of KSF was to facilitate nurses and other healthcare professionals to 
take on the dull and repetitive tasks of doctors but conflict arises over who is responsible 
for the new service and who is accountable should errors occur and who will accredit 
such practitioners, even if outcomes can be made explicit? (Manleyl 997). Again, it will 
be interesting to observe if the KSF will help give clarity and definition to extended role 
development and advanced practice nursing. This combined, with the new legislation for 
separate registration under the auspices of the NMC should in theory help resolve some 
of the questions raised, but may not answer all of them.
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5.0 Context of development of NHS KSF
This section refers to the political and socio-economic environment that helped to shape 
the development of the KSF. It then focuses on patient need and how this shaped the 
evolution of the policy, and describes the major players and the professional influences, 
and finally describes the KSF and conflict with the private sector.
5.1 Political and socio-economic environment
The labour government elected in May 1997 has set the reform of the welfare state to be 
one of its major tasks (Powell 2000). The third way has evolved, which is a new and 
distinctive policy approach, which differs from the old left and the new right (Klein 2001). 
It is argued that the third way is best summarized by a new acronym “PAP”, which is that 
of Pragmatism And Populism (Lister 2001; Powell 2000) and broadly speaking 
encapsulates the idea of an alternative to both capitalism and socialism (Heywood 
2003). Lister describes this “Populisiri’ as an attempt to “woo rather than lead the 
electoratd’ and “Pragmatisnri' as a “problem solving or what workS’ approach rather than 
a direct assault on structural inequalities (Lister 2001, p428). The KSF could be argued 
to be a populist policy in that it attempts to provide equanimity and as part of Agenda for 
Change modernize the pay structure. However it already excludes some healthcare 
professionals therefore it cannot be equal. Certainly it is a pragmatic approach to 
attempting to define the core competencies, which must exist if one is to provide an 
equal service and is an attempt to define the reality of healthcare provision and meet the 
needs of the population.
The new labour seeks to move from a passive to an active preventative welfare state 
and with the NHS focusing on more pro-active policies such as preventing illness rather 
than concern with repair or treatment (DOH 1998; DOH 1999b). Health system reform
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must balance two systems: in the short term they must utilize existing services to meet 
the needs of the population and at the same time improve the health of the nation (Black 
2002). It is no longer a question of just throwing money at the NHS in a reactive way but 
focusing on long-term issues in a continuous way. The emphasis is now on devolving 
responsibility back to the individual and this personal responsibility lies at the heart of the 
third way. The KSF fits with the principle of the third way in that it is seen as a continual 
process rather than a once off episode of development and certainly devolves 
responsibility back to the employee to maintain the necessary skills and knowledge in 
which to provide a quality service.
Finally, the third way embraces the idea of competition or market state. A competition 
state is:
"a state whose principal role Is to pursue strategies for national prosperity 
in conditions of intensifying giobal competition. The state should therefore 
concentrate upon social investment, which means improving the 
infrastructure of the economy, and, most importantly, strengthening the 
skills and knowledge of the country’s workforce" (Heywood 2003, p151).
This approach to the economy focuses on supply, aiming to boost production and 
improve competitiveness, rather than a democratic “demand” approach, which aims to 
increase consumption and eradicate poverty. Education and personal development is 
valued in this approach because it promotes employability and benefits the economy In 
an indirect way. From this perspective the government is merely an enabler, setting the 
scene by re-shaping the workforce attitudes, values, beliefs, skills and knowledge rather 
than directly shaping the economy. This has resulted in the UK government having an
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increased interest in competence. Essentially healthcare provision relies on the 
professionals possessing a variety of skills and being competent in those skills. In an 
increasingly litigious society it is essential there is proof of possession of skills. 
Furthermore, increasingly patients have rights to complain and there is increased 
consumer interest in healthcare standards, with media coverage and sometimes hype 
surrounding poor standards or errors or omissions of care. In theory, the KSF enables 
this process, legitimizing the knowledge and skills required to provide a service, and 
thereby is a format for providing evidence for particular skills should complaints arise. It 
could be seen as a way of protecting patients and the system from unsafe practitioners.
5.2 Demographic and epidemiological environment
Ultimately it is patients who create the demand for health services and trends 
undoubtedly influence this demand. Non-communicable disease will most likely 
represent the main burden of mortality and morbidity in the future with respiratory 
disease and cancer leading the field and increasing health risk related behaviours such 
as obesity and smoking (Sausman 2003). Furthermore, latest figures from WHO show 
that global cancer rates could Increase by 50 per cent to 15 million new cases by 2020 
(WHO 2003). There are several implications for the future workforce from the known 
trends in the burden of disease. First the prevention and treatment of chronic disease is 
likely to be a key function of future primary care, for example in the management of 
obesity and diabetes. Here it is envisaged, as in the Wanless report (Wanless 2002), 
that nurses will be taking on new roles in the prevention and treatment of chronic 
disease, in prescribing and in helping patients through treatment programs. Avoidable 
deaths from cancer and heart disease, suggest a more appropriate mix of services in the 
future of preventative, curative and community based and hospital based treatment. The
emphasis may be on lifestyle adjustment with emphasis on prevention and screening.
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This may mean new skills and knowledge development for the healthcare workforce, for 
example, health education and communication skills. The KSF has gone some way to 
meeting this new need, for example, by the inclusion of “health and well-bein^’ 
dimension, focusing on the protection of health, health promotion and prevention of 
adverse effects. This is the first time they have been formally valued as an aspect of 
service provision, previously emphasis was largely on effective treatments. Secondly, 
with the increase in chronic disease burden there is a need to reduce healthcare costs. 
It was described earlier the economic burden of the NHS continues and health promotion 
and disease prevention could be potential sources of reducing costs. Costs may be 
reduced indirectly by investing in staff education and development in health promotion 
skills and this would be a major driver in shaping the NHS KSF.
The introduction of new policy should be driven by patient needs and the growing 
concept of "patient centred care" is emerging. Although, widely used, it is a poorly 
understood concept in practice and in reality it is often doctor centred, hospital centred or 
diseases centred care, which is provided (Stewart 2001). As the Commission for Health 
Improvement said In 2003: “too often care is still organized round the convenience of the 
NHS rather than the people who use the service” (Which 2005). The government 
believes patient choice will drive up standards and improve efficiency as well as provide 
more flexible and personalized care for patients. A study by (Little et al 2001) asked 
patients about patient centred care and it revealed that many doctors do not provide 
patient-centred care and demonstrated a fixed style. There is evidence of tangible 
benefit of patient centred communication and it is positively associated with patient 
satisfaction, adherence and better health outcomes (Stewart 1995). A recent policy 
report executive summary on patient choice (Which 2005) expects choice to transform 
healthcare and the NHS, creating “a more personalized NHS that is responsive to
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consumers’ needS’ (p4). This represents a change in culture whereby choices about 
healthcare are about much more than reducing waiting times and choosing a provider for 
elective hospital care. The government wants an approach that puts patients at its heart 
and involves patients and the public in shaping the future of healthcare. Consumers of 
the healthcare service actually want “better locally provided services that are more 
flexible and treat them fastef’ (Which 2005; p11). This flexibility is at the heart of 
government reform including the philosophy, which underpins the KSF. This flexibility 
implies new ways of working, with perhaps different healthcare professionals taking on 
new roles to provide flexible care. This has been driven by patients, who want to see, 
“fewer faces and more personalized care” (Which 2005, p3). The current medical 
training does not sit nicely with this need, as rotation is required for training purposes; a 
possible solution is to use other healthcare professionals with extended roles and KSF 
may facilitate this development by providing a formal structure for the development of 
multidisciplinary teams working in new ways to provide this personal service. However, 
it may be there are opposing forces that prevent the use of alternative healthcare 
personnel to their full capacity and these will be discussed in more depth in the following 
section.
5.3 Major players
Contemporary healthcare involves a number of professional groups working together for
the benefit of patients, yet professions still remain independent. They are educated
separately, have different hierarchy, document care in different notes and even have
different language and different priorities, which was demonstrated in the research
project. However, there are very few healthcare tasks that are legally restricted to one
group yet the professions still remain entrenched in their respective colleges and
professional regulating bodies, however, in a number of areas the significant barriers are
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being diminished, for example nurses can prescribe although this has been a painfully 
slow process and is still fairly limited. Nurse Practitioners are taking over work from 
General Practitioners and the contribution of specialist nurses with advanced skills to 
clinical teams in acute care is now widely recognised, with nurses providing equal or 
better care than medical staff (Ford 1997; Horrocks et al 2002; Marchione and Garland
1997). The Primary Care Act 1997 opened up new structures for primary care provision 
and in a few pilots nurses are taking the lead in providing and managing primary care 
and even employing GPs. It Is clear from these examples that much effort has been put 
Into team building and improving communication skills but attempts at working together 
continue to be restrained by differences In styles of learning. In career patterns, in 
models of working and in regulatory mechanisms and these developments have been 
sporadic and driven by individuals rather than policy. Moreover there Is still little or no 
movement between professions, for example, it is no easier now for a highly experienced 
and skilled nurse to become a doctor than it was 30 years ago. The KSF still does not 
address this issue as medics are excluded but if “appropriate human resources are to be 
available to meet the healthcare needs of the coming decades these structural problems 
need to be addressed’ (Doyal and Cameron 2000, pi 023). If the nurse is teaching a 
medical colleague and providing clinical supervision where is this addressed in KSF 
therefore the equanimity that it promises to offer is lost. Where nurses take on the work 
of junior doctors (and in some instances senior doctors), for example in the case of the 
Nurse Practitioner there has often not been the supporting educational programme and It 
has been a case of “task drift’ (Doyal and Cameron 2000, pi 024) and have tended to be 
formulated locally and unsystematically (Dowie 1999). Under these circumstances the 
healthcare professionals report considerable stress of being unsupported in “no-man’s 
land’ and the danger may be that patient care could be compromised rather than 
enhanced.
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In assessing the strength of the varying professions and conflict of interests, the powerful 
position occupied by the medical profession is apparent (May 1992). Department of 
health policies that challenge the interests of key groups within a profession are likely to 
be resisted. The Blair government has been able to introduce changes to the regulation 
of the medical profession because of the accumulation of evidence about failures in 
clinical performance, for example, the Shipman report. But some of these changes have 
been painfully slow, for example, the time it has taken for clinical audit to become 
compulsory and independent review, such as the Cancer Peer Review measures. Such 
examples, “speak volumes about the ability of the profession to delay or resist policies 
that threaten clinical autonomf (Ham 2004, pi 84). The medical profession is 
undoubtedly extremely influential as a service provider thus creating an interesting 
relationship between the profession and the government. Ham (2004) suggests this 
power results in considerable discretion being accorded to the medical profession 
because of the strong position of the being them main influence In service provision. It is 
not surprising, therefore, the medical profession, resisted the pressure to be part of the 
NHS KSF, protecting the professional autonomy and retaining power. The other 
professions were more easily wooed, with the promise of improved salary and working 
lives with the introduction of KSF and Agenda for Change. The Trade Unions of the 
other professional bodies were consulted and agreed in 2002 and who could resist with 
promises of “supporting staff to develop’ (p5), “treating all individuals fairly and equablÿ’ 
(p4) and “simple and feasible to implement (p6) (DOH 2004). It will surely take time to 
evaluate the implementation of KSF and to audit if it truly has fulfilled its promises to all 
healthcare workers, with the exception of course, of the medics and senior management 
staff (DOH 2004). What policy measures will be put in place to ensure these latter two 
groups will have the necessary skills and knowledge to be competent?
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5.4 Private sector
Much of the infrastructure to prepare people for success in the world of work is in the 
public sector and this includes the NHS. The private sector will undoubtedly continue to 
grow but NHS policy has tended to ignore this growing sector of healthcare, not to 
mention the voluntary sector. If one returns to the Rushing and Smits model it is clear 
that all sectors should be included when preparing the ideal workforce. Ideally policy 
should encompass all healthcare systems if systems are to be seamless and in terms of 
KSF, if opportunities are to exist to advance knowledge and skills when healthcare 
professionals move from one system to another.
Patients currentiy have a choice whether to have treatment in the independent or public 
sector. Over six million people or around 11 per cent of the population are covered by 
private medical Insurance in the UK (Ham 2004). The number of people with insurance 
has increased steadily throughout the lifetime of the NHS and expansion was particularly 
rapid in the early 1980’s, probably due to the influences of the Thatcher government. 
This trend will probably continue, although in recent years there has been a substantial 
growth in the numbers of people paying for private hospital treatment out of their own 
pocket with some estimates suggesting a three-fold increase between 1997 and 2002 
(Timmins 2003). It is unclear if KSF will ensure the staff in this private sector will be 
appropriately competent and rewarded for their work. If one returns to the Rushing and 
Smits model of the ideal workforce planning consideration should be made to both 
private and public sectors. Just as patients have a choice about whether to have 
treatment in the independent sector so the professionals have a choice whether or not to 
work there. Independent sector employers have for many years attracted staff by 
implementing the “Improving Working Lives Agenda" (Taber 2002), offering flexible 
working hours, empowering staff and providing education and training, career
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development and a clean working environment. If the KSF and Agenda for Change 
improves these systems for the NHS staff it may Impact on the independent workforce 
(Kirk 2004). If healthcare professionals return to the NHS and deprive the private sector, 
how will this influence the choices offered to patients or vice versa? The exclusion of the 
independent sector from KSF contradicts the flexibility and patient choices outlined in 
other policy statements (DOH 2004; DOH 2005). It may be that in the current political 
arena the emphasis is on ensuring the NHS survives even at the cost of the private 
sector. The KSF is described as the “NHS KSF” and is not designed for knowledge and 
skills framework for both private and public sector therefore global health and workforce 
preparation is not being considered.
6.0 Support systems
This section refers to the systems that are required to sustain policy development and 
implementation. Firstly, the ever changing information and technology systems are 
described and how this will require flexibility in the workforce; secondly the human 
resource capacity issues are described, which will influence the degree of success of the 
KSF implementation. Finally this section concludes with a summary of the financial 
policies and climates that may contribute to sustainability of the KSF.
6.1 Information and Technology
The popularity of evidence-based medicine has offered the opportunity to challenge
traditional medical practice and resulted in the shift of power base (Harrison 1998). “The
essential character of a profession is that the members of it have specialized knowledge
and skills which the public will wish to use” (Merrison 1979, p3). This traditional concept
of a profession is being undermined by development in the volume of knowledge, which
now exceeds the abilities of the individual profession to master it (Harrison and Dixon
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2000). The pace at which new knowledge appears has increased and the emphasis on 
evidence-based medicine has undermined old practices. In other words it is becoming 
harder for individual professionals to master all the relevant knowledge and easier for 
non-professionals to gain access to it. In addition, increasing technology allows for 
greater ease of dissemination of knowledge, for example, it has been estimated there 
are 7 million websites, of which 100,000 pertain to health (Sastry and Carroll 2002). 
The combination of these factors should lead to a new approach to investing in 
knowledge and skill acquisition in terms of investment in people and providing a quality 
service. The rapid growth in clinical knowledge has been recognized through the 
introduction of continuing professional development for all the professions. The public, 
who are in fact the “ultimate financiers’ of the NHS (Harrison and Dixon 2000, p239) are 
more Informed, have access to the Internet and are no longer passive users of the 
servlce(Cockburn and Pit 1997). The NHS Direct On-line and the "Expert Patient” 
represent the increasing significance of the role of the user and reflect the increased 
power of the patient in shaping policy development.
It Is difficult to do justice to the current range of medical and technological advances. 
Web-based or IT based therapy may be offered in the future replacing some of what 
healthcare professionals do now (Sausman 2003) and information will be at hand on 
health Issues on virtually any dimension. This may mean patients could be as well- 
informed as the healthcare professional and in some ways it will be easier for the patient 
to be more knowledgeable about a single aspect of health than the healthcare 
professional who has to be knowledgeable about many aspects of healthcare. The 
Technology Foresight Programme in the 1990’s predicted that by 2010-2014,10 per cent 
of surgical interventions could be carried out by robotic techniques (Robert 1999) and 
although this sounds fantastical at the current time, who could have predicted the
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changes that keyhole surgery and angiography techniques would make? For the 
workforce such developments require the development of new skills and new knowledge. 
New surgical techniques, new therapies, on-line health services and electronic health 
databases will require specific skills in research, data and information management and 
other highly specific skill development. As well as the demand for new skills from the 
healthcare workforce, the impact of new and scientific developments will change existing 
roles from one professional group to another, and will need to influence the education 
and training of professionals. This need has forced the modernisation of competency- 
based care and the development of KSF. For example, this need has also included the 
recognition that information and technology skills must be formally integrated as valuable 
and necessary skills for the modern healthcare worker.
6.2 Human resources: national capacity
The NHS employs more professionals than any other sector of the economy. The labour 
force of the UK is projected to increase slowly in the future, reaching 29.8 million by 
Spring 2011 (Armitage and Scott 1998), with the proportion of women increasing to 
46.1% of the overall workforce. The labour force will also be a little older but this is even 
more marked in the nursing workforce (Buchan and Edwards 2000). The ageing health 
workforce will require sustained improvements in recruitment and retention but the NHS 
is traditionally seen as a rigid career, which may not offer the benefits in terms of 
flexibility and pay that other skilled service sector professions provide, and thereby be a 
less attractive option for the new workforce entrants. However, security of career may 
be an advantage if recession and insecurity returns to the UK. In the future it may be 
labour markets are not only influenced by national trends but also by international trends 
because of increased in movement and technology. If so, the health sector will be 
competing with other industries (and countries) for a skilled and educated workforce and
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there are some areas where there will be stiff competition (Sausman 2003) and there are 
ethical as well as supply issues when recruiting from other countries (Buchan 1998). In 
addition, dissatisfaction with national pay settlements has led many nurses to leave the 
NHS (Dowie and Langman1999). This means the health sector will need to deliver on 
making a career in the health service an attractive one in the future. The KSF and 
Agenda for Change have gone some way in delivering on this. The need for flexibility 
and increased pay under a modern system will alleviate some of these issues and this is 
to be welcomed but the decline in nurses and other healthcare workers is a real concern 
and may impinge on the success of creating a flexible workforce and Introduction of new 
ways of working.
There have also been issues with supply and demand for medical staff. Reasons for 
shortage include an accelerating trend for consultants to take early retirement, greater 
demand for consultant delivered (as opposed to consultant led) service and higher 
numbers of women doctors (more than 50% leaving medical school are women) working 
in hospital specialties, some of whom may choose to work part-time or take a career 
break (Allen 2000; Dowie and Langman 1999). The government accepted the Medical 
Workforce Standing Advisory Committee’s (the Campbell Committee) recommendations 
in its demand for a 20% increase in the number of medical students; however, it will be a 
number of years before this has a real impact. In addition, younger doctors are more like 
their contemporaries outside medicine in terms of education and aspirations. They want 
flexibility in their careers and they find it absurd to waste their time performing mundane 
tasks. Portfolio careers will soon be here in medicine and the days of 40 years in one 
specialty in one place will be over (Allen 2000). The professions are going to have to 
change, with more flexible training and multidisciplinary working but as stated earlier 
there is often resistance to change (Allen 2000). As she quotes the Prime Minister
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“There is the challenge for the professions to strip out unnecessary demarcations, 
introduce more flexible training and working practices and ensure that doctors do not use 
time dealing with patients who could be treated safely by other healthcare staff” (p 1533).
Another factor driving change in acute hospitals was the enforcement of the European 
working Time Directive which has made it difficult to provide 24 hour medical cover in 
many specialities and even more so in small hospitals. A government review examining 
decentralization of services suggested the development of extended roles for nurses and 
non-medical practitioners are essential to address the challenges of reduced availability 
of medical staff (DOH 2003). As mentioned previously the KSF supports this legitimising 
the process of role extension within a formal framework. This trend for frustration due to 
the time spent performing non-medical or mundane duties is growing in the medical 
profession. Since the 1980’s it has been known that a large proportion of the time of 
trained clinical staff is used up by documentation, scheduling tasks, meetings and other 
administrative duties (Black 2002; Lathrop 1993). This places pressure to provide 
systems and utilisation of non-clinical staff to reduce the non-clinlcal workload burden. 
The KSF should facilitate the development of new roles to support medical colleagues as 
well as non-medical staff and thereby reduce their time spent on non-clinical duties. For 
example, it may be that “schedulers” are employed to co-ordinate cancer care pathways, 
scheduling therapies, staging procedures and ensuring all results are available prior to 
consultation. Skilled Clinical Nurse Specialists, or medical staff, currently perform some 
of these tasks, but this may not be the best use of their time, and best utilisation of their 
skills and knowledge. Furthermore the Clinical Governance Agenda demands more time 
is spent on audit, risk management and other quality issues which places further 
demands on the clinicians time with medics spending an extra four hours a week on 
management, administrative and professional activities, compared with 1989 and 2
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hours less on clinical work (Dowie and Langman 1999). Some of this demand, however, 
may be relieved by the employment of clinical audit facilitators and quality assurance 
managers.
In summary, difficulties in recruitment are becoming so acute and widespread in the UK 
that they are likely to constrain service delivery and development (DOH 1999; Doyal and 
Cameron 2002; Masterson 2002). Workforce planning has been high on the agenda 
since the mid-1990's and the government has indicated that planning should examine 
how multi-professional teams can provide the best patient-focussed services irrespective 
of professional boundaries (DOH 2000). Although this could be considered as a major 
driver for the development of KSF and Agenda for Change, the threats to available future 
labour workforce are a real concern and may not in fact be a driver to change but a 
resistor to change.
6.3 Macro-economic and financial policies
NHS expenditure has steadily increased over the years (Table 6.3). These increases 
were necessary to enable the NHS to meet the demands created by changes in 
demography, technology and society as described earlier. Analysts of the health service 
pointed out that there was not a fixed quantity of disease but there is potentially infinite 
demand (Ham 2004). This is because of the greater use of services by older people, 
opportunities for diagnosis and treatment opened up by developments in medical 
technology and of course what was alluded to earlier, the emergence of a new 
generation of service users with high expectation of the standard of care to be provided.
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Table 6.3: NHS expenditure in the UK, 1949-2003 (Ham 2004, p74)
Calendar year Total (Em) Total cost at 1949 prices (Em)
1949 437 437
1954 539 434
1959 792 528
1964 1137 667
1969 1733 814
1974 3835 1151
1979 8855 1255
1984 16080 1447
1989 25690 1765
1994 39715 2200
1999 52264 2518
2003 74343 3229
High rates of growth in the 1960s and early 1970s gave way to lower increases in the
late 1970s and 1980s in terms of the cost of the NHS as a percentage of gross national
product (Ham 2004). The Thatcher government was a major influence in tighter control
of public expenditure with emphasis on efficiency, privatization and competition. Social
expenditure was subject to close scrutiny. This trend changed with the arrival of the
labour government in 1997 and the comprehensive spending review initiated by the
government, which from 1999 resulted in a return to higher increases. In 2002 the
Wanless report outlined the technological, demographic and medical trends which may
affect the NHS in an effort to determine the financial and other resources required to
ensure the NHS could continue as a publicly funded, comprehensive high quality service
on the basis of clinical need and not on the ability to pay. It was to inform the
government on future decision-making on NHS spending. It concluded that tax financing
of healthcare should continue and not be replaced by social insurance or private funding
as confirmed in the NHS Plan. It also noted that the UK were lagging behind some other
countries in health outcomes, partly because of the lower levels spent of expenditure on
health in the UK (Irvine et al 2002). It identified a number of factors likely to increase
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spending on health care over the next 20-year period including rising patient and public 
expectation, advances in technology and a recommendation that better use is made of 
information and computer technology. It also recommended the need for stronger links 
between health and social care and as stated earlier greater emphasis on disease 
prevention and health promotion. Although the Wanless review did not necessarily 
break new ground it was an extremely important influential report for securing the future 
financial sustainability of the NHS. In summary this government’s financial commitment 
to the NHS is reflected in the development of the KSF designed solely for sustainability 
of the NHS and protection of the workforce.
7.0 Conclusion
It is clear the NHS is continually being reshaped in response to changing needs and 
fashions, as well as the struggle for power between different professional groups. If one 
brings together the driving forces that led to the development of the KSF it has been a 
process that has evolved over many years. Inevitably tensions exist which may hinder 
the implementation of this policy, for example, problems already exist when professions 
work out-with their traditional boundaries in terms of existing advanced practice roles. 
These forces can be grouped and include drivers and resistors to change (Diagram 2.0). 
National and global policies and financial stability undoubtedly influence healthcare 
policy because they inevitably have an impact on the workforce. The purpose of this 
critical or discourse analysis of course, is not to provide definite answers, but more to 
reveal the hidden politics as well as reveal possible interpretations of the development 
and subsequent Implementation of the NHS KSF. It may also shed light on any flaws in 
the policy, for example, the exclusion of non-public sector healthcare workforce Issues, 
or forecast any problems with implementation of the policy. In summary, the 
development of the NHS KSF was Inevitable when the driving forces are examined
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(Diagram 2.0), however, it may be that now the policy is in place the “resistors” will 
prevent the successful implementation of this policy and there will only be lip service paid 
to the liberation of the professions.
it has been difficult for the NHS to examine long-term issues, including workforce 
development and therefore policy formulation has tended to be reactionary rather than 
visionary. Here the need is to create genuine flexibility between different professional 
roles, as there is the same ultimate goal of providing excellent service provision for the 
users of the NHS. Although such flexibility is creeping in there still remains some 
fundamental errors in the KSF policy. If boundaries are truly blurring why were medical 
staff not included in the KSF? Are their knowledge and skills any different to the other 
professions? And how is the UK to address this with its current shortage of doctors, 
nurses and other professionals? Perhaps the way of the future of the NHS is to provide 
teams of “Healthcare Professionals” equipped with the necessary knowledge and skills 
without any other restrictive professional bodies. These artificial barriers have hindered 
development in the past and there may be a need to become more open-minded at an 
individual and institutional level. However, if the professional bodies are disbanded, this 
may impact on the ethical and professional standards as there will be no regulatory 
systems or alternatively, new systems will have to be devised.
In terms of advanced practice nursing roles the KSF may help provide clarity as nurses 
struggle to fill gaps in the service and assist with the preparation of more junior 
colleagues for advanced roles. It may also assist with preparation of non-professionals 
to develop new knowledge and skills, which will ease the non-clinical burden from the 
clinical staff. However, it does not cover the multitude of shared responsibilities and 
shared learning in the workplace. An awareness of the resistors to KSF and the
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potential of outside forces to influence the successful implementation of this policy will 
hopefully prepare nurses in advanced clinical roles be aware of the pitfalls of role 
development. For example, failure to truly apply cross-professional knowledge and skills 
will be devastating in terms of service sustainability and will frustrate career pathway 
redesign, particularly for nurses taking on advanced practice roles. It is Important that 
the individual disciplines understand the longer term cultural, career, service, education 
and regulatory Impact of changes that are relevant to their sphere of practice as well as 
that of other colleagues who form part of the increasingly complex team.
The NHS KSF has tried to address certain kinds of knowledge, for example, non-clinical 
and managerial knowledge that have been previously neglected or deemed to be of 
secondary Importance. These gaps have become more evident as the NHS has been 
increasingly called to account for its performance as a system of care and a user of 
national funding. This “calling to accounf whether it is through more effective external 
audit or through politically driven measures to Improve performance has revealed an 
organisation short of many of the skills and the knowledge base required to provide an 
effective system of health care delivery. The KSF and Agenda for Change policy may 
offer signs of hope but time will tell. It may be the exclusion of medics and senior 
management staff will hold back the changes that KSF and Agenda for Change may 
have allowed, because ultimately these personnel form the bulk of the healthcare power 
base.
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Service Development Project: Assessment of cancer related anaemia and the 
Impact on blood transfusion practice
The service development project provided some of the stimulus and foundations for the 
research project, which was described in Part 1 (Chapter 3; section 3.3). It was a 
practice-orientated project to audit transfusion practice in oncology and haemato- 
oncology and to establish the transfusion triggers used in the clinical setting. This 
provided a baseline measurement of current transfusion practice in the clinical setting 
and a foundation for a change management programme to improve blood transfusion 
practice. The service development project was presented as a series of five slides and 
1000 words in support of the slides and these are presented below.
1.0 Introduction
Cancer Related Anaemia (CRA) is common in patients with haematological and solid 
tumours malignancies. The pathogenesis is variable, but may involve bleeding, erythroid 
hypoplasia, reduced red cell survival, nutritional deficiencies, decreased erythropoietin 
levels and poor Iron re-utilisation by bone marrow (Bokemeyer 2005; Estrin et al 1999). 
CRA Is exacerbated by myeiosuppressive chemotherapy and may be aggravated by 
radiotherapy (Barrett-Lee et al 2000). Cancer patients can experience such severe 
anaemia that blood transfusions are required for symptomatic palliation. The transfusion 
trigger is set at a pragmatic level of 8g/dl in this Trust with a few exceptions. The British 
Society of Haematology also recommends this trigger (BCSH 2001). Blood transfusion 
guidelines exist in this large acute teaching hospital but there was a perception these 
were not being adhered to and variation in transfusion practices in the treatment of CRA 
existed, between the sub-specialisms of haemato-oncology and oncology.
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2.0 Slide 1 : Background
Background:  R isk -Bene f i t  
evaluat ion o f  b lood transfusion in 
the treatment o f  C R A
Benefit
-R e lieves  symptoms of 
cancer-related anaemia, e.g. 
S O B , fatigue, tachycardia, loss 
of concentration ^
-Im m ed ia te  Î  In Hb and blood 
volume  
-Efficacious
Risk
-R isks of transfusion, e.g. 
Infections, Im m une reactions  
-Translent effect 
-D ecreas ing  efficacy In 
advanced  d isease  
-U nnecessary Transfusion?  
Treating sym ptom s due to 
other causes, e.g. disease, 
treatm ent factors
The presence of CRA decreases patients’ quality of life, impacts on fatigue (Demetri 
2001; Glaspy 2001; Ludwig and Strasser 2001) and is associated with shorter survival 
times in cancer patients (Caro et al 2001). Correction of anaemia may have a positive 
impact on treatment outcomes (Blohmer at al 2001; Glaser et al 2001; Grogan et al 
1999; Littlewood ef a/ 2001) however these studies have improved intrinsic haemoglobin 
levels by erythropoietin, not by transfusion.
There may be ritualistic practice in transfusion with a tendency to treat laboratory values
rather than do a full assessment of the impact of anaemia (Foubert and Wujcik 2005). It
can be difficult to distinguish between symptoms of disease and symptoms of anaemia,
resulting in a tendency to over-transfuse, particularly in advanced stage disease. In
addition, there is considerable variation in transfusion practice between different
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countries and even within different departments (Foubert and Wujcik 2005) in spite of the 
presence of clinical guidelines (Barrett-Lee ef a/2001).
Each unit transfused carries risk (Text Box 2.0). Exposing patients to blood transfusion 
may not be the best supportive care practice. The mandate from the NBTS and the RCN 
is to minimize exposure (RCN 2006) and prescribe biood only when it is really needed 
(McClelland 2002), hence the recommendation for single unit transfusions (Garrioch 
2003).
Text Box 2.0: Risks of transfusion (Nowrousian 2002)
Immunologic reactions including immunosuppression 
Transfusion Transmitted Infection (HIV, CMV, Hepatitis B,C, Bacterial 
infections, vCJD, malaria)
Transfusion errors
Acute haemolytic transfusion reactions 
Fluid overload
Severe allergic reaction or anaphylaxis 
Transfusion Associated Acute Lung Injury (TRALI)
Transfusion Associated Graft versus Host disease
Reactions due to other red cell antibodies other than anti-A and anti-B
Delayed haemolytic reactions
Post Transfusion Purpura
Febrile non-haemoiytic reactions
iron overload
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3.0 Slide 2: The audit
Agenda Setting; Incidence o f  C R A  and 
the use o f  blood
I u ilw  lu  i f I II ( 2 0 0 4 1 I Ik - I u ti> |H '.(ii c . iiiLi'i a iK K -in i.i s i i n  c \  I IK  AS I. I . i i r .  J of  (  ’n i u n . 411. p 2 2 'f  t -2 .tO ( i
Scri'icc Devc lo p in en t Pro ject A im s : To achieve o p t im a l  b lood
transfus ion  stratef>ies hy iniprovinf> c l in ic a l  decision in a k i i i f '  in the  
assessment a n d  tre a tm e n t  of ca n c e r -re la te d  a n a e m ia ,  thereby  
m in im is in f i  p a t ien t  r isk a n d  costs
The EGAS survey (n=15,367) was conducted to prospectively evaluate the prevalence, 
incidence and treatment of anaemia in European cancer patients (Ludwig et al 2004). A 
UK audit revealed a trigger of 7.9g/dl (n=103). The volume of transfusion varies 
according to diagnosis, complexity and tumour type (Appendix 1, Table 3.1a & 3.1b) 
(Bokemeyer 2005; Estrin et al 1999; Ludwig et al 2004). Eighty-eight per cent of 
transfusion episodes in the cancer population are 2 unit transfusions (Barrett-Lee et al 
2000). An audit was undertaken to examine blood usage in haemato-oncology and 
oncology in this acute Trust (Text Box 3.0). This project integrated well with other Trust- 
wide projects examining strategies of reducing blood transfusion.
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Text Box 3.0: Aims of the audit of blood usage in haemato-oncology and oncology
• To audit the blood product usage within haematology and oncology for 3 
months and establish the transfusion triggers
• To assess compliance with trust policy on blood product ordering thresholds.
• To assess the clinical decision making process in the assessment and 
treatment of CRA
3.1 Establishing transfusion triggers 
Method
• Obtain data of all blood transfusions in haemato-oncology and oncology
• Use EPR to establish haemoglobin level at time of transfusion (< 48hours)
Results
Number of 
transfusion episodes
Mean Hb transfusion 
trigger
Range
Haemato-
oncology
54 7.8g/dl 5.1-10.3g/dl
Oncology 202 9.1g/dl 5.8-12.8g/dl
3.2 Documentation of rationale for transfusion
Method: Twenty randomly selected case-notes were analyzed.
Results
• Only 2 out of 20 had details of assessment of CRA and reasons for transfusion.
• Reasons included breathlessness and tiredness. One of the patients had 
bilateral pleural effusions
• Mostly stated “2 units blood” with no assessment or decision-making details
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Timing of transfusion
11.8% (n=24) of oncology patients were transfused within 1 month of death. This data 
was unavailable for haemato-oncology.
Table 3.2: Single vs Multiple Unit Transfusions (Oncology only)
Number Percentage
Single unit 14 6.9
2 unit transfusion 162 80.2
3 unit transfusion 21 10.3
> 4 unit transfusion 5 2.5
Total 202
3.3 Costs of transfusion
Data was obtained for blood transfusion budgets and whether there was over or under 
spend on blood (Slide 2), which shows overspend on oncology blood product.
3.4 Audit Constraints
Unfortunately oncology diagnosis data was not accurate so it could not be established 
which tumour types or radiotherapy/chemotherapy treatment sub-groups received 
more/less blood transfusion. There was missing data in haemato-oncology, which 
resulted in the inability to compare transfusion practice in terms of single/multiple 
transfusions and timing of transfusions. Time constraints meant only 202 oncology blood 
transfusion patient episodes were examined.
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3.5 Summary of context analysis
Text box 3.5 shows a summary of the context of the audit and some preliminary ideas. 
Text Box 3.5
Haematology and oncology patients use large amounts of blood products with 
attached costs.
Patients may be admitted for transfusion because the Oncology Day Units do 
not offer a transfusion service necessitates admission unlikely to admit for 
single transfusion alone. This may increase actual costs.
Haemato-oncology Day Units offer a blood transfusion service facilitates 
single unit transfusion but need to establish the ratio of single unit/multiple unit 
transfusions
Local and national transfusion policy and guidelines exist but not adhered to
Blood prescribing behaviours are different between haemato-oncology and 
oncology
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4.0 Slide 3; Force field analysis
Force Field Analysis-(Driving &
Restraining forces, Lewin 1951 )
Patient Factors e.g. lab 
values, disease status, PS, 
treatment, choice
Knowledge & Skills of 
ealthcare Professional,
e.g. Weighting of 
evidence, fallible factœs, 
risks of transfusion
PtMicy e.g. local and 
national, NICE guidance
Global Influences
e.g. new pathogens, 
doncw shortage, T costs
Ethical Issues e.g. QoL 
issues, end of life issues
There are a number of theoretical models of change, which describe the processes 
where organizations successfully alter their practices, structure or climate. A diagnostic 
analysis identifying factors to influence the proposed change is useful. Lewin developed 
a three-step model for implementing change (Text Box 4.0) based on the concept of 
Force Field Analysis (FFA) (Lewin 1951). FFA change theory is based on the premise 
that driving forces must outweigh resisting forces if change is to be successful, however 
it assumes that simply introducing change will result in new practices being adopted or 
being sustained over a long period of time. There is a danger these forces are viewed 
as opposing but the aim of this FFA was to not create battle lines but to make a realistic 
all-round assessment of everything that could influence change (Appendix 2).
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Text Box 4.0: Three-step model (Lewin 1951)
“ Unfreezing” -getting the need to change to be accepted; involves dismantling 
processes or behaviours that support or maintain the previous behaviour 
Change/transition/moving-the new concept is introduced; an alternative; 
Introducing a clear and appealing option or new pattern of behaviour 
“ Re-freezing” - consolidating the revision so there is no reversion to the old 
behaviour
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5.0 Slide 4: Managing change
Developing a Strategy
(“ Unrrce/inti” -A T ra n s itio iw “ Refreeziniz")
Strategy
Directive Strategies
Expert Strategies
Negotiating strategies
Educative strategies
Participative strategies
Advantage
i Driven hy people in 
j power!III positions
I Driv en hy know ledge &
I expertise
I 1 he ability to recognise the 
I interests o f all parties 
! involved in the change 
I process
I "i'oin stall w ill have a hetter 
: inulerstandiiiii
Disadvantage
You may alienate those w ho 
w ill implement the change
The time it w ill take to adapt 
to new systems
C'oncessions may need to he 
made. Consider stakeholder 
perspective
Implementation w ill he time 
consuming
^'oii can make the hest use The process can he complex
ol all your stall resources and time consuming
It is a naïve assumption that when research evidence is made available it is accessed by 
practitioners, appraised and then applied in practice via Clinical Practice Guidelines 
(CPG) (NHS Executive 1996). Blood transfusion guidelines, including mandatory 
transfusion education, are practiced in all hospital settings, but optimal transfusion 
practices may not exist and the reasons for this are complex. A variety of strategies will 
be required if change is to be successful (slide 4). Barriers to change are summarised in 
Text Box 5.0. In addition, despite the growth of CPGs their actual value is infrequently 
assessed through formal evaluation procedures (Babinski 1996; Carter ef a /1996).
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Text Box 5.0: Barriers to change
1. Change models suggest that implementation programmes can be successful if 
they use interventions and activities that reduce restraining forces (Garside
1998).
2. Increased workload, lack of time, poor communication and traditional working 
practices may all contribute to resistance to change (Firth-Cozens 1997).
3. Multi-faceted interventions may be more expensive and/or time consuming so 
additional resources may be required
4. Health professionals may not believe the evidence: they may have other 
information, which suggests the contrary (e.g. use evidence from erythropoietin 
studies which show that patients QoL increases as the Hb increases)
5. Groups of health professionals make different decisions to those of individuals. 
Although a group may agree for example to not transfuse unless the 
haemoglobin is less than 8g/dl as per hospital guideline, a healthcare 
professional faced with an individual patient may tend to err on the side of 
caution or rely on personal experience
6. Decision-making is often affected by the severity of the potential outcomes in 
comparison to the anticipated regret for different pathways not taken (Col et al 
1997) e.g. a healthcare professional might be more likely to transfuse a patients 
because he/she considers the risks of anaemia to be greater and more worrying 
than the risks of transfusion.
5.1 Phase 1: “Unfreezing”
The first step is to highlight the need for change and get agreement from the major 
stakeholders that this project is worth tackling (Text Box 5.1) (Lomas 1993)
Text Box 5.1 : Getting agreement that a topic is worth tackling depends on:
Whether the issue is perceived as a significant problem by those who have to 
change
The extent to which it ties in with national policy and whether it will be supported by
those charged with implementing national policy
Whether all the major problems associated with the change can be solved
Whether there are key individuals or organisations who are strongly opposed to the
change
The nature of the vested interests, either in the proposed change of the status quo 
The resource implications of the change
Whether there is a significant gap between what people publicly say about the 
change and what they are prepared to do
The change delivers a relative advantage, whether it will be compatible with 
current beliefs or working practices or whether it can be piloted (Stocking 
1992)____________________________________________________________________
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5.2 Phase 2; Changing, moving and transition
A range of interventions has been shown to be effective in changing professional 
behaviour in some circumstances (Appendix 1 & 2). These are summarised in Text Box 
5.2.
Text Box 5.2: Summary of research findings on professional behaviour change
(Appendix 3 & 4)
1. There is little evidence that passive dissemination alone results in behaviour 
change [32] however, this approach may be useful for raising awareness of 
research methods
2. Most interventions are effective under some circumstances; none is effective 
under ail circumstances
3. Interventions based on assessment of potential barriers are more likely to be 
effective
4. Muiti-faceted interventions targeting different barriers to change are more 
likely to be effective than single interventions
5. Educational outreach is generally effective in changing prescribing behaviours
6. Reminder systems are generally effective for a range of behaviours
7. Audit and feedback, opinion leaders and other interventions had mixed effect 
and should be used selectively
Table 5.2: Action Plan
Restraining Forces ’ ■ Process t -’ LiaseWith
Limited stakeholder engagement Audit and feedback at 
Oncology/Haemato-oncology Clinical 
Audit Study Day
Haemato-oncology and 
Oncology Teams
Knowledge & Skills In assessment and 
treatment of CRA In oncology healthcare 
professionals (Medical & nursing staff)
Initiate and implement “Back-2-Basics- 
Anaemia” outreach education
Consultant 
haematologists 
Joint Nurse/Medical 
education sessions
Knowledge & Skills in blood minimisation 
strategies
Include In mandatory training Blood Transfusion 
Practitioners
Patient Information to address ethical 
Issues
Blood transfusion PIL Clinical staff In all areas
Limited oncology day unit capacity Contribute to Capacity & Demand 
Analysis of day unit services in the 
network chemotherapy review of 
services to ensure capacity includes 
transfusion
Lead Chemotherapy 
Nurse
Service Improvement 
Facilitator
Complexity of assessment of CRA Reminder systems in all clinical areas 
(flow chart/slide 5)
Clinical teams
Complexity of Clinical Practice 
Guidelines (CPG)
Add CRA specific section to CPG Blood Transfusion 
Practitioners; Consultant 
Haematologist 
(Transfusion)
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6.0 Slide 5: Developing a template for improved decision making
Does your patient need a 
transfusion?
Patient with 
suspected CRA
Signs and symptoms of 
CRA, Hb >8g/dlNo signs and symptoms of 
CRA  
Hb > 8g/dl
Signs and symptoms of 
CRA, Hb <8g/dl
Symptoms more likely to 
be due to therapy/disease 
or further T in Hb 
anticipated
Symptoms more likely to 
be due to anaemia 
or further f  in Hb 
anticipated
clinic < i-2  weeks with hold blood or give 1 
unit only
6.1 Phase 3: Refreezing and evaluation
Consolidating a change can be the greatest challenge. It is easy to return to previous 
practices without constant motivation and reminders (EHC 1994). A further challenge 
exists in the constantly mobile workforce so any change implementation strategies has to 
be continuous. Any systematic approach to changing professional practice should 
include plans to monitor, evaluate, maintain and reinforce any change, e.g. monitored by 
an annual audit programme or continuous surveillance.
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6.2 Discussion
In summary, the amelioration of CRA should be considered a priority in providing best 
supportive care in this population, with the emphasis on neither, over- or, under­
transfusing of blood. Further research is needed to evaluate the role of transfusion in the 
treatment of CRA for example:
• Do cancer patients who are exposed to transfusion have an increase in co­
morbidity?
• Can single unit transfusions be used effectively in this population, with scoring of 
symptoms after each unit transfused?
• Studies to examine healthcare professionals' CRA assessment skills.
As transfusion costs increase, or if blood becomes more scarce, it may be that 
erythropoietin will be re-considered by NICE but until this happens research must 
continue to enable optimal transfusion practice for the treatment of CRA.
422
Appendix
Appendix 1 : Frequency of anaemia and transfusions
Table 3.1a: Frequency of anaemia during cancer treatment and transfusion (Bokemeyer
Disease Anaemic patients (%) Patients receiving 
transfusions (%)
Multiple myeloma 47 22
Cervical cancer 34 16
Ovarian cancer 34 15
Lung cancer 34 13
Non-Hodgkin’s lymphoma 32 16
Testicular cancer 32 14
Prostate cancer 21 12
Colorectal 13 8
Breast Cancer 12 8
Table 3.1b: Significance of mean number of units transfused (Estrin et al
Overall No of blood units transfused
Mean P Value
Adults 5.8
Children 6.1
Difference 1.5 0.009
Complex patients 8.0
Common patients 4.2
Difference 3.8 0.000
Solid tumours 4.7
Haematological tumours 7.1
Difference 2.4 0.001
Males 6.5
Females 5.2
Difference 1.3 0.058
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Appendix 2; Transfuslon practice force field analysis summary
Patient factors:
Patients may be Influencing the decision to transfusion to relieve symptoms 
due to other causes, e.g. from perception that it will relieve fatigue as stated in 
Bacup Fatigue booklet.
Do they know the risks of transfusion? Have they consented?
Knowledge & Skills
Implication that oncology are over-using blood, which may be due to lack of 
skills and knowledge in assessment of CRA
Mandatory blood transfusion is in place for 4,500 healthcare professionals in 
the Trust and includes the management of risk of transfusion and safety issues 
but not the importance of minimising exposure
Global Influences
Around 3.4 million blood components are transfused every year in the UK. This 
increases every year (RCN 2006)
New pathogens, means the blood donor pool is shrinking and a scarce 
resource must be used carefully (Thomas 2005)
Costs are escalating as collection, testing, processing and administration 
systems become more complex (Varney and Guest 2003)
Prioritising & Rationing
Audits reveal 25% of cancer patients who require blood are admitted (Barrett- 
Lee et al 2000) = waste of resources as most transfusions can be undertaken 
on an out-patient basis if there were not a lack of day beds 
The actual number of blood donations increased by 2% in 2000-2001 but the 
cost of transfusion increased by 256% to £898 million (Varney and Guest 2003) 
with the direct cost of the blood product accounting for only 19% of the total 
cost of transfusion (Cremieux et a! 2000)
The NHS cost for an adult transfusion was estimated to be £635 for red blood 
cells, when hospital stay, management of complications and cost to society 
were included (Varney and Guest 2003)
Policy
NICE guidelines did not recommend erythropoietin therapy for routine treatment 
of CRA therefore blood transfusion remains the primary treatment option for 
CRA
National policy to reduce blood usage 
Ethical Issues
Ethical issues are powerful influences. It is difficult 
to withdraw blood transfusion in the palliative care setting if the patient 
has had blood transfusion support throughout active therapy period 
(Stone et a! 2000)
Risk of under-transfusing
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Appendix 3: Reviews of the effects of broad implementation strategies on professional 
practice
(CME=Continulng Medical Education; RCT= Randomised Controlled Trial; CCT=Controlled
Authors and 
focus
Inclusion criteria Main Results Main Conclusions
Effectiveness of 
CME
(Davis et al 1995)
Study design: ROT, OCT 
Participants: healthcare 
professionals
Intervention: Educational 
intervention
Outcomes: Objective 
measure of physician 
performance or healthcare 
outcomes
99 studies met the inclusion 
criteria. Improvements in at least 
one major endpoint in physician 
performance or patient outcome of 
care were identified in 66% of 
comparisons. Single strategies 
likely to be effective included 
educational outreach, opinion 
leaders, patient mediated 
interventions and reminders. 
Multi-faceted interventions were 
more likely to be successful. 
Studies which undertook a needs 
analysis to inform the development 
of the interventions appeared more 
likely to be positive
Widely used CME delivery 
methods such as conferences 
have little direct impact on 
improving professional practice. 
CME provides seldom use more 
effective methods such as 
systematic practice-based 
interventions and outreach visits.
Effectiveness of 
continuing education 
on nursing practice 
(Waddell 1991)
Study designs: 
not explicitly 
stated
Participants: nurses 
Intervention: Continuing 
nurse education 
interventions
Outcomes: Practice related 
behaviours
34 studies met the inclusion 
criteria
Education positively affects 
nursing practice. The average 
number of an intervention group 
performed as well as or better than 
77% of the members of control 
groups. Findings that related to 
mediating effects were 
inconclusive.
The overall effect supports the 
hypothesis that continuing 
education positively affects 
nursing practice. There was a 
greater likelihood of effect when 
learners were from the same 
practice environment and 
planned their continuing 
education activities accordingly
Relationship 
between compliance 
rates and the subject 
of practice guidelines 
(Schwartz et al 
1996)
Study design: Not explicitly 
stated (CBA, XS) 
Participants: Providers 
Intervention: Publication or 
dissemination of guidelines 
developed by official 
organisations
Other: studies of locally 
developed guidelines also 
included
23 studies with 143 
recommendations addressing 70 
different aspects of medical 
practice were included. The overall 
mean compliance rate was 55%. 
High complexity recommendations 
had significantly lower compliance 
rates. There was no significant 
difference in compliance between 
recommendations with high versus 
low observability
There was a high degree of 
variation in reported compliance 
rates and a low average 
compliance rate. High 
complexity/low triability 
recommendations may require 
more active dissemination 
activities to predispose 
practitioners to change their 
behaviour than low complexity 
/high trialibility recommendations 
where efforts can focus more 
quickly on enabling change at 
the local level
Effectiveness of 
strategies for 
implementing clinical 
practice guidelines 
(EHC 1994)
Study design: ROT, CBA, 
ITS
Participants: Medical staff 
Intervention: Guideline 
dissemination and/or 
implementation strategies 
Outcomes: Process of care 
or patient outcome
91 studies met the inclusion 
criteria
81 of 87 studies reported 
significant improvements in 
adherence to recommendations of 
practice guidelines 
12 of 17 that reported patient 
outcome also reported significant 
improvements
Properly developed guidelines 
can change clinical practice and 
may lead to changes in patient 
outcome
Guidelines are more likely to be 
effective if they take into account 
local circumstances, are 
disseminated by an active 
educational intervention, and 
implemented by patient specific 
reminders
Effectiveness of 
strategies for 
implementing clinical 
practice guidelines 
(Davis and Taylor- 
Vaisey 1997)
Study designs: not clear 
Participants: Practising 
clinicians
Intervention: Guideline 
implementation strategies 
Outcomes: Not clear
Weak interventions included 
didactic traditional CME and 
mailings; moderately effective 
interventions included audit and 
feedback; relatively strong 
interventions included reminder 
systems, academic detailing and 
multiple interventions
Future implementation strategies 
should be based on an 
understanding of the forces and 
variables influencing practice 
and through the use of methods 
that are practice and community 
based rather than didactic
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Appendix 4: Summary of systematic reviews of the effects of implementation targeting 
specific behaviours related to prescribing
(CME=Continulng Medical Education; RCT= Randomised Controlled Trial; CCT=Controlled 
Clinical Trial; CBA=Controlled before/after; XS=Cross Sectional; ITS=lnterrupted Time Series)
Authors and 
focus
Inclusion criteria Main Results Main Conclusions
Improving drug 
prescribing in 
primary care 
(Soumerai et al 
1989)
Study designs: ACT,
CBA, ITS)
Participants: Physicians 
Intervention: Non-
regulatory, non
commercial programmes 
to improve drug 
prescribing
Outcomes: Drug
prescribing practices
44% studies met inclusion
criteria. 85% of inadequately 
controlled studies reported
positive findings, compared to 
55% of well controlled studies. 
Dissemination of printed
educational materials alone 
reported to be ineffective in all 
adequately controlled studies, 
whereas every uncontrolled 
study reported positive effects
Mailed educational materials 
alone may change knowledge 
or attitudes, but had little or no 
effect on actual prescribing 
behaviour. Few well controlled 
studies have documented the 
effectiveness of group 
education. Ongoing feedback 
may be effective in improving 
certain types of prescribing 
practices, such as generic use 
of drugs in academic settings. 
Brief one-to-one educational 
outreach sessions are effective 
in substantially reducing 
prescribing.__________________
Review of 
techniques to 
improve prescribing 
behaviour 
(Anderson and 
Lexchin 1996)
Study designs: RCT 
Participants: Physicians 
Interventions:
Interventions to improve 
prescribing behaviour 
Outcomes: Not explicitly 
stated
9 studies met the inclusion 
criteria. Printed educational 
materials alone do not improve 
practice. Interventions
combining education and 
feedback were found to be 
more effective. Educational 
strategies involving face-to-face 
contact between the expert and 
the physician were successful. 
Feedback including specific 
recommendations for change in 
the use of medications were 
more successful than a 
description of current practice
Specific educational and
feedback strategies can
improve quality of care.
Results are limited due to the 
lack of data found on patient
outcomes. Need for further
research on prescribing and on 
providing information to
patients.
Effectiveness of 
interventions to 
improve prescribing 
behaviour 
(Gill 1998)
Study designs: RCT, CBA 
Participants: Physicians 
Interventions:
Professional interventions 
Outcomes: not explicitly 
stated
79 studies met inclusion 
criteria. 53 were single 
intervention studies and 22 
multi-faceted intervention 
studies. 51% of interventions 
changed prescribing behaviour 
in comparison to the control 
group. Multi faceted
interventions had some effect 
on changing prescribing 
behaviour
No clear differences between 
approaches. Multi-faceted 
approaches are most 
promising.
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Research Log
The research log provides an overview of the process and timelines involved in the 
research project. It describes the initiation, the planning, the literature review and the 
supervision sessions and concludes with a summary of the research project process.
1.0 Getting started
The quality of research expected at doctoral level is underpinned by the researcher’s 
imagination, inspiration, motivation and intellect and without it an original contribution to 
knowledge is unlikely. However, despite having original Ideas and questions, it was 
difficult to know where to start, but the doctorate structure provided guidance by 
demanding early pieces of written work, for example the policy review and topic review. 
The topic review was submitted in 2005 and was designed to assist with the literature 
review. The service development project in 2006 also assisted with focusing the 
development of the research question and this was described in the previous section, but 
some questions remained unanswered, for example, why did the variation in practice 
exist?
Although the researcher did the majority of the work, the project would not be achievable 
without the assistance of others, particularly the experience and wisdom of the 
supervisors, but also the clinicians in the workplace and key administrators who would 
assist with the approval processes. It was important therefore, at the outset of the 
research to start formulating lists of key people who could assist with the development of 
the research project and these key individuals are listed in Appendix 1, but their names 
have been excluded for anonymity purposes. In summary, starting the project was 
dependent upon speaking to the right people, sharing ideas, generating questions and
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starting to plan, which was dependent upon collaboration with the key people and 
negotiation with the supervisors.
2.0 Current and past research: the literature review
The researcher was fortunate to attend a bi-annual cancer related anaemia conference 
in Rome in 2005. This was a meeting of experts in cancer related anaemia and a vast 
summary of the literature was provided as well as an opportunity to meet experts in the 
field and listen to their presentations, which were inspirational (for example Drs Barrett- 
Lee, Glaspy, Aapro, Littlewood etc). It is important to note this was a pharmaceutical 
sponsored event and therefore the focus of the conference was on the erythropoietin 
literature. This opportunity also provided literature to contribute to the overall literature 
review.
The literature review is described in the research thesis in Chapter 2 (Parti) and the 
researcher had access to multiple libraries for example. The Royal Marsden library, 
University of Surrey Library and Kings College London. A relationship diagram was 
developed to focus the literature review and to ensure the different elements were 
explored. The literature review was an Iterative process as the project developed but in 
summary the aims were:
• To provide a summary of representative literature
• To provide an overview of the knowledge base, including methodology
• To identify gaps in knowledge and develop a specific focus that supported the
research being undertaken
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In summary, the literature review critically evaluated the literature with the aim of 
underpinning and justifying the research, clarifying and creating conceptual frameworks 
(e.g. symbolic interactionism) and helped to clarify areas that were less well understood 
(e.g. the reasons for variation in transfusion decision making).
3.0 Project management
Researchers are faced with a considerable amount of project management and guidance 
was needed to plan and co-ordinate the research project. Supervision was an essential 
component to enable successful completion of the doctorate thesis. Two experienced 
researchers facilitated this project and helped to:
• Bring together ideas
• Focus the research question
• Develop the methodology
• Direct the researcher to key experts in the field, research papers, theory and 
literature
• Ensure student achieved work within agreed time frames
The supervision sessions became more focussed as the research project progressed. A 
summary of supervisory meetings, their content and agreed objectives set at each 
meeting is demonstrated in Appendix 2. Early delays in submitting the proposal was due 
to time constraints imposed by work pressures, however, researcher activity increased In 
2007 and the research proposal was submitted to NRES, the local ethics committee and 
subsequently the university ethics committee September 2007. Data collection 
continued from December 2007 through to October 2008, with substantial amendment to 
the project in August 2007, which is described in Chapter 1 and Chapter 3 of the thesis.
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Supervision continued throughout and increased during the data analysis and writing up 
stage to ensure the project was managed within the timelines. The first draft of the 
thesis was submitted in December 2008 and final draft in February 2009. Amendments 
were made accordingly following feedback from the supervisors. Part 2 was compiled in 
January and submitted in February 2009 as was the “Overview of the integration of 
knowledge, research and practice" (Part 1 ). The clinical academic paper was drafted 
following the completion of all the other elements, and final feedback received, in order 
to ensure the academic paper was of the highest quality and there was clarity of the 
important elements of the research had been checked by the supervisors.
4.0 Reflexive ethnographic journal
The researcher kept an informal reflective diary in the form of the reflexive journal to 
record thoughts and meetings/discussions with any of the key people described in 
section 1.0 as well as preliminary analytic thoughts. This was an essential component of 
ethnography as described in Part 1 (Chapter 7, section 7.5). For example, early 
excerpts describe visits to the lung clinic “very busy, packed waiting room, people afraid 
to get up from seats in case they lose their slot” and observations from the day care unit 
“a patient wants a newspaper to read whilst he is waiting for his cannula to be put In and 
his blood to start'. Both of these observations are from December 2007 prior to formal 
observation and interview work but formed part of the ethnography in that the researcher 
was beginning to formulate a picture of what happened and where to ensure more 
focused observations and interviews could occur at a later stage.
Notes were also taken in the research journal when key meetings took place with key 
people who informed or assisted with this project and who are identified in Appendix 1.
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For example, during a meeting with an experienced ethnographer the following notes 
were made:
What do I want to observe in the clinic?
Are all the patients relevant?
What is the structure of the consultations?
Who is present in the Consultations?
What are the things that are shaping the clinic and how it functions?
Where do they (patients and clinicians) sit?
What took place?
What were the behaviours?”
These notes assisted the researcher focus during the subsequent observations in clinic 
and helped her to understand that It was not possible to record every consultation and 
every aspect of the clinic, but learn to focus on the important elements of the behaviours 
and environment within the clinical settings. It was the small interactions and exchanges 
of meaning (symbolic interactionism) that was important to capture during the fieldwork 
observation and interviews with key staff and patients. This meeting helped to clarify this 
for the researcher and therefore it is recommended to meet and discuss how to conduct 
the research with other experienced ethnographers if ethnography is the methodology of 
choice.
Early notes taken following some of the interviews and observation fieldwork revealed 
the beginnings of the sub-themes within the final research findings. These are described 
here as “analytic memod' and included notes were made on the “role of uncertaintf and 
“knowing the patient: Are relationships important?" as the researcher started to formulate
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ideas. The diary was kept throughout until completion of the thesis. The diary was also 
used to project manage and keep timelines and activities documented.
5.0 Summary
The project took four years to complete and the writing up was sporadic and dependent 
on research activity, although the final six months were the most intense. Ideas changed 
throughout therefore even when the final proposal was passed by the ethics committees 
in September 2007, it was important not to have fixed ideas about either the flow of the 
project or the outcomes. Several factors contributed to the successful completion and 
these included good relationships at work, for example, with the chairman of the ethics 
committee and face to face communications with the ethics committee and R&D 
committee administrators, as well as the clinical teams. Relationships with the research 
supervisors were also perceived to be positive because of their relevant experience, their 
accessibility and good communication, requests for work, and meticulous and timely 
feedback, and recommendations for reading.
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Appendix
Appendix 1 ; Key people
Identify people who 
may help
Date
contacted
Notes
Blood transfusion 
lead clinician
Dec 2005 Meeting 11.12.05 to discuss provisional plan, 
feasibility and obtain support
Blood Transfusion 
Practitioners
January 2006 Meeting 11.12.05 to discuss provisional plan, 
feasibility and obtain support
Consultant
Haematologists
February
2005
One of the haematologists is also LREC chair
Lung Oncologists January 2007 Informal meeting with both to gain approval 
and seek access to clinics
Lung ONSs April 2005 Informal meeting with both to gain approval 
and assistance with patient and staff 
recruitment
Haematology ONSs April 2005 Informal meeting with both to gain approval 
and assistance with patient and staff 
recruitment
Day Unit
Sisters/Charge
Nurses
April 2005 Informal meeting with all individually to gain 
approval and seek access to clinics/assistance 
with patient recruitment
Research Supervisor Feb 2005 Meeting with supervisors 12.6.05 (discuss 
process of projects for DCIinPrac )
Meeting with supervisor 3.8.05 (Policy Review 
and Personal Development)
Research Supervisor 
(changed)
October 2006 Changed one of the supervisors because 
project changed to include ethnography
Researcher 
experienced in 
observation 
techniques
October 2006 Advice and helpful hints meeting to assist with 
observation techniques
R&D Lead October 2006 Consultant haematologist
Informal meet to discuss process and attend
R&D meeting
R&D co-ordinator July 2007 Meet with R&D coordinator for Oncology & 
Haematology
LREC co-ordinator May 2007 Telephone conversation and e mail 
correspondence to ensure LREC submission 
process smooth
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Appendix 2: Summary of supervision sessions
Date Supervisor Supervision focus Actions
5.3.07 SF, HA Changes to study design; send proposal to 
Consultants for comment.
Reduce scope of study to focus on 
haemato-oncology and lung cancer using 
actigraphy/FACT -An
Focus on literature of traditional practices 
and culture , explore sociology literature
Widen literature review 
Remove action research and focus on 
ethnography literature 
Make changes to research proposal and re­
send to supervisors
22.5.07 SF. HA Positive feedback from Consultant 
Haematologists
“Stumbling block” of starting NRES 
application
Discussed time frames-short and long term 
with aim to submit final thesis by August 09
Refine inclusion and exclusion criteria
Seek Oncologist approval
Submit to ethics/NRES by end of June 07
Clarify funding for actigraphy hire
SF to send letter for NRES application
LB to e mail summary of supervision
2.7.07 SF Checked letters and ethics submissions 
Discussed process of R&D submission and 
LREC submission 
Discussed ethics of permission with 
observation and to seek clarity at LREC
Submit ethics for 14.9.07
Send pdf file of ethics submissions to
supervisors
University ethics
7.11.07 SF, HA Ethics approval with minor amendments 
only and queries about the volume of data 
GCP training completed 6.11.07
Submit to University ethics for approval 
Research triangulation in ethnography 
Send through transcripts to supervisors for 
comment
23.4.07 SF, HA Interviews going well
Observations started
Reflective diary (research journal) being
kept and used to document key insights,
e.g. oncology clinics (process) and
haemato-oncology clinics (education of
patients)One patient recruited
Start drawing out key themes 
Complete interviews after identifying themes 
Observations in day units 
Recruit patients
4.6.08 SF, HA Discussed themes in observation fieldwork 
(anaemia is not important, shared 
responsibility)
Run further literature search 
Reflective journal {"analytic memos’)
Continue data collection 
Update observation notes 
Continue analytic notes 
Annual review to complete and submit
3.7.08 SF, HA Discussed changing the design to include 
patient interviews rather than track patients 
using actigraphy
To submit to NRES for substantial 
amendment and chase 
Complete data analysis Oct/Nov 2008 
Write up and submit December 2008 
Amend submission date to February 2009
30.7.08 SF. HA Feels interview and obsen/ation data will 
emerge easily as good contacts 
Transcribing own data
Continue data collection
Use field diary to “test” hypothesis/thoughts
and feelings from the field
Consider decision making literature and
theoretical framework
4.10.08 HA, SF Submitted chapters for review (literature 
review, methodology)
Some areas well developed, others less so 
Consider knowledge, skills acquisition and 
Clarify interpretive stance within 
ethnography
Consider external examiners 
Agree previous time lines 
Re-submit integration paper and write log 
Re-submit first draft of thesis December 
2008
Meet in January
12.1.09 HA Discussed feedback on first draft 
Academic paper to focus on practice 
oriented journal of overview paper of four 
main themes
Second draft of thesis by 9*^  February 2009 
Read Giddens “social interactionism/ 
symbolic interactionism”
HA, SF to identify external examiners 
Feedback to Trust to be undertaken following 
completion of thesis
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Conclusion
This section concludes both parts of the thesis and is therefore a summary of all the 
conclusions and recommendations of the combined elements of the thesis (the research; 
clinical academic paper; overview of the integration of knowledge, research and practice;
policy review; service development project and the research log). The following is a
summary of the main conclusions:
• Variation in transfusion practice exists (see service development project)
• The culture of the clinical setting influences learning and clinical decision making 
in transfusion practice (see Chapter 5 for final themes).
• The hierarchy of skills and knowledge demonstrate different clinical priorities in 
the different professions. This thesis provides a theoretical framework to 
describe how different tasks may be apportioned low or high status in the clinical 
setting (see Chapter 6 and 7).
• Transfusion decisions are shared and “task drift' (see policy review, section 4.0) 
occurs where nurses are making transfusion decisions without the formal 
structures in place to support this practice.
• The KSF does not accommodate the tacit skills and intuitive knowledge and this 
is evident where skills cross professional boundaries, particularly with the medical 
profession, who are excluded from the KSF (see policy review).
The following is a summary of recommendations for practice and further research:
• Transfusion guidelines may be Improved if they are less didactic or designed to 
incorporate different clinical situations to incorporate the real variations in 
transfusion need. In other words if they accommodate patient-centred decision 
making.
• Non-medical teams, for example, nursing teams, can effectively manage chronic 
conditions as it is manipulation/maintenance/prevention of adverse events rather
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than diagnosis and management. This includes the management of cancer 
related anaemia which could provide a model for the management of other 
chronic conditions.
• Legitimisation of nurse prescribing of blood components is recommended and 
this change of clinical responsibilities should be formalised to avoid the “task drift” 
described above.
• Further research may Include longitudinal studies of transfusion and the effects of 
blood transfusion on outcomes of patients with different tumour types.
• Ethnographic methodology to explore other practices where uncertainty exists is 
recommended or to repeat this research following implementation of some of the 
recommendations for clinical practice, e.g. implementation of nurse prescribing of 
blood components.
Final words of the thesis are important and somehow need to capture the essence of the 
energies and creativity of the researcher but recognise the contribution of everyone 
involved in the final product. It will therefore conclude with the words of Winter^ et al 
(2000, p35) by stating that this thesis contributed to original knowledge by containing 
“innovation, speculation, imaginative reconstruction and cognitive excitement and the 
author has clearly wrestled with the method, trying to shape it to gain new insights” into 
practice in the clinical setting. The “wrestling’ was within the researcher’s own 
ontological perspective and with the supervisors’ guidance this was eventually resolved, 
and undoubtedly the researcher has changed and developed both intellectually and 
professionally because of this, which surely must be the overall aim of the Doctorate in 
Clinical Practice.
’ Winter R et al (2000) The academic qualities of practice: what are the criteria for a practice 
based PhD? Studies in Higher Education.25, 25-37
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